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Abstract 
A “second tier” regulation of signalling from Receptor Tyrosine Kinases (RTK) has 
been uncovered where the receptor can be activated without ligand stimulation. This 
is mediated from an interaction between SH3 domains and proline-rich motifs in the 
RTK C-terminal tail. Most RTKs have one or more proline-rich motifs in their C-
terminal tail. The outstanding question remains as to what is the importance of these 
interactions. Several high-throughput screens have been carried out to discover 
novel interactions between proline-rich motifs and SH3 domains. One potential 
candidate is the oncogenic LIM and SH3 domain protein 1 (LASP1). Work presented 
here demonstrates that LASP1 directly interacts with the C-terminal tail of several 
RTKs. The oncogenic RTK ErbB2 has been shown to directly interact with LASP1 
via the ErbB2 C-terminal tail. More importantly an endogenous interaction was 
demonstrated in the breast cancer cell line SkBr3. Both LASP1 and ErbB2 are found 
in the vicinity of each other on the chromosome, and co-overexpression of both 
proteins has been shown in breast cancers. LASP1 has also been shown to directly 
interact with Fibroblast Growth Factor Receptor  2 (FGFR2). This interaction 
happens via the C-terminal tail of FGFR2, which has previously been shown to be 
important in “second tier” signalling and regulation. Preliminary data suggests that 
the LASP1 and FGFR2 interaction may impact cell growth and migration. In another 
example of a “second tier” interaction, the SH3 domains from SRC family kinases 
FYN and SRC are shown to interact with ErbB2 under starved conditions, and the 
interaction between SRC and ErbB2 is mediated by a proline-rich motif in ErbB2. 
Taken together these data demonstrate a role for the C-terminal tail of several RTKs 
in interacting with proteins in a non-stimulated background, and challenges the 
canonical view of RTK signalling.   
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Chapter 1: Introduction 
1.1 Cell signalling  
Cells have developed an astonishingly complex way of communication. There are a 
large number of components involved and there is need for highly specific 
interactions and regulation. Signalling events are mainly activated by extracellular 
stimuli binding to specific receptors resulting in intracellular responses such as 
receptor conformational changes. Signalling events can activate cellular processes 
including cell proliferation, migration and differentiation. Perturbations of these 
signalling events have dramatic consequences for the cell and are often found to be 
involved in many disease states such as cancers. There are three main groups of 
cell surface receptors; ion channel coupled receptors, G-protein coupled receptors 
(GPCRs) and enzyme coupled receptors. Ion channel receptor activation by ligand 
binding opens up the channel to allow flow of ions such as K+, Ca2+, Na+ or Cl- 
leading to a change in membrane potential. GPCRs are the most abundant receptor 
type of the main groups. These have seven transmembrane helices and are 
activated by ligand binding in the extracellular loops (Trzaskowski et al., 2012). 
Conformational change from the ligand binding leads to G-protein activation and 
further downstream activation of pathways as determined by the G-protein subclass. 
Enzyme coupled receptors are transmembrane receptors and are activated by ligand 
binding at extracellular domains. The largest group among enzyme-coupled 
receptors are Receptor Tyrosine Kinases (Uings and Farrow, 2000).  
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1.2 Receptor Tyrosine Kinases 
RTKs consist of an extracellular region, a transmembrane domain, an intracellular 
kinase domain and a cytoplasmic tail. Most RTKs are activated by a similar 
mechanism. Ligand binding of two monomeric receptors at the extracellular domain 
causes receptor dimerisation. The receptor dimer undergoes a conformational 
change and the intracellular kinase domain trans-phosphorylates tyrosine residues in 
the intracellular tail and kinase domain. This allows the recruitment of proteins to the 
phosphorylated tyrosines (pY/pTyr) and further activation of signalling pathways 
(Lemmon and Schlessinger, 2010). Proteins can be recruited to multiple regions of 
the intracellular receptor, although many tyrosines are found in the cytoplasmic tail. 
This is a highly flexible region and is important for protein docking. Some of the 
flexibility of the C-terminus tail is facilitated by prolines, although another important 
feature of prolines in the C-terminal tail is binding proteins when the receptor 
molecules are not activated, which will be discussed in detail later. The 
juxtamembrane region can also be important for downstream signalling activation, 
with both allosteric regulation and protein recruitment, which will be discussed later. 
The human genome encodes for 58 RTKs which are distributed into 20 subfamilies 
(Robinson et al., 2000). The subfamilies have variabilities in the extracellular ligand 
binding site, highlighting the specificity for binding the activating ligand (Figure 1.1). 
On the intracellular region all receptors contains a tyrosine kinase domain. Activated 
kinase domains are highly similar across all kinase domain containing proteins. They 
contain a catalytic subunit which transfers phosphate from ATP to tyrosines (Nolen 
et al., 2004). A glycine-rich motif close to a lysine is important for ATP binding. The 
lysine forms hydrogen bonds with oxygen molecules within phosphate groups, and is 
essential for ATP binding. A conserved aspartic acid is important for the enzyme 
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activity, potentially as a result of the negative charge of aspartic acid assisting in 
substrate binding (Knighton et al., 1991). 
 
Figure 1-1 RTK subfamilies and domain structures 
This includes families such as Epidermal Growth Factor Receptor family (EGFR/ErbB), Insulin 
receptor family (Ins, InsRR and IGF1R), Platelet-Derived Growth Factor Receptor (PDGFR), Vascular 
Endothelial Growth Factor Receptor (VEGFR) and Fibroblast Growth Factor (FGFR) family (Lemmon 
and Schlessinger, 2010).  
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1.3 FGFR family 
The Fibroblast Growth Factor Receptor (FGFR) family consists of four members; 
FGFR1-FGFR4. A fifth receptor has been identified which is able to bind Fibroblast 
Growth Factors (FGF) but lacks a kinase domain (Sleeman et al., 2001). The FGF 
family contains 22 genes, out of which 18 members of the FGF family has been 
shown to bind to FGFRs on the extracellular domain and activate the receptor 
(Ornitz and Itoh, 2001; Ornitz and Itoh, 2015). The FGFs can be divided into 
subfamilies based on their function, such as paracrine or endocrine secretion or 
intracellular FGFs (FGF 11 and FGF13 are intracellular and does not bind FGFRs). 
There are 4 genes encoding FGFRs, but consists of 7 members from alternative 
splicing. Alternative splicing of the receptors produces different isoforms and the 
splicing can increase or decrease affinity of interactions with FGFs (Miki et al., 1992; 
Leung and Neal, 1997; Ornitz and Itoh, 2015) 
1.3.1 FGFR signalling 
The extracellular region of FGFRs consist of three immunoglobulin (Ig)-like domains 
which interact with FGFs and heparan sulphate proteoglycans (HSPGs). The FGF 
binding pocket is found between Ig II and Ig III (Figure 1.2). Alternative splicing of the 
Ig III domain determines FGF binding specificity. HSPGs sequester FGFs to the cell 
membrane by binding with low affinity and in a complex with FGFRs it increases the 
stability of the interaction (Turner and Grose, 2010). Once a dimer is formed by 
FGFRs, the intracellular kinase domain trans-phosphorylates tyrosine residues in a 
specific order, which serves as a docking site for proteins to activate a number of 
downstream pathways.  
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Figure 1-2 FGFR-FGF structure. 
Two FGF receptors, two FGFs and a heparan sulphate proteoglycans (HSPGs) chain forms a 
complex in which is the activated receptor. FGFs interact with FGFRs in a binding pocket between Ig 
II and Ig III (Turner and Grose, 2010).  
 
Pathways activated by FGFR include mitogen-activated protein kinase (MAPK) 
pathway, phospholipase C γ (PLCγ) and phosphoinositide 3-kinase (PI3K)-AKT 
signalling (Figure 1.3) (Turner and Grose, 2010; Brooks et al., 2012). FGFR 
substrate 2 (FRS2) binds at a NPXY motif (and not pTyr) in the juxtamembrane 
region of FGFR via the FRS2 phosphotyrosine binding domain (PTB). It is important 
to point out that FGFR1 and FGFR2 shows distinct mechanisms in interacting with 
FRS2. FGFR1 is found in a constitutive complex with FRS2 regardless of receptor 
activity, while for FGFR2 FRS2 is recruited upon receptor stimulation (Ahmed et al., 
2008). Once FRS2 is recruited, FGFR2 phosphorylates FRS2 (Ong et al., 2000a). 
Once phosphorylated FRS2, provides a recruitment site for downstream proteins 
such as growth factor receptor-bound protein 2 (GRB2), which then recruits son-of-
sevenless (SOS) and this leads to activation of the MAPK/ERK pathway via RAS 
(Kouhara et al., 1997). Additionally GRB2 can activate the PI3K/AKT pathway. 
PLCγ1 can interact with pTyr of FGFR (pY769 in FGFR2) via its SRC homology 2 
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(SH2) domain, and activated PLCγ1 hydrolyses phosphatidylinositol-4,5-
bisphosphate (PIP2) to Inositol trisphosphate (IP3, denoted PIP3 in figure 3, but they 
are not the same) and diacylglycerol (DAG) (Peters et al., 1992). DAG activates 
MAPK pathway via Protein Kinase C (PKC). Other pathways activated by FGFRs 
include Signal transducer and activator of transcription (STAT3) pathway (Hart et al., 
2000).  
 
 
Figure 1-3 Signalling pathways activated by FGFRs. 
FRS2 binds the FGFR2 juxtamembrane region and phosphorylation of FRS2 by FGFR sequesters 
GRB2 and SOS. The complex activated the MAPK pathway via RAS. GRB2 can also independently 
activate the PI3K/AKT pathway. PLCγ can interact with FGFRs via its SH2 domain and activated 
PLCγ hydrolyses PIP2 to IP3 (not PIP3 like in figure) and DAG. DAG can activate MAPK pathway via 
PKC. Other pathways that are activated by FGFRs includes STAT pathway (Brooks et al., 2012).  
7 
 
1.3.2 MAPK/ERK pathway 
MAPK pathways are activated by a number of receptors, including RTKs and 
GPCRs. Activation of these pathways leads to a wide range of cellular responses 
including proliferation, differentiation and apoptosis. Three different classes of MAPK 
pathways have been extensively studied; p38 MAPK pathway, JUN kinase (JNK) 
and Extracellular signal-Regulated Kinase (ERK), with ERK/MAPK being the best 
characterised RTK-activated signalling pathway. The three classes share the overall 
structure of the MAPK activation where phosphorylation drives the cascade. As 
previously mentioned ERK/MAPK can be activated in a number of ways, including by 
PKC and RAS, which activates RAF/MAPKKK. RAF/MAPKKK then phosphorylates 
MEK/MAPKK 1/2 which in turn phosphorylates ERK 1/2 (also known as MAPK 
p42/44). ERK 1/2 can further control protein activity or translocate to the nucleus to 
activate transcription (Zhang W, 2002; Roskoski, 2012).  
1.3.3 PI3K/Akt pathway 
Another pathway activated by a number of receptors is the PI3K/AKT pathway. PI3K 
phosphorylates PIP2, which is found enriched at the plasma membrane, to produce 
PIP3 (phosphatidylinositol-3,4,5-bisphosphate). PIP3 can recruit proteins containing 
pleckstrin homology (PH) domains such as the protein kinase AKT. AKT is activated 
by phosphorylation and then serves as a downstream mediator of the pathway. AKT 
activity is negatively regulated by Phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN), which dephosphorylates PIP3 to PIP2 and AKT can no 
longer be recruited to the plasma membrane (Franke et al., 1997; Campbell et al., 
2003; Engelman et al., 2006; Redfern et al., 2008). 
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1.3.4 FGFRs role in cancer 
Any perturbations of the signalling cascades that are regulated by FGFRs have the 
potential to induce detrimental effects in the cell. As a result, deregulated FGF 
signalling is often linked to cancers. Mutations of the receptors have been found in 
many human cancers including bladder, cervical and endometrial cancers (Turner 
and Grose, 2010). A single point mutation in the extracellular domain of FGFR3 
replacing serine with cysteine results in a disulphide bridge being formed between 
monomeric receptors forming a constitutively active dimeric receptor without ligand 
activation (di Martino et al., 2009). Receptor gene amplification of FGFR1 and 
FGFR2 is found in a subset of cancers such as breast cancers and gastric cancers 
(Jacquemier et al., 1994; Courjal et al., 1997; Kunii et al., 2008). Chromosomal 
translocations in which FGFR1 forms a fusion protein with zinc-finger containing 
protein ZNF198 are found in lymphoma and myeloid leukaemia. The fusion protein 
forms dimers and is constitutively active (Xiao et al., 1998; Roumiantsev et al., 
2004). Overexpression of growth factors is also linked to cancers. FGF1 was found 
to be overexpressed in ovarian cancer (Birrer et al., 2007) and inhibiting expression 
of FGF1/FGFR1 by antisense cDNA in mice with subcutaneous human melanomas 
showed tumour regression (Wang and Becker, 1997). These examples from multiple 
cancers and by various mechanisms illustrate the importance of the role of FGFR.  
1.3.5 FGFR2  
FGFR2 has two splicing variants, FGFR2 IIIb and FGFR2 IIIc which can interact with 
different FGFs (Figure 1.4). The isoforms are differentially expressed in tissues. The 
IIIb variant is predominantly found in epithelial cells while the IIIc isoform is 
expressed in mesenchymal cells (Katoh, 1992). FGFR2 mutations are associated 
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with a number of diseases. Missense mutations in the third Ig-domain or in the 
tyrosine kinase domain have been associated with congenital skeletal disorders 
(Katoh, 2009). FGFR2 gene amplification has been demonstrated in breast cancer 
and gastric cancer (Nakatani et al., 1990; Adnane et al., 1991). Missense mutations 
of FGFR2 are associated with several cancers such as breast cancer, lung cancer, 
gastric cancer and melanoma (Jang et al., 2001; Stephens et al., 2005; Davies et al., 
2005; Gartside et al., 2009). The canonical signalling from FGFR2 is like other 
activated RTKs with PTB and/or SH2-domain containing proteins that interact with 
pTyr. Interestingly a second-tier activation has been discovered involving proteins 
containing SH3 domains binding a proline-rich motif in the FGFR2 C-terminal tail, 
which will be discussed later.  
 
Figure 1-4 FGFR2 isoforms binds to different FGFs (Turner and Grose, 2010). 
1.3.6 SH2 domain 
SH2 domains are central in interactions with RTKs. Together with PTB domains they 
bind phosphorylated tyrosines. Proteins containing SH2 domains can be divided into 
two groups. One where the proteins also have enzymatic activity, like non-receptor 
tyrosine kinases such as the SRC family which contain both an SH2 and kinase 
domains. The second group often has single or tandem SH2 domains, sometimes in 
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conjunction with SH3 domains. These proteins act as adaptor or scaffold proteins, 
such as GRB2 (Schlessinger, 1994). The SH2 domain is structurally conserved 
amongst proteins and consists of a hydrophobic anti-parallel beta-sheet flanked by 
α-helices (Figure 1.5). It recognises a stretch of 3-6 amino acids, starting with pTyr. 
A conserved arginine interacts with the negative charge of the phosphate group and 
pTyr is buried into the pTyr binding pocket (Ladbury and Arold, 2000). 
 
Figure 1-5 SRC SH2 domain 
SRC SH2 domain consisting of three anti-parallel beta-sheets flanked by alpha-helices. A peptide 
containing a phosphorylated tyrosine (ball-and-stick) shows that pTyr interacts with the loop between 
two beta-sheets (Kohda et al., 1993).  
 
1.3.7 SH3 domains and Proline-rich motifs 
SH3 domains are abundant in the cell and about 300 SH3 domains are encoded by 
the human genome. Unlike SH2 domains, the SH3 domain interactions with proline-
rich motifs are generally much weaker interactions, where SH2 domains can interact 
with a pTyr of the preferred motif pYEEI with an affinities between 0.1-1 µM (Ladbury 
and Arold, 2000). For SH3 domains the affinities are weaker. For example, the SH3 
11 
 
domains of the GRB2 dimer interact with FGFR2 molecules with a KD of 0.1 and 25 
µM, while the PLCγ1 SH3 domain binds FGFR2 proline-rich motif with a KD of 40 µM 
(Lin et al., 2012; Timsah et al., 2014). Other examples include GRB2 interacting with 
peptides from SOS at affinities 5 and 21 µM (Ladbury and Arold, 2000). The 
structure of SH3 domains consists of a beta-barrel formed by two β-sheets (Figure 
1.6). The hydrophobic surface of SH3 domains contains small pockets conserved by 
aromatic residues, which can be occupied by prolines. Proline-rich motifs form a 
unique helical conformation, Polyproline (PP) II. The PPII helix contains three 
residues per turn and the prolines are trans-conformation, so they can occupy the 
ligand-binding pockets. PPII helices have been divided into two classes; class I that 
binds in a plus orientation and class II that binds in a minus orientation (Figure 1.7) 
(Mayer, 2001; Kurochkina and Guha, 2013). A consensus sequence of prolines that 
often bind SH3 domains is PXXP which forms the PPII conformation. P is proline and 
X can be any residue but is often hydrophobic. However, there is evidence that a 
much larger variety of proline-rich motifs can interact with SH3 domains. A high-
throughput analysis using a library of random peptides was used to identify binding 
partners of purified SH3 domains, and over half of the SH3 domains could interact 
with non-canonical peptides, and they also exhibited specificity for several peptides 
(Teyra et al., 2017).  
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Figure 1-6 LASP1 SH3 domain (PDB 3i35) 
 
 
Figure 1-7 Proline-rich motifs form helices that interacts with pockets on the SH3 domain 
surface (Teyra et al., 2017).  
1.3.8 FGFR2 under non-stimulated conditions 
The FGFR mediated phosphorylation of FRS2 serves as a docking site for the SH2 
domain of GRB2, which activates downstream responses. GRB2 contains an SH2 
domain flanked by two SH3 domains. Interestingly, it has been shown that under 
serum starved conditions the C-terminal SH3 domain of GRB2 can interact with a 
proline-rich motif found in the C-terminal tail of FGFR2 (Ahmed et al., 2010). After 
deleting this C-terminal sequence in FGFR2, which contains the proline-rich motif, an 
increase in MAPK activity coupled with decreased FGFR2 phosphorylation was 
observed. Furthermore, the presence of GRB2 impairs Dephosphorylation of FGFR2 
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by the phosphatase SHP2. SHP2 can interact with FRS2/FGFR1 complex and plays 
a role in activating MAPK, and this only occurs with the activated receptor and not in 
non-stimulated conditions (Ong et al., 2000b). Altogether this suggests that the 
GRB2 C-SH3 domain can regulate FGFR2 activity, possibly by sterically hindering 
the access of SHP2 phosphatase to FGFR2 (Figure 1.8).   
 
Figure 1-8 GRB2 C-SH3 domain can interact with FGFR2 C-terminal tail. 
A mutant FGFR2 lacking the SH3 binding site shows increased dephosphorylation mediated by SHP2 
phosphate (Ahmed et al., 2010).  
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Furthermore, under serum starved conditions a dimeric form of GRB2 can interact 
with the FGFR2 C-terminal tail and keep two receptor molecules in close proximity 
(Lin et al., 2012). The receptor maintains basal kinase activity in this state but is 
unable to activate any downstream MAPK pathway signalling. Upon ligand binding at 
the extracellular site, the tetramer undergoes a conformational change and 
phosphorylation of GRB2 Y209 causes it to be released from the receptor. In the 
absence of GRB2, FGFR2 then proceeds to its normal activated form (Figure 1.9). 
GRB2 can also be dephosphorylated by SHP2, allowing GRB2 to yet again form a 
heterotetramer with FGFR2 proteins (Ahmed et al., 2013). Altogether this 
demonstrates complex mechanisms controlling FGFR2 where GRB2 acts as a 
stabiliser of a dimeric state of FGFR2 under basal conditions.  
 
Figure 1-9 GRB2 interaction with FGFR2 
Dimeric GRB2 can interact with the C-terminal tail of FGFR2 under starved conditions (a). Some 
“background” phosphorylation is maintained. Upon ligand binding a conformational change occurs 
resulting in GRB2 phosphorylation and release from receptor (b). FGFR2 cross-phosphorylates 
tyrosines in the C-terminal tail (c) (Lin et al., 2012).  
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The GRB2 SH3 domain interacts directly with a proline-rich motif on the C-terminal 
tail of FGFR2, including proline residues P810 and P813. Under serum starved 
conditions, the SH3 domain of PLCγ1 competes for binding to the same proline-rich 
motif (Timsah et al., 2014). In serum starved cells, which are depleted of GRB2, 
recruitment of PLCγ1 to FGFR2 occurs. This results in increased pathway activation 
as measured by PIP2 turnover to IP3 and an increase in Ca2+ levels. Decreasing 
levels of PIP2 as a result of PLCγ1 activation leads to inhibition of PTEN. PTEN 
dephosphorylates PIP3 to PIP2, and negatively regulates AKT activity. Consequently 
inhibition of PTEN results in increased AKT activity as a result of PLCγ1 activity 
(Timsah et al., 2015). GRB2 SH3 and PLCγ1 SH3 interactions with the receptor are 
protein-concentration dependent as they bind to the receptor with similar affinities. 
GRB2-depleted cells showed increased cell migration and invasive behaviour as a 
result of phospholipase activity. Indeed, when comparing GRB2 and PLCγ1 protein 
levels in cancerous tissues from for example breast cancer and colon cancer, an 
increase in metastatic potential is observed when there are low GRB2 levels and 
high PLCγ1 levels (Timsah et al., 2014). Together these data suggest that complex 
regulation of FGFR2 exists and perturbations to this regulation result in 
consequences for downstream signal transduction. In this case, signalling events are 
controlled by protein concentration and occur under non-stimulated conditions, which 
challenges the canonical way of thinking of RTK signalling cascades.  
1.4 ErbB family 
The ErbB (from avian erythroblastosis oncogene B) family has four members, 
Epidermal Growth Factor Receptor (EGFR (ErbB1), ErbB2 (Her2), ErbB3 (Her3) and 
ErbB4 (Her4)). Like other RTKs they form dimers and can form either homodimers or 
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heterodimers (Lemmon and Schlessinger, 2010). The receptors can be activated by 
several growth factors such as EGF, transforming growth factor-α (TGF-α), 
amphiregulin and neuregulins 1-4. EGF, amphiregulin and TGF-α only activate 
EGFR whilst the neuregulins 1 and 2 can activate ErbB3 and ErbB4, neuregulins 3 
and 4 activates ErbB4 (Linggi and Carpenter, 2006). ErbB3 is kinase impaired and 
consequently has less autophosphorylation activity, but can still be phosphorylated 
and activate downstream signalling (Wee and Wang, 2017). The extracellular part of 
the ErbB receptors contain four domains, two homologous large domains (L1 and 
L2, or I and III) and two cysteine rich domains (CR1 and CR2, or II and IV) (Figure 
1.10 a). By forming disulphide bonds, the monomeric receptor is found in a tethered 
structure but upon monomeric ligand binding to domains I and III, the receptor 
undergoes a conformational change, exposing the extracellular domains, which then 
promotes dimerisation (Burgess et al., 2003). ErbB2 is an orphan receptor as it has 
no known ligand that binds the extracellular region. As a result of the receptor having 
its dimerisation arm constitutively exposed it is the preferred dimerisation partner of 
the other members of the ErbB family (Figure 1.10 b and c) (Tzahar et al., 1996; 
Burgess et al., 2003; Baselga and Swain, 2009). The activation of EGFR family 
receptors is different compared to other RTKs in which they do not require trans 
phosphorylation. An allosteric mechanism where the kinase domain of an EGFR 
receptor acts on the corresponding receptor kinase is important or activation, and the 
juxtamembrane region plays an important role in facilitating the allosteric activation 
(Red Brewer et al., 2009; Jura et al., 2009). 
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Figure 1-10 ErbB domain organisation. 
a) The extracellular part contains four domains, two large and two cysteine-rich. The transmembrane 
domain is followed by a juxtamembrane and the tyrosine kinase domain. The C-terminal tail contains 
several tyrosines that upon activation is phosphorylated (Burgess et al., 2003). b-c) EGFR, ErbB3 and 
ErbB4 has a tethered conformation of the extracellular domains, while ErbB2 has an extended 
conformation. This allows ErbB2 to be a preferred heterodimerisation partner of the other ErbB family 
members. ErbB3 does not have an intracellular kinase domain (Baselga and Swain, 2009). 
 
1.4.1 ErbB2 signalling 
The orphan receptor ErbB2 forms heterodimers with other members of the ErbB 
family. Residues that are involved in ligand binding of the other ErbB family 
receptors are not conserved in ErbB2, potentially explaining why an ErbB2 activating 
ligand has yet to be discovered (Garrett et al., 2003). As a result of the constitutively 
exposed dimerisation arm, ErbB2 is the preferred dimerisation partner of the other 
a) b) 
c) 
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ErbB family receptors, and upon heterodimerisation downstream pathways are 
activated (Graus-Porta et al., 1997). Additionally there is evidence suggesting that 
overexpressing ErbB2 can activate downstream signalling without ligand (Wildenhain 
et al., 1990). Phosphorylation of key tyrosines in the kinase domain and C-terminal 
tail allows for protein binding via their SH2 or PTB domains. In a phosphotyrosine 
interactome study for the ErbB family, several phosphorylated tyrosines on ErbB2 
and new interaction partners were identified (Schulze et al., 2005). GRB2 has been 
shown to interact with pY1139, the SH3 domain binding protein SH3BGRL at pY923, 
the phosphatase PTP-2c (also known as PTPN11) at pY1023, and finally SHC was 
found to interact with phosphorylated tyrosine residues in the C-terminus of the 
receptor (pY735, pY1005, pY1196, pY1222 and pY1248). SHC recognises an amino 
sequence NPXY which is incorporated into sequences proximal to both Y1196 and 
Y1248 (Campbell et al., 1994). Moreover phosphorylation of Y1248 is linked to the 
RAS-RAF-MAPK pathway (Ben-Levy et al., 2018). GRB2 plays an importan role in 
linking SHC to the MAPK pathway.  The SH2 domain from GRB2 interacts with pTyr 
on SHC, and activates MAPK pathway. And in the case of ErbB2, phosphorylation of 
pY1248 links the SHC:GRB2 complex to the MAPK pathway (Harmer and DeFranco, 
1997).  
1.4.2 The role of ErbB2 in cancer 
ErbB2 is overexpressed in many types of cancers including ovarian, lung, stomach 
and most notably breast cancer (Holbro, Civenni, et al., 2003; Janni et al., 2015; 
Wolfson et al., 2016). ErbB2 has been shown to be overexpressed in 25-30% of 
breast cancer tumours and is correlated to increased aggressiveness and mortality 
(Slamon et al., 1987). ErbB2 overexpression is a result of gene amplification and 
breast cancers have been shown to have 25-50 gene copies, resulting in 40-100 fold 
19 
 
increase in ErbB2 expression (Moasser, 2007). The elevated levels of ErbB2 
increase both homodimerisation and heterodimerisation with other ErbB members, 
and can lead to increased proliferation, invasiveness, survival and metabolic 
functions. Increased dimerisation between ErbB2/ErbB3 has been shown to activate 
the PI3K/AKT pathway, which controls a number of cellular responses such as 
proliferation, survival and invasiveness (Ram and Ethier, 1996; Holbro, Beerli, et al., 
2003). Cell polarisation and adhesion have been shown to be dysregulated from 
either homodimerisation of ErbB2 or heterodimerisation with EGFR. In addition the 
EGFR/ErbB2 dimer promotes invasive behaviour through activation of PI3K/AKT, 
RAS/MAPK and PLCγ pathways (Muthuswamy et al., 2001; Zhan et al., 2006). The 
monoclonal antibody Trastuzumab (Herceptin) is used in treatment of ErbB2-positive 
breast cancer patients. Trastuzumab interacts with the extracellular part of ErbB2 
with high affinity and leads to tumour regression, although the mechanisms behind it 
are not fully understood. Some studies suggests that Trastuzumab causes ErbB2 
internalisation and degradation as an immune-mediated response, and also 
upregulation of cell cycle inhibitors (Bange et al., 2001).  Administration of 
Trastuzumab on its own has a response in 30-40% of ErbB2-positive metastatic 
breast cancers. The overall efficiency of Trastuzumab suggests that there is some 
initial and acquired resistance to the drug (Vogel et al., 2002; Pohlmann et al., 2009).  
1.4.3 ErbB2 regulates the cell cycle 
Regulation of the cell cycle is controlled by a large number of components, primarily 
cyclins and cyclin dependent kinases (CDKs) and drives the cell into the different cell 
cycle phases, Gap 1 (G1), Synthesis (S), Gap 2 (G2) and mitosis (M) (K. A. Schafer, 
1998). Protein levels of cyclins rise and fall throughout the cycle in an orderly 
fashion, and as a result periodically activate specific CDKs, which in turn initiate cell 
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cycle progression (Figure 1.11). G1-phase entry is controlled by Cyclin Ds (D1, D2 
and D3), where the cell prepares for DNA synthesis. Cyclin E is important in the 
transition from G1 to S-phase. Cyclin A is expressed during S-phase and G2-phase, 
but in complex with different CDKs. In the S-phase DNA replication occurs and the 
intermediate phase G2 prepares the cell for M phase. CDK1/Cyclin A complex drives 
the cell into M-phase and a complex formed by CDK1 and Cyclin B continues to 
regulate mitosis (Vermeulen et al., 2003).  
Deregulation of D-type cyclins and consequently G1/S transition leads to cell 
proliferation. Overexpression of ErbB2 and Cyclin D1 has been reported in breast 
cancers, and overexpression of ErbB2 in various cell types was followed by an 
upregulation of Cyclin D1 (Harari and Yarden, 2000).  
 
Figure 1-11 Cell cycle phases and components. 
Cyclins are expressed at various stages and regulates CDK activity, which in turn regulate cell cycle 
phases (Vermeulen et al., 2003).  
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1.4.4 ErbB2 interacts with a member of SRC family non-receptor kinases 
The C-terminal tail of ErbB2 is enriched in proline residues, and several of them form 
canonical proline-rich motifs. This could suggest that the C-terminal tail of ErbB2 
could exhibit similar responses as FGFR2 by interacting with cytoplasmic SH3 
domains. Indeed, one proline-rich motif near the C-terminus has been shown to 
interact with the SH3 domain of the SRC family kinase FYN (Bornet et al., 2014). 
The authors used Surface Plasmon Resonance (SPR) and Nuclear Magnetic 
Resonance (NMR) to determine that a peptide based on a proline-rich motif in ErbB2 
consisting of the amino acid sequence R1146PQPPSPRE1154 interacts with the SH3 
domain of FYN with a KD of 0.9 mM. Using mutants of the peptide it was decided that 
the important residues in binding the SH3 domain were Arg1146, Pro1149 and 
Pro1152 (R1146PQP1149PSP1152RE). The physiological importance of this interaction 
is yet to be determined. It would be interesting to speculate whether an interaction 
via the SH3 domain of SRC family kinases can be a tumour escape mechanism. In 
the absence of ligand activation where SRC SH3 domain interacting with the C-
terminal tail of ErbB2, and the ErbB2 kinase can activate SRC by phosphorylation. 
This could be a possible explanation to how some patients develop resistance to 
Trastuzumab.   
1.5 SRC family kinases 
SRC was first discovered as an oncogene encoded by Rous sarcoma virus. The 
oncogene could insert itself into chicken genome and cause cancer, which gave the 
protein its name, SRC short for sarcoma (Stehelin et al., 1977). Since the discovery 
of viral SRC, several homologues have been found in the human genome. SRC 
family kinases are non-receptor tyrosine kinases and consist of at least 14 members 
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including SRC, FYN, YES, LCK and LYN. Some of the members are ubiquitously 
expressed, such as SRC, FYN and YES, while other members are expressed in 
specific cell types and tissues such as myeloid cells, B-cells, NK cells, T cells and 
brain (Parsons and Parsons, 2004). SRC kinases play an important role in cell 
signalling and regulate key cellular processes.  SRC can activate he cell survival 
pathway PI3K/AKT, and cell proliferation via MAPK/ERK pathway.  
1.5.1 SRC structure and conformation 
Members of the SRC family kinases have similar domains and conformation, 
including SRC (c-SRC or cellular SRC). In the cell, SRC is found in either a closed 
conformation, an inactive form or an open and active conformation. SRC kinases 
consist of an SH2, SH3 and a kinase domain (Figure 1.12). At the N-terminus there 
is a myristoylation site (Myr) which is responsible for recruiting SRC to the cell 
membrane. There is a proline-rich motif in the linker region between the SH2 domain 
and kinase domain which interacts with the SH3 domain when SRC is in its inactive 
form (Figure 1.13). There are two regulatory phosphotyrosine sites, 416 and 530 
(Tyr416 or Y416 and Tyr530 or Y530). Phosphorylation of Tyr530 inactivates SRC 
by its interaction with the SH2 domain, causing SRC to fold up on itself. In this 
inactive form the SH2 and SH3 domains are less accessible for binding ligands, and 
under basal conditions 90-95% of SRC is found in closed conformation (Zheng et al., 
2000).  Dephosphorylation of Tyr530 opens up the protein to its active form. The 
kinase domain adopts the typical kinase structure having an N-lobe and a C-lobe. 
The N-lobe anchors and orientates ATP while the C-lobe binds the protein substrate. 
The catalytic site of the kinase lies in a pocket between the two lobes and movement 
of the two lobes can open or close the pocket. In the open form ATP can be 
catalysed by the kinase transferring one phosphate group to the tyrosine residues of 
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the substrate protein. A tyrosine (Y416) sits in the activation loop, which is buried in 
the pocket between the lobes in the closed conformation and which can be 
autophosphorylated by the kinase domain, leading to a hyperactive protein 
(Roskoski, 2004).  
 
Figure 1-12 SRC family kinase structure and domains.  
They contain a kinase domain, SH2 and SH3 domains and a myristoylation site which allows the 
protein to be anchored to the membrane.  
 
Figure 1-13 SRC family kinase open/active and closed/inactive conformation structure.  
A phosphorylated tyrosine at the C-terminal tail (Y530) binds the SH2 domain while a proline-rich 
motif in the linker region between the SH2 domain and kinase interacts with the SH3 domain. 
Dephosphorylation of Y530 opens up the protein and the kinase domain can autophosphorylate 
Tyr416.  
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1.5.2 The role of SRC in cancer 
The functional role of activated SRC is linked with several cellular processes such as 
proliferation, survival and invasion. Consequently disruption of these processes 
could potentially lead to abnormal growth and migration, which are hallmarks of 
cancer. SRC is overexpressed in several cancers, including colon and breast 
cancers (Frame, 2002). It has been demonstrated that expression of the 
phosphatase PTP1B (protein-tyrosine phosphatase 1B), which has been shown to 
dephosphorylate Y530, is elevated in breast cancers (Bjorge et al., 2000). The 
tyrosine kinase CSK (C-terminal SRC kinase) inactivates SRC by phosphorylating 
Y530 and in hepatocellular carcinoma the expression of the kinase CSK is reduced, 
suggesting a tumour suppressor role for CSK (Masaki et al., 1999). Overexpression 
of SRC in breast cancers is seen with and without ErbB2 overexpression. 
Overexpression of ErbB2 in mammary epithelial cells resulted in activation of SRC, 
suggesting that ErbB2 can activate SRC in tumourigenesis (Sheffield, 1998). In 
addition, it appears that SRC functions upstream of ErbB2. SRC can phosphorylate 
ErbB2 on its activation loop (Y877) and in doing so  activate ErbB2 (Xu et al., 2007). 
SRC also enhances ErbB2/ErbB3 dimerisation and activity (Ishizawar et al., 2007). 
SRC and ErbB2 directly interact via the SRC SH2 domain and ErbB2 
phosphorylated tyrosines, and the formation of the heterocomplex is suggested to be 
the cause of enhanced growth in the breast cancer cell lines UACC-12, MDA-MB-
361 and MDA-MB-453. Additionally recruitment of SRC to ErbB2 results in 
modulation of cell polarity (Muthuswamy and Muller, 1995; Belsches-Jablonski et al., 
2001; Kim et al., 2005). It is clear that SRC plays a role in several cancers, with or 
without ErbB2 overexpression.  
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1.6 LASP1 domains and interacting partners 
LIM and SH3 domain protein 1 (LASP1) was first discovered as a gene amplified and 
overexpressed in breast carcinomas. It is located in close proximity to the ErbB2 and 
BRCA1 genes on chromosome 17, two known oncogenes in breast cancers 
(Tomasetto, Régnier, et al., 1995). It contains a LIM domain, two nebulin repeats and 
an SH3 domain (Figure 1.14). The nebulin repeats have been shown to directly 
interact with filamentous actin (Schreiber et al., 1998). The nebulin repeats have also 
been shown to interact with Kelch related protein 1 (KRP1), which is involved with 
cell migration (Miao et al., 1994). LASP1 SH3 domain has been shown to interact 
with many proline-rich motif containing proteins, such as dynamin, Lipoma preferred 
partner (LPP), palladin, Vasodilator-stimulated phosphoprotein (VASP) and Zonula 
occludens protein 2  (ZO-2). Additionally Zyxin interacts with LASP1 SH3 domain 
(Okamoto et al., 2002; Kwiatkowski et al., 2003; Li et al., 2004; Keicher et al., 2004; 
Rachlin and Otey, 2006; Grunewald et al., 2009; Mihlan et al., 2013). LIM domains 
have acquired its name from the proteins it was discovered in, LIN11, LSL-1 & MEC-
3 (Bach, 2000). The LASP1 LIM domain has been shown to interact with the 
chemokine receptor CXCR2 (C-X-C motif chemokine receptor 2, also known as 
Interleukin 9 receptor, beta), a GPCR which is activated by the chemokine 
Interleukin-8. The LASP1 LIM domain binds specifically to the LKIL motif in the 
carboxy-terminal domain of CXCR2 (Raman et al., 2010). The LIM domain is 
structurally a zinc-finger domain, and it is interesting to speculate whether LASP1 
LIM domain interacts with DNA. Especially as phosphorylation of serine 146 by 
Protein Kinase A (PKA) causes the release of LPP, Zyxin and actin, and LASP1 can 
be translocated to the nucleus in a complex with the nuclear shuttling protein ZO-2 
(Figure 1.15). Dephosphorylation by Serine/Threonine-protein phosphatase 2B 
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(PP2B) relocates LASP1/ZO-2 complex to the nucleus (Mihlan et al., 2013; Orth et 
al., 2014). Additionally the cytoplasmic kinases SRC and ABL phosphorylate tyrosine 
residue 171 in LASP1 (Schreiber et al., 1998; Lin et al., 2004).  
 
Figure 1-14 LASP1 structure and domains. At the N-terminal there is a LIM domain, followed by 
two nebulin repeats and at the C-terminal an SH3 domain.  
 
Figure 1-15 In a complex with ZO-2, LASP1 translocates to the nucleus after phosphorylation 
by PKA. LASP1 is dephosphorylated by PP2B. Adapted from (Orth et al., 2014).  
 
1.6.1 LASP1 function and role in cancer 
LASP1 interacts with filamentous actin directly and several of the interaction partners 
of LASP1 are also involved in actin organisation. LASP1 locates in focal adhesions, 
leading edges of lamellopodia and filapodia, which are involved in cell migration, 
adhesion and signalling events (Chew, 2002). Phosphorylation of LASP1 by SRC in 
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activated platelets relocated LASP1 to leading lamellae of a migrating cell (Lin et al., 
2004). LASP1 is overexpressed in various cancers such as ovarian, bladder, 
prostate and also breast cancer where LASP1 was originally identified. In Chronic 
myeloid leukaemia (CML) patients, phosphorylation of Y171 in LASP1 was reported 
by the oncoprotein BCR-ABL which leads to interactions between pY171 and CRK-
like protein (CRKL). BCR-ABL is a fusion protein between breakpoint cluster region 
protein (BCR) and Abelson murine leukemia viral oncogene homolog 1 (ABL). BCR-
ABL activates MAPK/ERK and PI3K/AKT pathways, which leads to cell proliferation 
(Frietsch et al., 2014). LASP1 is overexpressed in 8% of breast carcinomas, and 
overexpression correlates with tumour size, suggesting LASP1 can be related to 
worse prognosis (Grunewald et al., 2007). LASP1 expression is higher in patient 
breast cancer tumours that are also ErbB2-positive (Glynn et al., 2012). Additionally 
there is evidence that LASP1 is localised to the nucleus in breast cancer patients 
and is correlated with poorer survival. In breast cancer cell lines this was confirmed 
and also an increase of protein expression was seen in S-phase and G2/M-phase 
(Grunewald et al., 2007; Frietsch et al., 2010). Silencing LASP1 expression by 
siRNA in breast cancer cell lines caused reduced migration, proliferation and the 
cells were arrested in the G2/M-phase of the cell cycle. Consequently 
overexpression of LASP1 in cells with no endogenous LASP1 lead to increased cell 
motility (Grunewald et al., 2006). Taken together it is clear that LASP1 plays a role in 
several cancers and not surprisingly cell migration is increased when LASP1 is 
overexpressed.  
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1.7 Aims and objectives 
A second tier of signalling has been discovered for FGFR2. Unlike canonical RTK 
signalling this second tier signalling happens in the absence of extracellular stimuli. 
The interactions occur between SH3 domains and proline-rich motifs in the C-
terminal tail, and not the canonical SH2/pTyr which requires receptor ligand binding. 
Additionally an interaction between FYN SH3 domain and ErbB2 proline-rich motif 
has been demonstrated using NMR, demonstrating another possible RTK interacting 
with SH3 domain. Investigation of these interactions between ErbB2 and FYN, and 
FYN homologue SRC would be important to investigate. SRC and ErbB2 have been 
shown to interact directly in breast cancer cell lines but there is no evidence of this 
interaction in the breast cancer cell line SkBr3 (Belsches-Jablonski et al., 2001). 
Several examples of RTKs interacting with proteins containing SH3 domains could 
suggest that there might be a second tier receptor modification which has gone 
largely unnoticed because of the weak and transient nature of these interactions. 
One can speculate if any deregulation of this system in cancers can play a role in 
cellular processes leading to tumour formation. The aims and objectives for this 
thesis are: 
Aim 1: Identify novel interactions between SH3 domains and proline-rich motifs from 
RTKs.  
Using mass spectrometry (MS) serves as a high throughput method to identify these 
novel interactions. Combined with peptides containing proline-rich motifs from RTKs 
and lysates from cells, MS will be utilised in order to discover novel proteins 
containing SH3 domains interacting with the proline-rich motifs. 
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Additionally a dot blot will be carried out to identify direct interactions. In this work 
purified C-terminal tails of several RTKs and purified LASP1 with and without the 
SH3 domain will be used to identify novel interacting partners for LASP1 SH3 
domain. 
Further verification and characterisation of some of the potential interactions will be 
carried out using immunofluorescence, pull down experiments and biophysical 
methods. 
Aim 2: Prove interaction between FGFR2 proline-rich motif and LASP1. 
Preliminary data suggest that LASP1 and FGFR2 interact. This will be carried out 
using a range of techniques including pull-down experiments and 
immunofluorescence to verify this interaction in a cellular context. A biophysical 
assay will be utilised to characterise the interaction further.  
In addition to interaction verification and characterisation, cell motility and growth 
assays will be carried out to determine whether this interaction has any impact on 
cellular responses, and if it is physiologically relevant. 
Aim 3: Verify the interaction between ErbB2 proline-rich motif and the SH3 domain 
from SRC in SkBr3 cells. 
Cellular techniques such as co-immunoprecipitation and fluorescence in SkBr3 cells 
will be used to verify an interaction between SRC and ErbB2 in starved conditions, 
and demonstrating it in a cellular context. 
Further characterisation of this interaction will be carried out using pull-down 
experiments, immunofluorescence and biophysical methods in order to determine 
the domains of SRC and region of ErbB2 involved in this interaction. 
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Chapter 2: Materials and Methods 
2.1 Bacterial cell culture 
2.1.1 Bacteria growth and storage 
Amplification of DNA plasmids was performed in the Escherichia coli strains DH5α or 
XL10. E. coli were grown on lysogeny broth (LB) agar and in liquid shaking cultures 
in LB medium overnight at 37°C. Appropriate antibiotics were used for selection (50 
μg/μl Kanamycin, 100 μg/μl Ampicillin). Long-term storage bacterial cells were 
suspended in 50% liquid overnight culture/50% glycerol and stored at -80ºC. Protein 
expression was performed in the E. coli strain BL21. Similar growth conditions were 
used for BL21, DH5α and XL10 strains of bacteria, unless otherwise stated.  
2.1.2 Transformation 
E. coli was transformed by adding 2 µl of plasmid DNA to 25 µl competent DH5α, 
XL10 or BL21 cells. The cells were incubated on ice for 10 minutes followed by heat 
shock treatment at 42ºC for 45 seconds, before additional incubation on ice for 2 
minutes. LB medium was then added to the cultures followed by 1-2 hour incubation 
shaking at 37ºC. The culture was then plated on LB agar plates containing the 
appropriate antibiotic.  
2.1.3 Preparation of plasmid DNA 
Commercially available kits were used for the small and large-scale purification of 
plasmid DNA (Qiagen), follwing the manufacturers’ guidelines. Overnight cultures 
varied between 5-20 ml for miniprep and 50-200 ml for maxiprep purification, 
depending on the copy number of the plasmid.  
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2.2 Molecular cloning 
2.2.1 Polymerase chain reaction (PCR) 
Point mutations in ErbB2 was done using In-Fusion Mutagenesis kit (Clontech, 
639648). Primers were designed to contain all three mutations (Table 1). The 
polymerase chain reaction (PCR) mastermix (CloneAmp HiFi 
Polymerase, dNTPs, and optimized buffer) was prepared according to protocol 
(Table 2) and PCR was run for 35X cycles (Table 3). 
Table 1 Oligonucleotides for mutagenesis.  
Overlapping nucleotides in green, point mutations in yellow 
Gene Forward primer Reverse primer Comments 
ErbB2 triple 
mutant 
5’AATATGTGAACCAGCCA
GATGTTGCGCCCCAGGCC
CCTTCGG 3’ 
 
3’GCGCCCCAGGCCCCTT
CGGCCCGAGAGGGCCC
TCTGCCTGCT 3’ 
 
R1146A/P1149A/
P1152A 
 
Table 2 PCR reagents for mutagenesis  
Reagent Volume/concentration  
CloneAmp HiFi PCR Premix 12.5 µl 
Forward primer 250 nM 
Reverse primer 250 nM 
Template DNA 0.1 ng 
H2O To make total volume of 25 µl 
Table 3 PCR steps for mutagenesis 
Step Temperature Time 
Denaturing 98°C 10 sec 
Annealing 55°C 5 sec 
Elongation 72°C 5 sec/kb 
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2.2.2 Agarose gel electrophoresis and gel extraction 
To check whether the mutagenesis had worked the PCR product was run on an 
agarose gel and the DNA was extracted (Zymoclean Gel DNA Recovery kit, D4007). 
The agarose gel was run at 80 V. DNA was extracted by cutting out the DNA band 
from the gel, agarose dissolving buffer was added followed by heating at 55°C until 
completely dissolved. The mixture was then run through the spin columns to capture 
the DNA, then washed twice with wash buffer before eluting with elution buffer (8 µl). 
Recovered DNA was then ligated.  
2.2.3 DNA ligation reactions 
Linear DNA from PCR was ligated by adding ligase (1 µl) and ligation buffer (1 µl, 50 
mM Tris-HCl, 10 mM MgCl2, 10 mM Dithiothreitol, 1 mM ATP) to the extracted DNA 
(8 µl, ~10 µg). The ligation reaction was left at room temperature overnight before 
being transformed into Stellar competent E. coli cells (Clontech, 636763).  
2.3 Protein expression and purification 
Starter cultures of BL21 (DE3) were incubated overnight at 37ºC, and then used to 
inoculate larger cultures of 1-2L. Larger cultures were grown to OD600 = 0.8-1.0 and 
expression was induced by adding IPTG (0.1 mM) to the cultures. Cultures were 
then grown at the indicate temperatures and harvested at the designated time points. 
Cells were pelleted by centrifugation at 1990xg at 4ºC for 20 minutes and either 
stored at -20ºC or resuspended in appropriate buffer for further experiments (see 
below). Resuspended pellets were sonicated prior to centrifugation at 1990xg at 4ºC 
for 30 minutes to separate cell debris and supernatant containing the protein. Protein 
intergrity was then analysed by SDS-PAGE.   
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2.3.1 Maltose Binding Protein (MBP) 
MBP tagged proteins (Table 4) were purified by resuspending the bacterial pellet in 
HEPES buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 1 mM β-mercaptoethanol). 
After sonification and centrifugation the supernatant was incubated with 100 µL 
amylose resin (New England Biolabs, E8021S) overnight at 4ºC. Beads were then 
washed 5x with HEPES buffer to remove unbound proteins and beads were either 
stored in 20% glycerol at -20ºC for further use in MBP pull downs, or the bound 
proteins eluted using 10 mM maltose in HEPES buffer.  
2.3.2 Glutathione-S-Transferase (GST) 
GST tagged proteins (Table 4) were purified by resuspending the bacterial pellet in 
Tris buffer (20 mM Tris pH 8, 150 nM NaCl, 1 mM β-mercaptoethanol).  After 
sonification and centrifugation the supernatant was incubated with either 100 µL 
(purification for GST pull down) or 1 mL (purification for MST) glutathione agarose 
beads resin (Sigma, G4510) overnight at 4ºC. Beads were then washed 5x with Tris 
buffer to get rid of unbound proteins and beads were either stored in 20% glycerol at 
-20ºC for further use in GST pull downs, or the bound protein were eluted using 20 
mM reduced glutathione in Tris buffer, pH 8.  
Table 4 Proteins expressed and purified 
Protein Tag Molecular weight  Plasmid of expression vector origin 
LASP1 wild type GST 38 kDa Elke Butt, Universitätsklinikum Würzburg 
LASP1 ∆SH3 GST 23.1 kDa Elke Butt, Universitätsklinikum Würzburg 
LASP1 ∆LIM GST 23.5 kDa Elke Butt, Universitätsklinikum Würzburg 
SRC SH3 GST 6.9 kDa Andrew Macdonald, University of Leeds 
FYN SH3 GST 8.0 kDa Andrew Macdonald, University of Leeds 
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FGFR2 C58 GST 6.5 kDa Chi-Chuan Lin, University of Leeds 
FGFR2 C58 P800A GST 6.4 kDa Chi-Chuan Lin, University of Leeds 
FGFR2 C58 P802A GST 6.4 kDa Chi-Chuan Lin, University of Leeds 
FGFR2 C58 P804A GST 6.4 kDa Chi-Chuan Lin, University of Leeds 
FGFR2 C58 P807A GST 6.4 kDa Chi-Chuan Lin, University of Leeds 
FGFR2 C58 P810A GST 6.4 kDa Chi-Chuan Lin, University of Leeds 
FGFR2 C58 P813A GST 6.4 kDa Chi-Chuan Lin, University of Leeds 
FGFR2 C58 ∆3 GST 6.1 kDa Chi-Chuan Lin, University of Leeds 
FGFR2 C58 ∆6 GST 5.9 kDa Chi-Chuan Lin, University of Leeds 
FGFR2 C58 ∆9 GST 5.5 kDa Chi-Chuan Lin, University of Leeds 
FGFR2 C58 ∆12 GST 5.1 kDa Chi-Chuan Lin, University of Leeds 
FGFR2 C58 ∆15 GST 4.8 kDa Chi-Chuan Lin, University of Leeds 
FGFR2 C58 ∆23 GST 3.9 kDa Chi-Chuan Lin, University of Leeds 
C-terminal EGFR MBP 25.6 kDa Chi-Chuan Lin, University of Leeds 
C-terminal ErbB2 MBP 28.3 kDa Chi-Chuan Lin, University of Leeds 
C-terminal ErbB3 MBP 41.0 kDa Chi-Chuan Lin, University of Leeds 
C-terminal ErbB4 MBP 36.6 kDa Chi-Chuan Lin, University of Leeds 
C-terminal INSR MBP 9.2 kDa Chi-Chuan Lin, University of Leeds 
C-terminal INSRR MBP 4.6 kDa Chi-Chuan Lin, University of Leeds 
C-terminal IGF1R MBP 10.7 kDa Chi-Chuan Lin, University of Leeds 
C-terminal VEGFR1 MBP 20.0 kDa Chi-Chuan Lin, University of Leeds 
C-terminal VEGFR2 MBP 21.2 kDa Chi-Chuan Lin, University of Leeds 
C-terminal VEGFR3 MBP 21.1 kDa Chi-Chuan Lin, University of Leeds 
C-terminal FGFR1 MBP 7.2 kDa Chi-Chuan Lin, University of Leeds 
C-terminal FGFR2 MBP 6.8 kDa Chi-Chuan Lin, University of Leeds 
C-terminal FGFR2 C2 MBP 2.8 kDa Chi-Chuan Lin, University of Leeds 
C-terminal FGFR3 MBP 4.5 kDa Chi-Chuan Lin, University of Leeds 
C-terminal FGFR4 MBP 4.7 kDa Chi-Chuan Lin, University of Leeds 
C-terminal PDGFRA MBP 16.0 kDa Chi-Chuan Lin, University of Leeds 
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C-terminal ALK MBP 30.0 kDa Chi-Chuan Lin, University of Leeds 
MBP MBP 42.0 kDa Chi-Chuan Lin, University of Leeds 
 
2.4 Protein biochemistry 
2.4.1 Protein concentration determination 
Total protein concentration from cell lysates was determined using Coomassie Assay 
reagents (ThermoFisher, 23238) and measuring absorbance at 595 nm. 30-50 µg 
total protein was used for western blot analysis. For purified proteins concentration 
was quantified using a Nanodrop spectrophotometer by measuring absorbance at 
280 nm (Thermo Scientific, NanoDrop 2000).  
2.4.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Cell lysates or purified proteins were mixed with 4X sample buffer (Biorad, 1610747), 
boiled for 5-7 minutes at 95ºC and loaded onto 4-20% Mini-PROTEAN Precast gels 
(Biorad, 4561096) for analysis. Gel tanks were filled with running buffer (35 mM 
SDS, 250 mM Tris Base, 192 mM glycine) and a constant voltage (120V) for 65 
minutes.  
2.4.3 Western blot  
Proteins separated by SDS-PAGE were transferred from the gel to PVDF 
membranes via semi-dry transfer (Biorad Trans-Blot). Membranes were activated by 
methanol and membranes and filter papers were soaked in transfer buffer (25 mM 
Tris Base, 192 mM glycine, 10% methanol). The filter papers and membrane were 
made into a “transfer sandwich” and a constant voltage was applied at 20V for 55 
minutes. Membranes were then blocked by incubating for 1 hour at room 
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temperature in blocking solution, 1X Tris buffer (10X 0.40 mM Tris HCl, 0.1 M Tris 
Base, 1.5 mM NaCl) containing 5% skimmed milk powder and 0.2% Tween-20. 
Primary antibody in blocking solution (Table 5) was added to the membrane and 
incubated overnight at 4ºC. Membranes were washed 3x10 minutes in TBS-T at 
room temperature before incubation with secondary antibody in blocking solution for 
1 hour at room temperature. The membranes were then washed again in TBS-T 
3x10 minutes before briefly incubated with enhanced chemiluminescence (ECL) 
substrate. Proteins were detected by exposure onto X-ray films for an appropriate 
length of time. 
Table 5 Primary and secondary antibodies used for detection of Western blots 
Antibody Size of target Manufacturer, catalogue number 
ALK 220 kDa/140 kDa CST, #3633 
ErbB2 185 kDa CST, #4290 
ErbB2 pY1221/1222 185 kDa CST, #2243 
ErbB2 pY1248 185 kDa CST, #2247 
FGFR2 (Bek C17) 150 kDa Santa Cruz, sc-122 
Fyn 59 kDa CST, #4023P 
GAPDH 35.8 kDa Santa Cruz, sc-47724 
GFP 37 kDa CST, #2956 
GFP 37 kDa Santa Cruz, sc-9996 
GST 26.7 kDa CST, #2622S 
LASP1 38 kDa Santa Cruz, sc-374059 
MBP 42 kDa CST, #2396S 
P42/44 MAPK 42/44 kDa CST, #4370S 
RFP/mCherry 25 kDa Abcam, ab167453 
Src 60 kDa CST, #2108 
Src 60 kDa Santa Cruz, sc-19 
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Src 60 kDa Santa Cruz, sc-5266 
Src pY416 60 kDa CST, #2101 
Src pY530 60 kDa Santa Cruz, sc-101803 
β-actin 42 kDa CST, #4970S 
 
2.4.4 Dot blot 
Purified MBP tagged receptors were dotted on nitrocellulose membranes (2 µl, 0.05-
0.25 mg/ml) and the membrane was left to dry (10-15 minutes) before blocking for 1h 
at room temperature (5% BSA, 0.1% tween-20 in HEPES buffer (HBST+5%BSA)). 
Membranes were then incubated with second purified protein for 2h at room 
temperature, and then washed 3x5 minutes with HBST before incubating with 
primary antibody for 2h at room temperature. Membranes were then washed 3x5 
minutes with HBST before adding secondary antibody. Before detection membranes 
were washed 3x5 minutes with HBST and finally ECL was added. The blots were 
detected using Syngene G:box, an imager for chemiluminescent blots.  
2.5 Mammalian cell culture 
2.5.1 Cell lines and maintenance  
Human cell lines (Table 6) were maintained in Dulbecco's modified Eagle's high-
glucose medium (DMEM), supplemented with 1% Penicillin/Streptomycin 
(ThermoFisher Gibco™, 10378016) and 10% v/v Gibco® foetal bovine serum (FBS, 
Life Technologies™). All cells were kept in in a humidified incubator at 37 °C with 5% 
CO2. Cells were passaged twice per week at 1:10.  
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Table 6 Cell lines used in mammalian cell culture 
Cell line Growth medium Comments 
HEK 293T DMEM + 10% FBS + 1% Pen/Strep   
SkBr3 DMEM + 10% FBS + 1% Pen/Strep   
MCF7 DMEM + 10% FBS + 1% Pen/Strep   
SH-SY5Y DMEM + 10% FBS + 1% Pen/Strep   
HEK 293 gRNA2 DMEM + 10% FBS + 1% Pen/Strep  GRB2 knockdown, Amy 
Stainthorp, University of Leeds 
HEK 293 scr DMEM + 10% FBS + 1% Pen/Strep  Scramble knockdown, Amy 
Stainthorp, University of Leeds 
HeLa DMEM + 10% FBS + 1% Pen/Strep   
2.5.2 Transient transfections 
Cells were seeded to 6-well plates (250 000 cells) or 10 cm2 tissue culture dishes 
(500 000 cells) and incubated until 80% confluency. Plasmid DNA  (Table 7) (2-15 
µg) was diluted in 50-200 μL optimem and incubated with Lipofectamine2000 (1:1 
ratio DNA to volume Lipofectamine) for 15-20 minutes before adding the 
DNA:Lipofectamine complex drop-wise to cells. The transfection medium was 
replaced with fresh media after 12 hours incubation.   
Table 7 Plasmids for mammalian transfection 
Plasmid Encoded gene Selection Origin Tag 
perbB2-EGFP ErbB2 Ampicillin AddGene Plasmid #39321 GFP 
FGFR2-GFP FGFR2 Kanamycin (Ahmed et al., 2010) GFP 
EGFP-FGFR2 
∆25 
FGFR2 ∆25, 
deletion of last 25 
amino acids 
Kanamycin Chi-Chuan Lin, University 
of Leeds 
GFP 
mCherry-Lasp1-
N-10 
LASP1 Kanamycin AddGene Plasmid #55071 mCherry 
(N-
terminal) 
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pcDNA3-MTS-
WT-c-Src-FLAG 
SRC Ampicillin AddGene Plasmid #44652 Flag 
pcDNA3-MTS-
KD-c-Src-FLAG 
SRC K298M, 
kinase dead 
mutant 
Ampicillin AddGene Plasmid #44653 Flag 
pcDNA3-MTS-
CA-c-Src-FLAG 
SRC Y530F, open 
conformation 
mutant 
Ampicillin AddGene Plasmid #44654 Flag 
NS5A NS5A Kanamycin Andrew Macdonald, 
University of Leeds 
GFP 
RFP RFP Ampicillin Chi-Chuan Lin, University 
of Leeds 
RFP 
GFP GFP Kanamycin Chi-Chuan Lin, University 
of Leeds 
GFP 
mCardinal-N2 mCardinal Kanamycin AddGene Plasmid #54590 mCardinal 
 
2.5.3 Cell lysis 
Cells were seeded out in 10 cm2 culture dishes and at 80% confluency starved 
overnight. Cells were then either stimulated with FBS (15 min), EGF (100 nM, 5 min) 
or kept as starved. Medium was removed and cells were washed with cold PBS and 
placed on ice. Cells were then scraped into an Eppendorf tube and cell lysis buffer 
was added (150 mM NaCl, 50 mM Tris-HCl pH 7.4, 1% Nonidet P-40, 0.25% Sodium 
Deoxycholate, 1 mM EGTA, 1mM PMSF, Protease inhibitor cocktail, 1 mM activated 
Na3VO4 and 1mM NaF). Tubes were incubated for 15 minutes on ice before 
spinning down cell debris. Supernatant was transferred to a fresh tube.  
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2.6 Immunocytochemistry 
2.6.1 Growing cells on coverslips and fixation 
Glass coverslips were washed in 70% ethanol and treated with poly-L-lysine (5 
minutes). Cells in suspension were seeded on top of the coverslips, and medium 
was added (2 ml/well). Cells were transfected at 40% confluency and any further 
treatments performed (e.g. serum starvation) undertaken when cells were at 50% 
confluency. Treated cells were fixed to the coverslips by treatment with 4% 
paraformaldehyde, for 10 minutes at room temperature. Paraformaldehyde was 
removed and coverslips were washed 3x with PBS. Samples were then analysed by 
proximity ligation assay (PLA) or immuno-cytochemistry (ICC).  
2.6.2 Proximity ligation assay and ICC 
Fixed cells on coverslips were permeabilised (0.01% BSA, 1% NP-40 in PBS) for 10 
minute at room temperature. Cells were blocked (0.01% BSA, 1% NP-40, 5% NGS 
(normal goat serum) in PBS) for 1h at room temperature. Primary antibodies were 
added at 1:100 dilution in 0.01% BSA, 5% NGS in PBS for 1h room temperature. 
Coverslips were washed 3x5 minutes with PBS before either adding the PLA minus 
and plus probes (Sigma, Duo92004). Probes were incubated for 1h at 37°C, and 
washed off 3x5 minutes using Wash buffer A from PLA kit (Sigma, DUO82049-4L). 
The ligation step was performed using ligase and ligase buffer and was incubated at 
37°C for 30 minutes. Coverslips were then washed 3x5 minutes with wash buffer A 
and the amplification of the signal was achieved by adding polymerase and 
polymerase buffer at 37ºC for 100 minutes. Coverslips were then washed 2x5 
minutes with wash buffer B and 1x5 minutes 0.01% wash buffer B. Coverslips were 
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added inverted to glass-slides containing a drop of DAPI solution and then imaged 
by confocal microscopy.  
2.6.3 Microscopy 
Cells from PLA and ICC was images using Zeiss LSM700 confocal microscope at 
the Bioimaging and Flow Cytometry facilities at University of Leeds. 
2.6.4 Statistics for PLA 
Statistics for PLA signals were done in ImageJ, two different methods were used in 
the analysis, which was either whole images imaged by confocal microscopy or 
individual cells. For whole images channels were split and the channel containing the 
PLA signal was taken forward. The channel was changed to RBG colour and colour 
threshold was changed. Signals were analysed by analyse particles and the 
parameters were selected as following; 0.1-5 uM size and 0-1 circularity. Number of 
particles counted were summarised. For each condition this was repeated for 8 or 
more images and graphically represented. Signal from individual cells were used to 
analyse PLA signal from transfected cells. Channels were split, then merged. 
Selection tool was used to draw around individual cells. Right click inside the cell and 
select duplicate. Channels were again split and the PLA signal channel was 
selected. Colour was changed to RGB and colour threshold was changed before 
analysing particles using the same parameters as for whole images. 15 or more cells 
were analysed and graphically represented. To test statistical significance unpaired 
standard t-test was used. Statistically significant differences were indicated by *(P Յ 
0.05), **(P Յ 0.01) or ***(P Յ 0.001).  
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2.7 Immunoprecipitation and pull downs 
2.7.1 Sample preparation for Mass Spectrometry 
Biotinylated peptides was incubated with cell lysate (500 µg total protein 
concentration) and streptavidin beads (New England Biolabs, S1420S). The mixture 
was incubated overnight at 4°C rotating. Beads were then washed with cold PBS 
twice and sample buffer were added. Samples were then sent for mass spectrometry 
analysis to FingerPrints Proteomics, University of Dundee 
2.7.2 Co-IP  
Cell lysate (500-2000 µg total protein concentration) was added to 5 µl Protein A/G 
PLUS-Agarose (Santa Cruz, sc-2003) beads to remove any proteins that interacts 
non-specifically with the beads. The beads and cell lysate mixture were incubated for 
1 hour at 4ºC, rotating. Supernatant was collected by centrifugation and appropriate 
antibody was added (1-2 µg). Pre-cleared cell lysate and antibodies were incubated 
overnight at 4ºC rotating. Agarose beads (20 µl per sample) were prepared by one 
wash with PBS and then added to the cell lysate/antibody mixture and incubated for 
a further 2 hours at room temperature or overnight at 4ºC rotating. Beads were then 
washed two times with cell lysis buffer (1 ml) and one wash PBS (1 ml). 4X sample 
buffer containing β-mercaptoethanol was added (25 µl) to the beads and the mixture 
was boiled at 95ºC for 5-7 minutes. Eluted proteins were analysed by SDS-PAGE 
and western blotting. 
2.7.3 GFP/RFP pull down 
Magnetic GFP- or RFP-trap beads (ChromoTek, gtma or rtma) were used in with cell 
lysate for pull downs. For each reaction 25 µl bead slurry was added to a clean 
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microcentrifuge tube. Ice-cold dilution buffer (10 mM Tris/Cl, pH: 7.5, 150 mM NaCl, 
0.5 mM EDTA) (500 µl) containing 1x phosphatase inhibitor cocktail was added to 
the beads, and the beads were washed with this solution three times using a 
magnetic rack. Cell lysates were diluted in dilution buffer to a total volume of 1 mL, 
and beads were added. Beads and cell lysates were either incubated for 1 hour at 
room temperature or overnight at 4ºC rotating. Beads were then magnetically 
separated and the supernatant was discarded. Beads were then washed 3-5 times 
with ice-cold dilution buffer (500 µl). Beads were then resuspended in 25 µl 4X 
sample buffer containing β-mercaptoethanol. Immunocomplexes was dissociated 
from beads by boiling at 95ºC for 5-10 minutes before SDS-PAGE gel separation of 
supernatant.  
2.7.4 GST/MBP pull down 
Glutathione or amylose agarose beads (5-10 µl) with either GST or MBP tagged 
expressed and purified proteins were washed with Tris (GST) or HEPES (MBP) 
buffer before being incubated with cell lysate (0.5-1 mg). Beads were incubated 
overnight at 4ºC rotating before being washed 3x Tris/HEPES buffer. After removing 
the last wash 25 µl of 4x sample buffer was added and samples were boiled before 
running SDS-PAGE and Western blot analysis.  
2.8 Microscale thermophoresis (MST) 
2.8.1 Protein labelling 
Purified proteins were concentrated to 100 µM using appropriately sized columns for 
protein of interest (Merck Amicon Ultra Centrifugal Filters, 10 kDa (UFC501024), 3 
kDa (UFC500324), and 30 kDa (UFC503024)). Concentrated protein (10 µl at 100 
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µM) was mixed with labelling buffer (0.1 M sodium bicarbonate pH: 8.3) and Atto488 
NHS ester (Sigma-Aldrich, catalogue number 41698). The solution was incubated for 
1 hour in the dark before separation of labelled protein and free dye on gel filtration 
column.  
2.8.2 Microscale thermophoresis 
A dilution of the unlabelled protein was made in a 16 times2 dilution series, starting 
concentration varied from 100 µM to 1 mM depending on protein or peptide used. 
Labelled protein was added to all 16 samples at a final concentration of 50-100 nM. 
Solution containing labelled and unlabelled protein was transferred to capillaries 
(Monolith, MO-K022) by capillary action and inserted into MST equipment 
(Monolith™ NT.115). LED colour was set to green and power was selected so that 
the maximum fluorescence from the capillaries was between 300-1200 counts. Other 
parameters included MST power and repeats, a view of a typical set up with 
parameters can be seen in Figure 2.1. 
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Figure 2-1 A typical experimental setup of Microscale Thermophoresis interface. 
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2.9 Growth and migration assays 
2.9.1 Growth assays 
For both soft agar and colony formation assays cells were seeded out in 6-well 
plates for transfection. HEK293T (gRNA or scr) were seeded at 100 000 cells/well. 
HeLa cells were seeded at 150 000 cells/well. Cells were transfected the following 
day and medium with DNA:Lipofectamine complex was removed after 12 hours. 
Cells were resuspended 48 hours after transfection and taken forward to either soft 
agar or colony formation assay.  
2.9.1.1 Anchorage-independent (Soft agar) assay 
1% agarose was melted and cooled to 40°C in a water bath (TopVision Low Melting 
Point Agarose. Cat No. – R0801). 2X DMEM (Merck; Cat No. SLM-202-B) with 2X 
FBS and 2X antibiotics was warmed to 37°C. Equal volumes of 1% agarose and 2X 
DMEM was mixed and 1 mL was added to wells in a 6-well plate. The plates were 
left to set at 4°C. Before use the plates were brought to room temperature.  
0.7% agarose was made and melted, and cooled to 40°C, then mixed with 
prewarmed 2X DMEM with FBS and antibiotics. Transfected cells were trypsinized 
and 500-1000 (HeLa and HEK293 respectively) cells were resuspended in 1.5 mL 
0.7% agarose and 1.5 mL 2X DMEM (Figure 2.2). 1 mL from this mixture was added 
to the base layer of agarose. Plates were left to set for an hour at 4°C before normal 
DMEM was added on top. Plates were left at 37°C in humidified incubator for 10 to 
30 days, until visible colonies were formed. 
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Figure 2-2 Soft agar assay illustration. A typical well for Soft agar assay consisted of a base 
layer of 1% agarose mixed with 2X DMEM. Cells were mixed with a top layer of 0.7% 
agarose and 2X DMEM. 
2.9.1.2 Anchorage-dependent (colony formation) assay 
Transfected cells were trypsinized and 500-1000/well (HeLa and HEK293 
respectively) were seeded to a 6-well plate. 2 mL DMEM was added to each well. 
Plates were left at 37°C in humidified incubator for 10 to 30 days and medium 
replaced every two days. When visible colonies were formed the medium was 
removed and wells were washed with PBS. 1 mL crystal violet solution was added 
(1% crystal violet stain, 25% methanol in water). Plates were left to incubate at room 
temperature for 15 minutes before removing the crystal violet solution. Plates were 
washed thoroughly and left to dry before colonies were counted.  
2.9.2 Scratch wound assay 
HEK293T (gRNA or scr) were seeded at 250 000 cells/well in a 6-well plate. Cells 
were transfected the following day and medium with DNA:Lipofectamine complex 
was removed after 12 hours. After 48 hours a scratch wound was made using a 
pipette tip and wells were imaged using fluorescent microscope (EVOS FL, Life 
Technologies). Cells were left at 37°C in humidified incubator and imaged again after 
24 hours.   
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Chapter 3: High-throughput analysis to detect SH3 containing 
proteins which interact with the proline-rich motifs of receptor 
tyrosine kinases 
An important mechanism for receptor activation under non-stimulated conditions was 
discovered for FGFR2 and could be a previously undiscovered regulation of RTKs. 
This chapter focuses on discovering novel interactions which can play a role in this 
potential “second tier” signalling, using high-throughput techniques.  
Published data provides precedent for a critical role of SH3 domain interactions with 
a proline-rich motif in the carboxyl terminus of the RTK FGFR2 (Ahmed et al., 2010; 
Timsah et al., 2014). This interaction could result in an inhibition of downstream 
signalling, as seen with the GRB2 dimer interaction with a proline-rich motif on the C-
terminal tail of FGFR2 (Ahmed et al., 2010; Lin et al., 2012) or alternatively could 
result in activation of downstream signalling, as observed for the interaction between 
PLC1 and the same proline-rich motif of FGFR2, which stimulates downstream 
signalling in a PLCγ1 concentration dependent manner (Timsah et al., 2014). There 
are 58 RTKs in the human proteome and most of them contain one or more proline-
rich motifs in their C-terminal tail. Moreover, there are approximately 300 SH3 
domains found in proteins, most of which can be found in the cytoplasm which can 
potentially interact with these proline-rich motifs. These interactions could potentially 
have diverse effects on receptor mediated signalling. Canonical RTK activation and 
consequently downstream signalling is through extracellular ligand binding which 
causes receptor dimerization and trans-autophosphorylation of specific tyrosine 
residues in the cytoplasmic domains of the RTK. Activation of these receptors 
through interactions between SH3 domains and proline-rich motifs has the potential 
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to serve as a “second tier” form of RTK-mediated signalling. Discovering novel 
interactions between SH3 domains and the proline-rich motifs of RTKs is thus 
important and might uncover previously unrecognised signalling. To begin to 
investigate this potential form of interaction, a preliminary screen was performed in 
which purified recombinant SH3 or WW (an alternative small protein domain capable 
of interacting with proline-rich motifs) domains were arrayed on a nitrocellulose 
coated glass slide and then incubated with fluorophore tagged peptides containing 
the proline-rich sequences from the RTKs ALK, ErbB2, FGFR1, FGFR2, INSR, 
PDGFRB and IGFR (Figure 3.1). Detection of a fluorescent signal would be 
indicative of a potential interaction between the proline-rich peptide and the 
recombinant SH3 or WW domain. This high-throughput assay which is able to 
identify novel protein-protein interactions has previously been described (Espejo et 
al., 2002). Results from the screen indicate that a number of SH3 domains from 
various proteins can interact with the RTK peptides (Figure 3.1) (screen performed 
by Prof. M. Bedford (MD Anderson Cancer Centre), unpublished). The top five SH3 
domain hits from each receptor is summarised in Table 8. These interactions can be 
taken further to validate and characterise the interaction. The screen consisted of 40 
different purified SH3 domains and is therefore limited, as other proteins in the cell 
can also potentially interact with the proline-rich motifs and as such will remain 
undiscovered.  
Based on previous publications and preliminary data it is interesting to investigate a 
potential new role for SH3 domains as regulators of RTKs. This chapter will focus on 
the different high throughput techniques that have been applied to identify proteins 
with the potential to interact with RTK proline-rich motifs via their SH3 domains. This 
will include techniques such as mass spectrometry (MS) with proline-rich peptides in 
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order to uncover other SH3 domain containing proteins interacting with RTKs. 
Following this approach, a dot blot method will be described that looks specifically at 
an interesting protein containing an SH3 domain and its interaction with RTKs. 
Finally, approaches and various techniques will be described that have been used to 
validate the interactions uncovered by the dot blot.  
Table 8 High-throughput screen of C-terminal tails and SH3 domains done by Prof. M. Bedford. 
Relative fluorescence for each SH3 domain was measured and here are the top five hits 
presented. 
Receptor C-terminal Top 5 SH3 domains measured by 
fluorescence 
ALK SH3PXD2B 
FYN 
Shank1 
SPTAN1 
NCK1 
FGFR1 SH3PXD2B 
ARHGEF7-1 
ARHGAP12 
FYN 
ARHGEF16 
FGFR2 Shank1 
SH3PXD2B 
ARHGAP12 
VAV3 
ARHGEF7-1 
PDGFRB Shank1 
ARHGAP12 
SH3PXD2B 
MPP2 
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ARHGEF7-1 
ErbB2-1 LYN 
FYN 
PLCG2 
PLCG1 
Shank1 
ErbB2-2 SH3PXD2B 
FYN 
LASP1 
NEB 
NCK1 
IGFR FYN 
LASP1 
SH3PXD2B 
YES1 
NEB 
INSR FYN 
PIK3R1 
YES1 
SH3PXD2B 
LYN 
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Figure 3-1 Fluorescent screen with purified SH3 and WW domains incubated with peptides containing proline-rich motifs from various RTKs. 
(a) The purified domains are arrayed in a specific order onto a glass slide and then incubated with fluorophore tagged peptides from ALK, ErbB2, FGFR1, 
FGFR2, INSR, PDGFRB and IGFR. (b) If there is an interaction between the peptide and a specific domain it will give a fluorescent signal upon laser 
scanning  
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3.1.1 The use of mass spectrometry to detect SH3 domain containing 
proteins 
The proline-rich sequences from the C-terminal tails of a number of RTKs were 
generated as biotinylated peptides. These peptides were coupled to Streptavidin 
beads and then incubated with lysates from the human HEK293T cell line overnight.  
The identification of any bound protein was next determined by MS analysis 
(FingerPrints Proteomics, University of Dundee). The full dataset from the analysis 
can be found in Appendix A. Pull-down experiments were performed in duplicate and 
bound proteins were then determined from unique peptides detected by the mass 
spectrometer. Only proteins that were identified in both duplicates from the pull-down 
screens were taken forward for further analysis (Appendix B). These proteins were 
then compared to a control peptide. The control peptide was a randomised peptide 
containing no prolines and was used to eliminate proteins that bind non-specifically. 
Many proteins that were detected by the peptides containing proline-rich motifs were 
also detected with the control peptide, suggesting a non-specific binding. To avoid 
missing true interactions with peptides containing proline-rich motifs the number of 
unique peptides for each protein was compared to unique peptides from the same 
protein for the control peptide. If the number of unique peptides from proteins 
detected from peptides containing proline-rich motifs were higher compared to the 
control peptide, or if they were only detected for the proline-rich peptides the proteins 
could be considered as specific interactions. Next, the accession numbers from 
protein hits were used to verify that the protein target contained a known SH3 
domain. Finally, cell atlas was used to check if the proteins in question are 
expressed in HEK293T cells or if they were contaminants from the procedure such 
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as trypsin or human contaminants from handling the samples such as keratin. This 
step was critical as a number of contaminating proteins were detected, which were 
both detected in the control peptide samples as well as in the RTK peptide samples. 
Strikingly, bioinformatic analysis demonstrated that none of the proteins found in the 
mass spec analysis contained SH3 domains. In contrast, one protein detected, 
MAGI-1, did contain a WW domain, which can also bind proline-rich motifs. Despite 
the lack of canonical proline-rich motif interaction domains in the interaction partners 
identified, the data pulldown may have revealed a potential novel interaction partner 
that interacted with the proline-rich peptides by an unknown mechanism. As such, a 
closer look at the integrity of the datasets was carried out. Datasets from each 
peptide were compared to the control peptide to check which proteins could be 
classed as a true interacting partners with the proline-rich motif. Each protein as a 
measurement of unique peptides was then plotted for both the receptor peptide and 
control peptide. For example, analysis revealed that most of the proteins precipitated 
by the ALK RTK peptide could also be precipitated by the control peptide (Figure 3.2 
a). Indeed, the highest number of unique peptides from both precipitations originated 
from keratin proteins, which are known contaminants. Disappointingly, there were no 
proteins that were pulled down with the ALK peptide that resulted in a larger number 
of unique peptides, suggesting that none of them bind specifically to the ALK 
peptide. Similarly, many of the peptides identified from the first ErbB2 peptide could 
also be found in the control peptide samples (Figure 3.2 b). However, there were 
also two interesting proteins detected that showed a higher number of unique 
peptides compared to the control. These are entry A0A024R0Y2 which is the protein 
HCG30204, isoform CRA_a. This protein is highly similar to Acetyl-CoA carboxylase 
1 which utilises as a cofactor for biotin. The protein does not have an SH3 domain 
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and could possibly have been interacting with the biotin part of the peptide, and 
potentially the ErbB2-1 peptide has strengthened the interaction. The second is entry 
P50402 which is emerin. Emerin is a nuclear membrane protein and anchors the 
cytoskeleton to the membrane, and is also involved in actin polymerisation amongst 
other functions  (Berk et al., 2013). ErbB2 has previously been shown to 
phosphorylate emerin on an unknown tyrosine (Tifft et al., 2009). ErbB2 contains 
several proline-rich motifs in the C-terminal tail, and for this screen two peptides 
were generated based on two different motifs.  The second peptide containing 
proline-rich motif from ErbB2 (Figure 3.2 c) shows no real differences in the number 
of unique peptides compared to control apart from entry F6KPG5. This is albumin, 
which comes up in several screens, and is a contaminant. FGFR2 also has several 
proline-rich motifs in the C-terminal tail, and two peptides based on two proline-rich 
motifs were generated and used in the mass spec screen. The first FGFR2 peptide 
shows no interesting differences compared to the control (Figure 3.2 d). Whilst the 
second peptide interacts with entry P31151 (Figure 3.2 e). This is protein S100-A7, 
also known as psoriasin as it is upregulated in the skin of psoriasis patients (Madsen 
et al., 1991). Psoriasin contains two EF-hand domains, and is part of the S100 family 
of proteins which bind calcium ions, via their EF-hand domains. The S100 family is 
involved in many biological processes including cellular differentiation, proliferation 
and migration and members are implicated in many cancers, either as a promoter of 
growth and metastasis or even as tumour suppressors (L. Geczy et al., 2012; 
Bresnick et al., 2015a). Extracellular S100A13 has been shown to interact with FGF1 
(LaVallee et al., 2002). S100-A7 is overexpressed in breast cancer but no 
expression is detected in normal breast epithelial cells. S100-A7 can either activate 
pro-survival pathways in ERα-negative breast cancer cells but inhibit proliferation in 
56 
 
ERα-positive breast cancer cells (Bresnick et al., 2015b). The question remains what 
part of S100-A7 interacts with the FGFR2 peptide and what is the biological impact 
of this interaction. For the PDGFRB peptide no significant differences between the 
proline-rich peptide and the control peptide was observed (Figure 3.2 f). The IGFR 
peptide generated a small number of entries that could be of potential interest 
(Figure 3.2 g). This was the only peptide that pulled out a protein containing a 
domain which can bind specifically to proline-rich motifs. Entry A0A087WXD2 is 
membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 
(MAGI-1). As its name suggests, it contains two WW domains and five PDZ 
domains. It is part of the superfamily membrane-associated guanylate kinases 
(MAGUK), which can contain PDZ, SH3 and GUK domains (Godreau et al., 2004). 
This interaction was also picked up in the fluorescent screen from Prof M. Bedford, 
where two WW domains from MAGI was used. A fluorescent signal can be detected 
for both WW domains for all the tested RTK peptides. The next entry of interest is 
Q53HF2 which is Heat shock 70 kDa protein 8 isoform 2 variant. Interestingly this 
entry also showed up for the first ErbB2 peptide in a 3:1 ratio compared to control 
peptide. The heat shock protein 70kDa family of proteins are involved in protein 
folding (Mayer and Bukau, 2005). 
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Figure 3-2 Number of unique peptides from each protein that were pulled 
down by proline-rich peptides from receptors 
ALK (a), ErbB2-1 (b), ErbB2-2 (c), FGFR2-1 (d), FGFR2-2 (e), PDGFRB (f) 
and IGFR (g) plotted together with control peptide containing no prolines. 
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3.1.2 Using purified peptides of the C-terminal tails of RTKs in a dot blot  
The MS screen yielded no novel interactions between SH3 domains and proline-rich 
motifs from RTKs, suggesting that the screen must undergo various steps of 
optimisation, or further exploration of techniques which are able to detect these weak 
interactions. To further test the hypothesis that proline-rich motifs can interact with 
SH3 domains, a screen using purified peptides from the C-terminal tail of RTKs and 
purified LASP1 was performed. LASP1 is a cytoplasmic protein that contains an SH3 
domain. The SH3 domain has been shown to interact with proline-rich motifs of a 
range of different proteins (Orth et al., 2014). Additionally the screen from Prof M. 
Bedford showed that the SH3 domain from LASP1 might directly interact with several 
of the RTK proline-rich motifs (Figure 3.1). The accessibility to LASP1 with and 
without the SH3 domain, the ease of purifying it and the stability of the protein 
provided a good starting point for evaluating the dot blot as a technique, but is not 
limited to LASP1.  
The C-terminal tails of a range of RTKs were cloned into vectors containing maltose 
binding protein (MBP) tag (work by Dr. Chi-Chuan Lin, University of Leeds). After 
bacterial expression and purification the MBP tagged C-terminal peptides were 
arrayed onto a nitrocellulose membrane and incubated with recombinant GST-
tagged LASP1 (Figure 3.3 a) or a mutant LASP-1 lacking the SH3 domain (LASP1 
ΔSH3, (Figure 3.3 b). Blotting was then performed with an antibody raised against 
GST. Any GST signal was indicative of an interaction between LASP1 and the MBP 
tagged RTK peptide. Both the wild type and ΔSH3 mutant LASP1 appeared to 
interact with the C-terminal tails of several RTKs, with the most intense signal 
originating from the ALK fusion. Signals were also detected from C-terminal tails of 
EGFR, ErbB2 and FGFR1, and even weaker signals detected from other receptor 
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tails. The interactions are summarised in a graph showing relative intensity and 
summarised in Table 9 (Figure 3.3 c and Table 9). The membrane was also probed 
for MBP to confirm the presence of the C-terminal peptide fusions on the dot blot 
(Figure 3.3 d). Another membrane was dotted with LASP1 wild type and ΔSH3 
mutant and analysed for GST (Figure 3.3 e). Additionally, an SDS PAGE gel was run 
to confirm the molecular weight of the various C-terminal tail fusions (Figure 3.3 f, 
Table 10). According to the molecular weight of the C-terminal tails some of the 
receptors possibly only contain the MBP tag (42 kDa), such as ErbB3, ErbB4, 
VEGFR3 and ALK. This is quite surprising as ALK gave the strongest signal in the 
dot blot. A closer look at the western blot reveals that for ErbB3, ErbB4 and ALK two 
bands with similar molecular weight is detected. Additionally, the ErbB4 lane also 
shows a faint band at a higher molecular weight which corresponds to full length 
MBP-ErbB4. Some run lower than they were predicted to such as VEGFR1 and 
VEGFR2. The disparity of the predicted molecular weights and how the proteins run 
on the gel could be the way the samples are prepared, denaturing by boiling.  The 
MBP tag can in some cases be cleaved off, as a result of proteolytic cleavage, and in 
the case of ErbB3, ErbB4 and ALK would leave two species at 42 kDa (MBP) and 
41/36.6/30 kDa. This could explain the double bands at similar molecular weights 
that are seen on the western blot. INSRR runs higher than the predicted molecular 
weight which could be the result of a dimerization which was not lost in the 
preparation of the samples. Insulin receptors exist at the cell membrane as dimers 
stabilised by disulphide bonds. With ligand binding they undergo conformational 
changes which activates the receptor and consequently downstream signalling 
(Maruyama, 2014). The pre-existing INSRR dimer does not explain the results from 
the western blot as only the INSRR C-terminal tail was used in these experiments. 
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The dot blot method can detect interactions between the C-terminal tails of several 
RTKs and LASP1. Some of the RTKs interact with the SH3 mutant differently to wild 
type LASP1. The dot blot method can be further used with other proteins containing 
an SH3 domain, or even just the SH3 domains from various proteins on its own. 
Having to express and purify proteins or domains of proteins can be limiting, and the 
dot blot as a method overall is limited as interactions might still remain uncovered 
based on the fact that purified proteins or domains are used. 
Table 9 Interactions between RTK C-terminal tail and LASP1 with and without the SH3 domain 
based on relative intensity from dot blot (Figure 3.3) 
C-terminal tail LASP1 WT LASP1 ΔSH3 
EGFR ++++ +++ 
ErbB2 ++++ +++ 
ErbB3 ++ +++ 
ErbB4 ++  
IGFR1 ++++ ++ 
INSR +++ ++ 
INSRR + ++ 
VEGFR1 ++++ + 
VEGFR2 +++ + 
VEGFR3  + 
FGFR1 ++++++ ++ 
FGFR2 ++++ + 
FGFR2-C2 + ++ 
FGFR3  +++++ 
FGFR4  +++++ 
PDGFRA ++++++ ++ 
ALK ++++++++ +++++++ 
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Figure 3-3 Dot blot with purified MBP-tagged 
C-terminal tails of RTKs.  
Nitrocellulose membranes were incubated with 
purified GST-tagged LASP1 wild type (a) or 
LASP1 ΔSH3 (b). The intensity of each dot was 
quantified using ImageJ and normalised to the 
background. The relative intensity was 
summarised in a graph showing the differences 
between wild type and ΔSH3 mutant (c). The dot blot was also incubated with antibody raised 
against MBP (d) and GST (e). MBP-tagged receptor tails were also run on a gel to separate them 
and confirm molecular weights (f)  
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Table 10 List of C-terminal tail peptides and molecular weight used in dot blot 
C-terminal tail Molecular weight (with MBP tag) (kDa) 
EGFR 25.6 (67.6) 
ErbB2 28.3 (70.3) 
ErbB3 41.0 (83.0) 
ErbB4 36.6 (78.6) 
IGF1R 10.7 (52.7) 
INSR 9.2 (51.2) 
INSRR 4.6 (46.6) 
VEGFR1 20.0 (62.0) 
VEGFR2 21.2 (63.2) 
VEGFR3 21.1 (63.1) 
FGFR1 7.2 (49.2) 
FGFR2 6.8 (48.8) 
FGFR2-C2 2.8 (44.8) 
FGFR3 4.5 (46.5) 
FGFR4 4.7 (46.7) 
PDGFRA 16.0 (58.0) 
ALK 30.0 (72.3) 
 
3.1.3 Verifying LASP1 binding to selected receptors from the dot blot 
Some of the putative interactions identified from the dot blot were taken forward for 
validation in a cellular environment. Recombinant GST-LASP1, GST-LASP-1 ΔSH3 
and GST-LASP1 ΔLIM fusion proteins were generated in E. coli and used in pull 
down experiments. According to the dot blot the C-terminal tail of ALK can interact 
with LASP1 regardless of whether the SH3 domain is present, suggesting a role for 
other domains and regions of LASP1. For this reason a mutant lacking the LIM-
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domain was used in order to evaluate whether the ALK interaction was with this 
domain. The GST pull down experiments were performed with lysates from SH 
SY5Y cells. SH SY5Y is a human neuroblastoma cell line derived from a biopsy of a 
metastatic bone marrow tumour and further subcloned. They have a neuronal like 
phenotype and are often used in research on amyloid proteins (Kovalevich and 
Langford, 2013). Based on data from cell atlas SH SY5Y cells highly express ALK 
and were considered a good source for the GST pull down. As seen from the cell 
lysates, ALK could be detected in two forms, a full length protein (220 kDa), and also 
a cleaved form of 140 kDa form, the cleaved form lacks the extracellular domains 
(Figure 3.4 a) (Moog-Lutz et al., 2005; Mazot et al., 2012).  Because the cleavage of 
ALK affects the extracellular domains it is thought not to interfere with the potential 
interaction with LASP-1, which would most likely happen in the cytoplasm. Indeed, 
both forms of ALK were pulled down with all three recombinant LASP1 proteins, but 
not with GST alone (Figure 3.4 a). This suggests that ALK can interact with LASP-1 
via another region of the LASP-1 protein, such as the nebulin repeats. Based on 
these findings, purified GST-LASP1 and MBP-ALK C-terminal receptor were taken 
forward to determine binding affinity using microscale thermophoresis (MST). MST is 
a biophysical method and a powerful tool which can be used to determine binding 
affinity between two molecules. A concentration dilution series is incubated with a 
fluorescently labelled protein at a constant concentration. An IR-laser focused on the 
capillary containing the solution generates a temperature gradient. Molecules move 
either away from, or towards the laser point to lower temperature regions until an 
equal distribution is created. Because a protein in a complex moves with a reduced 
velocity compared to when it is isolated, the measured fluorescence is distributed 
differentially across the protein concentration gradient, based on the concentration 
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titration of the unlabelled protein. A sigmoidal binding curve can be created as a 
function of changes of temperature, fluorescence and concentration, and the 
dissociation constant KD can be determined from the curve. The KD between C-
terminal tail of ALK and LASP1 was determined to 365 µM (Figure 3.4 b). The 
binding curve determined by MST is not a true sigmoidal curve fit as the 
concentration of the ALK peptide was not high enough to reach complete binding of 
LASP1 WT, so some caution should be taken with the KD determined. Nevertheless, 
taken together the data suggests that LASP-1 directly interacts with ALK in the C-
terminal tail part of the receptor and that this interaction is independent of either SH3 
or LIM domain.  
According to the dot blot, the C-terminal tail of ErbB2 also interacts with LASP-1. 
SkBr3 cell lysates were used in a GST pull down experiment. SkBr3 cells is a breast 
cancer cell line which overexpress ErbB2. Wild type LASP1, LASP1 ΔSH3 and 
LASP1 ΔLIM could all pull down ErbB2. The ΔSH3 mutant appeared to pull down 3-
fold the amount of Erbb2 relative to wild type and the ΔLIM mutant (Figure 3.4 c). A 
proximity ligation assay (PLA) was performed to verify the ErbB2 and LASP1 
interaction. Furthermore, in addition to verify the interaction, PLA can show that this 
interaction can happen endogenously and that it could be physiologically important. 
PLA uses antibodies that are specific to the two proteins of interest, but originate 
from different species. Two probes acting as a secondary antibody detects the 
primary antibody, one for each species the primary antibody was raised in. A DNA 
probe attached to the secondary antibody serves as a template for oligonucleotide 
amplification if the probes are in close proximity of each other.  The DNA probes can 
undergo rolling circle DNA synthesis in a ligation step which can then be amplified. 
Fluorescently tagged oligonucleotides in the amplification step binds and this allows 
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for fluorescently visualisation. A signal indicates that the proteins are in close 
proximity to each other. Data from the PLA suggests that endogenous LASP1 and 
ErbB2 interact in SkBr3 cells (Figure 3.4 d). Taken together these data suggest that 
LASP1 and ErbB2 interact endogenously in the breast cancer cell line SkBr3 and 
this interaction is not through either the SH3 domain or LIM domain. In fact, the 
LASP-1 mutant lacking the SH3 domain appeared to pull down 3-fold more ErbB2 
compared to wild type and ΔLIM mutant. Possibly the full length LASP1 could be 
sterically hindering ErbB2 access to the binding site of LASP1 and removing the SH3 
domain changes the conformation of LASP-1 in such a way as to allow for tighter 
binding, by for example having more of the surface area that interacts with ErbB2 
exposed. It would be interesting to compare MST analysis with and without the SH3 
domain to see if a higher affinity could be obtained  Regardless, LASP1 can interact 
with ErbB2 in a breast cancer cell line.
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Figure 3-4 Validation of LASP1 interactions.  
a) GST pull down using wild type LASP1, ΔSH3 and ΔLIM mutant with cell lysate from SH SY5Y cells. Both wild type and the mutant LASP1 was able to pull 
down ALKs. b) MST determined a KD of 365 µM between wild type LASP1 and the C-terminal tail of ALK. Experiment was done at pH 7.5 in HEPES buffer. c) 
GST pull down using cell lysate from SkBr3 cells shows that wild type LASP1 can pull down ErbB2, as can the ΔLIM and ΔSH3 mutants. White arrows show 
the molecular weights of GST-LASP1 WT, GST-LASP1 ΔSH3 and LASP1 ΔLIM. Graph illustrates the relative intensity of the ErbB2 bands.  d) PLA using 
SkBr3 cells shows that LASP1 and ErbB2 interact endogenously in the cells. 
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3.1.4 Discussion 
This chapter focusses on two different methods to discover previously unknown 
interactions between SH3 domains and proline-rich motifs. MS is a very sensitive 
method for analysing unknown proteins and is often used for that reason in high 
throughput screens. Theoretically, it would be a powerful technique to identify novel 
interactions but in reality yielded few hits, suggesting that experimental set up and/or 
conditions would have to be optimised. The majority of the unique peptides identified 
stem from various contaminants, and none of the proteins identified had a bona fide 
SH3 domain. Interestingly, one protein did contain a WW domain which are also able 
to bind proline-rich sequences and further verification and characterisation of this 
interaction would be interesting. Interactions between SH3 domains and proline-rich 
motifs are weak interactions and therefore inherently difficult to discover or capture. 
Different approaches could have been taken to ensure a better and larger dataset 
containing SH3 domain containing proteins would be discovered such as using 
additional cell lines to ensure fuller coverage from that perspective. The biotin-
streptavidin interaction is a strong interaction but the wash steps of the streptavidin 
beads might have been too harsh for proteins bound to the peptide, and buffer 
content could be further explored to ensure the stability of binding. In addition the 
length of the linker between the peptide and biotin could be further optimised, where 
a longer peptide could potentially increase the interaction potential. Furthermore the 
streptavidin beads can also play a role in restricting interactions as they come in 
different sizes (1-10 µm), so bead sizes used in the experiments could be explored. 
Using the MS service was not very cost effective so exploration of the protocol 
contents such as buffer content could end up costing a lot of money. Other 
approaches could be using bioID where not the peptide itself is biotinylated but 
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rather the peptide is fused to a biotin ligase and upon expression in cells it can 
biotinylate proteins in close proximity (Roux et al., 2013). There are some interesting 
proteins that came from the MS screen which could be followed up on but as none 
contained SH3 domains they fell short of the scope of this project. The focus then 
shifted to a semi high throughput approach for looking specifically at the SH3 domain 
containing protein LASP1 and its interaction with the C-terminal tail of several RTKs. 
The SH3 domain of LASP1 was previously demonstrated by Prof M. Bedford to 
interact with several C-terminal tails from RTKs, as demonstrated by fluorescent 
signal where LASP1 SH3 domain was immobilised and incubated with fluorescently 
labelled RTK peptides (Figure 3.1 and Table 8). The dot blot method is limited to 
discovering novel proteins interacting through the SH3 domain, but can be applied to 
many proteins or protein domains given that they can be expressed and purified. 
Using the dot blot with purified LASP1 and LASP1 ΔSH3 gave an opportunity to see 
if there was a difference in receptor tail interacting with either protein and suggestive 
of it being through the SH3 domain. A strong signal was detected for both wild type 
and mutant with ALK and a pull down experiment and binding study confirmed that 
this was indeed a real interaction and KD was determined to be 365 µM. Another 
confirmation of interaction was with ErbB2. This interaction also came up as one of 
the top hits from the preliminary fluorescent screen done by Prof. M. Bedford (Figure 
3.1 and Table 8). Results presented here demonstrates using both GST pull down 
and PLA that LASP1 and ErbB2 interacts, but again this was not through the SH3 
domain. Intriguingly the interaction between LASP1 and ErbB2 was shown 
endogenously in a breast cancer cell line. LASP1 was originally discovered in 
metastatic breast cancer tissue and is reported to be overexpressed in 8% of breast 
carcinomas (Tomasetto, Régnier, et al., 1995; Tomasetto, Moog-Lutz, et al., 1995; 
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Bièche et al., 1996). Further work would have to be done to identify how ALK and 
ErbB2 interact with LASP1, and which regions of the proteins are necessary for 
mediating the interaction. A crystal structure trial could be set up with wild type 
LASP1 and the C-terminal tails of ALK and ErbB2. Cloning the nebulin repeats into a 
GST construct to see if they are the only parts of LASP1 needed to pull down ALK or 
ErbB2 could be an alternative approach. Once the interaction site has been identified 
it would be even more interesting to see if the interactions have any impact 
physiologically on the cells. All three proteins are oncoproteins and implicated in a 
wide range of cancers. It would be interesting to see if the LASP1-ErbB2 interaction 
has any impact on breast cancer cell phenotypes. One potential way of analysing the 
phenotype would be knocking down LASP1 and determining if this impacts cell 
growth and migration. ALK is normally found to be oncogenic as a fusion protein that 
makes the kinase region of ALK constitutively active (Chiarle et al., 2008). These 
data suggest that LASP1 interacts with full length ALK, and it would be interesting to 
further investigate what this interaction means for the cell. One potential way to study 
this would be to observe the signalling events downstream of ALK in the presence or 
absence of LASP1. Furthermore this illustrates that the dot blot has provided 
preliminary data for an interaction, and that this has been confirmed in cells. 
Additionally, the relative intensity for IGF1R, VEGFR1, VEGFR2, FGFR1, FGFR2 
and PDGFRB all showed a more intense dot for wild type LASP1 compared to the 
SH3 mutant, and would all be interesting to further verify and investigate.  
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Chapter 4: Interaction between LASP1 and FGFR2 proline-rich motif 
and physiological significance of the interaction in cells 
Preliminary data suggest that FGFR2 can interact with the SH3 domain of LASP1. 
This chapter focuses on characterising the interaction, as well as establishing it in a 
cellular context. Demonstrating that the LASP1 SH3 domain can interact with a 
proline-rich motif on FGFR2 adds value to a possible “second tier” RTK regulation 
and signalling.  
FGFR2 has been previously demonstrated to be important in the “second tier” RTK 
regulation. A proline-rich motif in the FGFR2 C-terminal tail has been shown to 
interact with both GRB2 and PLC1 in a concentration dependent matter (Timsah et 
al., 2014). While a dimeric GRB2 holds two receptor molecules in close proximity to 
each other, the receptor itself is not activated (Lin et al., 2012). PLCγ1 competes for 
binding to the same proline-rich motif and GRB2 depleted cells have been shown to 
have increased migration and growth potential as a result of phospholipase activity 
from the PLCγ1 interaction with FGFR2 (Timsah et al., 2014; Timsah et al., 2015). 
This was the first demonstration of a non-stimulated RTK activation from protein 
concentration alone, i.e. where a higher PLCγ1 concentration compared to GRB2 
leads to activation. Some evidence suggests that the SH3 domain from LASP1 can 
interact with a peptide containing the proline-rich motif from FGFR2. SH3 domains 
from various proteins were arrayed on a nitrocellulose coated glass slide and then 
incubated with fluorophore tagged FGFR2 peptide (Figure 4.1 a). A weak signal was 
detected from the LASP1 SH3 domain (blue circles), suggesting that the SH3 
domain interacts with FGFR2 peptide (screen performed by Prof. M. Bedford (MD 
Anderson Cancer Centre), unpublished). In addition a weak signal was detected 
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when LASP1 was incubated with the dot blot containing MBP-tagged FGFR2 C-
terminal tail (Chapter 3, Figure 3.3 and Table 9). When the dot blot was incubated 
with the mutant LASP1 lacking the SH3 domain, the detected signal was 3-fold 
weaker suggesting that the interaction is primarily mediated by SH3 domains and the 
C-terminal tail of FGFR2. LASP1 is a ubiquitously expressed protein containing a 
LIM domain, two nebulin repeats (R1 and R2) and an SH3 domain (Figure 4.1 b). 
After first being discovered in metastatic lymph nodes originating from breast cancer, 
LASP1 has since been shown to be overexpressed in many cancers (Butt and 
Raman, 2018). This chapter focuses on characterisation of the LASP1 interaction 
with FGFR2, and some preliminary work has been undertaken to study the 
physiological outcome of this interaction.  
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Figure 4-1 Preliminary fluorescent screen with FGFR2 peptide 
a) Screen using purified SH3 domains arrayed onto a glass slide and incubated with fluorophore 
tagged FGFR2 peptide containing proline-rich motifs shows a weak signal for LASP1 SH3 domain 
suggesting an interaction. b) LASP1 contains a LIM domain, two nebulin repeats (R1 and R2) and a 
SH3 domain.  
 
4.1.1 FGFR2 C-terminal tail interacts with LASP1 SH3 domain in cells 
To validate the data from the fluorescent screen and the dot blot, and to determine 
whether the interaction occurs in cells, GST pull downs and PLA were performed. 
GST-tagged LASP1 and two mutants lacking either the SH3 or LIM domains (ΔSH3 
and ΔLIM respectively) were expressed in E. coli and purified prior to incubation with 
cell lysates from HEK293T cells. The lysates were from cells that had been 
transfected with FGFR2. Cells were also starved overnight to ensure that the 
potential interaction was with a non-activated receptor. LASP1 effectively pulled 
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down FGFR2 while the ΔSH3 mutant was unable to (Figure 4.2 a). Interestingly, the 
ΔLIM mutant appeared to pull down 3-fold more FGFR2 compared to wild type. 
Taken together the data suggests that LASP1 and FGFR2 interact and that it is 
mediated by the LASP1 SH3 domain. As there is currently no structure of full length 
LASP1,  only speculations can be made as to why the LIM domain is potentially 
restricting FGFR2 binding. The domain could potentially be a steric hindrance from 
how the protein is folded, there could be interactions between the SH3 and LIM 
domain. A repeat experiment was performed to include controls for the GST and 
GFP tags. Cell lysate from starved HEK293T cells that had been transfected with 
GFP-FGFR2 and also a GFP-FGFR2 construct lacking the last 25 amino acids of the 
C-terminal tail of FGFR2 (FGFR2 Δ25) was incubated with GST, GST-LASP1 or 
GST-ΔSH3. Again wild type LASP1 pulled down FGFR2 but not the ΔSH3 mutant 
(Figure 4.2 b). Interestingly FGFR2 Δ25 mutant was not pulled down with wild type 
LASP1 to the same extent as wild type FGFR2 suggesting that the interaction lies 
within the C-terminal tail of FGFR2. Additionally, the C-terminal tail of FGFR2 was 
able to pull down LASP1 in a GST-pull down experiment. A GST-tagged construct 
consisting of 58 amino acids from the C-terminal tail of FGFR2 (C58) was incubated 
with lysates from starved HEK 293T, which had been transfected with LASP1. GST-
C58 was able to pull down LASP1 but not GST alone (Figure 4.2 c), further 
confirming that this interaction is through the FGFR2 C-terminal tail. 
Further confirmation of the interaction between LASP1 and FGFR2 was observed by 
PLA in HEK293T cells that had been transfected with either GFP-FGFR2 or GFP-
FGFR2 Δ25. Cells were serum starved overnight and then either stimulated with 
FBS and taken forward to PLA analysis, or taken directly to PLA analysis. PLA signal 
was detected for GFP/LASP1 in both serum starved (Figure 4.3 a) and stimulated 
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(Figure 4.3 b) cells when cells were transfected with FGFR2. Less or no signal was 
detected when cells were transfected with the Δ25 mutant. A quantification of the 
PLA signal in individual cells was undertaken by analysing particles in ImageJ 
(Figure 4.3 c-e) and showed a significant difference between cells transfected with 
wild type FGFR2 and the FGFR2 Δ25 mutant, further confirming that LASP1 interact 
with the C-terminal tail of FGFR2. The interaction happened irrespective of whether 
the receptor was activated. 
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Figure 4-2 GST pull downs 
shows LASP1 interaction 
with FGFR2  
a) Purified GST tagged LASP1, 
and mutants lacking the SH3 
and LIM domains (ΔSH3 and 
ΔLIM) were incubated with cell 
lysate from starved HEK 293T 
cells overexpressing FGFR2. 
Both LASP1 and ΔLIM can pull 
down FGFR2 but not the ΔSH3 mutant suggesting an interaction between FGFR2 
and LASP1 SH3 domain. Graph shows relative intensity of FGFR2 being pulled 
down b) A repeat experiment incorporating controls such as GST only and GFP 
transfected cells again shows that LASP1 can pull down FGFR2 but not the ΔSH3 
domain. Another construct of FGFR2 lacking the last 25 amino acids in the C-
terminus (FGFR2 Δ25) was also transfected into cells and incubated with GST-
LASP1. Less FGFR2 Δ25 was pulled down by LASP1 suggesting that the 
interaction is in the C-terminal region of FGFR2. c) GST-tagged C-terminal tail of 
FGFR2 consisting of 58 amino acids (C58) was incubated with starved HEK293T 
cell lysate overexpressing LASP1. LASP1 was pulled down by GST-C58 but not 
GST alone
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Figure 4-3 PLA demonstrated that FGFR2 and LASP1 interacts 
in HEK293T cells and that it is through the C-terminal tail 
PLA shows that FGFR2 and LASP1 can interact in HEK293T cells 
transfected with FGFR2-GFP in both starved (a) and FBS stimulated 
cells (b). When cells are transfected with FGFR2 Δ25 the signal is 
lost suggesting that LASP1 interacts with FGFR2 in the C-terminal 
tail. This is true for both starved (a) and stimulated (b) cells. Analysis 
of signal per cell was performed using ImageJ and analyse particles 
(c) and a graphic representation of the difference between FGFR2 
and FGFR2 Δ25 for starved (d) and FBS stimulated cells (e) is 
statistically significant. Serum (FBS) stimulation of cells was done for 
15 minutes. DAPI was used to visualise the cell nucleus. Scale bar 
15 µm. Mean values and standard errors are represented. Using 
standard t-test the statistically significant differences are indicated by 
* (P Յ 0.05), ** (P Յ 0.01) or *** (P Յ 0.001). 
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4.1.2 Further characterisation of the FGFR2 and LASP1 interaction 
using MST and mutants 
Most SH3 interactions with proline-rich motifs are weak and can therefore be difficult 
to discover. Having demonstrated the binding between LASP1 and FGFR2 in cells it 
was of interest to determine how strong the affinity  is. Towards this, MST studies 
were used to determine binding affinities in vitro. LASP1 was labelled with Atto488 at 
the N-terminal amine. Unlabelled FGFR2 C58 was titrated from 1 mM to 30 nM. A 
binding curve was obtained (Figure 4.5 a) and a KD was determined to be 37.2 ± 4.7 
µM. This is a similar affinity to that seen for PLCγ1 binding FGFR2 proline-rich motif, 
which is 40 µM (Timsah et al., 2014). Initially an experiment using labelled LASP1 
ΔSH3 and C58 gave a binding curve showing no binding (Figure 4.5 b, left), 
suggesting that the interaction is through the SH3 domain from LASP1. However the 
concentration of C58 was from 125 µM to 1.9 nM, lower when compared to LASP1 
WT, suggesting that the concentration was not high enough to be able to determine 
the KD. The experiment was repeated using C58 at a concentration range from 1 mM 
as highest concentration which gave a binding curve and a KD between C58 and 
LASP1 ΔSH3 was determined to 62.2 ± 4.8 µM (Figure 4.5 b, right). Together these 
data suggest that LASP1 interacts with the C-terminal tail of FGFR2, irrespective of 
the SH3 domain. Further investigations of the interaction focused on which parts of 
C58 interact with LASP1. Constructs of C58 where prolines were mutated to 
alanines and deletion constructs of C58 were utilised (Figure 4.4, see Appendix C for 
full amino acid sequnces). The prolines were mutated to alanines individually and 
included prolines that were already established as interaction partners of GRB2 and 
PLCγ1 (P810 and P813). Additionally, P800, P802, P804 and P807 were also 
included in the analysis (Figure 4.5 c-h). In some cases mutating individual prolines 
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(P802, P804 and P813) increased the affinity of the C58 – LASP1 interaction (see 
Table 11). Mutating P800 and P807 decreased the binding affinity. The binding 
affinities obtained from MST for the point mutated C58 constructs and LASP1 
interaction vary over two orders of magnitude, ranging from ~1-100 µM. One proline, 
P810, seemed to be particularly important for the C58 interaction as no KD could be 
obtained for this particular alanine mutant. Comparing the graph for P810A shows a 
similar binding curve to, for example P807A and P800A, suggesting that some 
optimisation such as increasing the C58 concentration could potentially produce a 
graph where KD can be determined. Deletion mutants of C58, six in total, between 
the final 3 amino acids of C58 and the final 23 amino acids (Δ3, Δ6, Δ9, Δ12, Δ15 
and Δ23) were employed in order to further investigate which region of C58 interacts 
with LASP1 (Figure 4.5 i-n). Deleting the 6 last amino acids from C58 increased the 
affinity for LASP1 as both C58 Δ3 and Δ6 with LASP1 produced a binding curve 
giving a KD of ~1 µM and 234 nM respectively (Table 11). The more amino acids 
removed the lower the C58 affinity to LASP1 becomes, from 149 and 117 µM for Δ9 
and Δ15 respectively, to no binding curve for Δ12 and Δ23. This does to some extent 
follow the binding affinities from the point mutations, as Δ12, Δ15 and Δ23 has had 
P810 removed.  
 
Figure 4-4 Mutations in the C58 construct. The last 25 amino acids are used here to highlight 
the different deletion mutants and point mutations used in the MST experiments.   
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Figure 4-5 Binding affinities determined by MST 
a) Labelled LASP1 was at a constant concentration of 100 nM while C58 was titrated into the 
capillaries at starting concentration 1 mM. KD was determined to be 37.2 µM. b) C58 was titrated into 
labelled LASP1 ΔSH3 at 100 nM. Two different experiments were run with variable starting 
concentrations for C58. The first shows no binding curve when the highest C58 concentration was 
125 µM. A repeat experiment increasing the highest C58 concentration to 1 mM gave a KD of 62.2 
µM. Next page: c-h) Constructs with point mutations changing prolines to alanines in C58 were 
expressed and purified for MST, and titrated into labelled LASP1 at fixed concentration of 100 nM. KD 
for LASP1 and C58 P800A were determined to be 126 µM (c), C58 P802A was 4.3 µM (d), C58 
P804A was 11.7 µM (e), C58 P807A was 108 µM (f), No KD could be measured for LASP1 and C58 
P810A (g) and finally LASP1 and C58 P813A had a KD determined to be 1.35 µM. i-n) Constructs of 
C58 having amino acids deleted from 3-23 final amino acids were expressed and purified for MST, 
and titrated into labelled LASP1 at fixed concentration of 100 nM. C58 Δ3 and LASP1 produced a 
binding curve which gave a KD of 1.05 µM (i), C58 Δ6 and LASP1 produced a KD at 0.234 µM (j), C58 
Δ9 and LASP1 KD was determined to 149 µM (k), C58 Δ12 and LASP1 did not produce a binding 
curve (l), C58 Δ15 and LASP1 KD was determined to 117 µM (m) and finally a binding curve for C58 
Δ23 and LASP1 could not be determined (n). All experiments was performed in HEPES buffer at pH 
7.5 
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Table 11 MST binding affinities. Labelled proteins are listed first and always at a concentration 
of 100 nM 
Protein  Binding affinity (µM) 
LASP1 + C58  37.2 ± 4.7 
LASP1 ΔSH3 + C58  62.2 ± 4.8 
LASP1 + C58 P800A 126 ± 35.2 
LASP1 + C58 P802A 4.3 ± 0.6 
LASP1 + C58 P804A 11.7 ± 2.4 
LASP1 + C58 P807A 108 ± 25 
LASP1 + C58 P810A - 
LASP1 + C58 P813A 1.35 ± 0.1 
LASP1 + C58 Δ3 1.05 ± 0.17 
LASP1 + C58 Δ6 0.234 ± 0.05 
LASP1 + C58 Δ9 149 ± 13.2 
LASP1 + C58 Δ12 - 
LASP1 + C58 Δ15 117 ± 8.6 
LASP1 + C58 Δ23 - 
4.1.3 Physiological relevance of the LASP1 and FGFR2 interaction 
The data previously presented in this chapter established an interaction between 
LASP1 and the C-terminal tail of FGFR2, and demonstrated that this is not mediated 
by the LASP1 SH3 domain. No previous reports have shown this interaction. 
Importantly, as both LASP1 and FGFR2 are considered oncoproteins it is vital to see 
what impact the interaction has in cells. While the interactions were previously 
demonstrated in HEK 293T cells, further work was carried out in HEK293 gRNA 
(gRNA) which had the GRB2 gene removed by CRISPR/Cas9 technology (work by 
Amy Stainthorpe, University of Leeds). From the MST data it is likely that LASP1 
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binds to the same region of FGFR2 as GRB2, and GRB2 binding to FGFR2 could 
potentially disrupt LASP1 access to FGFR2. As a control, HEK293 scrambled (scr) 
were used. These cells contain a scramble RNA construct with Cas9 to ensure that 
any cellular changes seen in gRNA are not from the CRISPR/Cas9 process (work by 
Amy Stainthorpe, University of Leeds). In addition to the two HEK293 cell lines, 
HeLa cells were used as a more relevant to disease cell line. All three cell lines were 
co-transfected with either RFP/FGFR2, GFP/LASP1 or LASP1/FGFR2. It has also 
been established that the interaction between the FGFR2 C-terminal tail and LASP1 
happens irrespective of receptor activation so cells were not starved before any of 
the further analysis. Changes in key components of the cell cycle were analysed by 
western blot (Figure 4.6 a). For both gRNA and scr no apparent changes could be 
detected in expression of Cyclin B1 and E1 when FGFR2 and LASP1 were 
expressed on their own compared to co-expression, suggesting that the 
FGFR2/LASP1 interaction has no impact on these particular components of the cell 
cycle machinery. Cyclin B1 expression increases when the cells go from the G2-
Phase to Mitosis. Cyclin E1 expression begins at the end of the G1-Phase and 
carries on into S-Phase. In HeLa cells, Cyclin B1 seems to decrease with LASP1 
expression, while Cyclin E1 goes up, as quantified by ImageJ (Figure 4.6 b-c). This 
suggests that LASP1 could potentially affect the cell cycle and drive the cells into S-
Phase, but this is independent on the interaction with FGFR2. Cyclin D1 is required 
for the progression into G1-Phase and it is degraded in S-Phase. No Cyclin D1 was 
detected for any of the cells. Further western blot analysis shows the expected 
difference in GRB2 expression for gRNA compared to scr and HeLa cells. As these 
cells are grown under serum containing conditions FGFR2 is activated. FRS2 can 
then bind to a phosphorylated tyrosine on the receptor, SOS and GRB2 are recruited 
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to form a complex which can activate MAPK pathway. In gRNA cells no GRB2 
expression is detected and consequently phosphorylated ERK (pERK, p42/44) as a 
readout of activation of the MAPK pathway is not detected in gRNA cells. 
Interestingly in scr cells co-transfected with FGFR2 and LASP1 pERK was higher 
compared to FGFR2 or LASP1 on their own, as quantified by ImageJ (Figure 4.6 d).
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Figure 4-6 Western blot analysis of protein changes under LASP1 and 
FGFR2 overexpression 
a) Western blot analysis was performed to establish expression in the three 
cell lines used. HeLa, HEK 293 gRNA and HEK 293 Scr was transfected 
with RFP and FGFR2, GFP and LASP1 and finally LASP1 and FGFR2. 
Expression of Cyclins B1, E1 and D1, GRB2 and pERK was evaluated. 
GAPDH was used as loading control. b) Quantification of Cyclin B1 
expression in HeLa. c) Quantification of Cyclin E1 in HeLa. d) Quantification 
of pErk in scr. 
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To assess cells survival and proliferative capacity a number of techniques can be 
used. Commonly used are colony formation assay and soft agar assay. Soft agar 
assays are anchorage independent. A low number of cells were seeded into agar 
containing medium. When the agar was set the plates were left with feeding medium 
and growth was monitored until colonies were visible (Figure 4.7 a). Colonies were 
counted for each treatment and a graphic representation shows that in scr and HeLa 
cells anchorage dependent growth increases when LASP1 is transfected, and when 
FGFR2 is co-transfected with LASP1 growth further increases (Figure 4.7 b). For 
gRNA growth is increased when FGFR2 is transfected on its own. Co-transfection 
with LASP1 decreases growth compared to FGFR2 on its own. To look at 
anchorage-dependent growth, colony formation assay was performed. A low number 
of cells were seeded directly to plates and growth was monitored until colonies were 
visible. Colonies were then visualised using crystal violet solution (Figure 4.7 c), 
counted and graphically represented (Figure 4.7 d). gRNA cells show similar 
anchorage dependent and independent growth. FGFR2 promotes more growth than 
LASP1, and when LASP1 is co-transfected with FGFR2 growth decreases. Moderate 
growth differences are seen for transfected scr in the colony formation assay. 
Colonies formed by transfected HeLa cells shows similarities with the soft agar 
assay, LASP1 on its own increases growth and expression of both LASP1 and 
FGFR2 further increases growth.  
LASP1 is thought to have a structural role in cytoskeletal organisation and 
stabilisation of the actin network. LASP1 can interact with filamentous actin via the 
nebulin repeats, and are also found accumulated in focal adhesions (Schreiber et al., 
1998; Chew, 2002). Both filamentous actin and focal adhesions plays a central role 
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in cell migration, so it would be interesting to elucidate whether the interaction 
between FGFR2 and LASP1 has an impact on cell migration. gRNA and scr cells 
were transfected with RFP/FGFR2, GFP/LASP1 or LASP1/FGFR2. A scratch wound 
was generated and cells were imaged at 0h and 24h (Figure 4.8). For both gRNA 
and scr it appears that when LASP1 is transfected on its own cells migrate further 
compared to FGFR2 on its own. However when both FGFR2 and LASP1 are 
overexpressed together the cells migrate less compared to LASP1 on its own, and 
this is comparable to cell migration affected by FGFR2 on its own. 
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Figure 4-7. Growth assays for FGFR2 and LASP1 interaction 
a) Soft agar assay was used to determine anchorage independent growth of cells, this is an example 
of what to expect to see after 2-3 weeks of growth. b) Graphical representation of transfected cells 
growing in a soft agar plate. N=3 for each transfection. c) Colony formation assay was used to 
determine growth in an anchorage dependent way. Crystal violet was used to visualise colonies.        
d) Graphical representation of colonies counted for cells that were transfected and seeded for colony 
formation assay. N=3 for each transfection. 
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Figure 4-8 Migration assay for LASP1 and FGFR2 interaction. 
gRNA and scr cells were transfected with RFP/FGFR2, GFP/LASP1 or LASP1/FGFR2. At 100% 
confluency a scratch wound was produced and cells were imaged at 0h and 24h to track cell 
migration.  
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4.1.4 Discussion 
Several experiments have been performed to show that FGFR2 and LASP1 interact. 
GST-pull downs and PLA showed that this interaction is mediated by the C-terminal 
tail of FGFR2. Some evidence suggests that in cells it is the SH3 domain of LASP1 
that interacts with FGFR2, although in vitro assays using MST demonstrate lower 
dependence on the SH3 domain. Data from MST suggests that both wild type and 
ΔSH3 mutant interact with FGFR2 with similar affinities at ~40 µM and ~60 µM, 
suggesting that there is a different region of LASP1 that interacts with the C-terminal 
tail of FGFR2. It would be interesting to see whether the LASP1 ΔLIM mutant could 
increase affinity compared to wild type as in the GST-pull down more FGFR2 was 
pulled down with this mutant. Unfortunately, after purification the protein was not 
stable being suspended in MST buffer for long enough to carry out the experiment. 
Many proteins have been shown to interact with LASP1 in the cell (Orth et al., 2014). 
This includes filamentous actin which interacts with the nebulin repeats, and the 
chemokine receptor CXCR2 which interacts with the LASP1 LIM domain. Removing 
the SH3 domain could mean easier access for other binding partners of other 
domains in LASP1, and with a higher affinity compared to FGFR2. For example 
would removing the SH3 domain mean easier access to the filamentous actin 
network, and in this way affect cell motility? In a GST-pull down these interacting 
partners could preferably bind LASP1 ΔSH3 instead of FGFR2. Interestingly the 
LASP1/FGFR2 interaction occurs irrespectively of the cells being starved or serum 
stimulated.  
Further characterisation of the interaction focused on the C-terminal tail of FGFR2. 
Point mutations of prolines and deletion mutants of C58 were used in MST with 
labelled LASP1 to determine binding curves. Several of the point mutations 
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increased the affinity of the interaction. Proline has a distinctive structure compared 
to other amino acids and are often found in turns, a protein secondary structure. By 
mutating prolines to alanines in C58 the peptide might be found in a different 
secondary conformation that favours binding to LASP1. Consequently when prolines 
in other positions of the peptide are mutated the change in conformation can reduce 
affinity. In the case of P810A the KD could not be determined, although the graph 
forms a shape similar to sigmoidal, and it is possible that with optimisation a binding 
curve can be formed. Deleting the 6 final amino acids of the C58 peptide increased 
affinity. The length of the peptide could potentially have a role in the interaction, and 
a shorter peptide can in some cases decrease affinity. Deleting a range from 9-23 
amino acids in C58 reduces affinity and in some cases abolishes the peptides ability 
to interact. This does follow to some degree what was seen with the point mutations 
as P810 was deemed to be important for binding and deletion mutant Δ12, Δ15 and 
Δ23 does not include this particular proline. Some buffer optimisation could also be 
carried out to expand on what effect pH and buffer composition has on binding. 
HEPES was used in all the MST experiments, and the chemical structure of HEPES 
show some similarity to prolines, would this have an impact on the mutants 
interacting with LASP1. Conclusively this data supports that C58 interacts with 
LASP1, and P810 is important in this interaction. Using a mammalian plasmid 
containing FGFR2 with the P810A mutation could be used to further investigate the 
interaction in cells, and if the mutation is also important in a cellular environment.  
Further investigations were performed to look at what effect the interaction has in 
cells. MST data suggests that LASP1 binds FGFR2 in the same region as GRB2, so 
experiments were also undertaken in cells where the GRB2 gene had been removed 
by CRISPR/Cas9. A control cell line expressing a scramble guide RNA in 
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CRISPR/Cas9 was used to ensure that any effects seen were not as a result of the 
CRISPR/Cas9 methodology. Additionally HeLa cells were utilised as a cell line with 
relevance to cancer. While establishing the interaction is important, determining 
whether it has any physiological relevance in cells, especially cancerous cells as 
both LASP1 and FGFR2 are oncoproteins. As the interaction between FGFR2 and 
LASP1 has not been established in HeLa cells, caution must be taken concluding 
anything from cell cycle and growth results in HeLa cells. Different cyclins are 
expressed at various stages of the cell cycle and the analysis of expression of the 
different cyclins is a suitable method for determining cell cycle progression (K. A. 
Schafer, 1998). Certain treatments and proteins can trap the cells in a specific phase 
of the cell cycle. In HeLa cells Cyclin B1 expression was reduced when LASP1 was 
overexpressed while Cyclin E1 expression was increased, suggesting that 
overexpression of LASP1 potentially can keep HeLa cells in a G1/S-Phase. This is 
independent of FGFR2 expression. Further work needs to be carried out to elucidate 
what impact LASP1 and FGFR2 have on the cell cycle, such as knocking down 
LASP1 and/or FGFR2 expression. 
In both anchorage dependent and independent colony formation assays expression 
of LASP1 increased growth. FGFR2 co-expression with LASP1 seemed to have 
more impact on cell growth compared to LASP1 alone. One can only speculate 
whether this is linked to a possible FGFR2 interaction with LASP1 at this stage. In 
gRNA and scr no apparent difference in any of the cyclins were detected. More 
interestingly in the presence of GRB2 a difference in pERK was detected when 
LASP1 and FGFR2 were co-overexpressed. LASP1 has been shown to have a role 
in MAPK signalling before. miR-133a has been shown to target and suppress LASP1 
expression. miR-133a also inactivates MAPK pathway by dephosphorylation of ERK. 
93 
 
This suggest a potential role for LASP1 in the MAPK pathway where overexpression 
of LASP1 causes miR-133a to suppress LASP1 translation rather than MAPK 
pathway inactivation (Xu et al., 2014). So whether the increase in pERK is from 
overexpressing two proteins known to be involved in the MAPK pathway individually 
or if it is a result of an interaction is not clear at this point. Expression of LASP1 and 
FGFR2 either individually or together had different impacts on growth, and whether 
GRB2 is expressed or not. In gRNA cells LASP1 expression reduced growth in both 
anchorage dependent and independent assays. FGFR2 growth is also reduced 
when co-expressed with LASP1. In scr cells anchorage-independent growth 
increased with LASP1 expression and co-expression of LASP1 and FGFR2 further 
increased the growth. This effect could again originate from roles of FGFR2 and 
LASP1 that are independent of each other. Interestingly, no apparent difference was 
seen in anchorage-dependent growth. Taken together it suggests that when GRB2 is 
absent LASP1 suppress growth, but this is not necessarily dependent on an 
interaction with FGFR2 as growth increases when LASP1 and FGFR2 are both 
overexpressed. Scratch wound healing assays demonstrated that when LASP1 was 
expressed cells migrated further compared to when FGFR2 is overexpressed alone 
or with LASP1. This is independent of GRB2 expression. It is possible that the 
LASP1 interaction with FGFR2 C-terminal tail might be inhibitory of LASP1 impact on 
cell migration. Taken together there is evidence that LASP1 interacts in the C-
terminal tail of FGFR at an affinity of ~40 µM. Some data suggest that this interaction 
can potentially have an impact on growth and migration, but further work would need 
to be carried out in order to establish specifically what these events are.  
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Chapter 5: ErbB2 and SRC interact in starved conditions in a breast 
cancer cell line 
The “second tier” RTK regulation has been demonstrated with FGFR2. The 
possibility that this regulation can be found across RTKs remains to be answered. 
Demonstrating that other RTKs can interact with and be regulated by SH3 domains 
in proteins would add value to what would be a paradigm shift in RTK signalling 
biology. In this chapter the results demonstrates an interaction between ErbB2 and 
SRC, and some data indicates that this is through the SRC SH3 domain and ErbB2 
proline rich motif.  
The C-terminal tail of ErbB2 is rich in proline residues (Figure 5.1 a), and several of 
them in the typical canonical proline rich motif PXXP (underlined). Previous 
published reports demonstrated that a proline-rich motif from ErbB2 bound directly to 
the SH3 domain from the SRC family non-receptor kinase FYN (Bornet et al., 2014). 
In this chapter an investigation of the interaction of the proline-rich motif of this 
receptor with the proto oncogene SRC was carried out. A sequence alignment of the 
SH3 domains from FYN and SRC shows a 76% sequence homology (Figure 5.1 b). 
The residues marked in green for FYN SH3 were found to be important in the ErbB2 
proline-rich motif interaction from the Bornet paper, and the residues marked in 
orange for SRC SH3 domain are the ones that differ from the FYN residues. SRC 
kinases consist of an SH2, SH3 and a kinase domain (Figure 5.1 c). At the N-
terminal end there is a myristoylation site (Myr) allowing SRC to be associated with 
the cell membrane. There is a proline-rich motif in the linker region between the SH2 
domain and kinase domain which interacts with the SH3 domain when SRC is in its 
inactive form. Prior to this research a screen of SH3 domains from a broad range of 
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proteins was performed to determine whether any were ligands for a selected 
proline-rich sequence from ErbB2. A preliminary screen used to identify proteins with 
SH3 domains which interact with a peptide corresponding to the proline-rich 
sequence from ErbB2 has been carried out (Figure 5.1 d) (screen performed by Prof. 
M. Bedford (MD Anderson Cancer Centre), unpublished). A glass slide with 40 SH3 
domains from different proteins immobilized in discrete spots on its surface was 
incubated with a two peptides peptide containing proline-rich motifs from ErbB2 
fused to a green fluorescent protein tag. The cognate SH3 domain can be identified 
from the position of the spot. Several proteins containing SH3 domains directly 
interact with the ErbB2 peptide. These preliminary data shows that the proline-rich 
sequence from the ErbB2 interacts with several members of the SRC family of 
kinases including LYN, YES and FYN (Figure 5.1 d, circles). The intensity showed 
that they were part of the top hits for the ErbB2 proline-rich peptides in this particular 
screen (Chapter 4, Table 8). This screen further supports the previously reported 
interaction between the proline-rich motif on ErbB2 and FYN and suggests that 
investigation of interactions between the SH3 domains of other SRC family kinases 
could prevail.  Indeed alignment of the SH3 domain from FYN and SRC show 76% 
sequence identity (Figure 5.1 b). The preliminary screens and published data 
suggest that several of the Src family members interact with ErbB2 via the SH3 
domain, but does not provide evidence for an endogenous interaction. Additionally 
there is some evidence suggesting that the SRC family kinase SRC interacts with 
ErbB2 in breast cancer cell lines, but this interaction was not detected in the breast 
cancer cell line SkBr3. Preliminary results suggest a role for SRC family kinase SH3 
domains and proline-rich motifs from ErbB2. These are weak interactions and would 
not necessarily been picked up by previous studies looking at SRC interaction with 
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ErbB2. The following chapter investigates the interaction between ErbB2 and the 
SRC family kinase, SRC and whether it interacts endogenously in SkBr3 cells and if 
it is via the SH3 domain and proline-rich motif.  
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Figure 5-1 ErbB2 proline-rich motifs and Src/Fyn homology 
a) ErbB2 C-terminal tail contains 16% prolines (in red) and several proline-rich motifs (underlined). b) 
An amino acid alignment of the SH3 domain of FYN and SRC highlights the similarity. The residues 
important for FYN SH3 interaction with ErbB2 proline-rich peptide is highlighted in green and in 
orange is the residues that are different in the SH3 domain of SRC. c) SRC family kinases are 
structurally similar having an SH2 and SH3 domain, a kinase domain and a myristoylation site (Myr) in 
the unique region (U). d) A high throughput assay using proteins containing SH3 domains arrayed on 
a glass plate highlights how various SRC family kinases LYN, FYN and YES1 can interact with ErbB2 
peptides demonstrated by fluorescence.  
98 
 
5.1.1 SRC and ErbB2 interact in the breast cancer cell line SkBr3 under 
starved conditions 
To investigate whether SRC and ErbB2 interact endogenously, the cancer cell line 
SkBr3 was used. SkBr3 is a breast cancer cell line that overexpresses ErbB2. Initial 
work was carried out looking at ErbB2 expression in SkBr3 cells by 
immunofluorescence (Figure 5.2 a). Cells were fixed on a glass slide and incubated 
with an antibody specific for ErbB2, and then a secondary antibody which was 
conjugated with a fluorescent tag for visualisation by confocal microscopy. In cells 
that were starved for 12 hours ErbB2 are found in clusters at what appeared to be 
the plasma membrane. Despite ErbB2 being an orphan receptor, EGF enhances the 
accumulation of ErbB2 on the membrane of SkBr3 cells. ErbB2 is known to form 
heterodimers with EGFR (see Introduction Chapter). EGF is a known ligand for 
EGFR and on binding is known to promote a conformational change to the 
extracellular region of the receptor which is recognized by the ligand-free ErbB2. 
Stimulation of SkBr3 cells with EGF resulted in an increase in population of 
heterodimers consisting of EGFR and ErbB2. The reduction in the fluorescent signal 
suggests that this complex is subsequently internalised and degraded. In further 
experiments EGF was used along with serum stimulation to differentiate SRC and 
ErbB2 interaction under starved and stimulated conditions. To investigate whether 
SRC and ErbB2 interact endogenously, a co-immunoprecipitation using cell lysate 
from SkBr3 cells and antibodies against SRC was used. SRC co-precipitated with 
ErbB2 under starved and serum stimulated conditions, but not when cells are 
stimulated with EGF (Figure 5.2 b). However, the experiment revealed that ErbB2 is 
phosphorylated in starved conditions. As a result our data cannot confirm the SH3 
domain-proline-rich motif because an interaction between the SH2 of SRC and a 
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pTyr on the receptor cannot be ruled out. It is interesting to speculate at this point 
whether recruitment of SRC via its SH3 domain could activate the SRC kinase 
domain through a conformational change similar to that experienced on binding of 
the SH2 domain (see Introduction Chapter). This could then be responsible for 
phosphorylation of pTyr on ErbB2. To further validate the interaction a PLA was 
performed in starved and stimulated SkBr3 cells. ErbB2 and SRC are shown to be in 
close proximity to each other under starved conditions, serum stimulation and EGF 
stimulation (Figure 5.3 a), suggesting an interaction between SRC and ErbB2. PLA 
signal was quantified and compared to control PLA images where no primary 
antibodies against SRC and ErbB2 were used (Figure 5.3 b).  
Upon stimulation there is a possibility that the signal comes from a heterodimer 
between EGFR and ErbB2 as EGFR is a known interacting partner of SRC 
(McCarley et al., 2006). Additionally SRC can interact with pTyr on either receptor 
via the SH2 domain. To address this PLA was next performed in MCF7 cells that 
lack endogenous EGFR expression (Figure 5.4 a) Expression of ErbB2 was also 
lower compared to SkBr3 cells and hence the appearance of pTyr is reduced. PLA 
signal is maintained in both starved and EGF-stimulated conditions, suggesting that 
the interaction is not from a EGFR/ErbB2 heterocomplex or SH2/pTyr interaction 
(Figure 5.4 b). Together these data suggest an  interaction between endogenously 
expressed SRC and ErbB2 in both the breast cancer cell lines SkBr3 and MCF7.  
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Figure 5-2 ErbB2 and SRC interact endogenously in breast cancer cell line SkBr3.  
a) ErbB2 is internalised in SkBr3 cells when treated with EGF shown here by 
immunofluorescence. Using antibody specific for ErbB2 (1:100) shows that under starved 
conditions the receptor remains at the cell membrane while upon stimulation it is internalised. DAPI was used to visualise the cell nucleus. Scale bar 15 µm. 
b) Co-immunoprecipitation was performed using antibody specific for SRC, and SRC is able to pull down ErbB2 in starved and serum stimulated conditions in 
SkBr3 cells, but not in EGF stimulated cells. Total protein concentration of cell lysate was determined to be 1 mg. SkBr3 cells were starved for 24 hour before 
stimulation. EGF stimulation of starved cells were done at 100 ng/mL for 5 minutes, and serum (FBS) stimulation was done for 15 minutes. 
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Figure 5-3 ErbB2 and SRC 
interact endogenously in 
breast cancer cell line SkBr3 
a) Proximity ligation assay 
shows that ErbB2 and SRC 
interact endogenously in 
SkBr3 cells under starved 
conditions, EGF stimulation 
and serum stimulation. There 
is no signal when no primary 
antibodies for SRC and ErbB2 
was used. Scale bar 15 µm. b) 
To determine the difference in PLA signal between starved, serum stimulated 
and EGF stimulated cells compared to signal from no primary antibody ImageJ 
was used to quantify the signal. Images with similar cell average per image was 
selected and PLA signal was quantified by using analyse particles. A minimum 
of 5 images per condition was used. All conditions shows a significant difference 
compared to the no primary antibody sample. Mean values and standard errors 
are represented. Using standard t-test the statistically significant differences are 
indicated by * (P Յ 0.05), ** ( P Յ 0.01) or *** ( P Յ 0.001). Scale bar 15 µm. 
DAPI was used for nucleus visualisation. SkBr3 cells were starved for 24 hour 
before stimulation. EGF stimulation of starved cells were done at 100 ng/mL for 5 minutes, and serum (FBS) stimulation was done for 15 minutes.
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Figure 5-4 ErbB2 and SRC interact in absence of EGFR  
a) Western blot comparing EGFR expression between MCF7 and SkBr3 cells, ErbB2 expression and 
tyrosine phosphorylation of Y1221/1222 in ErbB2. b) PLA signal between ErbB2 and SRC is 
maintained under starved and EGF stimulated conditions in MCF7. Scale bar 15 µm. MCF7 cells were 
starved for 24 hour before stimulation. EGF stimulation of starved cells were done at 100 ng/mL for 5 
minutes, and serum (FBS) stimulation was done for 15 minutes. DAPI was used to visualise cells. 
  
103 
 
5.1.2 ErbB2 interacts with the SH3 domain of SRC and FYN  
The SH3 domains of SRC and FYN were expressed and purified from E. coli and 
used in a pull down with SkBr3 cell lysate. Both SH3 domains were able to pull down 
ErbB2 in serum stimulated conditions (Figure 5.5). These results confirm the 
interaction between FYN SH3 domain and ErbB2 from Bornet et al, but additionally 
demonstrates the interaction in a cellular lysate context (Bornet et al., 2014). SRC 
SH3 was also able to pull down ErbB2 from the lysates of serum starved cells. 
Stimulation of the receptor should presumably not have any impact on SH3 
interacting with ErbB2, although these results demonstrates that the SRC SH3 
domain pulls down 5-fold the amount of ErbB2 from lysates of stimulated cells 
compared to starved cells. This could potentially come from a complex formation 
around the SRC SH3 domain. In some cases phosphorylated tyrosines can 
strengthen an interaction between proline-rich motifs and SH3 domains. Based on 
the paper suggesting an interaction between FYN SH3 domain and ErbB2 peptide 
several tyrosines are involved in the interaction interface (Figure 5.1 b, (Bornet et al., 
2014)). Additionally there is evidence that some RTKs C-terminal tail can bind itself 
in the kinase-domain when it is inactive (Lemmon and Schlessinger, 2010). If this is 
the case for ErbB2 activating the receptor might mean better access for SRC SH3 
domain to interact when the cells are serum stimulated. 
In the cell SRC switches between open and closed conformations (Figure 5.6 a). 
Phosphorylation of Y530 allows the tyrosine to form an intramolecular interaction 
with the SH2 domain and the constrict the kinase is in its inactive form. 
Dephosphorylation of Y530 causes a conformational change to an active state. This 
leads to a conformational change which opens up the structure making the kinase 
domain accessible resulting in auto-phosphorylation of Y416 in the active site, which 
104 
 
in turn increases SRC kinase activity (Xu, Wenqing, 1997; Xu et al., 1999). When 
SRC is in its open conformation, all of the domains – including the SH3 domain - are 
more easily accessible. Using a constitutively active and kinase dead form of the 
kinase SRC mutants were used to determine whether the specific conformation of 
SRC plays a role in mediating the interaction with ErbB2. Substitution of the tyrosine 
in the 530 position by phenylalanine prevents phosphorylation of the tyrosine making 
it permanently constitutively active SRC (Y530F). In addition the lysine residue in the 
298 position was substituted by a methionine (K298M). Lysines are positively 
charged and essential for turnover of ATP by the kinase. Therefore, substitution with 
the neutral methionine renders the protein kinase dead. HEK 293T cells were 
transfected with ErbB2 and either FLAG epitope tagged wild type SRC, constitutively 
active SRC mutant (Y530F) or kinase-dead SRC (298M) (Figure 5.6 b). A FLAG-pull 
down using anti-FLAG beads was performed. In serum starved cells the constitutive 
active mutant, which should be conformationally open was able to pull down 3-fold 
the amount of ErbB2 relative to wild type and kinase dead SRC (Figure 5.6 c). This 
could potentially suggest that the receptor has easier access to binding with an open 
conformation SRC. In serum stimulated cells the kinase dead SRC mutant 
precipitated 2-fold less ErbB2 compared to either the wild type or constitutively active 
mutant, suggesting that phosphorylated Y416 could potentially have an impact on 
the interaction. It has been shown that auto-phosphorylation at Y416 reduces the 
ability of SRC to bind pTyr via its SH2 domain (Sun et al., 2001).  
Overexpressing ErbB2 in cells causes receptor activation as evidenced by the pTyr 
and pErk blots in both starved and stimulated cells (Harari and Yarden, 2000). To 
overcome the problem of artificially overexpressing ErbB2 and subsequently 
activating the receptor, SkBr3 cells were used which endogenously express a lower 
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level of ErbB2. In these cells less pTyr was seen in the starved cells compared to 
stimulated cells (Figure 5.6 c). In starved SkBr3 cells wild type SRC was able to pull 
down 2-fold more the amount of ErbbB2 compared to the mutants (Figure 5.6 e). In 
stimulated cells the kinase dead mutant was able to pull down 2-fold more ErbB2 
relative to the wild type or Y530F mutant. Taken together the results from the flag 
pull down are inconclusive regarding the importance of SRC conformation and 
interaction with ErbB2. The different cell types might play a role, SkBr3 cells express 
more endogenous SRC compared to HEK293T which can compete for binding (Sam 
et al., 2007).  In all the pull downs ErbB2 was pulled down to various levels further 
supporting an interaction between SRC and ErbB2. The phosphorylated state of 
ErbB2 throughout means that a pTyr/SH2 domain interaction cannot be ruled out in 
these experiments. Mutating the SH2 domain to prevent pTyr interaction would help 
elucidate whether the interaction is SH2 dependent. ErbB2 pTyr was still detected in 
cells that were transfected with the kinase dead SRC, suggesting that SRC is not 
responsible for phosphorylation of ErbB2.   
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Figure 5-5 The SH3 domain of SRC is interacting with ErbB2.  
A GST-pull down experiment using GST tagged SH3 domains of SRC and FYN can pull down ErbB2 
in serum stimulated conditions. SRC SH3 domain can also pull down ErbB2 under starved conditions. 
SkBr3 cell lysate was used at 1 mg/ml.
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Figure 5-6 SRC interaction with ErbB2 could be dependent on SRC 
conformation.  
a) SRC family kinases are found both in open and active conformation, and a closed inactive conformation in the cell. The conformation is determined by a 
deactivating phosphorylation of Tyr530. Auto-phosphorylation of Tyr416 renders a hyperactive enzyme. b) HEK293T cells were transfected with ErbB2 and 
either wild type SRC, SRC Y530F or SRC K298M. Cells were then serum-starved and then either taken forward to a FLAG-pull down or serum stimulated 
before used in a FLAG-pull down  (cont) 
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c) SkBr3 cell were transfected with either wild type SRC, 
Y530F or K298M and serum-starved or serum-
stimulated lysates was used in a FLAG-pull down. d) 
Relative intensity of ErbB2 being pulled down by wild 
type and mutant SRC in HEK293T. In cells that was 
starved the Y530F mutant was able to pull down 4-fold 
the amount of ErbB2 relative to wild type and K298M. In 
cells that had been stimulated with FBS both wild type 
and Y530F was able to pull down two-fold ErbB2 
compared to K298M e) Relative intensity of ErbB2 being 
pulled down by wild type and mutant SRC in SkBr3. In 
starved SkBr3 wild type SRC was able to pull down two-
fold more ErbB2 in a flag pull down than the mutants. In 
FBS stimulated cells the kinase dead mutant K298M was 
able to pull down 1.5-fold more ErbB2 relative to wild 
type SRC, and 2-fold the amount of ErbB2 compared to 
Y530F
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5.1.3 A proline-rich motif in ErbB2 C-terminal tail interacts SRC 
To further investigate the interaction between ErbB2 and SRC, cells that express 
lower levels of ErbB2 were used. HeLa cells express 27-fold lower levels of ErbB2 
compared to SkBr3 cells and, as expected, a lower level of signal was detected in 
the PLA assay (Figure 5.7 a and b). ImageJ was used to quantify PLA signals in both 
SkBr3 and HeLa cells and the difference between them are shown. These data 
reveal a statistical difference between the different cell types in both starved and 
EGF stimulated cells (Figure 5.7 c). These results demonstrated that HeLa cells 
were useful for further studies of the interaction by transfecting in the ErbB2 
receptor. To assess the interaction of the receptor with SRC, the proline-rich motif 
which has been shown to bind SRC family kinases was corrupted by three 
mutations, i.e. arginine in the 1146 position, proline 1149 and proline 1152 were 
mutated to alanine (R1146A/P1149A/P1152A). HeLa cells were then transfected 
with either GFP-tagged wild type ErbB2 or the triple mutant. PLA signal was 
observed in HeLa cells transfected with wild type ErbB2 in both starved and 
stimulated cells (Figure 5.7 d and e). Interestingly, in cells transfected with the triple 
mutant ErbB2 plasmid the PLA signal was not rescued in starved cells. Stimulation 
of the cells however resulted in rescue of the signal. This further supports the idea 
that SRC and ErbB2 interact under both starved and stimulated conditions, but 
strongly suggest that this interaction occurs through distinct mechanisms. In EGF 
stimulated conditions heterocomplex formation between EGFR/ErbB2 could lead to a 
SRC interaction with pTyr residues in the receptors. Importantly, these results also 
support that in starved conditions this interaction might instead occur via the proline-
rich motif found in the C-terminal tail of ErbB2.
110 
 
 
Figure 5-7 The C-terminal tail of ErbB2 is interacting with SRC.  
a) Western blot and relative intensity graph shows that HeLa cells express 27-fold lower levels of 
ErbB2 compared SkBr3 b) PLA signal is detected for SRC and ErbB2 interaction in both starved and 
stimulated conditions in HeLa c) To look at the difference in PLA signal between HeLa and SkBr3 
cells ImageJ was used to quantify the signal. Images with similar cell average per image was selected 
and PLA signal was quantified by using analyse particles. A minimum of 8 images per condition was 
used. In both starved and EGF stimulated cells SkBr3 has a significant higher signal compared to 
HeLa (continues next page)  
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d-e) HeLa cells were transfected with ErbB2 and mutant ErbB2 (R1146A/P1149A/P1152A) where a 
proline-rich motif in the C-terminal tail was mutated. With wild type ErbB2 PLA signal was rescued in 
both starved and EGF stimulated cells. With mutant ErbB2 signal was rescued only in EGF stimulated 
cells and not starved cells. Scale bar 15 µm. DAPI was used to visualise the nucleus. Mean values 
and standard errors are represented. Using standard t-test the statistically significant differences are 
indicated by * (P Յ 0.05) , ** ( P Յ 0.01) or *** ( P Յ 0.001).
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5.1.4 Binding affinities between ErbB2 peptides and SRC SH3 
domain suggest a weak interaction 
ErbB2 has six canonical PXXP proline-rich motifs in the cytoplasmic region. 
To explore their potential contribution to the interaction with SRC, six 
peptides were created and used for binding measurements by MST 
measurements to determine binding affinity between the proline-rich motifs 
and the SH3 domain of SRC. Peptide 1 is based on the same amino acid 
sequence as previously reported to interact with FYN SH3 domain (Bornet et 
al., 2014). The binding affinity (expressed at the dissociation constant, KD) 
between peptide 1 and FYN SH3 domain was found to be 1.4 mM in the 
MST experiments. This was similar to the KD reported by Bornet et al (Table 
12 and Figure 5.8 a) which was 0.9 mM. The affinity of the interaction 
between SRC SH3 domain and the same peptide was slightly weaker (KD 
=7.1 mM)( Figure 5.8 b). The same order of affinity was recorded for several 
of the other peptides (Figure 5.8 c-g and Table 12). Peptide 5 shows a non-
traditional binding curve, but it could be that two events are happening here. 
The first event where the peptide concentration is between 0.1-100 µM 
(potential binding affinity at 10 µM) and the next event happens when the 
peptide concentration reaches 1 mM. Further exploration of this peptide 
should be done by for example using a lower peptide concentration to obtain 
the possible binding affinity of the first event. The obtained affinities for 
peptide 1, 2, 4 and 8 are extremely low and do not represent the affinities 
that would be expected for the full length intact proteins in the cell. 
Interactions between SH3 domains and proline-rich motifs are normally quite 
weak (Ladbury and Arold, 2000). For example the SH3 domain from FYN 
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could interact with peptides containing proline-rich motifs from known 
interacting proteins with a KD ranging from 16-2002 µM. The SH3 domain 
from GRB2 was shown to interact with two peptides based on proline-rich 
motifs from SOS at 5 and 21 µM. A control peptide was used based on a 
reported interaction between NS5A and SRC family kinase SH3 domains, 
and a KD was measured to 258 µM, a magnitude lower than for the ErbB2 
peptides (Figure 5.8 h) (Macdonald et al., 2005).  
Table 12 Peptides containing proline-rich motifs from ErbB2 C-terminal tail and NS5A. 
MST was used to determine binding affinity between the peptides and SH3 
domains from SRC and FYN 
Peptide Sequence SH3 domain Binding affinity  
ErbB2 peptide 1* NQPDVRPQPPSPREGPL SRC 7.1 mM 
ErbB2 peptide 1 NQPDVRPQPPSPREGPL FYN 1.4 mM 
ErbB2 peptide 2 LEKGERLPQPPICTID SRC 6.4 mM 
ErbB2 peptide 3 VIQNEDLGPASPLDSTFYR SRC - 
ErbB2 peptide 4 GLEPSEEEAPRSPLAPSEG SRC 3.7 mM 
ErbB2 peptide 5 LQRYSEDPTVPLPSETDGY SRC - 
ErbB2 peptide 6 GGAAPQPHPPPAFSPAFD SRC 6.7 mM 
NS5A peptide PP2.1/PP2.2† GSPLPPAKAPPIPPPRRKRTV SRC 258 µM 
 
* Sequence is based on data from Bornet et al., 2014 
† Sequence is based on data Macdonald et al., 2004
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Figure 5-8 MST was used to determine binding affinities between peptides based 
on sequences in the C-terminal tail of ErbB2 containing proline-rich motifs and the 
SH3 domains of either SRC or FYN.  
Peptides, the amino acid sequence and binding affinity obtained from MST 
measurements are summarised in Table 122. a) FYN SH3 domain was labelled and a 
peptide (ErbB2 peptide 1) containing a proline-rich motif previously reported to interact 
with FYN SH3 domain (Bornet et al., 2014) was used in a dilution series to determine 
binding affinity between FYN SH3 and peptide 1. The affinity was determined to be 1.4 
mM. b) ErbB2 peptide 1 was added in a dilution series to labelled SRC SH3 domain and 
MST measurements was used to determine the binding affinity, 7.1 mM. c-g) Labelled 
SRC SH3 was used in MST measurements with peptides based on proline-rich motifs in 
the C-terminal tail of ErbB2, peptide 2-6. Binding affinities was obtained for some of the 
peptides. h) Additionally a peptide based on a previously reported binding partner of SRC 
kinases SH3 domain, NS5A was used (Macdonald et al., 2004). A binding affinity of 258 
µM was measured with labelled SRC SH3 and the control peptide 
All experiments was performed in HEPES buffer at pH 7.5 
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5.1.5 Discussion 
There is previously reported evidence of a direct interaction between SRC 
and ErbB2. This has been shown in vitro to be through the SH2 domain of 
SRC and pTyr residues of ErbB2 (Muthuswamy et al., 1994), or through a 
combination of SH2/SH3 domains where SH2/SH3 complex was able to pull 
down more ErbB2 than the SH2 domain on its own (Luttrellt et al., 1994). 
The data in this chapter demonstrate that SRC and ErbB2 interact 
endogenously, and that this interaction can also be measured when the cells 
are starved. One of the key questions is whether this interaction is through 
the SH2 domain and pTyr of ErbB2, since phosphorylation of the receptor 
can prevail in starved cells as observed in SkBr3. Using a different cell line, 
MCF7 in which phosphorylation of tyrosine residues on ErbB2 was negligible 
the SRC/ErbB2 interaction was still visible suggesting that this interaction is 
not mediated by the SRC SH2 and ErbB2 pTyr. The PLA study using MCF7 
cells also shows that the interaction is unlikely to be between a pTyr on 
ErbB2 which has been phosphorylated in the context of a heterodimer with 
EGFR, because MCF7 cells do not express EGFR. The PLA signal is 
observed for the interaction of SRC and ErbB2 in these cells. Combined with 
our ex vivo evidence that suggests that the association with SRC and ErbB2 
is through the SRC SH3 domain and a proline-rich motif in the C-terminal tail 
of ErbB2 in vitro assays using MST show direct binding. The KD values for 
interactions between peptides containing proline-rich motifs derived from the 
C-terminus of ErbB2 and the SRC SH3 domain suggest that the binding 
affinity is in the mM range. This provides evidence of an interaction, although 
it would be interesting whether using full length proteins could yield an 
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increased affinity. It is also possible that the interaction with the receptor 
could require a combination of the SH2 and SH3 domains of SRC interacting 
with pTyr and a proline-rich motif. Another example of a SRC interaction that 
requires both the SH2 and SH3 domains is with the SRC substrate Sam68 
(Src-associated in mitosis). A higher affinity interaction is obtained when 
both domains are involved (Taylor and Shalloway, 1994; Fumagalli et al., 
1994). An association of ErbB2 with both SH2 and SH3 domains of SRC 
could potentially stabilise the open conformation of SRC and allow a 
prolonged SRC activity (Figure 5.9). The flag pull down in starved HEK293T 
supports this observation as the Y530F mutant pulled down more ErbB2. 
SRC conformation has previously been shown to be important when SRC 
interacts with ErbB2 (Marcotte et al., 2009). An open conformation of SRC 
can interact with the kinase domain of ErbB2 and this interaction is not 
dependent on SH2 or SH3 domains, and only the kinase domain of SRC is 
required for interaction but independently of kinase activity. Both SH2/pTyr 
and SH3/PXXP interactions are transient interactions as the cell needs to be 
able to switch on and off signalling in a quick manner and a prolonged 
interaction can be achieved by having both SH2 and SH3 domains interact 
with the receptor. Whether a prolonged interaction can have any impact on 
SRC and ErbB2 activity and downstream signalling remains to be 
elucidated. 
Evidence presented here suggest an interaction between SRC and ErbB2 in 
breast cancer cell line SkBr3, most importantly when the cells are starved. 
Some evidence suggest that this is partially or fully through the SH3 domain. 
This further demonstrates that there is interactions happening between 
RTKs C-terminal tail and cytoplasmic SH3 domains, and could potentially 
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have a massive impact on how RTK signalling is regulated. More intriguingly 
this is the first demonstration of these interactions in a different RTK, and not 
just FGFR2.    
 
Figure 5-9 Proposed model for SRC and ErbB2 interaction. Both SH2 and SH3 can 
interact with the receptor, either with pTyr or a PXXP motif on the C-terminal tail 
of ErbB2. 
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Chapter 6: Discussion 
The discovery of a “second tier” RTK regulation should lead to a paradigm 
shift in cell signalling, and there might be a whole network of signalling that 
is waiting to be uncovered. Data presented here further adds to this 
previously under-investigated field. 
PLCγ1 has been shown to interact with FGFR2, resulting in PLCγ1 pathway 
activation (Timsah et al., 2014; Timsah et al., 2015). The interaction is 
mediated by SH3 domain and proline-rich motifs. RTKs contain one or 
several proline-rich motifs in the C-terminal tail and SH3 domains are 
abundant in the cell. SH3 interactions with proline-rich motifs are considered 
weak interactions in the cell and for this reason difficult to demonstrate. 
Therefore it is interesting to question the potential of a new and possible 
“second tier” of signalling from RTKs, which have largely remained 
undiscovered in the complexity that is cell signalling.  
Several approaches were used to identify new interactions between SH3 
domains and proline-rich motifs in the C-terminal tail of a range of RTKs. 
Peptides containing proline-rich motifs from 5 RTKs were used in a high-
throughput MS screen. The results yielded a substantial number of proteins. 
After a rigorous comparison system using a control peptide to reveal specific 
hits, the list was narrowed down. Comparing the number of unique peptides 
from the RTK peptides to the control peptide demonstrated that most of the 
remaining hits were largely non-specific and the high scoring proteins were 
contaminants such as keratin. Keratin is not expressed in HEK293T which 
was used as the default cell line to test the MS approach, suggesting that 
any keratin found must be from the handling of samples before MS. 
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Altogether the results from the MS suggest that further optimisation would 
have to be carried out such as optimising the peptide lengths to ensure 
binding, buffer conditions and a way to remove human contaminants. Using 
MS is not very cost-effective and it would therefore be useful to look at other 
approaches rather than optimising the conditions. BioID would be a useful 
approach to explore. Plasmids containing the peptides with proline-rich 
motifs together with the gene for biotin ligase can be transfected into the cell 
line of choice, and in this way will ensure that proteins in close proximity to 
the peptide will be biotinylated and can be pulled out and sent for MS. This 
avoids the intermediate and possible weak interaction between the peptide 
and the protein of interest, and instead directly biotinylates the protein of 
interest, resulting in a stronger interaction that can be pulled out by 
streptavidin. Although none of the proteins contained an SH3 domain, some 
proteins that were discovered in the screen could be of interest for further 
characterisation, although not within the scope of this project.  
Further work was carried out focusing on the LASP1 SH3 domain using a 
dot blot with the C-terminal tails of several RTKs. This approach yielded 
several hits, and some were further demonstrated in cells, although none of 
the characterised interactions were SH3 domain specific. Other RTKs can 
be taken further to characterise the LASP1 interaction and demonstrate a 
specific SH3 domain interaction. Unfortunately due to time constraints it was 
not carried out. Since some of the hits in the dot blot also occur in cells 
suggests that this method could also be applied to other proteins with SH3 
domains as well. Compared to MS-based analysis, the dot blot is more 
constrained as a method to detect novel interactions. The proteins that are 
used must be expressed and purified and it is currently constrained to one 
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protein. Further approaches in making a library of SH3 domains from several 
proteins could be carried out to create a high throughput screen. This could 
potentially be a better method of discovering interactions between SH3 
domains and proline-rich motifs. The SH3 domain-proline-rich interactions 
are inherently low affinity and there is the potential that the use of small 
peptides and cell lysate, in a MS-based analysis might not be capable of 
identifying the proteins. Both methods requires optimisation and using the 
dot blot could potentially serve as a more cost-effective path. Regardless of 
method, interactions should be further characterised. In addition the 
interactions should be demonstrated to occur in the cell as a proof of 
principle.  
LASP1 was shown to interact with both RTKs ALK and ErbB2. These data 
further support the importance of RTK C-terminal tails, despite the lack of a 
SH3 domain specific binding to the receptors. The genes encoding LASP1 
and ErbB2 are found in close proximity on the chromosome and have been 
demonstrated to be co-overexpressed in breast cancers. Results presented 
here suggest a direct role for LASP1 and ErbB2, and they were shown to 
interact endogenously in the breast cancer cell line SkBr3. LASP1 does not 
contain any SH2 domains to bind pTyr in ErbB2 C-terminal tail. The direct 
interaction between the ErbB2 C-terminal tail and LASP1 suggest therefore 
another mechanism for protein-protein interactions in the RTK C-terminal 
tail. Further work would have to be carried out to demonstrate the 
physiological relevance of this interaction. 
A preliminary method from Prof. Bedford’s group at the MD Anderson 
Cancer Center, TX, USA showed that LASP1 SH3 could also interact with 
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FGFR2. Some evidence of this interaction was recapitulated with the dot 
blot, but this approach suggested that it is a low affinity interaction, i.e. the 
intensity of the dot was low, but there was a 3-fold difference in binding 
FGFR2 between wild type LASP1 and the mutant LASP1 lacking the SH3 
domain. Further work with FGFR2 and LASP1 demonstrated that the 
interaction can occur in cells, and that it involves the C-terminal tail of 
FGFR2. This is consistent with the dot blot analysis which is based on an 
immobilised C-terminal tail of FGFR2. Binding affinities were obtained and 
LASP1 ΔSH3 was also able to bind the FGFR2 C-terminal tail with slightly 
lower affinity compared to wild type LASP1, suggesting that the SH3 domain 
could potentially be important in stabilising the interaction but is not critical. 
Conclusively LASP1 interacts with FGFR2 but not via the SH3 domain. 
Crystallising either full length LASP or the SH3 on its own with the C58 
peptide could further elucidate how C58 interacts with LASP1, and how 
important the SH3 domain is for this interaction. Further binding studies, 
based on site-specific mutations, suggested that P810 is important for this 
interaction. Because the SH3 domain was shown to only strengthen the 
interaction rather than being essential, it was interesting to see that prolines 
are still important for the interaction. Prolines have unique roles in protein 
structure and folding, and can be viewed as a structural disruptor of proteins. 
Removing the prolines can therefore have a detrimental effect on the overall 
structure of the C58 peptide and result in no binding with LASP1.  
The physiological effect of the LASP1 interaction with the FGFR2 C-terminal 
tail suggests that it can affect cell growth and migration. In cells that are 
depleted for GRB2, cell growth is higher when FGFR2 is overexpressed on 
its own. This is potentially a result of FGFR2 interacting with PLCγ1, with 
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LASP1 and PLCγ1 competing for binding. When LASP1 and FGFR2 are co-
overexpressed cell growth decreased. The KD determined for FGFR2/LASP1 
and FGFR2/PLCγ1 are both ~40 µM. In the GRB2-depleted cells, LASP1 
and PLCγ1 can compete for binding to the C-terminal tail of FGFR2 and 
LASP1. In this way LASP1 could inhibit PLCγ1 activation. Further work 
needs to be carried out, such as MST competition studies to elucidate 
whether LASP1 and PLCγ1 actually compete for binding. For the growth and 
migration assays the cells were not starved but grown in serum-containing 
medium. It is therefore also a possibility that other pathways might be 
activated by phosphorylated tyrosines. This could also be the reason why 
the effects of overexpression in either scr or HeLa cells are different to the 
GRB2-depleted cells. Both FGFR2 and LASP1 can contribute to cell growth 
on their own, through other mechanisms such as FRS2/GRB2 activation. 
The increased growth when LASP1 and FGFR2 are co-overexpressed could 
be the result of individual effects. The most intriguing result is the effect that 
FGFR2/LASP1 has on cell migration. LASP1 is known to interact with the 
cytoskeleton and is involved in cell migration. Co-overexpressing LASP1 
with FGFR2 decrease of migration, suggesting an inhibitory role for FGFR2 
on LASP1-mediated cell migration. These initial observations of a 
physiological effect from a LASP1 and FGFR2 interaction on both growth 
and migration serves as an interesting starting point.  
The preliminary screen from Prof. Bedford’s group also identified a number 
of SRC family kinase members with the potential to interact with ErbB2. In 
addition it has been demonstrated that the FYN SH3 domain can specifically 
interact with a proline-rich motif in the ErbB2 C-terminal tail (Bornet et al., 
2014). These preliminary results suggest that several SRC kinases are able 
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to interact but this has not been shown in cells. The members of the SRC 
family are homologues, suggesting that an interaction between SRC and 
ErbB2 is also possible. Both SRC and ErbB2 are oncogenes that are 
upregulated in breast cancers (Sheffield, 1998). Although an interaction 
between SRC and ErbB2 has been demonstrated in breast cancer cell lines, 
this is driven through interaction with the SRC SH2 domain and 
phosphorylated tyrosine of ErbB2. However, this interaction was not been 
demonstrated in the breast cancer cell line SkBr3, but in the UACC-812, 
MDA-MB-361 and MDA-MB-453 cell lines (Muthuswamy and Muller, 1995; 
Belsches-Jablonski et al., 2001; Kim et al., 2005). Breast cancer cell lines 
are heterogeneous and have different features. The genetic make-up that 
leads to tumour formation varies between them (Riaz et al., 2013). MDA-MB-
361 and MDA-MB-453 belong to the “MDA” series (Cailleau et al., 1978). 
Between them they show heterogeneity, as MDA-MB361 is positive for the 
breast cancer markers ErbB2, Estrogen receptor (ER) and progesterone 
receptor (PR) while MDA-MB453 is only ErbB2 positive. UAC-812 is also 
positive for ErbB2, ER and PR (Dai et al., 2017). SkBr3 cells overexpress 
ErbB2, but is not positive for either ER or PR. An interaction between SRC 
and ErbB2 has been demonstrated here in both SkBr3 and MCF7 breast 
cancer cell lines. The breast cancer cell line MCF7 is positive for both ER 
and PR markers, but ErbB2 is not overexpressed. Some ErbB2 expression 
is detected but no tyrosine phosphorylation which is seen in SkBr3 cells 
where ErbB2 is overexpressed. This suggests that in MCF7 cells the 
interaction with SRC is not through the SH2 domain which was 
demonstrated in the other breast cancer cell lines.  
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Some evidence indicates that the SH3 domain is important for the interaction 
with ErbB2 in SkBr3 cells. However in vitro assays suggest that this is a 
weak interaction and physiologically unlikely to happen endogenously in the 
cell. The GST-pull downs shows that SH3 domains from both FYN and SRC 
are able to interact with ErbB2 directly. Using high concentrations of cell 
lysates with ErbB2 overexpressed could potentially overcome the low affinity 
which was demonstrated between the SRC SH3 domain and an ErbB2 
peptide using MST and artificially force the interaction using high levels of 
receptor. This leads to a proposed model that SRC can potentially interact 
with ErbB2 via both the SH2 and SH3 domains in SkBr3 cells. Such an 
interaction can stabilise the interaction and keep SRC in an open 
conformation, allowing the kinase domain to remain functional for a 
prolonged period. Further work needs to be carried out to demonstrate and 
validate the proposed model. If this model is true for SkBr3 cells, is there a 
possibility that this can also happen in the other breast cancer cell lines 
where an interaction between SRC and ErbB2 was demonstrated? 
Another question that remains unanswered is by what mechanism does 
SRC interact with ErbB2 in MCF7 cells? A PLA signal was detected in both 
serum-starved and stimulated cells for SRC and ErbB2. In accordance with 
previous results the SH3 domain was not solely responsible for this 
interaction. In the MCF7 cells, phosphorylation of tyrosines 1221/1222 were 
used as a readout of receptor activation, but could other tyrosines in ErbB2 
be phosphorylated? A scenario could be that ErbB2 has some background 
phosphorylation, but with the receptor not fully activated, and this allows 
SRC to interact via the SH2 domain. Another explanation could be complex 
formation at the receptor. PLA detects signal from antibodies that are in 
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close proximity to each other within 40 nm. SRC has been suggested to also 
have a role downstream of ErbB2, therefore the PLA signal could be the 
result of complex formation between SRC, ErbB2 and an unknown 
adaptor/scaffold protein.  
The C-terminal tail of ErbB2 is important for SRC binding. A proline-rich 
motif in the C-terminal tail of ErbB2 was demonstrated to bind FYN SH3 at 
low affinity in NMR and SPR experiments (Bornet et al., 2014). When the 
proline-rich motif was mutated it abolished binding between SRC and mutant 
ErbB2 in transfected, and serum-starved HeLa cells. In HeLa cells that have 
been stimulated the interaction still occurred, suggesting different 
mechanisms for SRC and ErbB2 interaction in serum-starved and stimulated 
HeLa cells. One can speculate whether the interaction in starved cells is 
mediated via the SH3 domain, despite being a rejected theory based on 
biophysical data.  
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Chapter 7: Conclusions and further directions 
Several novel interactions have been demonstrated between RTKs and 
either LASP1 or SRC. Some of these interactions provide further examples 
of how important the RTK C-terminal tail is. More importantly this work 
shows several RTKs other than FGFR2 interacting with SH3 domains and 
under serum-starved conditions, an important requisite for “second-tier” 
signalling. This lays down some of the groundwork which can ultimately lead 
to a paradigm shift in RTK regulation.  
Two different approaches were taken to discover novel interactions between 
proline-rich motifs from RTKs and SH3 domains. Neither provided a straight 
forward technique to use and both require further optimisation, to 
accommodate the difficulties of identifying weak interactions. Further work 
could also look into using BioID as an approach, which would potentially 
overcome the difficulties of weak interactions at the same time as being an 
unbiased approach.  
The dot blot uncovered new interactions and further verification showed that 
the oncogenic protein LASP1 can interact with both ALK and ErbB2. Both 
receptors are known oncogenes, and these data shows that the C-terminal 
tail is important in binding LASP1. These are both novel interactions, and 
further exploration can unravel the importance of them.  
An interaction between LASP1 and the C-terminal tail of FGFR2 was also 
demonstrated, and some preliminary data suggested that it can have an 
effect on cell growth and cell migration. Further work looking into effects of 
knocking out LASP1 and FGFR2 expression using siRNA can be carried out, 
and would hopefully demonstrate that the effects seen are indeed 
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specifically from an interaction between FGFR2 and LASP1. The effects of 
FGFR2 on LASP1-mediated cell migration is an intriguing preliminary result. 
It would be interesting to see whether FGFR2 expression varies in tumours 
that overexpress LASP1 and if FGFR2 expression can determine tumour 
aggressiveness.  
There are many questions remaining to elucidate the interaction between 
SRC and ErbB2. One thing is clear is that breast cancer cell lines are 
heterogeneous, and do not retain the same biological responses and 
processes. A model is proposed where SRC is in a stabilised interaction with 
ErbB2 via both the SH2 and SH3 domains. Further work will have to be 
carried out to strengthen this theory. Mutant SRC lacking the ability to bind 
phosphorylated tyrosines can be utilised to demonstrate a difference in PLA 
signal or in IP experiments, compared to wild type SRC. A GST-pull down 
experiment using the SRC SH2 domain can be performed to show this 
interaction. Further biophysical analysis using the C-terminal tail of ErbB2 
(phosphorylated and unphosphorylated) and individual domains of SRC can 
be used to determine binding affinities. If these further experiments support 
the proposed model it would be very interesting to see what effects it would 
have physiologically. If both the SH2 and SH3 domains interact with ErbB2, 
SRC is held in an open conformation. SRC kinase can then have prolonged 
activity and activate downstream effectors, which can have a detrimental 
effect on the cell.  
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Appendix A: All identified proteins from MS screen using peptides with proline-rich motifs from RTKs 
ALK-1 
Accession Description # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs 
MW 
[kDa] 
calc. 
pI 
H6VRF8 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - [H6VRF8_HUMAN] 16 24 26 105 644 66.0 8.12 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 2 24 24 100 623 62.0 5.24 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 25 23 26 83 584 58.8 5.21 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 14 16 23 53 639 65.4 8.00 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 41 9 12 46 472 51.5 5.16 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] 19 9 17 24 590 62.3 7.74 
B4DRR0 cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A OS=Homo sapiens PE=2 SV=1 - [B4DRR0_HUMAN] 24 2 11 16 535 57.8 8.00 
Q6UXS9 Inactive caspase-12 OS=Homo sapiens GN=CASP12 PE=2 SV=2 - [CASPC_HUMAN] 1 1 1 6 341 38.8 6.02 
Q45KI0 Trypsin I (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q45KI0_HUMAN] 17 1 1 4 84 9.2 9.99 
Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 - [HORN_HUMAN] 1 2 2 4 2850 282.2 10.0
4 
Q9GZZ8 Extracellular glycoprotein lacritin OS=Homo sapiens GN=LACRT PE=1 SV=1 - [LACRT_HUMAN] 2 3 3 4 138 14.2 5.50 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] 1 3 3 3 110 11.3 6.54 
A0A087WW
T3 
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=1 - [A0A087WWT3_HUMAN] 14 3 3 3 396 45.1 6.10 
A0A075B6
Z2 
Protein TRAJ56 (Fragment) OS=Homo sapiens GN=TRAJ56 PE=4 SV=1 - [A0A075B6Z2_HUMAN] 2 1 1 10 21 2.2 10.2
9 
O75556 Mammaglobin-B OS=Homo sapiens GN=SCGB2A1 PE=1 SV=1 - [SG2A1_HUMAN] 1 2 2 2 95 10.9 5.78 
B3KX99 cDNA FLJ45019 fis, clone BRAWH3015825 OS=Homo sapiens PE=2 SV=1 - [B3KX99_HUMAN] 2 1 1 3 333 38.5 8.97 
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F8VV32 Lysozyme OS=Homo sapiens GN=LYZ PE=1 SV=1 - [F8VV32_HUMAN] 3 2 2 2 104 11.5 9.07 
H3BUH7 Fructose-bisphosphate aldolase (Fragment) OS=Homo sapiens GN=ALDOA PE=1 SV=1 - 
[H3BUH7_HUMAN] 
19 2 2 2 155 16.9 8.56 
Q9HB00 Desmocollin 1, isoform CRA_b OS=Homo sapiens GN=DSC1 PE=4 SV=1 - [Q9HB00_HUMAN] 2 2 2 2 840 93.8 5.53 
Q19KS2 Lactoferrin (Fragment) OS=Homo sapiens PE=2 SV=1 - [Q19KS2_HUMAN] 13 2 2 2 353 39.1 9.03 
Q8WUW7 Pyruvate kinase (Fragment) OS=Homo sapiens GN=PKM2 PE=2 SV=2 - [Q8WUW7_HUMAN] 8 2 2 3 343 37.3 8.22 
Q5VSP4 Putative lipocalin 1-like protein 1 OS=Homo sapiens GN=LCN1P1 PE=5 SV=1 - [LC1L1_HUMAN] 2 2 2 2 162 17.9 5.00 
Q5TDG9 DnaJ (Hsp40) homolog, subfamily C, member 16, isoform CRA_a OS=Homo sapiens GN=DNAJC16 PE=1 
SV=1 - [Q5TDG9_HUMAN] 
4 1 1 2 595 69.3 7.15 
F8WF65 Elongation factor 1-beta OS=Homo sapiens GN=EEF1B2 PE=1 SV=1 - [F8WF65_HUMAN] 4 1 1 1 29 3.1 4.46 
F8VXZ7 Tubulin alpha-1A chain (Fragment) OS=Homo sapiens GN=TUBA1A PE=4 SV=1 - [F8VXZ7_HUMAN] 22 1 1 1 26 2.7 4.89 
J3QSA3 Polyubiquitin-B (Fragment) OS=Homo sapiens GN=UBB PE=1 SV=1 - [J3QSA3_HUMAN] 37 1 1 1 43 4.9 5.19 
O95968 Secretoglobin family 1D member 1 OS=Homo sapiens GN=SCGB1D1 PE=1 SV=1 - [SG1D1_HUMAN] 1 1 1 1 90 9.9 9.25 
Q86W20 Protease serine 1 (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q86W20_HUMAN] 6 1 1 1 84 9.2 10.2
7 
H0YDD8 60S acidic ribosomal protein P2 (Fragment) OS=Homo sapiens GN=RPLP2 PE=1 SV=1 - 
[H0YDD8_HUMAN] 
2 1 1 1 92 9.1 4.46 
B2R4M6 Protein S100 OS=Homo sapiens PE=2 SV=1 - [B2R4M6_HUMAN] 2 1 1 1 114 13.2 6.13 
A0A0A0M
RQ5 
Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 - [A0A0A0MRQ5_HUMAN] 6 1 1 1 97 10.7 8.72 
Q5D862 Filaggrin-2 OS=Homo sapiens GN=FLG2 PE=1 SV=1 - [FILA2_HUMAN] 1 1 1 1 2391 247.9 8.31 
D6R9F0 Leucine-rich repeat-containing G-protein-coupled receptor 6 OS=Homo sapiens GN=LGR6 PE=1 SV=1 - 
[D6R9F0_HUMAN] 
1 1 1 1 348 39.2 7.74 
Q15203 Prothymosin alpha OS=Homo sapiens PE=4 SV=2 - [Q15203_HUMAN] 18 1 1 1 73 8.2 3.76 
E9PN25 Heat shock cognate 71 kDa protein (Fragment) OS=Homo sapiens GN=HSPA8 PE=1 SV=1 - 
[E9PN25_HUMAN] 
35 1 1 1 132 14.6 6.55 
P04080 Cystatin-B OS=Homo sapiens GN=CSTB PE=1 SV=2 - [CYTB_HUMAN] 1 1 1 1 98 11.1 7.56 
F8VVB8 Meiosis arrest female protein 1 OS=Homo sapiens GN=KIAA0430 PE=1 SV=1 - [F8VVB8_HUMAN] 2 1 1 1 1037 112.9 8.38 
C9IYG1 BRCA1-associated RING domain protein 1 (Fragment) OS=Homo sapiens GN=BARD1 PE=1 SV=1 - 
[C9IYG1_HUMAN] 
9 1 1 1 216 24.4 8.47 
B7Z5E7 cDNA FLJ51046, highly similar to 60 kDa heat shock protein, mitochondrial OS=Homo sapiens PE=2 SV=1 
- [B7Z5E7_HUMAN] 
5 1 1 1 517 55.0 5.60 
Q7RTY7 Ovochymase-1 OS=Homo sapiens GN=OVCH1 PE=2 SV=2 - [OVCH1_HUMAN] 1 1 1 1 1134 125.0 8.32 
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C9JG98 Probable ATP-dependent RNA helicase DHX58 (Fragment) OS=Homo sapiens GN=DHX58 PE=1 SV=1 - 
[C9JG98_HUMAN] 
5 1 1 1 302 34.0 6.71 
A0A0A0M
RX7 
Transcription factor TFIIIB component B'' homolog OS=Homo sapiens GN=BDP1 PE=1 SV=1 - 
[A0A0A0MRX7_HUMAN] 
5 1 1 1 846 95.5 8.15 
O00186 Syntaxin-binding protein 3 OS=Homo sapiens GN=STXBP3 PE=1 SV=2 - [STXB3_HUMAN] 1 1 1 1 592 67.7 7.80 
I3L1H9 Zymogen granule protein 16 homolog B (Fragment) OS=Homo sapiens GN=ZG16B PE=1 SV=1 - 
[I3L1H9_HUMAN] 
5 1 1 1 69 7.5 9.32 
H0YGI8 Stress-induced-phosphoprotein 1 (Fragment) OS=Homo sapiens GN=STIP1 PE=1 SV=1 - 
[H0YGI8_HUMAN] 
3 1 1 1 137 15.9 6.19 
B7Z1V3 cDNA FLJ54733, highly similar to General transcription factor 3C polypeptide 5 OS=Homo sapiens PE=2 
SV=1 - [B7Z1V3_HUMAN] 
1 1 1 1 412 45.6 9.45 
B7Z5R3 Src family associated phosphoprotein 2, isoform CRA_c OS=Homo sapiens GN=SCAP2 PE=2 SV=1 - 
[B7Z5R3_HUMAN] 
3 1 1 1 187 21.6 4.46 
F8WCH0 Actin, gamma-enteric smooth muscle OS=Homo sapiens GN=ACTG2 PE=1 SV=1 - [F8WCH0_HUMAN] 43 1 1 1 52 5.6 6.49 
B8ZZ51 Malate dehydrogenase, cytoplasmic OS=Homo sapiens GN=MDH1 PE=1 SV=1 - [B8ZZ51_HUMAN] 3 1 1 1 169 18.7 5.94 
A0PJ54 PEX12 protein (Fragment) OS=Homo sapiens GN=PEX12 PE=2 SV=1 - [A0PJ54_HUMAN] 1 1 1 1 324 36.9 9.98 
O14594 Neurocan core protein OS=Homo sapiens GN=NCAN PE=1 SV=3 - [NCAN_HUMAN] 2 1 1 1 1321 143.0 5.38 
Q96MA3 cDNA FLJ32709 fis, clone TESTI2000695, weakly similar to KINESIN HEAVY CHAIN (Fragment) OS=Homo 
sapiens PE=2 SV=1 - [Q96MA3_HUMAN] 
4 1 1 1 648 73.5 5.31 
B4DIJ7 Histone-lysine N-methyltransferase OS=Homo sapiens PE=2 SV=1 - [B4DIJ7_HUMAN] 2 1 1 1 323 37.2 8.78 
Q53RS3 Putative uncharacterized protein DDEF2 (Fragment) OS=Homo sapiens GN=DDEF2 PE=4 SV=1 - 
[Q53RS3_HUMAN] 
2 1 1 1 635 69.2 5.74 
L0R5A1 Alternative protein CSF2RB OS=Homo sapiens GN=CSF2RB PE=4 SV=1 - [L0R5A1_HUMAN] 1 1 1 1 108 11.6 11.3
0 
Q59EC6 Ret finger protein isoform beta variant (Fragment) OS=Homo sapiens PE=2 SV=1 - [Q59EC6_HUMAN] 1 1 1 1 382 43.4 8.16 
G3V3Y2 Fibulin-5 (Fragment) OS=Homo sapiens GN=FBLN5 PE=1 SV=1 - [G3V3Y2_HUMAN] 5 1 1 1 91 9.9 6.37 
H0YJY2 Signal-induced proliferation-associated 1-like protein 1 (Fragment) OS=Homo sapiens GN=SIPA1L1 PE=1 
SV=5 - [H0YJY2_HUMAN] 
1 1 1 1 262 30.3 7.24 
F5H6Q3 Ubiquitin carboxyl-terminal hydrolase 28 (Fragment) OS=Homo sapiens GN=USP28 PE=1 SV=1 - 
[F5H6Q3_HUMAN] 
2 1 1 1 46 5.3 8.57 
B3KQA6 cDNA FLJ90055 fis, clone HEMBA1003047, highly similar to Cubilin OS=Homo sapiens PE=2 SV=1 - 
[B3KQA6_HUMAN] 
4 1 1 1 350 38.7 5.60 
B4E0Q6 cDNA FLJ60209, highly similar to Transcriptional repressor p66 alpha OS=Homo sapiens PE=2 SV=1 - 
[B4E0Q6_HUMAN] 
1 1 1 1 262 28.6 9.95 
A0A0A0M
TR7 
E3 ubiquitin-protein ligase RNF213 OS=Homo sapiens GN=RNF213 PE=1 SV=1 - [A0A0A0MTR7_HUMAN] 3 1 1 1 5207 591.0 6.48 
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A0A0A7UX
25 
MHC class I antigen (Fragment) OS=Homo sapiens GN=HLA-C PE=3 SV=1 - [A0A0A7UX25_HUMAN] 1 1 1 1 91 10.6 5.01 
 
ALK-2 
Accession Description # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs 
MW 
[kDa] 
calc
. pI 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 2 24 24 1
3
8 
623 62.0 5.2
4 
H6VRF8 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - [H6VRF8_HUMAN] 16 27 32 1
4
8 
644 66.0 8.1
2 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 22 24 27 1
0
6 
584 58.8 5.2
1 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 7 18 26 6
8 
639 65.4 8.0
0 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 36 7 17 5
2 
472 51.5 5.1
6 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - [K1C16_HUMAN] 32 6 14 5
0 
473 51.2 5.0
5 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] 16 10 19 3
5 
590 62.3 7.7
4 
B4DRR0 cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A OS=Homo sapiens PE=2 SV=1 - [B4DRR0_HUMAN] 18 3 13 2
8 
535 57.8 8.0
0 
Q0IIN1 Keratin 77 OS=Homo sapiens GN=KRT77 PE=1 SV=1 - [Q0IIN1_HUMAN] 7 4 7 2
0 
578 61.8 5.8
5 
Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2 - [K1C17_HUMAN] 26 1 8 1
1 
432 48.1 5.0
2 
Q14CN4 Keratin, type II cytoskeletal 72 OS=Homo sapiens GN=KRT72 PE=1 SV=2 - [K2C72_HUMAN] 7 1 4 1
2 
511 55.8 6.8
9 
F6KPG5 Albumin (Fragment) OS=Homo sapiens PE=2 SV=1 - [F6KPG5_HUMAN] 14 7 7 9 585 66.5 6.0
4 
Q6KB66 Keratin, type II cytoskeletal 80 OS=Homo sapiens GN=KRT80 PE=1 SV=2 - [K2C80_HUMAN] 9 1 2 5 452 50.5 5.6
7 
O75556 Mammaglobin-B OS=Homo sapiens GN=SCGB2A1 PE=1 SV=1 - [SG2A1_HUMAN] 1 2 2 3 95 10.9 5.7
8 
- 155 - 
B2MV14 Truncated lactoferrin OS=Homo sapiens GN=LTF PE=3 SV=1 - [B2MV14_HUMAN] 16 6 6 7 585 64.2 8.0
7 
Q45KI0 Trypsin I (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q45KI0_HUMAN] 17 1 1 3 84 9.2 9.9
9 
Q8N1N4 Keratin, type II cytoskeletal 78 OS=Homo sapiens GN=KRT78 PE=2 SV=2 - [K2C78_HUMAN] 3 3 3 5 520 56.8 6.0
2 
F8WF65 Elongation factor 1-beta OS=Homo sapiens GN=EEF1B2 PE=1 SV=1 - [F8WF65_HUMAN] 4 1 1 3 29 3.1 4.4
6 
Q9HB00 Desmocollin 1, isoform CRA_b OS=Homo sapiens GN=DSC1 PE=4 SV=1 - [Q9HB00_HUMAN] 2 3 3 4 840 93.8 5.5
3 
O95968 Secretoglobin family 1D member 1 OS=Homo sapiens GN=SCGB1D1 PE=1 SV=1 - [SG1D1_HUMAN] 1 2 2 4 90 9.9 9.2
5 
Q9GZZ8 Extracellular glycoprotein lacritin OS=Homo sapiens GN=LACRT PE=1 SV=1 - [LACRT_HUMAN] 2 3 3 3 138 14.2 5.5
0 
A0A0C4
DGN4 
Zymogen granule protein 16 homolog B OS=Homo sapiens GN=ZG16B PE=1 SV=1 - [A0A0C4DGN4_HUMAN] 5 2 2 2 178 19.6 5.9
5 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] 1 3 3 3 110 11.3 6.5
4 
J3QSA3 Polyubiquitin-B (Fragment) OS=Homo sapiens GN=UBB PE=1 SV=1 - [J3QSA3_HUMAN] 37 1 1 2 43 4.9 5.1
9 
F8VV32 Lysozyme OS=Homo sapiens GN=LYZ PE=1 SV=1 - [F8VV32_HUMAN] 3 3 3 4 104 11.5 9.0
7 
Q5VSP4 Putative lipocalin 1-like protein 1 OS=Homo sapiens GN=LCN1P1 PE=5 SV=1 - [LC1L1_HUMAN] 2 2 2 3 162 17.9 5.0
0 
Q99456 Keratin, type I cytoskeletal 12 OS=Homo sapiens GN=KRT12 PE=1 SV=1 - [K1C12_HUMAN] 1 1 2 3 494 53.5 4.7
8 
A0A0A0
MRX7 
Transcription factor TFIIIB component B'' homolog OS=Homo sapiens GN=BDP1 PE=1 SV=1 - 
[A0A0A0MRX7_HUMAN] 
5 1 1 3 846 95.5 8.1
5 
B3KX99 cDNA FLJ45019 fis, clone BRAWH3015825 OS=Homo sapiens PE=2 SV=1 - [B3KX99_HUMAN] 2 1 1 4 333 38.5 8.9
7 
Q6UXS9 Inactive caspase-12 OS=Homo sapiens GN=CASP12 PE=2 SV=2 - [CASPC_HUMAN] 1 1 1 2 341 38.8 6.0
2 
P25311 Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=2 - [ZA2G_HUMAN] 3 2 2 2 298 34.2 6.0
5 
A9UFC0 Caspase 14 OS=Homo sapiens GN=CASP14 PE=2 SV=1 - [A9UFC0_HUMAN] 2 2 2 2 242 27.6 5.3
4 
A0A075
B6Z2 
Protein TRAJ56 (Fragment) OS=Homo sapiens GN=TRAJ56 PE=4 SV=1 - [A0A075B6Z2_HUMAN] 2 1 1 1
0 
21 2.2 10.
29 
Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 - [HORN_HUMAN] 1 1 1 1 2850 282.
2 
10.
04 
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H0YDD8 60S acidic ribosomal protein P2 (Fragment) OS=Homo sapiens GN=RPLP2 PE=1 SV=1 - [H0YDD8_HUMAN] 2 1 1 1 92 9.1 4.4
6 
J3KSP2 60S ribosomal protein L38 (Fragment) OS=Homo sapiens GN=RPL38 PE=1 SV=1 - [J3KSP2_HUMAN] 4 1 1 1 21 2.6 9.9
9 
Q86W20 Protease serine 1 (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q86W20_HUMAN] 6 1 1 1 84 9.2 10.
27 
P12273 Prolactin-inducible protein OS=Homo sapiens GN=PIP PE=1 SV=1 - [PIP_HUMAN] 1 1 1 1 146 16.6 8.0
5 
E5RGE1 14-3-3 protein zeta/delta (Fragment) OS=Homo sapiens GN=YWHAZ PE=1 SV=5 - [E5RGE1_HUMAN] 8 1 1 1 52 5.9 4.7
8 
Q5HY57 Emerin OS=Homo sapiens GN=EMD PE=1 SV=1 - [Q5HY57_HUMAN] 2 1 1 1 219 24.9 5.0
2 
E7EN95 Filamin-B OS=Homo sapiens GN=FLNB PE=1 SV=1 - [E7EN95_HUMAN] 4 1 1 1 2409 256.
1 
5.7
3 
Q5D862 Filaggrin-2 OS=Homo sapiens GN=FLG2 PE=1 SV=1 - [FILA2_HUMAN] 1 1 1 1 2391 247.
9 
8.3
1 
Q8NFZ8 Cell adhesion molecule 4 OS=Homo sapiens GN=CADM4 PE=1 SV=1 - [CADM4_HUMAN] 1 1 1 1 388 42.8 6.3
0 
L8ECQ7 Alternative protein C10orf112 OS=Homo sapiens GN=C10orf112 PE=4 SV=1 - [L8ECQ7_HUMAN] 1 1 1 1 130 14.3 10.
02 
F8WCH0 Actin, gamma-enteric smooth muscle OS=Homo sapiens GN=ACTG2 PE=1 SV=1 - [F8WCH0_HUMAN] 43 1 1 1 52 5.6 6.4
9 
G3V361 Calmodulin (Fragment) OS=Homo sapiens GN=CALM1 PE=1 SV=1 - [G3V361_HUMAN] 8 1 1 1 98 11.1 4.2
5 
B7Z1V3 cDNA FLJ54733, highly similar to General transcription factor 3C polypeptide 5 OS=Homo sapiens PE=2 SV=1 
- [B7Z1V3_HUMAN] 
1 1 1 1 412 45.6 9.4
5 
O43283 Mitogen-activated protein kinase kinase kinase 13 OS=Homo sapiens GN=MAP3K13 PE=1 SV=1 - 
[M3K13_HUMAN] 
1 1 1 1 966 108.
2 
6.4
9 
S4R457 Heterogeneous nuclear ribonucleoprotein K OS=Homo sapiens GN=HNRNPK PE=1 SV=1 - [S4R457_HUMAN] 8 1 1 1 77 8.8 4.8
8 
K7EMM8 Putative oxidoreductase GLYR1 (Fragment) OS=Homo sapiens GN=GLYR1 PE=1 SV=2 - [K7EMM8_HUMAN] 4 1 1 1 524 57.3 9.2
3 
Q15203 Prothymosin alpha OS=Homo sapiens PE=4 SV=2 - [Q15203_HUMAN] 18 1 1 1 73 8.2 3.7
6 
A0A0A0
MRQ0 
Tetratricopeptide repeat protein 39A OS=Homo sapiens GN=TTC39A PE=1 SV=1 - [A0A0A0MRQ0_HUMAN] 4 1 1 1 426 48.3 7.0
8 
E9PN25 Heat shock cognate 71 kDa protein (Fragment) OS=Homo sapiens GN=HSPA8 PE=1 SV=1 - [E9PN25_HUMAN] 35 1 1 1 132 14.6 6.5
5 
P31151 Protein S100-A7 OS=Homo sapiens GN=S100A7 PE=1 SV=4 - [S10A7_HUMAN] 1 1 1 1 101 11.5 6.7
7 
- 157 - 
B7Z5E7 cDNA FLJ51046, highly similar to 60 kDa heat shock protein, mitochondrial OS=Homo sapiens PE=2 SV=1 - 
[B7Z5E7_HUMAN] 
5 1 1 1 517 55.0 5.6
0 
Q15461 Pregnancy-specific beta-1 glycoprotein-11 (Fragment) OS=Homo sapiens GN=PSG11 PE=4 SV=1 - 
[Q15461_HUMAN] 
10 1 1 1 236 26.8 7.4
4 
P05109 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 - [S10A8_HUMAN] 1 1 1 1 93 10.8 7.0
3 
F8VRZ4 Tubulin alpha-1A chain (Fragment) OS=Homo sapiens GN=TUBA1A PE=4 SV=1 - [F8VRZ4_HUMAN] 15 1 1 1 112 12.2 5.7
7 
C9JCF9 WD repeat-containing protein 81 (Fragment) OS=Homo sapiens GN=WDR81 PE=1 SV=1 - [C9JCF9_HUMAN] 2 1 1 1 172 18.7 9.6
3 
A8KA05 Protein argonaute-3 OS=Homo sapiens GN=EIF2C3 PE=2 SV=1 - [A8KA05_HUMAN] 1 1 1 1 860 97.3 9.1
1 
Q16478 Glutamate receptor ionotropic, kainate 5 OS=Homo sapiens GN=GRIK5 PE=2 SV=2 - [GRIK5_HUMAN] 1 1 1 1 980 109.
2 
8.2
1 
P12004 Proliferating cell nuclear antigen OS=Homo sapiens GN=PCNA PE=1 SV=1 - [PCNA_HUMAN] 3 1 1 1 261 28.8 4.6
9 
H7C5S2 Sarcolemmal membrane-associated protein (Fragment) OS=Homo sapiens GN=SLMAP PE=1 SV=1 - 
[H7C5S2_HUMAN] 
8 1 1 1 65 7.4 5.2
4 
V9HWK3 Carboxylic ester hydrolase OS=Homo sapiens GN=HEL126 PE=2 SV=1 - [V9HWK3_HUMAN] 3 1 1 1 525 58.2 6.5
2 
D6RF99 Synaptotagmin-15 (Fragment) OS=Homo sapiens GN=SYT15 PE=1 SV=1 - [D6RF99_HUMAN] 5 1 1 1 136 15.8 8.2
8 
G3V3Y2 Fibulin-5 (Fragment) OS=Homo sapiens GN=FBLN5 PE=1 SV=1 - [G3V3Y2_HUMAN] 5 1 1 1 91 9.9 6.3
7 
Q9H637 cDNA: FLJ22628 fis, clone HSI06177 OS=Homo sapiens PE=2 SV=1 - [Q9H637_HUMAN] 2 1 1 1 1133 131.
2 
7.5
3 
A0A075
B7G2 
Zinc finger protein 208 OS=Homo sapiens GN=ZNF208 PE=4 SV=2 - [A0A075B7G2_HUMAN] 2 1 1 1 1167 134.
3 
9.0
9 
H0YHR3 Protein phosphatase Slingshot homolog 1 (Fragment) OS=Homo sapiens GN=SSH1 PE=1 SV=1 - 
[H0YHR3_HUMAN] 
2 1 1 1 95 11.0 4.9
4 
B7ZA99 cDNA, FLJ79113, highly similar to Zinc finger SWIM domain-containing protein 3 OS=Homo sapiens PE=2 
SV=1 - [B7ZA99_HUMAN] 
1 1 1 1 690 78.3 7.5
0 
B4DMV5 cDNA FLJ51248, weakly similar to Melanoma-associated antigen C3 OS=Homo sapiens PE=2 SV=1 - 
[B4DMV5_HUMAN] 
1 1 1 1 126 13.4 5.1
0 
A8K651 cDNA FLJ75700, highly similar to Homo sapiens complement component 1, q subcomponent binding protein 
(C1QBP), nuclear gene encoding mitochondrial protein, mRNA OS=Homo sapiens PE=2 SV=1 - 
[A8K651_HUMAN] 
2 1 1 1 282 31.4 4.8
4 
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ErbB2-1-1 
Accession Description # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs 
MW 
[kDa] 
calc. 
pI 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 2 31 32 325 623 62.0 5.24 
H6VRF8 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - [H6VRF8_HUMAN] 14 33 39 277 644 66.0 8.12 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 13 29 35 196 584 58.8 5.21 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 5 29 38 201 639 65.4 8.00 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 25 10 29 114 472 51.5 5.16 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - [K1C16_HUMAN] 25 9 23 89 473 51.2 5.05 
P04259 Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 SV=5 - [K2C6B_HUMAN] 9 1 22 71 564 60.0 8.00 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] 14 17 29 64 590 62.3 7.74 
B4DRR0 cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A OS=Homo sapiens PE=2 SV=1 - [B4DRR0_HUMAN] 16 4 27 55 535 57.8 8.00 
Q0IIN1 Keratin 77 OS=Homo sapiens GN=KRT77 PE=1 SV=1 - [Q0IIN1_HUMAN] 5 12 15 41 578 61.8 5.85 
Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2 - [K1C17_HUMAN] 17 2 16 34 432 48.1 5.02 
Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 - [DSG1_HUMAN] 1 10 10 21 1049 113.7 5.03 
A0A024R0Y2 HCG30204, isoform CRA_a OS=Homo sapiens GN=hCG_30204 PE=4 SV=1 - [A0A024R0Y2_HUMAN] 18 16 16 20 2268 257.1 6.61 
A1A4E9 Keratin 13 OS=Homo sapiens GN=KRT13 PE=1 SV=1 - [A1A4E9_HUMAN] 6 3 8 20 458 49.6 4.96 
F6KPG5 Albumin (Fragment) OS=Homo sapiens PE=2 SV=1 - [F6KPG5_HUMAN] 14 12 12 20 585 66.5 6.04 
E7EQB2 Lactotransferrin (Fragment) OS=Homo sapiens GN=LTF PE=1 SV=1 - [E7EQB2_HUMAN] 16 12 12 17 696 76.6 8.02 
Q6KB66 Keratin, type II cytoskeletal 80 OS=Homo sapiens GN=KRT80 PE=1 SV=2 - [K2C80_HUMAN] 8 4 5 15 452 50.5 5.67 
Q3SY84 Keratin, type II cytoskeletal 71 OS=Homo sapiens GN=KRT71 PE=1 SV=3 - [K2C71_HUMAN] 8 1 4 18 523 57.3 6.61 
B3KPS3 cDNA FLJ32131 fis, clone PEBLM2000267, highly similar to Tubulin alpha-ubiquitous chain OS=Homo 
sapiens PE=2 SV=1 - [B3KPS3_HUMAN] 
38 8 8 12 416 46.2 5.12 
Q8N1N4 Keratin, type II cytoskeletal 78 OS=Homo sapiens GN=KRT78 PE=2 SV=2 - [K2C78_HUMAN] 4 7 9 11 520 56.8 6.02 
P15924 Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 - [DESP_HUMAN] 7 9 9 11 2871 331.6 6.81 
Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 - [HORN_HUMAN] 1 5 5 7 2850 282.2 10.0
4 
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Q15323 Keratin, type I cuticular Ha1 OS=Homo sapiens GN=KRT31 PE=1 SV=3 - [K1H1_HUMAN] 19 2 6 9 416 47.2 4.88 
A0A0C4DG
N4 
Zymogen granule protein 16 homolog B OS=Homo sapiens GN=ZG16B PE=1 SV=1 - 
[A0A0C4DGN4_HUMAN] 
5 4 4 7 178 19.6 5.95 
Q9HB00 Desmocollin 1, isoform CRA_b OS=Homo sapiens GN=DSC1 PE=4 SV=1 - [Q9HB00_HUMAN] 2 6 6 7 840 93.8 5.53 
Q9GZZ8 Extracellular glycoprotein lacritin OS=Homo sapiens GN=LACRT PE=1 SV=1 - [LACRT_HUMAN] 2 4 4 7 138 14.2 5.50 
P50402 Emerin OS=Homo sapiens GN=EMD PE=1 SV=1 - [EMD_HUMAN] 2 5 5 8 254 29.0 5.50 
A0A0G2JM
B2 
Uncharacterized protein OS=Homo sapiens PE=4 SV=1 - [A0A0G2JMB2_HUMAN] 13 1 3 6 340 36.5 6.10 
A0A087X2I
6 
Keratin, type I cuticular Ha3-II OS=Homo sapiens GN=KRT33B PE=1 SV=1 - [A0A087X2I6_HUMAN] 18 1 6 8 404 46.1 4.84 
Q99456 Keratin, type I cytoskeletal 12 OS=Homo sapiens GN=KRT12 PE=1 SV=1 - [K1C12_HUMAN] 1 1 3 7 494 53.5 4.78 
A0A024R1X
8 
Junction plakoglobin, isoform CRA_a OS=Homo sapiens GN=JUP PE=4 SV=1 - [A0A024R1X8_HUMAN] 12 6 6 7 745 81.7 6.14 
O95968 Secretoglobin family 1D member 1 OS=Homo sapiens GN=SCGB1D1 PE=1 SV=1 - [SG1D1_HUMAN] 1 2 2 6 90 9.9 9.25 
P01876 Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1 PE=1 SV=2 - [IGHA1_HUMAN] 10 1 3 5 353 37.6 6.51 
Q9NSB2 Keratin, type II cuticular Hb4 OS=Homo sapiens GN=KRT84 PE=2 SV=2 - [KRT84_HUMAN] 4 1 4 11 600 64.8 7.56 
Q53HF2 Heat shock 70kDa protein 8 isoform 2 variant (Fragment) OS=Homo sapiens PE=1 SV=1 - 
[Q53HF2_HUMAN] 
33 5 6 6 493 53.5 5.86 
Q45KI0 Trypsin I (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q45KI0_HUMAN] 17 1 1 3 84 9.2 9.99 
P31025 Lipocalin-1 OS=Homo sapiens GN=LCN1 PE=1 SV=1 - [LCN1_HUMAN] 2 4 4 5 176 19.2 5.58 
O75556 Mammaglobin-B OS=Homo sapiens GN=SCGB2A1 PE=1 SV=1 - [SG2A1_HUMAN] 1 3 3 5 95 10.9 5.78 
B3KRK8 cDNA FLJ34494 fis, clone HLUNG2005030, highly similar to VIMENTIN OS=Homo sapiens PE=2 SV=1 - 
[B3KRK8_HUMAN] 
29 6 6 7 407 46.9 5.00 
B4DVQ0 cDNA FLJ58286, highly similar to Actin, cytoplasmic 2 OS=Homo sapiens PE=2 SV=1 - 
[B4DVQ0_HUMAN] 
60 5 5 6 333 37.3 5.71 
B7Z597 cDNA FLJ54373, highly similar to 60 kDa heat shock protein, mitochondrial OS=Homo sapiens PE=2 
SV=1 - [B7Z597_HUMAN] 
10 4 4 5 564 60.0 5.74 
Q2VPJ6 HSP90AA1 protein (Fragment) OS=Homo sapiens GN=HSP90AA1 PE=1 SV=1 - [Q2VPJ6_HUMAN] 17 6 6 7 585 68.3 5.19 
P05089 Arginase-1 OS=Homo sapiens GN=ARG1 PE=1 SV=2 - [ARGI1_HUMAN] 1 3 3 5 322 34.7 7.21 
Q8TC04 Keratin 23 (Histone deacetylase inducible) OS=Homo sapiens GN=KRT23 PE=2 SV=1 - 
[Q8TC04_HUMAN] 
1 1 1 7 422 48.1 6.54 
P04040 Catalase OS=Homo sapiens GN=CAT PE=1 SV=3 - [CATA_HUMAN] 3 5 5 5 527 59.7 7.39 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] 1 4 4 4 110 11.3 6.54 
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B7Z1V7 cDNA FLJ51811, highly similar to Stress-70 protein, mitochondrial OS=Homo sapiens PE=2 SV=1 - 
[B7Z1V7_HUMAN] 
7 2 2 4 437 47.3 6.61 
O76011 Keratin, type I cuticular Ha4 OS=Homo sapiens GN=KRT34 PE=2 SV=2 - [KRT34_HUMAN] 6 1 4 5 436 49.4 5.06 
B3KX99 cDNA FLJ45019 fis, clone BRAWH3015825 OS=Homo sapiens PE=2 SV=1 - [B3KX99_HUMAN] 2 1 1 5 333 38.5 8.97 
Q9NP55 BPI fold-containing family A member 1 OS=Homo sapiens GN=BPIFA1 PE=1 SV=1 - [BPIA1_HUMAN] 1 3 3 3 256 26.7 5.76 
A0A0A0MSI
0 
Peroxiredoxin-1 (Fragment) OS=Homo sapiens GN=PRDX1 PE=1 SV=1 - [A0A0A0MSI0_HUMAN] 4 3 4 4 171 19.0 6.92 
B4E1T6 cDNA FLJ54342, highly similar to Heat shock 70 kDa protein 1 OS=Homo sapiens PE=2 SV=1 - 
[B4E1T6_HUMAN] 
23 2 3 3 398 43.0 5.39 
Q5D862 Filaggrin-2 OS=Homo sapiens GN=FLG2 PE=1 SV=1 - [FILA2_HUMAN] 1 2 2 3 2391 247.9 8.31 
Q6B823 Histone H4 (Fragment) OS=Homo sapiens PE=3 SV=1 - [Q6B823_HUMAN] 3 2 2 3 43 4.9 10.9
2 
B4DF70 cDNA FLJ60461, highly similar to Peroxiredoxin-2 (EC 1.11.1.15) OS=Homo sapiens PE=2 SV=1 - 
[B4DF70_HUMAN] 
4 2 3 3 183 20.1 8.78 
P61626 Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1 - [LYSC_HUMAN] 3 3 3 4 148 16.5 9.16 
A0M8Q9 C1 segment protein (Fragment) OS=Homo sapiens GN=C1 segment PE=4 SV=1 - [A0M8Q9_HUMAN] 59 1 1 2 105 11.3 7.87 
A0A024RC2
9 
Desmocollin 3, isoform CRA_b OS=Homo sapiens GN=DSC3 PE=4 SV=1 - [A0A024RC29_HUMAN] 3 3 3 3 896 99.9 6.10 
Q96C29 Putative uncharacterized protein (Fragment) OS=Homo sapiens PE=2 SV=1 - [Q96C29_HUMAN] 33 2 2 3 248 26.3 9.29 
A0A075B6Z
2 
Protein TRAJ56 (Fragment) OS=Homo sapiens GN=TRAJ56 PE=4 SV=1 - [A0A075B6Z2_HUMAN] 2 1 1 14 21 2.2 10.2
9 
H0YKZ7 Annexin (Fragment) OS=Homo sapiens GN=ANXA2 PE=1 SV=1 - [H0YKZ7_HUMAN] 18 2 2 3 119 13.0 8.13 
B2R4M6 Protein S100 OS=Homo sapiens PE=2 SV=1 - [B2R4M6_HUMAN] 2 3 3 4 114 13.2 6.13 
A0JNT2 KRT83 protein OS=Homo sapiens GN=KRT83 PE=2 SV=1 - [A0JNT2_HUMAN] 13 1 3 3 447 49.6 5.39 
P12273 Prolactin-inducible protein OS=Homo sapiens GN=PIP PE=1 SV=1 - [PIP_HUMAN] 1 3 3 3 146 16.6 8.05 
Q9UGM3 Deleted in malignant brain tumors 1 protein OS=Homo sapiens GN=DMBT1 PE=1 SV=2 - 
[DMBT1_HUMAN] 
1 1 1 2 2413 260.6 5.44 
Q0EFA5 S protein OS=Homo sapiens GN=S PE=4 SV=1 - [Q0EFA5_HUMAN] 7 1 1 2 512 49.9 8.13 
P25311 Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=2 - [ZA2G_HUMAN] 3 4 4 4 298 34.2 6.05 
Q59H57 Fusion (Involved in t(12;16) in malignant liposarcoma) isoform a variant (Fragment) OS=Homo sapiens 
PE=2 SV=1 - [Q59H57_HUMAN] 
8 2 2 2 300 32.0 9.52 
M0R1I1 Tubulin beta-4A chain (Fragment) OS=Homo sapiens GN=TUBB4A PE=1 SV=1 - [M0R1I1_HUMAN] 27 1 1 1 74 7.8 4.94 
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Q53RR5 Putative uncharacterized protein YWHAQ (Fragment) OS=Homo sapiens GN=YWHAQ PE=4 SV=1 - 
[Q53RR5_HUMAN] 
31 2 2 2 98 11.2 6.70 
B2R7Z6 cDNA, FLJ93674 OS=Homo sapiens PE=2 SV=1 - [B2R7Z6_HUMAN] 2 2 2 2 484 52.5 7.55 
P78386 Keratin, type II cuticular Hb5 OS=Homo sapiens GN=KRT85 PE=1 SV=1 - [KRT85_HUMAN] 5 1 3 3 507 55.8 6.55 
J3KRG2 Gasdermin-A (Fragment) OS=Homo sapiens GN=GSDMA PE=1 SV=5 - [J3KRG2_HUMAN] 2 3 3 3 159 17.9 6.02 
A9UFC0 Caspase 14 OS=Homo sapiens GN=CASP14 PE=2 SV=1 - [A9UFC0_HUMAN] 2 2 2 2 242 27.6 5.34 
Q15203 Prothymosin alpha OS=Homo sapiens PE=4 SV=2 - [Q15203_HUMAN] 18 1 1 2 73 8.2 3.76 
Q3SYB5 SERPINB12 protein OS=Homo sapiens GN=SERPINB12 PE=2 SV=1 - [Q3SYB5_HUMAN] 2 2 2 2 183 20.9 5.87 
J3QSA3 Polyubiquitin-B (Fragment) OS=Homo sapiens GN=UBB PE=1 SV=1 - [J3QSA3_HUMAN] 37 1 1 1 43 4.9 5.19 
P05109 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 - [S10A8_HUMAN] 1 2 2 3 93 10.8 7.03 
E7EUT5 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=1 - 
[E7EUT5_HUMAN] 
3 1 1 1 260 27.9 6.95 
E5RJN0 Heparan-alpha-glucosaminide N-acetyltransferase OS=Homo sapiens GN=HGSNAT PE=1 SV=1 - 
[E5RJN0_HUMAN] 
2 1 1 1 352 38.9 8.32 
Q86W20 Protease serine 1 (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q86W20_HUMAN] 6 1 1 1 84 9.2 10.2
7 
C9JZ65 Serpin B4 (Fragment) OS=Homo sapiens GN=SERPINB4 PE=1 SV=1 - [C9JZ65_HUMAN] 10 1 1 1 211 24.4 6.61 
A0A087WU
V8 
Basigin OS=Homo sapiens GN=BSG PE=1 SV=1 - [A0A087WUV8_HUMAN] 6 1 1 1 189 20.5 6.68 
M0QZK8 Uncharacterized protein OS=Homo sapiens PE=4 SV=1 - [M0QZK8_HUMAN] 4 1 1 1 103 11.6 4.92 
J3KSP2 60S ribosomal protein L38 (Fragment) OS=Homo sapiens GN=RPL38 PE=1 SV=1 - [J3KSP2_HUMAN] 4 1 1 1 21 2.6 9.99 
V9GZN0 Histone H2A gene (lambda-HHG55) (Fragment) OS=Homo sapiens PE=4 SV=1 - [V9GZN0_HUMAN] 19 1 1 1 47 5.0 11.9
0 
Q8IWS0 PHD finger protein 6 OS=Homo sapiens GN=PHF6 PE=1 SV=1 - [PHF6_HUMAN] 1 1 1 1 365 41.3 8.68 
P04080 Cystatin-B OS=Homo sapiens GN=CSTB PE=1 SV=2 - [CYTB_HUMAN] 1 1 1 1 98 11.1 7.56 
O75531 Barrier-to-autointegration factor OS=Homo sapiens GN=BANF1 PE=1 SV=1 - [BAF_HUMAN] 1 1 1 1 89 10.1 6.09 
C9IYG1 BRCA1-associated RING domain protein 1 (Fragment) OS=Homo sapiens GN=BARD1 PE=1 SV=1 - 
[C9IYG1_HUMAN] 
9 1 1 1 216 24.4 8.47 
P07737 Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 - [PROF1_HUMAN] 2 1 1 1 140 15.0 8.27 
K7EJT5 60S ribosomal protein L22 (Fragment) OS=Homo sapiens GN=RPL22 PE=1 SV=1 - [K7EJT5_HUMAN] 8 1 1 1 47 5.1 9.42 
Q5TIG5 Afadin OS=Homo sapiens GN=MLLT4 PE=1 SV=1 - [Q5TIG5_HUMAN] 5 1 1 1 1665 189.0 6.49 
- 162 - 
B4DL87 cDNA FLJ52243, highly similar to Heat-shock protein beta-1 OS=Homo sapiens PE=2 SV=1 - 
[B4DL87_HUMAN] 
3 1 1 1 170 18.5 6.95 
B7Z1V3 cDNA FLJ54733, highly similar to General transcription factor 3C polypeptide 5 OS=Homo sapiens PE=2 
SV=1 - [B7Z1V3_HUMAN] 
1 1 1 1 412 45.6 9.45 
A0A075B6G
4 
Protein crumbs homolog 1 OS=Homo sapiens GN=CRB1 PE=4 SV=1 - [A0A075B6G4_HUMAN] 6 1 1 1 674 74.6 5.59 
H0YH81 ATP synthase subunit beta (Fragment) OS=Homo sapiens GN=ATP5B PE=1 SV=1 - [H0YH81_HUMAN] 3 1 1 1 362 38.2 5.55 
C9JM43 Zinc finger protein 621 (Fragment) OS=Homo sapiens GN=ZNF621 PE=4 SV=1 - [C9JM43_HUMAN] 2 1 1 1 152 17.3 5.29 
H0YLF3 Beta-2-microglobulin (Fragment) OS=Homo sapiens GN=B2M PE=1 SV=1 - [H0YLF3_HUMAN] 7 1 1 1 71 8.5 5.15 
A8K651 cDNA FLJ75700, highly similar to Homo sapiens complement component 1, q subcomponent binding 
protein (C1QBP), nuclear gene encoding mitochondrial protein, mRNA OS=Homo sapiens PE=2 SV=1 - 
[A8K651_HUMAN] 
2 1 1 1 282 31.4 4.84 
B4DSX3 cDNA FLJ58938, moderately similar to Syntaxin-1A OS=Homo sapiens PE=2 SV=1 - [B4DSX3_HUMAN] 8 1 1 1 171 19.4 4.96 
Q59H71 Sodium channel protein type II alpha subunit variant (Fragment) OS=Homo sapiens PE=2 SV=1 - 
[Q59H71_HUMAN] 
7 1 1 1 1315 149.2 5.49 
K7EMV3 Histone H3 OS=Homo sapiens GN=H3F3B PE=1 SV=1 - [K7EMV3_HUMAN] 15 1 1 1 92 10.3 11.8
2 
P31151 Protein S100-A7 OS=Homo sapiens GN=S100A7 PE=1 SV=4 - [S10A7_HUMAN] 1 1 1 1 101 11.5 6.77 
P12004 Proliferating cell nuclear antigen OS=Homo sapiens GN=PCNA PE=1 SV=1 - [PCNA_HUMAN] 3 1 1 1 261 28.8 4.69 
H7C1V0 Cathepsin D (Fragment) OS=Homo sapiens GN=CTSD PE=1 SV=1 - [H7C1V0_HUMAN] 2 1 1 1 189 20.4 8.44 
E5RI98 Nucleophosmin (Fragment) OS=Homo sapiens GN=NPM1 PE=1 SV=1 - [E5RI98_HUMAN] 16 1 1 1 111 11.9 4.35 
Q16378 Proline-rich protein 4 OS=Homo sapiens GN=PRR4 PE=1 SV=3 - [PROL4_HUMAN] 2 2 2 3 134 15.1 7.06 
B4DHW6 cDNA FLJ54930, highly similar to Homo sapiens Dbf4-related factor 1 (DRF1), transcript variant 2, mRNA 
OS=Homo sapiens PE=2 SV=1 - [B4DHW6_HUMAN] 
3 1 1 1 154 16.7 10.2
7 
Q8NH58 Olfactory receptor OS=Homo sapiens PE=3 SV=1 - [Q8NH58_HUMAN] 1 1 1 1 276 30.4 7.71 
L0R5A1 Alternative protein CSF2RB OS=Homo sapiens GN=CSF2RB PE=4 SV=1 - [L0R5A1_HUMAN] 1 1 1 1 108 11.6 11.3
0 
Q9HA72 Calcium homeostasis modulator protein 2 OS=Homo sapiens GN=CALHM2 PE=2 SV=1 - 
[CAHM2_HUMAN] 
1 1 1 1 323 36.2 7.69 
Q96FX8 p53 apoptosis effector related to PMP-22 OS=Homo sapiens GN=PERP PE=2 SV=1 - [PERP_HUMAN] 1 1 1 1 193 21.4 7.03 
O43915 Vascular endothelial growth factor D OS=Homo sapiens GN=FIGF PE=1 SV=1 - [VEGFD_HUMAN] 1 1 1 1 354 40.4 7.81 
E5RGH4 Heterogeneous nuclear ribonucleoprotein H (Fragment) OS=Homo sapiens GN=HNRNPH1 PE=1 SV=1 - 
[E5RGH4_HUMAN] 
17 1 1 1 100 11.2 6.79 
B3KMI5 alpha-1,2-Mannosidase OS=Homo sapiens PE=2 SV=1 - [B3KMI5_HUMAN] 1 1 1 1 287 32.7 8.21 
- 163 - 
Q96QW8 DJ576K7.1 (FK506 binding protein 12-rapamycin associated protein 1) (Fragment) OS=Homo sapiens 
GN=FRAP1 PE=4 SV=1 - [Q96QW8_HUMAN] 
3 1 1 1 895 102.9 7.28 
F8WCJ1 Eukaryotic translation initiation factor 5A OS=Homo sapiens GN=EIF5A2 PE=1 SV=1 - 
[F8WCJ1_HUMAN] 
8 1 1 1 105 11.7 9.14 
G3V4X3 Protein NDRG2 OS=Homo sapiens GN=NDRG2 PE=1 SV=1 - [G3V4X3_HUMAN] 1 1 1 1 77 8.9 7.21 
K7ENC2 Coiled-coil domain-containing protein 159 (Fragment) OS=Homo sapiens GN=CCDC159 PE=4 SV=5 - 
[K7ENC2_HUMAN] 
5 1 1 1 110 12.7 5.96 
H0Y9T2 Collagen alpha-5(VI) chain (Fragment) OS=Homo sapiens GN=COL6A5 PE=4 SV=1 - [H0Y9T2_HUMAN] 5 1 1 1 443 50.2 5.00 
B4DXS1 Glycylpeptide N-tetradecanoyltransferase OS=Homo sapiens PE=2 SV=1 - [B4DXS1_HUMAN] 7 1 1 1 310 36.0 9.54 
Q6ZSX8 cDNA FLJ45139 fis, clone BRAWH3039623 OS=Homo sapiens PE=2 SV=1 - [Q6ZSX8_HUMAN] 1 1 1 2 136 15.5 10.0
7 
B3KQ62 cDNA FLJ32946 fis, clone TESTI2007872, weakly similar to INTRACELLULAR PROTEIN TRANSPORT 
PROTEIN USO1 OS=Homo sapiens PE=2 SV=1 - [B3KQ62_HUMAN] 
4 1 1 1 405 47.2 6.90 
B4DN11 cDNA FLJ54270 OS=Homo sapiens PE=2 SV=1 - [B4DN11_HUMAN] 4 1 1 1 140 16.1 6.42 
B4DS32 cDNA FLJ56236, highly similar to Exportin-2 OS=Homo sapiens PE=2 SV=1 - [B4DS32_HUMAN] 5 1 1 1 569 64.3 5.69 
 
ErbB2-1-2 
Accession Description # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs 
MW 
[kDa] 
calc
. pI 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 2 28 28 181 623 62.0 5.2
4 
H6VRF8 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - [H6VRF8_HUMAN] 16 31 36 168 644 66.0 8.1
2 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 23 25 28 109 584 58.8 5.2
1 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 8 21 29 74 639 65.4 8.0
0 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 39 8 25 83 472 51.5 5.1
6 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - [K1C16_HUMAN] 40 9 21 69 473 51.2 5.0
5 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] 15 10 18 37 590 62.3 7.7
4 
- 164 - 
B4DRR0 cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A OS=Homo sapiens PE=2 SV=1 - [B4DRR0_HUMAN] 17 7 16 31 535 57.8 8.0
0 
Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2 - [K1C17_HUMAN] 31 2 14 27 432 48.1 5.0
2 
Q0IIN1 Keratin 77 OS=Homo sapiens GN=KRT77 PE=1 SV=1 - [Q0IIN1_HUMAN] 7 2 5 20 578 61.8 5.8
5 
A0A024R
0Y2 
HCG30204, isoform CRA_a OS=Homo sapiens GN=hCG_30204 PE=4 SV=1 - [A0A024R0Y2_HUMAN] 13 8 8 10 2268 257.1 6.6
1 
Q14CN4 Keratin, type II cytoskeletal 72 OS=Homo sapiens GN=KRT72 PE=1 SV=2 - [K2C72_HUMAN] 10 1 3 10 511 55.8 6.8
9 
P50402 Emerin OS=Homo sapiens GN=EMD PE=1 SV=1 - [EMD_HUMAN] 2 5 5 10 254 29.0 5.5
0 
Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 - [HORN_HUMAN] 1 4 4 7 2850 282.
2 
10.
04 
Q45KI0 Trypsin I (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q45KI0_HUMAN] 17 1 1 4 84 9.2 9.9
9 
Q6KB66 Keratin, type II cytoskeletal 80 OS=Homo sapiens GN=KRT80 PE=1 SV=2 - [K2C80_HUMAN] 9 1 2 5 452 50.5 5.6
7 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] 1 3 3 5 110 11.3 6.5
4 
F6KPG5 Albumin (Fragment) OS=Homo sapiens PE=2 SV=1 - [F6KPG5_HUMAN] 14 4 4 5 585 66.5 6.0
4 
Q9GZZ8 Extracellular glycoprotein lacritin OS=Homo sapiens GN=LACRT PE=1 SV=1 - [LACRT_HUMAN] 2 3 3 4 138 14.2 5.5
0 
Q19KS2 Lactoferrin (Fragment) OS=Homo sapiens PE=2 SV=1 - [Q19KS2_HUMAN] 15 3 3 4 353 39.1 9.0
3 
B3KRK8 cDNA FLJ34494 fis, clone HLUNG2005030, highly similar to VIMENTIN OS=Homo sapiens PE=2 SV=1 - 
[B3KRK8_HUMAN] 
5 3 3 5 407 46.9 5.0
0 
B3KX99 cDNA FLJ45019 fis, clone BRAWH3015825 OS=Homo sapiens PE=2 SV=1 - [B3KX99_HUMAN] 2 1 1 3 333 38.5 8.9
7 
J3QSA3 Polyubiquitin-B (Fragment) OS=Homo sapiens GN=UBB PE=1 SV=1 - [J3QSA3_HUMAN] 37 1 1 2 43 4.9 5.1
9 
Q53HF2 Heat shock 70kDa protein 8 isoform 2 variant (Fragment) OS=Homo sapiens PE=1 SV=1 - [Q53HF2_HUMAN] 37 2 2 3 493 53.5 5.8
6 
C9K0U8 Single-stranded DNA-binding protein, mitochondrial (Fragment) OS=Homo sapiens GN=SSBP1 PE=1 SV=1 - 
[C9K0U8_HUMAN] 
6 2 2 2 121 14.1 9.5
7 
Q8N532 TUBA1C protein OS=Homo sapiens GN=TUBA1C PE=2 SV=1 - [Q8N532_HUMAN] 34 3 3 4 325 36.6 7.9
6 
A0A024
RC29 
Desmocollin 3, isoform CRA_b OS=Homo sapiens GN=DSC3 PE=4 SV=1 - [A0A024RC29_HUMAN] 3 2 2 2 896 99.9 6.1
0 
Q59H57 Fusion (Involved in t(12;16) in malignant liposarcoma) isoform a variant (Fragment) OS=Homo sapiens PE=2 
SV=1 - [Q59H57_HUMAN] 
8 2 2 3 300 32.0 9.5
2 
- 165 - 
B7Z597 cDNA FLJ54373, highly similar to 60 kDa heat shock protein, mitochondrial OS=Homo sapiens PE=2 SV=1 - 
[B7Z597_HUMAN] 
9 2 2 2 564 60.0 5.7
4 
Q9HB00 Desmocollin 1, isoform CRA_b OS=Homo sapiens GN=DSC1 PE=4 SV=1 - [Q9HB00_HUMAN] 2 2 2 2 840 93.8 5.5
3 
O95968 Secretoglobin family 1D member 1 OS=Homo sapiens GN=SCGB1D1 PE=1 SV=1 - [SG1D1_HUMAN] 1 2 2 2 90 9.9 9.2
5 
P61626 Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1 - [LYSC_HUMAN] 3 2 2 3 148 16.5 9.1
6 
Q14568 Heat shock protein HSP 90-alpha A2 OS=Homo sapiens GN=HSP90AA2P PE=1 SV=2 - [HS902_HUMAN] 14 2 2 2 343 39.3 4.6
5 
Q8N1N4 Keratin, type II cytoskeletal 78 OS=Homo sapiens GN=KRT78 PE=2 SV=2 - [K2C78_HUMAN] 1 1 1 2 520 56.8 6.0
2 
O75556 Mammaglobin-B OS=Homo sapiens GN=SCGB2A1 PE=1 SV=1 - [SG2A1_HUMAN] 1 1 1 1 95 10.9 5.7
8 
O75531 Barrier-to-autointegration factor OS=Homo sapiens GN=BANF1 PE=1 SV=1 - [BAF_HUMAN] 1 1 1 1 89 10.1 6.0
9 
Q6B823 Histone H4 (Fragment) OS=Homo sapiens PE=3 SV=1 - [Q6B823_HUMAN] 3 1 1 1 43 4.9 10.
92 
H0YDD8 60S acidic ribosomal protein P2 (Fragment) OS=Homo sapiens GN=RPLP2 PE=1 SV=1 - [H0YDD8_HUMAN] 2 1 1 1 92 9.1 4.4
6 
Q86W20 Protease serine 1 (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q86W20_HUMAN] 6 1 1 1 84 9.2 10.
27 
P05089 Arginase-1 OS=Homo sapiens GN=ARG1 PE=1 SV=2 - [ARGI1_HUMAN] 1 1 1 1 322 34.7 7.2
1 
Q5VSP4 Putative lipocalin 1-like protein 1 OS=Homo sapiens GN=LCN1P1 PE=5 SV=1 - [LC1L1_HUMAN] 2 1 1 1 162 17.9 5.0
0 
B4DVQ0 cDNA FLJ58286, highly similar to Actin, cytoplasmic 2 OS=Homo sapiens PE=2 SV=1 - [B4DVQ0_HUMAN] 50 2 2 2 333 37.3 5.7
1 
Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 - [DSG1_HUMAN] 1 2 2 2 1049 113.
7 
5.0
3 
V9GZN0 Histone H2A gene (lambda-HHG55) (Fragment) OS=Homo sapiens PE=4 SV=1 - [V9GZN0_HUMAN] 19 1 1 1 47 5.0 11.
90 
H7BZV2 Cilia- and flagella-associated protein 69 (Fragment) OS=Homo sapiens GN=CFAP69 PE=4 SV=1 - 
[H7BZV2_HUMAN] 
3 1 1 1 478 53.7 7.6
2 
X6RKN2 Neurofascin (Fragment) OS=Homo sapiens GN=NFASC PE=1 SV=1 - [X6RKN2_HUMAN] 2 1 1 1 1165 131.
0 
6.8
4 
Q08ES8 Cell growth-inhibiting protein 34 OS=Homo sapiens PE=2 SV=1 - [Q08ES8_HUMAN] 2 1 1 1 177 20.1 9.6
0 
A8MXP8 Reticulocalbin-2 OS=Homo sapiens GN=RCN2 PE=1 SV=1 - [A8MXP8_HUMAN] 2 1 1 1 216 24.8 4.4
2 
- 166 - 
O00186 Syntaxin-binding protein 3 OS=Homo sapiens GN=STXBP3 PE=1 SV=2 - [STXB3_HUMAN] 1 1 1 1 592 67.7 7.8
0 
B4DJC9 cDNA FLJ56952 OS=Homo sapiens PE=2 SV=1 - [B4DJC9_HUMAN] 1 1 1 1 130 13.9 11.
14 
A0A024
R1X8 
Junction plakoglobin, isoform CRA_a OS=Homo sapiens GN=JUP PE=4 SV=1 - [A0A024R1X8_HUMAN] 2 1 1 1 745 81.7 6.1
4 
P05109 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 - [S10A8_HUMAN] 1 2 2 2 93 10.8 7.0
3 
Q5D862 Filaggrin-2 OS=Homo sapiens GN=FLG2 PE=1 SV=1 - [FILA2_HUMAN] 1 1 1 1 2391 247.
9 
8.3
1 
A1L378 STRC protein OS=Homo sapiens GN=STRC PE=2 SV=1 - [A1L378_HUMAN] 4 1 1 1 1002 110.
6 
5.1
7 
Q5JC44 KLHL9 protein OS=Homo sapiens PE=2 SV=1 - [Q5JC44_HUMAN] 2 1 1 2 617 69.4 6.3
5 
A0A0C4
DGT3 
IQ motif and SEC7 domain-containing protein 1 OS=Homo sapiens GN=IQSEC1 PE=1 SV=1 - 
[A0A0C4DGT3_HUMAN] 
5 1 1 1 814 91.9 7.5
6 
A8K651 cDNA FLJ75700, highly similar to Homo sapiens complement component 1, q subcomponent binding protein 
(C1QBP), nuclear gene encoding mitochondrial protein, mRNA OS=Homo sapiens PE=2 SV=1 - 
[A8K651_HUMAN] 
2 1 1 1 282 31.4 4.8
4 
A8MTF1 Phosphatidylinositol 4-kinase alpha (Fragment) OS=Homo sapiens GN=PI4KA PE=1 SV=2 - [A8MTF1_HUMAN] 8 1 1 1 435 49.6 5.8
2 
Q5TDF0 Cancer-related nucleoside-triphosphatase OS=Homo sapiens GN=NTPCR PE=1 SV=1 - [Q5TDF0_HUMAN] 1 1 1 1 228 25.1 9.4
2 
B3KRI8 cDNA FLJ34373 fis, clone FEBRA2017333, highly similar to Dual specificity protein kinase CLK3 (EC 2.7.12.1) 
OS=Homo sapiens PE=2 SV=1 - [B3KRI8_HUMAN] 
2 1 1 1 638 73.5 9.9
5 
A0A075
B6Z2 
Protein TRAJ56 (Fragment) OS=Homo sapiens GN=TRAJ56 PE=4 SV=1 - [A0A075B6Z2_HUMAN] 2 1 1 3 21 2.2 10.
29 
L0R5A1 Alternative protein CSF2RB OS=Homo sapiens GN=CSF2RB PE=4 SV=1 - [L0R5A1_HUMAN] 1 1 1 1 108 11.6 11.
30 
B4DKX6 cDNA FLJ53584, highly similar to Desmoplakin (Fragment) OS=Homo sapiens PE=2 SV=1 - [B4DKX6_HUMAN] 4 1 1 1 954 112.
2 
6.7
3 
Q504Q3 PAB-dependent poly(A)-specific ribonuclease subunit PAN2 OS=Homo sapiens GN=PAN2 PE=1 SV=3 - 
[PAN2_HUMAN] 
1 1 1 1 1202 135.
3 
5.9
9 
Q96NR3 Patched domain-containing protein 1 OS=Homo sapiens GN=PTCHD1 PE=2 SV=2 - [PTHD1_HUMAN] 1 1 1 1 888 101.
3 
8.2
7 
Q8WVZ7 E3 ubiquitin-protein ligase RNF133 OS=Homo sapiens GN=RNF133 PE=2 SV=1 - [RN133_HUMAN] 1 1 1 1 376 42.3 7.4
9 
A0A024
R731 
Uncharacterized protein OS=Homo sapiens GN=NAG6 PE=4 SV=1 - [A0A024R731_HUMAN] 4 1 1 1 957 111.
5 
4.6
8 
B4DKS8 cDNA FLJ57121, highly similar to Heterogeneous nuclear ribonucleoprotein F OS=Homo sapiens PE=2 SV=1 - 
[B4DKS8_HUMAN] 
2 1 1 1 338 37.2 6.0
5 
- 167 - 
B2R4M6 Protein S100 OS=Homo sapiens PE=2 SV=1 - [B2R4M6_HUMAN] 2 1 1 1 114 13.2 6.1
3 
H0Y908 Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase-like protein MGAT4D (Fragment) 
OS=Homo sapiens GN=MGAT4D PE=4 SV=1 - [H0Y908_HUMAN] 
1 1 1 1 91 11.3 9.9
4 
A0JLQ0 AZGP1 protein (Fragment) OS=Homo sapiens GN=AZGP1 PE=2 SV=1 - [A0JLQ0_HUMAN] 3 1 1 1 159 18.7 8.9
7 
H3BQL7 Paired amphipathic helix protein Sin3a OS=Homo sapiens GN=SIN3A PE=1 SV=1 - [H3BQL7_HUMAN] 1 1 1 1 156 17.1 9.9
2 
E5RGW4 Nucleophosmin (Fragment) OS=Homo sapiens GN=NPM1 PE=1 SV=1 - [E5RGW4_HUMAN] 3 1 1 1 59 6.9 4.4
8 
J3QLE0 E3 ubiquitin-protein ligase MIB2 (Fragment) OS=Homo sapiens GN=MIB2 PE=1 SV=1 - [J3QLE0_HUMAN] 6 1 1 1 57 6.7 11.
41 
B4DX83 Sodium channel protein OS=Homo sapiens PE=2 SV=1 - [B4DX83_HUMAN] 3 1 1 1 483 54.7 5.4
1 
H3BUZ5 Pseudopodium-enriched atypical kinase 1 (Fragment) OS=Homo sapiens GN=PEAK1 PE=1 SV=1 - 
[H3BUZ5_HUMAN] 
3 1 1 1 656 71.9 6.5
5 
Q5DTC5 Dendritic-cell specific protein CREA7-4 OS=Homo sapiens GN=CREA7-4 PE=2 SV=1 - [Q5DTC5_HUMAN] 6 1 1 1 215 24.8 6.8
4 
B3KR56 cDNA FLJ33721 fis, clone BRAWH2016792, highly similar to Angiomotin-like protein 2 OS=Homo sapiens PE=2 
SV=1 - [B3KR56_HUMAN] 
2 1 1 1 405 44.6 7.5
0 
A9UFC0 Caspase 14 OS=Homo sapiens GN=CASP14 PE=2 SV=1 - [A9UFC0_HUMAN] 2 1 1 1 242 27.6 5.3
4 
H9KVB3 Otogelin OS=Homo sapiens GN=OTOG PE=4 SV=2 - [H9KVB3_HUMAN] 2 1 1 1 2913 313.
2 
5.7
7 
 
ErbB2-2-1 
Accession Description # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs 
MW 
[kDa] 
calc
. pI 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 2 27 27 142 623 62.0 5.2
4 
H6VRF8 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - [H6VRF8_HUMAN] 15 29 33 151 644 66.0 8.1
2 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 25 22 26 98 584 58.8 5.2
1 
- 168 - 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 12 19 27 68 639 65.4 8.0
0 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 40 8 15 59 472 51.5 5.1
6 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - [K1C16_HUMAN] 36 5 12 51 473 51.2 5.0
5 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] 15 8 13 25 590 62.3 7.7
4 
Q0IIN1 Keratin 77 OS=Homo sapiens GN=KRT77 PE=1 SV=1 - [Q0IIN1_HUMAN] 9 1 4 15 578 61.8 5.8
5 
B4DRR0 cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A OS=Homo sapiens PE=2 SV=1 - [B4DRR0_HUMAN] 17 2 8 16 535 57.8 8.0
0 
K7ERE3 Keratin, type I cytoskeletal 13 OS=Homo sapiens GN=KRT13 PE=1 SV=1 - [K7ERE3_HUMAN] 25 1 5 9 415 45.2 4.8
1 
A0A024R
0Y2 
HCG30204, isoform CRA_a OS=Homo sapiens GN=hCG_30204 PE=4 SV=1 - [A0A024R0Y2_HUMAN] 13 5 5 7 2268 257.1 6.6
1 
F6KPG5 Albumin (Fragment) OS=Homo sapiens PE=2 SV=1 - [F6KPG5_HUMAN] 14 5 5 6 585 66.5 6.0
4 
Q14CN4 Keratin, type II cytoskeletal 72 OS=Homo sapiens GN=KRT72 PE=1 SV=2 - [K2C72_HUMAN] 12 1 3 6 511 55.8 6.8
9 
Q6KB66 Keratin, type II cytoskeletal 80 OS=Homo sapiens GN=KRT80 PE=1 SV=2 - [K2C80_HUMAN] 10 1 2 5 452 50.5 5.6
7 
Q45KI0 Trypsin I (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q45KI0_HUMAN] 17 1 1 3 84 9.2 9.9
9 
Q9GZZ8 Extracellular glycoprotein lacritin OS=Homo sapiens GN=LACRT PE=1 SV=1 - [LACRT_HUMAN] 2 3 3 4 138 14.2 5.5
0 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] 1 3 3 4 110 11.3 6.5
4 
B3KX99 cDNA FLJ45019 fis, clone BRAWH3015825 OS=Homo sapiens PE=2 SV=1 - [B3KX99_HUMAN] 2 1 1 4 333 38.5 8.9
7 
Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 - [DSG1_HUMAN] 1 3 3 3 1049 113.
7 
5.0
3 
Q19KS2 Lactoferrin (Fragment) OS=Homo sapiens PE=2 SV=1 - [Q19KS2_HUMAN] 15 3 3 4 353 39.1 9.0
3 
Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 - [HORN_HUMAN] 1 2 2 2 2850 282.
2 
10.
04 
J3QSA3 Polyubiquitin-B (Fragment) OS=Homo sapiens GN=UBB PE=1 SV=1 - [J3QSA3_HUMAN] 37 1 1 2 43 4.9 5.1
9 
Q5HY57 Emerin OS=Homo sapiens GN=EMD PE=1 SV=1 - [Q5HY57_HUMAN] 2 3 3 3 219 24.9 5.0
2 
O95968 Secretoglobin family 1D member 1 OS=Homo sapiens GN=SCGB1D1 PE=1 SV=1 - [SG1D1_HUMAN] 1 2 2 2 90 9.9 9.2
5 
- 169 - 
Q6UXS9 Inactive caspase-12 OS=Homo sapiens GN=CASP12 PE=2 SV=2 - [CASPC_HUMAN] 1 1 1 2 341 38.8 6.0
2 
P05109 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 - [S10A8_HUMAN] 1 2 2 2 93 10.8 7.0
3 
E9PN25 Heat shock cognate 71 kDa protein (Fragment) OS=Homo sapiens GN=HSPA8 PE=1 SV=1 - 
[E9PN25_HUMAN] 
35 1 1 2 132 14.6 6.5
5 
A0A075
B6Z2 
Protein TRAJ56 (Fragment) OS=Homo sapiens GN=TRAJ56 PE=4 SV=1 - [A0A075B6Z2_HUMAN] 2 1 1 8 21 2.2 10.
29 
P61626 Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1 - [LYSC_HUMAN] 3 3 3 3 148 16.5 9.1
6 
Q86W20 Protease serine 1 (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q86W20_HUMAN] 6 1 1 1 84 9.2 10.
27 
P12273 Prolactin-inducible protein OS=Homo sapiens GN=PIP PE=1 SV=1 - [PIP_HUMAN] 1 1 1 1 146 16.6 8.0
5 
Q53RR5 Putative uncharacterized protein YWHAQ (Fragment) OS=Homo sapiens GN=YWHAQ PE=4 SV=1 - 
[Q53RR5_HUMAN] 
3 1 1 1 98 11.2 6.7
0 
A0A0C4
DGN4 
Zymogen granule protein 16 homolog B OS=Homo sapiens GN=ZG16B PE=1 SV=1 - [A0A0C4DGN4_HUMAN] 3 1 1 1 178 19.6 5.9
5 
Q9HB00 Desmocollin 1, isoform CRA_b OS=Homo sapiens GN=DSC1 PE=4 SV=1 - [Q9HB00_HUMAN] 2 1 1 1 840 93.8 5.5
3 
J3QRT3 Uncharacterized protein KIAA0195 (Fragment) OS=Homo sapiens GN=KIAA0195 PE=1 SV=5 - 
[J3QRT3_HUMAN] 
1 1 1 1 89 9.5 6.7
6 
P31151 Protein S100-A7 OS=Homo sapiens GN=S100A7 PE=1 SV=4 - [S10A7_HUMAN] 1 1 1 1 101 11.5 6.7
7 
G3V361 Calmodulin (Fragment) OS=Homo sapiens GN=CALM1 PE=1 SV=1 - [G3V361_HUMAN] 8 1 1 1 98 11.1 4.2
5 
Q5VSP4 Putative lipocalin 1-like protein 1 OS=Homo sapiens GN=LCN1P1 PE=5 SV=1 - [LC1L1_HUMAN] 2 1 1 1 162 17.9 5.0
0 
B7Z5E7 cDNA FLJ51046, highly similar to 60 kDa heat shock protein, mitochondrial OS=Homo sapiens PE=2 SV=1 - 
[B7Z5E7_HUMAN] 
5 1 1 1 517 55.0 5.6
0 
O14942 Heat shock protein beta (Fragment) OS=Homo sapiens PE=4 SV=1 - [O14942_HUMAN] 12 1 1 1 130 14.1 4.7
9 
C9IYG1 BRCA1-associated RING domain protein 1 (Fragment) OS=Homo sapiens GN=BARD1 PE=1 SV=1 - 
[C9IYG1_HUMAN] 
9 1 1 1 216 24.4 8.4
7 
Q14222 EEF1A protein (Fragment) OS=Homo sapiens GN=EEF1A PE=2 SV=1 - [Q14222_HUMAN] 29 1 1 1 227 24.2 9.5
8 
A0PJ54 PEX12 protein (Fragment) OS=Homo sapiens GN=PEX12 PE=2 SV=1 - [A0PJ54_HUMAN] 1 1 1 1 324 36.9 9.9
8 
A0A087
WUV8 
Basigin OS=Homo sapiens GN=BSG PE=1 SV=1 - [A0A087WUV8_HUMAN] 6 1 1 1 189 20.5 6.6
8 
- 170 - 
H0YKZ7 Annexin (Fragment) OS=Homo sapiens GN=ANXA2 PE=1 SV=1 - [H0YKZ7_HUMAN] 16 1 1 1 119 13.0 8.1
3 
E7EWK3 ATP-dependent RNA helicase DHX36 (Fragment) OS=Homo sapiens GN=DHX36 PE=1 SV=1 - 
[E7EWK3_HUMAN] 
3 1 1 1 797 91.4 7.2
8 
A9UFC0 Caspase 14 OS=Homo sapiens GN=CASP14 PE=2 SV=1 - [A9UFC0_HUMAN] 2 1 1 2 242 27.6 5.3
4 
B4DKP2 cDNA FLJ54362, highly similar to Serine/threonine-protein kinase Duet (EC 2.7.11.1) OS=Homo sapiens PE=2 
SV=1 - [B4DKP2_HUMAN] 
4 1 1 1 489 55.7 6.3
8 
P07737 Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 - [PROF1_HUMAN] 2 1 1 1 140 15.0 8.2
7 
Q15203 Prothymosin alpha OS=Homo sapiens PE=4 SV=2 - [Q15203_HUMAN] 18 1 1 1 73 8.2 3.7
6 
Q2Y0W8 Electroneutral sodium bicarbonate exchanger 1 OS=Homo sapiens GN=SLC4A8 PE=1 SV=1 - [S4A8_HUMAN] 1 1 1 1 1093 122.
9 
6.6
8 
I3L1U9 Actin, cytoplasmic 2 (Fragment) OS=Homo sapiens GN=ACTG1 PE=1 SV=1 - [I3L1U9_HUMAN] 16 1 1 1 214 23.8 5.4
4 
H3BSE0 Ubiquitin-like protein 7 (Fragment) OS=Homo sapiens GN=UBL7 PE=1 SV=1 - [H3BSE0_HUMAN] 4 1 1 1 114 11.7 4.5
1 
Q16378 Proline-rich protein 4 OS=Homo sapiens GN=PRR4 PE=1 SV=3 - [PROL4_HUMAN] 2 1 1 1 134 15.1 7.0
6 
P81133 Single-minded homolog 1 OS=Homo sapiens GN=SIM1 PE=2 SV=2 - [SIM1_HUMAN] 1 1 1 1 766 85.5 7.4
3 
Q96K75 Zinc finger protein 514 OS=Homo sapiens GN=ZNF514 PE=2 SV=1 - [ZN514_HUMAN] 1 1 1 1 400 45.9 8.8
7 
B3KU25 Pyruvate dehydrogenase kinase, isozyme 4, isoform CRA_b OS=Homo sapiens GN=PDK4 PE=2 SV=1 - 
[B3KU25_HUMAN] 
3 1 1 1 375 42.6 6.1
9 
Q8IU77 Breast and ovarian cancer susceptibility protein (Fragment) OS=Homo sapiens GN=BRCA2 PE=4 SV=1 - 
[Q8IU77_HUMAN] 
1 1 1 2 35 3.9 8.5
9 
H3BV44 Unconventional myosin-IXa (Fragment) OS=Homo sapiens GN=MYO9A PE=1 SV=1 - [H3BV44_HUMAN] 3 1 1 1 1398 157.
9 
7.8
7 
A0JLQ0 AZGP1 protein (Fragment) OS=Homo sapiens GN=AZGP1 PE=2 SV=1 - [A0JLQ0_HUMAN] 3 1 1 1 159 18.7 8.9
7 
B4DVL1 cDNA FLJ54179 OS=Homo sapiens PE=2 SV=1 - [B4DVL1_HUMAN] 1 1 1 1 159 16.0 11.
30 
Q9BRJ0 HECTD1 protein (Fragment) OS=Homo sapiens GN=HECTD1 PE=2 SV=2 - [Q9BRJ0_HUMAN] 7 1 1 1 121 13.4 8.2
8 
F8WF90 PRA1 family protein 3 OS=Homo sapiens GN=ARL6IP5 PE=1 SV=1 - [F8WF90_HUMAN] 7 1 1 1 59 6.9 6.6
0 
Q0VAH5 Zinc finger protein 366 OS=Homo sapiens GN=ZNF366 PE=2 SV=1 - [Q0VAH5_HUMAN] 2 1 1 1 744 85.0 8.5
9 
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B4DS47 cDNA FLJ59745, highly similar to Trophinin OS=Homo sapiens PE=2 SV=1 - [B4DS47_HUMAN] 4 1 1 1 795 78.5 6.6
1 
L8EAR9 Alternative protein ERP44 OS=Homo sapiens GN=ERP44 PE=4 SV=1 - [L8EAR9_HUMAN] 20 1 1 1 57 6.2 9.4
2 
B4DYA3 cDNA FLJ52290, highly similar to F-box only protein 25 OS=Homo sapiens PE=2 SV=1 - [B4DYA3_HUMAN] 3 1 1 1 330 38.9 8.2
1 
A8K651 cDNA FLJ75700, highly similar to Homo sapiens complement component 1, q subcomponent binding protein 
(C1QBP), nuclear gene encoding mitochondrial protein, mRNA OS=Homo sapiens PE=2 SV=1 - 
[A8K651_HUMAN] 
2 1 1 1 282 31.4 4.8
4 
 
ErbB2-2-2 
Accession Description # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs 
MW 
[kDa] 
calc. 
pI 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 25 28 32 148 584 58.8 5.21 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 2 28 29 121 623 62.0 5.24 
H6VRF8 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - [H6VRF8_HUMAN] 17 30 33 121 644 66.0 8.12 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 10 23 29 77 639 65.4 8.00 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 42 5 15 44 472 51.5 5.16 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - [K1C16_HUMAN] 37 3 13 39 473 51.2 5.05 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] 16 7 13 23 590 62.3 7.74 
A0A024R0Y
2 
HCG30204, isoform CRA_a OS=Homo sapiens GN=hCG_30204 PE=4 SV=1 - [A0A024R0Y2_HUMAN] 17 14 14 17 2268 257.1 6.61 
F6KPG5 Albumin (Fragment) OS=Homo sapiens PE=2 SV=1 - [F6KPG5_HUMAN] 14 3 3 6 585 66.5 6.04 
Q45KI0 Trypsin I (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q45KI0_HUMAN] 17 1 1 3 84 9.2 9.99 
Q9GZZ8 Extracellular glycoprotein lacritin OS=Homo sapiens GN=LACRT PE=1 SV=1 - [LACRT_HUMAN] 2 3 3 5 138 14.2 5.50 
Q14CN4 Keratin, type II cytoskeletal 72 OS=Homo sapiens GN=KRT72 PE=1 SV=2 - [K2C72_HUMAN] 11 1 4 7 511 55.8 6.89 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] 1 3 3 5 110 11.3 6.54 
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Q53HF2 Heat shock 70kDa protein 8 isoform 2 variant (Fragment) OS=Homo sapiens PE=1 SV=1 - 
[Q53HF2_HUMAN] 
39 3 3 4 493 53.5 5.86 
J3QRT3 Uncharacterized protein KIAA0195 (Fragment) OS=Homo sapiens GN=KIAA0195 PE=1 SV=5 - 
[J3QRT3_HUMAN] 
1 1 1 3 89 9.5 6.76 
B3KPS3 cDNA FLJ32131 fis, clone PEBLM2000267, highly similar to Tubulin alpha-ubiquitous chain OS=Homo 
sapiens PE=2 SV=1 - [B3KPS3_HUMAN] 
35 4 4 4 416 46.2 5.12 
Q19KS2 Lactoferrin (Fragment) OS=Homo sapiens PE=2 SV=1 - [Q19KS2_HUMAN] 15 3 3 3 353 39.1 9.03 
B3KX99 cDNA FLJ45019 fis, clone BRAWH3015825 OS=Homo sapiens PE=2 SV=1 - [B3KX99_HUMAN] 2 1 1 3 333 38.5 8.97 
Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 - [HORN_HUMAN] 1 1 1 1 2850 282.2 10.0
4 
Q8TC04 Keratin 23 (Histone deacetylase inducible) OS=Homo sapiens GN=KRT23 PE=2 SV=1 - 
[Q8TC04_HUMAN] 
1 1 1 3 422 48.1 6.54 
F8WCH0 Actin, gamma-enteric smooth muscle OS=Homo sapiens GN=ACTG2 PE=1 SV=1 - 
[F8WCH0_HUMAN] 
43 1 1 2 52 5.6 6.49 
M0R1V7 Ubiquitin-60S ribosomal protein L40 (Fragment) OS=Homo sapiens GN=UBA52 PE=1 SV=1 - 
[M0R1V7_HUMAN] 
40 2 2 2 63 7.1 5.36 
A0A075B6
Z2 
Protein TRAJ56 (Fragment) OS=Homo sapiens GN=TRAJ56 PE=4 SV=1 - [A0A075B6Z2_HUMAN] 2 1 1 10 21 2.2 10.2
9 
Q5VSP4 Putative lipocalin 1-like protein 1 OS=Homo sapiens GN=LCN1P1 PE=5 SV=1 - [LC1L1_HUMAN] 2 2 2 2 162 17.9 5.00 
O75556 Mammaglobin-B OS=Homo sapiens GN=SCGB2A1 PE=1 SV=1 - [SG2A1_HUMAN] 1 1 1 1 95 10.9 5.78 
L0R5A1 Alternative protein CSF2RB OS=Homo sapiens GN=CSF2RB PE=4 SV=1 - [L0R5A1_HUMAN] 1 1 1 2 108 11.6 11.3
0 
Q86W20 Protease serine 1 (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q86W20_HUMAN] 6 1 1 1 84 9.2 10.2
7 
A0A087W
YX2 
Histone lysine demethylase PHF8 OS=Homo sapiens GN=PHF8 PE=1 SV=1 - 
[A0A087WYX2_HUMAN] 
2 1 1 1 303 33.8 10.0
8 
E9PMG1 RalBP1-associated Eps domain-containing protein 1 OS=Homo sapiens GN=REPS1 PE=1 SV=1 - 
[E9PMG1_HUMAN] 
2 1 1 1 737 80.4 5.87 
B4DPU1 cDNA FLJ60776 OS=Homo sapiens PE=2 SV=1 - [B4DPU1_HUMAN] 3 1 1 1 181 21.0 9.41 
Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 - [DSG1_HUMAN] 1 2 2 2 1049 113.7 5.03 
A8K2T2 cDNA FLJ75519 (Fragment) OS=Homo sapiens PE=2 SV=1 - [A8K2T2_HUMAN] 4 1 1 1 1173 130.7 9.01 
F8WCJ1 Eukaryotic translation initiation factor 5A OS=Homo sapiens GN=EIF5A2 PE=1 SV=1 - 
[F8WCJ1_HUMAN] 
8 1 1 1 105 11.7 9.14 
Q5HY57 Emerin OS=Homo sapiens GN=EMD PE=1 SV=1 - [Q5HY57_HUMAN] 2 1 1 1 219 24.9 5.02 
Q5TDG9 DnaJ (Hsp40) homolog, subfamily C, member 16, isoform CRA_a OS=Homo sapiens GN=DNAJC16 
PE=1 SV=1 - [Q5TDG9_HUMAN] 
4 1 1 1 595 69.3 7.15 
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V9GZN0 Histone H2A gene (lambda-HHG55) (Fragment) OS=Homo sapiens PE=4 SV=1 - [V9GZN0_HUMAN] 19 1 1 1 47 5.0 11.9
0 
Q9BRJ0 HECTD1 protein (Fragment) OS=Homo sapiens GN=HECTD1 PE=2 SV=2 - [Q9BRJ0_HUMAN] 7 1 1 1 121 13.4 8.28 
J3KP89 Adenylate kinase 9 OS=Homo sapiens GN=AK9 PE=1 SV=1 - [J3KP89_HUMAN] 2 1 1 1 736 84.8 5.02 
B2R4M6 Protein S100 OS=Homo sapiens PE=2 SV=1 - [B2R4M6_HUMAN] 2 1 1 2 114 13.2 6.13 
B4DKX6 cDNA FLJ53584, highly similar to Desmoplakin (Fragment) OS=Homo sapiens PE=2 SV=1 - 
[B4DKX6_HUMAN] 
4 1 1 1 954 112.2 6.73 
Q86XH1 IQ and AAA domain-containing protein 1 OS=Homo sapiens GN=IQCA1 PE=2 SV=1 - 
[IQCA1_HUMAN] 
3 1 1 3 822 95.3 9.47 
Q16378 Proline-rich protein 4 OS=Homo sapiens GN=PRR4 PE=1 SV=3 - [PROL4_HUMAN] 2 1 1 1 134 15.1 7.06 
Q9UHP3 Ubiquitin carboxyl-terminal hydrolase 25 OS=Homo sapiens GN=USP25 PE=1 SV=4 - 
[UBP25_HUMAN] 
1 1 1 1 1055 122.1 5.34 
G3V3Y2 Fibulin-5 (Fragment) OS=Homo sapiens GN=FBLN5 PE=1 SV=1 - [G3V3Y2_HUMAN] 5 1 1 1 91 9.9 6.37 
Q6ZSX8 cDNA FLJ45139 fis, clone BRAWH3039623 OS=Homo sapiens PE=2 SV=1 - [Q6ZSX8_HUMAN] 1 1 1 1 136 15.5 10.0
7 
 
FGFR1-1 
Accession Description # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs 
MW 
[kDa] 
calc. 
pI 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 2 28 29 121 623 62.0 5.24 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 23 24 28 115 584 58.8 5.21 
H6VRF8 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - [H6VRF8_HUMAN] 14 29 31 115 644 66.0 8.12 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 14 17 25 70 639 65.4 8.00 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 35 5 19 50 472 51.5 5.16 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - [K1C16_HUMAN] 33 5 16 44 473 51.2 5.05 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] 19 10 19 37 590 62.3 7.74 
B4DRR0 cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A OS=Homo sapiens PE=2 SV=1 - 
[B4DRR0_HUMAN] 
23 6 16 30 535 57.8 8.00 
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Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2 - [K1C17_HUMAN] 27 2 13 21 432 48.1 5.02 
Q0IIN1 Keratin 77 OS=Homo sapiens GN=KRT77 PE=1 SV=1 - [Q0IIN1_HUMAN] 9 1 4 11 578 61.8 5.85 
F6KPG5 Albumin (Fragment) OS=Homo sapiens PE=2 SV=1 - [F6KPG5_HUMAN] 14 3 3 7 585 66.5 6.04 
Q14CN4 Keratin, type II cytoskeletal 72 OS=Homo sapiens GN=KRT72 PE=1 SV=2 - [K2C72_HUMAN] 10 1 4 8 511 55.8 6.89 
O75556 Mammaglobin-B OS=Homo sapiens GN=SCGB2A1 PE=1 SV=1 - [SG2A1_HUMAN] 1 3 3 5 95 10.9 5.78 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] 1 3 3 5 110 11.3 6.54 
A0A075B6
Z2 
Protein TRAJ56 (Fragment) OS=Homo sapiens GN=TRAJ56 PE=4 SV=1 - [A0A075B6Z2_HUMAN] 2 1 1 35 21 2.2 10.2
9 
Q45KI0 Trypsin I (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q45KI0_HUMAN] 17 1 1 3 84 9.2 9.99 
J3QRT3 Uncharacterized protein KIAA0195 (Fragment) OS=Homo sapiens GN=KIAA0195 PE=1 SV=5 - 
[J3QRT3_HUMAN] 
1 1 1 4 89 9.5 6.76 
Q9GZZ8 Extracellular glycoprotein lacritin OS=Homo sapiens GN=LACRT PE=1 SV=1 - [LACRT_HUMAN] 2 3 3 4 138 14.2 5.50 
Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 - [HORN_HUMAN] 1 1 1 2 2850 282.2 10.0
4 
Q86W20 Protease serine 1 (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q86W20_HUMAN] 6 1 1 3 84 9.2 10.2
7 
Q19KS2 Lactoferrin (Fragment) OS=Homo sapiens PE=2 SV=1 - [Q19KS2_HUMAN] 15 2 2 4 353 39.1 9.03 
A0A087W
TG3 
Cullin-3 OS=Homo sapiens GN=CUL3 PE=1 SV=1 - [A0A087WTG3_HUMAN] 1 1 1 2 342 39.1 9.48 
H7C2X0 Translation initiation factor eIF-2B subunit epsilon (Fragment) OS=Homo sapiens GN=EIF2B5 PE=1 
SV=1 - [H7C2X0_HUMAN] 
4 1 1 2 92 9.4 9.41 
F8WCJ1 Eukaryotic translation initiation factor 5A OS=Homo sapiens GN=EIF5A2 PE=1 SV=1 - 
[F8WCJ1_HUMAN] 
8 1 1 2 105 11.7 9.14 
Q6UXS9 Inactive caspase-12 OS=Homo sapiens GN=CASP12 PE=2 SV=2 - [CASPC_HUMAN] 1 1 1 1 341 38.8 6.02 
B3KX99 cDNA FLJ45019 fis, clone BRAWH3015825 OS=Homo sapiens PE=2 SV=1 - [B3KX99_HUMAN] 2 1 1 2 333 38.5 8.97 
L0R5A1 Alternative protein CSF2RB OS=Homo sapiens GN=CSF2RB PE=4 SV=1 - [L0R5A1_HUMAN] 1 1 1 3 108 11.6 11.3
0 
Q9NR48 Histone-lysine N-methyltransferase ASH1L OS=Homo sapiens GN=ASH1L PE=1 SV=2 - 
[ASH1L_HUMAN] 
1 1 1 1 2969 332.6 9.39 
F8WCH0 Actin, gamma-enteric smooth muscle OS=Homo sapiens GN=ACTG2 PE=1 SV=1 - 
[F8WCH0_HUMAN] 
43 1 1 1 52 5.6 6.49 
D6R9F0 Leucine-rich repeat-containing G-protein-coupled receptor 6 OS=Homo sapiens GN=LGR6 PE=1 
SV=1 - [D6R9F0_HUMAN] 
1 1 1 1 348 39.2 7.74 
M0QZJ2 Cytochrome P450 2B6 OS=Homo sapiens GN=CYP2B6 PE=1 SV=1 - [M0QZJ2_HUMAN] 4 1 1 1 255 29.1 7.15 
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Q5VSP4 Putative lipocalin 1-like protein 1 OS=Homo sapiens GN=LCN1P1 PE=5 SV=1 - [LC1L1_HUMAN] 2 2 2 2 162 17.9 5.00 
P31151 Protein S100-A7 OS=Homo sapiens GN=S100A7 PE=1 SV=4 - [S10A7_HUMAN] 1 1 1 1 101 11.5 6.77 
E7ERU0 Dystonin OS=Homo sapiens GN=DST PE=1 SV=1 - [E7ERU0_HUMAN] 6 1 1 1 5375 615.3 5.74 
P05109 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 - [S10A8_HUMAN] 4 2 2 2 93 10.8 7.03 
Q8WXG9 G-protein coupled receptor 98 OS=Homo sapiens GN=GPR98 PE=1 SV=2 - [GPR98_HUMAN] 1 1 1 1 6306 692.6 4.64 
B2R4M6 Protein S100 OS=Homo sapiens PE=2 SV=1 - [B2R4M6_HUMAN] 2 1 1 1 114 13.2 6.13 
L8ECQ7 Alternative protein C10orf112 OS=Homo sapiens GN=C10orf112 PE=4 SV=1 - [L8ECQ7_HUMAN] 1 1 1 1 130 14.3 10.0
2 
A0A024RC
53 
Phosphodiesterase 8A, isoform CRA_a OS=Homo sapiens GN=PDE8A PE=4 SV=1 - 
[A0A024RC53_HUMAN] 
2 1 1 1 582 66.0 6.02 
C9IYG1 BRCA1-associated RING domain protein 1 (Fragment) OS=Homo sapiens GN=BARD1 PE=1 SV=1 - 
[C9IYG1_HUMAN] 
9 1 1 1 216 24.4 8.47 
A0A087W
YX2 
Histone lysine demethylase PHF8 OS=Homo sapiens GN=PHF8 PE=1 SV=1 - [A0A087WYX2_HUMAN] 2 1 1 1 303 33.8 10.0
8 
B4DPU1 cDNA FLJ60776 OS=Homo sapiens PE=2 SV=1 - [B4DPU1_HUMAN] 3 1 1 1 181 21.0 9.41 
Q5HY57 Emerin OS=Homo sapiens GN=EMD PE=1 SV=1 - [Q5HY57_HUMAN] 2 1 1 1 219 24.9 5.02 
Q6ZRA8 cDNA FLJ46514 fis, clone THYMU3032798, highly similar to Focal adhesion kinase 2 (EC 2.7.1.112) 
OS=Homo sapiens PE=2 SV=1 - [Q6ZRA8_HUMAN] 
1 1 1 1 596 68.0 5.60 
C9JG98 Probable ATP-dependent RNA helicase DHX58 (Fragment) OS=Homo sapiens GN=DHX58 PE=1 
SV=1 - [C9JG98_HUMAN] 
5 1 1 1 302 34.0 6.71 
P46019 Phosphorylase b kinase regulatory subunit alpha, liver isoform OS=Homo sapiens GN=PHKA2 PE=1 
SV=1 - [KPB2_HUMAN] 
1 1 1 1 1235 138.3 6.44 
K7EMZ7 Uncharacterized protein C19orf57 OS=Homo sapiens GN=C19orf57 PE=1 SV=1 - [K7EMZ7_HUMAN] 2 1 1 1 243 26.5 9.51 
B4DK31 cDNA FLJ54634, highly similar to Acetyl-CoA carboxylase 1 (EC 6.4.1.2) OS=Homo sapiens PE=2 
SV=1 - [B4DK31_HUMAN] 
9 1 1 1 306 35.6 6.38 
Q6ZSX8 cDNA FLJ45139 fis, clone BRAWH3039623 OS=Homo sapiens PE=2 SV=1 - [Q6ZSX8_HUMAN] 1 1 1 2 136 15.5 10.0
7 
O95968 Secretoglobin family 1D member 1 OS=Homo sapiens GN=SCGB1D1 PE=1 SV=1 - [SG1D1_HUMAN] 1 1 1 1 90 9.9 9.25 
B2RU33 POTE ankyrin domain family member C OS=Homo sapiens GN=POTEC PE=2 SV=2 - 
[POTEC_HUMAN] 
7 1 1 1 542 61.1 6.76 
Q9ULV8 E3 ubiquitin-protein ligase CBL-C OS=Homo sapiens GN=CBLC PE=1 SV=3 - [CBLC_HUMAN] 1 1 1 1 474 52.4 7.69 
Q9NY74 Ewing's tumor-associated antigen 1 OS=Homo sapiens GN=ETAA1 PE=1 SV=2 - [ETAA1_HUMAN] 1 1 1 1 926 103.4 7.62 
P80108 Phosphatidylinositol-glycan-specific phospholipase D OS=Homo sapiens GN=GPLD1 PE=1 SV=3 - 
[PHLD_HUMAN] 
1 1 1 1 840 92.3 6.37 
- 176 - 
H7C0N5 Engulfment and cell motility protein 1 (Fragment) OS=Homo sapiens GN=ELMO1 PE=1 SV=1 - 
[H7C0N5_HUMAN] 
3 1 1 1 124 14.1 9.14 
A0A087W
UV8 
Basigin OS=Homo sapiens GN=BSG PE=1 SV=1 - [A0A087WUV8_HUMAN] 6 1 1 1 189 20.5 6.68 
G3V3Y2 Fibulin-5 (Fragment) OS=Homo sapiens GN=FBLN5 PE=1 SV=1 - [G3V3Y2_HUMAN] 5 1 1 1 91 9.9 6.37 
A0A087X0
99 
Protocadherin-17 (Fragment) OS=Homo sapiens GN=PCDH17 PE=1 SV=1 - [A0A087X099_HUMAN] 2 1 1 1 184 20.2 5.06 
I3L1H9 Zymogen granule protein 16 homolog B (Fragment) OS=Homo sapiens GN=ZG16B PE=1 SV=1 - 
[I3L1H9_HUMAN] 
5 1 1 1 69 7.5 9.32 
 
FGFR1-2 
Accession Description # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs 
MW 
[kDa] 
calc
. pI 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 2 30 31 199 623 62.0 5.2
4 
H6VRF8 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - [H6VRF8_HUMAN] 14 29 34 188 644 66.0 8.1
2 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 23 28 32 128 584 58.8 5.2
1 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 11 21 29 99 639 65.4 8.0
0 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - [K1C16_HUMAN] 32 10 21 58 473 51.2 5.0
5 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 31 6 21 56 472 51.5 5.1
6 
P04259 Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 SV=5 - [K2C6B_HUMAN] 12 2 21 54 564 60.0 8.0
0 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] 18 11 23 41 590 62.3 7.7
4 
B4DRR0 cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A OS=Homo sapiens PE=2 SV=1 - [B4DRR0_HUMAN] 20 3 23 41 535 57.8 8.0
0 
Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2 - [K1C17_HUMAN] 27 4 16 25 432 48.1 5.0
2 
Q14CN4 Keratin, type II cytoskeletal 72 OS=Homo sapiens GN=KRT72 PE=1 SV=2 - [K2C72_HUMAN] 8 1 4 11 511 55.8 6.8
9 
- 177 - 
Q53HF2 Heat shock 70kDa protein 8 isoform 2 variant (Fragment) OS=Homo sapiens PE=1 SV=1 - [Q53HF2_HUMAN] 32 5 7 10 493 53.5 5.8
6 
F6KPG5 Albumin (Fragment) OS=Homo sapiens PE=2 SV=1 - [F6KPG5_HUMAN] 14 4 4 7 585 66.5 6.0
4 
Q45KI0 Trypsin I (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q45KI0_HUMAN] 17 1 1 4 84 9.2 9.9
9 
B3KY79 cDNA FLJ46620 fis, clone TLUNG2000654, highly similar to Keratin, type II cytoskeletal 7 OS=Homo sapiens 
PE=2 SV=1 - [B3KY79_HUMAN] 
15 1 4 8 445 49.0 5.4
8 
B4E1T6 cDNA FLJ54342, highly similar to Heat shock 70 kDa protein 1 OS=Homo sapiens PE=2 SV=1 - 
[B4E1T6_HUMAN] 
27 1 3 6 398 43.0 5.3
9 
P15924 Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 - [DESP_HUMAN] 6 5 5 6 2871 331.
6 
6.8
1 
Q8N1N4 Keratin, type II cytoskeletal 78 OS=Homo sapiens GN=KRT78 PE=2 SV=2 - [K2C78_HUMAN] 4 3 4 5 520 56.8 6.0
2 
A0A024
R0Y2 
HCG30204, isoform CRA_a OS=Homo sapiens GN=hCG_30204 PE=4 SV=1 - [A0A024R0Y2_HUMAN] 10 4 4 5 2268 257.
1 
6.6
1 
Q6KB66 Keratin, type II cytoskeletal 80 OS=Homo sapiens GN=KRT80 PE=1 SV=2 - [K2C80_HUMAN] 8 1 2 4 452 50.5 5.6
7 
B7Z597 cDNA FLJ54373, highly similar to 60 kDa heat shock protein, mitochondrial OS=Homo sapiens PE=2 SV=1 - 
[B7Z597_HUMAN] 
11 3 3 3 564 60.0 5.7
4 
F8VVB9 Tubulin alpha-1B chain (Fragment) OS=Homo sapiens GN=TUBA1B PE=1 SV=5 - [F8VVB9_HUMAN] 33 4 4 5 247 27.5 5.2
0 
Q19KS2 Lactoferrin (Fragment) OS=Homo sapiens PE=2 SV=1 - [Q19KS2_HUMAN] 15 2 2 4 353 39.1 9.0
3 
O75556 Mammaglobin-B OS=Homo sapiens GN=SCGB2A1 PE=1 SV=1 - [SG2A1_HUMAN] 1 1 1 2 95 10.9 5.7
8 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] 1 3 3 4 110 11.3 6.5
4 
B3KX99 cDNA FLJ45019 fis, clone BRAWH3015825 OS=Homo sapiens PE=2 SV=1 - [B3KX99_HUMAN] 2 1 1 4 333 38.5 8.9
7 
J3QSA3 Polyubiquitin-B (Fragment) OS=Homo sapiens GN=UBB PE=1 SV=1 - [J3QSA3_HUMAN] 37 1 1 2 43 4.9 5.1
9 
Q86W20 Protease serine 1 (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q86W20_HUMAN] 6 1 1 2 84 9.2 10.
27 
E5RGE1 14-3-3 protein zeta/delta (Fragment) OS=Homo sapiens GN=YWHAZ PE=1 SV=5 - [E5RGE1_HUMAN] 31 2 2 2 52 5.9 4.7
8 
Q2VPJ6 HSP90AA1 protein (Fragment) OS=Homo sapiens GN=HSP90AA1 PE=1 SV=1 - [Q2VPJ6_HUMAN] 15 4 4 4 585 68.3 5.1
9 
Q9GZZ8 Extracellular glycoprotein lacritin OS=Homo sapiens GN=LACRT PE=1 SV=1 - [LACRT_HUMAN] 2 2 2 2 138 14.2 5.5
0 
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E5RJN0 Heparan-alpha-glucosaminide N-acetyltransferase OS=Homo sapiens GN=HGSNAT PE=1 SV=1 - 
[E5RJN0_HUMAN] 
2 1 1 2 352 38.9 8.3
2 
H7C2X0 Translation initiation factor eIF-2B subunit epsilon (Fragment) OS=Homo sapiens GN=EIF2B5 PE=1 SV=1 - 
[H7C2X0_HUMAN] 
4 1 1 2 92 9.4 9.4
1 
Q6UXS9 Inactive caspase-12 OS=Homo sapiens GN=CASP12 PE=2 SV=2 - [CASPC_HUMAN] 1 1 1 2 341 38.8 6.0
2 
J3QRT3 Uncharacterized protein KIAA0195 (Fragment) OS=Homo sapiens GN=KIAA0195 PE=1 SV=5 - 
[J3QRT3_HUMAN] 
1 1 1 2 89 9.5 6.7
6 
I3L1U9 Actin, cytoplasmic 2 (Fragment) OS=Homo sapiens GN=ACTG1 PE=1 SV=1 - [I3L1U9_HUMAN] 47 2 2 2 214 23.8 5.4
4 
A0A0C4
DFV9 
Protein SET OS=Homo sapiens GN=SET PE=1 SV=1 - [A0A0C4DFV9_HUMAN] 6 1 1 2 266 31.1 4.2
3 
A0A087
WTG3 
Cullin-3 OS=Homo sapiens GN=CUL3 PE=1 SV=1 - [A0A087WTG3_HUMAN] 1 1 1 3 342 39.1 9.4
8 
P25311 Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=2 - [ZA2G_HUMAN] 1 1 1 2 298 34.2 6.0
5 
B4DEF7 cDNA FLJ60062, highly similar to 78 kDa glucose-regulated protein OS=Homo sapiens PE=2 SV=1 - 
[B4DEF7_HUMAN] 
2 1 2 2 278 30.4 6.0
5 
F8VV32 Lysozyme OS=Homo sapiens GN=LYZ PE=1 SV=1 - [F8VV32_HUMAN] 3 2 2 2 104 11.5 9.0
7 
Q6ZSX8 cDNA FLJ45139 fis, clone BRAWH3039623 OS=Homo sapiens PE=2 SV=1 - [Q6ZSX8_HUMAN] 1 1 1 7 136 15.5 10.
07 
Q86Y65 KIAA1529 protein (Fragment) OS=Homo sapiens GN=KIAA1529 PE=2 SV=2 - [Q86Y65_HUMAN] 4 1 1 1 900 104.
4 
5.2
4 
C9JD91 Tyrosine-protein phosphatase non-receptor type 23 (Fragment) OS=Homo sapiens GN=PTPN23 PE=1 SV=5 - 
[C9JD91_HUMAN] 
5 1 1 1 170 19.2 7.4
2 
Q6ICA1 DJ402G11.9 protein OS=Homo sapiens GN=dJ402G11.9 PE=2 SV=1 - [Q6ICA1_HUMAN] 3 1 1 1 543 59.5 8.7
2 
A0A087
WXD2 
Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 OS=Homo sapiens 
GN=MAGI1 PE=1 SV=1 - [A0A087WXD2_HUMAN] 
7 1 1 1 980 106.
8 
6.4
6 
H0YKZ7 Annexin (Fragment) OS=Homo sapiens GN=ANXA2 PE=1 SV=1 - [H0YKZ7_HUMAN] 16 1 1 1 119 13.0 8.1
3 
Q8NGY2 Olfactory receptor 6K2 OS=Homo sapiens GN=OR6K2 PE=2 SV=1 - [OR6K2_HUMAN] 1 1 1 1 324 36.5 7.9
3 
B7Z1V7 cDNA FLJ51811, highly similar to Stress-70 protein, mitochondrial OS=Homo sapiens PE=2 SV=1 - 
[B7Z1V7_HUMAN] 
6 1 1 1 437 47.3 6.6
1 
P05109 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 - [S10A8_HUMAN] 1 1 1 2 93 10.8 7.0
3 
D3DS15 Uncharacterized protein OS=Homo sapiens GN=FLJ10357 PE=4 SV=1 - [D3DS15_HUMAN] 3 1 1 1 1498 162.
7 
6.4
7 
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Q14222 EEF1A protein (Fragment) OS=Homo sapiens GN=EEF1A PE=2 SV=1 - [Q14222_HUMAN] 29 1 1 1 227 24.2 9.5
8 
Q5ZEY3 Glyceraldehyde-3-phosphate dehydrogenase (Fragment) OS=Homo sapiens GN=GAPD PE=2 SV=1 - 
[Q5ZEY3_HUMAN] 
6 1 1 1 86 9.2 9.7
2 
H0YB22 40S ribosomal protein S14 (Fragment) OS=Homo sapiens GN=RPS14 PE=1 SV=1 - [H0YB22_HUMAN] 3 1 1 1 120 12.9 9.8
5 
C9IYG1 BRCA1-associated RING domain protein 1 (Fragment) OS=Homo sapiens GN=BARD1 PE=1 SV=1 - 
[C9IYG1_HUMAN] 
9 1 1 1 216 24.4 8.4
7 
B4DHR1 cDNA FLJ53009, highly similar to Calreticulin OS=Homo sapiens PE=2 SV=1 - [B4DHR1_HUMAN] 5 1 1 1 212 24.3 5.1
1 
A0A0A0
MRQ5 
Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 - [A0A0A0MRQ5_HUMAN] 6 1 1 1 97 10.7 8.7
2 
P07737 Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 - [PROF1_HUMAN] 2 1 1 1 140 15.0 8.2
7 
Q5BQ95 Kallikrein 13 splice variant 7 OS=Homo sapiens GN=KLK13 PE=2 SV=1 - [Q5BQ95_HUMAN] 1 1 1 1 98 10.7 9.6
9 
A0A0A0
MTR7 
E3 ubiquitin-protein ligase RNF213 OS=Homo sapiens GN=RNF213 PE=1 SV=1 - [A0A0A0MTR7_HUMAN] 3 1 1 1 5207 591.
0 
6.4
8 
Q7Z5L4 Spermatogenesis-associated protein 19, mitochondrial OS=Homo sapiens GN=SPATA19 PE=2 SV=2 - 
[SPT19_HUMAN] 
1 1 1 1 167 19.2 6.9
6 
B4DWS6 cDNA FLJ61181, highly similar to Homo sapiens hydroxysteroid (17-beta) dehydrogenase 12 (HSD17B12), 
mRNA OS=Homo sapiens PE=2 SV=1 - [B4DWS6_HUMAN] 
4 1 1 1 304 33.5 9.3
9 
L8ECQ7 Alternative protein C10orf112 OS=Homo sapiens GN=C10orf112 PE=4 SV=1 - [L8ECQ7_HUMAN] 1 1 1 1 130 14.3 10.
02 
Q9HB00 Desmocollin 1, isoform CRA_b OS=Homo sapiens GN=DSC1 PE=4 SV=1 - [Q9HB00_HUMAN] 2 1 1 1 840 93.8 5.5
3 
A0PJ54 PEX12 protein (Fragment) OS=Homo sapiens GN=PEX12 PE=2 SV=1 - [A0PJ54_HUMAN] 1 1 1 1 324 36.9 9.9
8 
Q15203 Prothymosin alpha OS=Homo sapiens PE=4 SV=2 - [Q15203_HUMAN] 18 1 1 1 73 8.2 3.7
6 
A0A024
R3V9 
HCG37498, isoform CRA_b OS=Homo sapiens GN=hCG_37498 PE=4 SV=1 - [A0A024R3V9_HUMAN] 5 1 1 1 92 11.0 9.7
4 
P31151 Protein S100-A7 OS=Homo sapiens GN=S100A7 PE=1 SV=4 - [S10A7_HUMAN] 1 1 1 1 101 11.5 6.7
7 
K7ESD3 Zinc finger and SCAN domain-containing protein 5B (Fragment) OS=Homo sapiens GN=ZSCAN5B PE=4 SV=2 - 
[K7ESD3_HUMAN] 
1 1 1 1 137 15.8 6.5
2 
A0A024
R1X8 
Junction plakoglobin, isoform CRA_a OS=Homo sapiens GN=JUP PE=4 SV=1 - [A0A024R1X8_HUMAN] 2 1 1 1 745 81.7 6.1
4 
Q3SYB5 SERPINB12 protein OS=Homo sapiens GN=SERPINB12 PE=2 SV=1 - [Q3SYB5_HUMAN] 2 1 1 1 183 20.9 5.8
7 
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B4DHW6 cDNA FLJ54930, highly similar to Homo sapiens Dbf4-related factor 1 (DRF1), transcript variant 2, mRNA 
OS=Homo sapiens PE=2 SV=1 - [B4DHW6_HUMAN] 
3 1 1 1 154 16.7 10.
27 
Q9H700 cDNA: FLJ21617 fis, clone COL07481 OS=Homo sapiens PE=2 SV=1 - [Q9H700_HUMAN] 1 1 1 1 244 27.6 9.2
2 
Q8TC57 Meiosis 1 arrest protein OS=Homo sapiens GN=M1AP PE=1 SV=1 - [M1AP_HUMAN] 1 1 1 1 530 59.3 6.8
7 
Q562R1 Beta-actin-like protein 2 OS=Homo sapiens GN=ACTBL2 PE=1 SV=2 - [ACTBL_HUMAN] 1 1 1 1 376 42.0 5.5
9 
Q8WVV4 Protein POF1B OS=Homo sapiens GN=POF1B PE=1 SV=3 - [POF1B_HUMAN] 1 1 1 1 589 68.0 6.3
2 
F5GXD8 Stress-induced-phosphoprotein 1 OS=Homo sapiens GN=STIP1 PE=1 SV=1 - [F5GXD8_HUMAN] 4 1 1 1 138 15.6 8.2
5 
D6RJF7 Serine/threonine-protein kinase Nek11 OS=Homo sapiens GN=NEK11 PE=4 SV=1 - [D6RJF7_HUMAN] 6 1 1 1 212 24.2 9.2
2 
A0A087
WU05 
C-Maf-inducing protein OS=Homo sapiens GN=CMIP PE=1 SV=1 - [A0A087WU05_HUMAN] 4 1 1 1 586 65.2 5.9
4 
A0A075
B6Z2 
Protein TRAJ56 (Fragment) OS=Homo sapiens GN=TRAJ56 PE=4 SV=1 - [A0A075B6Z2_HUMAN] 2 1 1 14 21 2.2 10.
29 
F8WE65 Peptidyl-prolyl cis-trans isomerase OS=Homo sapiens GN=PPIA PE=1 SV=1 - [F8WE65_HUMAN] 6 1 1 1 120 13.0 6.7
7 
Q96HI1 Similar to plastin 3 (T isoform) (Fragment) OS=Homo sapiens PE=2 SV=1 - [Q96HI1_HUMAN] 5 1 1 1 409 46.0 6.6
7 
F6KRJ2 MHC class I antigen (Fragment) OS=Homo sapiens GN=HLA-A PE=3 SV=1 - [F6KRJ2_HUMAN] 1 1 1 1 181 21.2 7.5
0 
H0YJ59 Tyrosine-protein phosphatase non-receptor type 21 (Fragment) OS=Homo sapiens GN=PTPN21 PE=1 SV=1 - 
[H0YJ59_HUMAN] 
3 1 1 1 128 14.0 6.2
8 
Q8TC04 Keratin 23 (Histone deacetylase inducible) OS=Homo sapiens GN=KRT23 PE=2 SV=1 - [Q8TC04_HUMAN] 1 1 1 2 422 48.1 6.5
4 
Q7Z5Z5 NPC-A-12 OS=Homo sapiens PE=2 SV=1 - [Q7Z5Z5_HUMAN] 1 1 1 1 103 11.8 9.8
6 
A8K651 cDNA FLJ75700, highly similar to Homo sapiens complement component 1, q subcomponent binding protein 
(C1QBP), nuclear gene encoding mitochondrial protein, mRNA OS=Homo sapiens PE=2 SV=1 - 
[A8K651_HUMAN] 
2 1 1 1 282 31.4 4.8
4 
A0A096L
P30 
Hemicentin-2 OS=Homo sapiens GN=HMCN2 PE=1 SV=1 - [A0A096LP30_HUMAN] 2 1 1 1 5059 541.
6 
5.8
7 
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FGFR2-1 
Accession Description # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs 
MW 
[kDa] 
calc. 
pI 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 2 30 31 254 623 62.0 5.24 
H6VRF8 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - [H6VRF8_HUMAN] 16 29 35 218 644 66.0 8.12 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 22 29 33 146 584 58.8 5.21 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 7 26 34 127 639 65.4 8.00 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 35 11 28 73 472 51.5 5.16 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - [K1C16_HUMAN] 36 13 26 67 473 51.2 5.05 
P04259 Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 SV=5 - [K2C6B_HUMAN] 9 2 19 59 564 60.0 8.00 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] 16 13 24 49 590 62.3 7.74 
B4DRR0 cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A OS=Homo sapiens PE=2 SV=1 - [B4DRR0_HUMAN] 17 3 21 45 535 57.8 8.00 
Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2 - [K1C17_HUMAN] 28 9 21 33 432 48.1 5.02 
Q0IIN1 Keratin 77 OS=Homo sapiens GN=KRT77 PE=1 SV=1 - [Q0IIN1_HUMAN] 7 4 7 24 578 61.8 5.85 
Q14CN4 Keratin, type II cytoskeletal 72 OS=Homo sapiens GN=KRT72 PE=1 SV=2 - [K2C72_HUMAN] 11 1 4 15 511 55.8 6.89 
P15924 Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 - [DESP_HUMAN] 6 10 10 14 2871 331.6 6.81 
Q6KB66 Keratin, type II cytoskeletal 80 OS=Homo sapiens GN=KRT80 PE=1 SV=2 - [K2C80_HUMAN] 9 3 4 10 452 50.5 5.67 
Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 - [HORN_HUMAN] 1 1 1 5 2850 282.2 10.0
4 
B2R4M6 Protein S100 OS=Homo sapiens PE=2 SV=1 - [B2R4M6_HUMAN] 2 4 4 7 114 13.2 6.13 
Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 - [DSG1_HUMAN] 1 3 3 5 1049 113.7 5.03 
A0A087W
WT3 
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=1 - [A0A087WWT3_HUMAN] 14 2 2 5 396 45.1 6.10 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] 1 3 3 4 110 11.3 6.54 
Q99456 Keratin, type I cytoskeletal 12 OS=Homo sapiens GN=KRT12 PE=1 SV=1 - [K1C12_HUMAN] 1 1 3 5 494 53.5 4.78 
B2MV14 Truncated lactoferrin OS=Homo sapiens GN=LTF PE=3 SV=1 - [B2MV14_HUMAN] 16 4 4 5 585 64.2 8.07 
Q8N1N4 Keratin, type II cytoskeletal 78 OS=Homo sapiens GN=KRT78 PE=2 SV=2 - [K2C78_HUMAN] 3 4 4 4 520 56.8 6.02 
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O75556 Mammaglobin-B OS=Homo sapiens GN=SCGB2A1 PE=1 SV=1 - [SG2A1_HUMAN] 1 3 3 3 95 10.9 5.78 
Q45KI0 Trypsin I (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q45KI0_HUMAN] 17 1 1 2 84 9.2 9.99 
A0A024R1
X8 
Junction plakoglobin, isoform CRA_a OS=Homo sapiens GN=JUP PE=4 SV=1 - [A0A024R1X8_HUMAN] 2 3 3 4 745 81.7 6.14 
I3L1U9 Actin, cytoplasmic 2 (Fragment) OS=Homo sapiens GN=ACTG1 PE=1 SV=1 - [I3L1U9_HUMAN] 48 3 3 3 214 23.8 5.44 
M0R1V7 Ubiquitin-60S ribosomal protein L40 (Fragment) OS=Homo sapiens GN=UBA52 PE=1 SV=1 - 
[M0R1V7_HUMAN] 
40 2 2 2 63 7.1 5.36 
B3KX99 cDNA FLJ45019 fis, clone BRAWH3015825 OS=Homo sapiens PE=2 SV=1 - [B3KX99_HUMAN] 2 1 1 3 333 38.5 8.97 
Q9GZZ8 Extracellular glycoprotein lacritin OS=Homo sapiens GN=LACRT PE=1 SV=1 - [LACRT_HUMAN] 2 2 2 2 138 14.2 5.50 
O95968 Secretoglobin family 1D member 1 OS=Homo sapiens GN=SCGB1D1 PE=1 SV=1 - [SG1D1_HUMAN] 1 2 2 2 90 9.9 9.25 
Q9HB00 Desmocollin 1, isoform CRA_b OS=Homo sapiens GN=DSC1 PE=4 SV=1 - [Q9HB00_HUMAN] 2 2 2 3 840 93.8 5.53 
A0A0A0M
RQ5 
Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 - [A0A0A0MRQ5_HUMAN] 6 2 2 2 97 10.7 8.72 
P05109 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 - [S10A8_HUMAN] 4 3 3 4 93 10.8 7.03 
P25311 Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=2 - [ZA2G_HUMAN] 3 2 2 3 298 34.2 6.05 
Q86W20 Protease serine 1 (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q86W20_HUMAN] 6 1 1 1 84 9.2 10.2
7 
A0A024RC
29 
Desmocollin 3, isoform CRA_b OS=Homo sapiens GN=DSC3 PE=4 SV=1 - [A0A024RC29_HUMAN] 3 1 1 1 896 99.9 6.10 
P47929 Galectin-7 OS=Homo sapiens GN=LGALS7 PE=1 SV=2 - [LEG7_HUMAN] 1 1 1 1 136 15.1 7.62 
V9H0H9 Uncharacterized protein OS=Homo sapiens PE=2 SV=1 - [V9H0H9_HUMAN] 1 1 1 1 246 29.2 9.79 
Q0EFA5 S protein OS=Homo sapiens GN=S PE=4 SV=1 - [Q0EFA5_HUMAN] 7 1 1 1 512 49.9 8.13 
P31151 Protein S100-A7 OS=Homo sapiens GN=S100A7 PE=1 SV=4 - [S10A7_HUMAN] 1 1 1 1 101 11.5 6.77 
Q5VSP4 Putative lipocalin 1-like protein 1 OS=Homo sapiens GN=LCN1P1 PE=5 SV=1 - [LC1L1_HUMAN] 2 1 1 1 162 17.9 5.00 
E9PN51 NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial (Fragment) OS=Homo sapiens 
GN=NDUFS8 PE=1 SV=1 - [E9PN51_HUMAN] 
6 1 1 1 110 12.4 9.98 
Q5ZEY3 Glyceraldehyde-3-phosphate dehydrogenase (Fragment) OS=Homo sapiens GN=GAPD PE=2 SV=1 - 
[Q5ZEY3_HUMAN] 
6 1 1 1 86 9.2 9.72 
H0YKZ7 Annexin (Fragment) OS=Homo sapiens GN=ANXA2 PE=1 SV=1 - [H0YKZ7_HUMAN] 16 1 1 1 119 13.0 8.13 
A0A087W
YX2 
Histone lysine demethylase PHF8 OS=Homo sapiens GN=PHF8 PE=1 SV=1 - [A0A087WYX2_HUMAN] 2 1 1 1 303 33.8 10.0
8 
C9J2I1 Armadillo repeat-containing protein 8 (Fragment) OS=Homo sapiens GN=ARMC8 PE=1 SV=1 - 
[C9J2I1_HUMAN] 
1 1 1 1 352 39.9 7.85 
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B4DFN7 cDNA FLJ59676, highly similar to Myosin-18A OS=Homo sapiens PE=2 SV=1 - [B4DFN7_HUMAN] 7 1 1 1 320 36.8 4.81 
E9PML7 Deoxyribose-phosphate aldolase (Fragment) OS=Homo sapiens GN=DERA PE=1 SV=1 - 
[E9PML7_HUMAN] 
3 1 1 1 236 26.0 9.04 
J3KSP2 60S ribosomal protein L38 (Fragment) OS=Homo sapiens GN=RPL38 PE=1 SV=1 - [J3KSP2_HUMAN] 4 1 1 1 21 2.6 9.99 
A1L378 STRC protein OS=Homo sapiens GN=STRC PE=2 SV=1 - [A1L378_HUMAN] 4 1 1 1 1002 110.6 5.17 
B4DK31 cDNA FLJ54634, highly similar to Acetyl-CoA carboxylase 1 (EC 6.4.1.2) OS=Homo sapiens PE=2 SV=1 - 
[B4DK31_HUMAN] 
8 1 1 1 306 35.6 6.38 
B4DUR8 T-complex protein 1 subunit gamma OS=Homo sapiens GN=CCT3 PE=1 SV=1 - [B4DUR8_HUMAN] 5 1 1 1 500 55.6 5.64 
A0A0A0M
RX7 
Transcription factor TFIIIB component B'' homolog OS=Homo sapiens GN=BDP1 PE=1 SV=1 - 
[A0A0A0MRX7_HUMAN] 
5 1 1 1 846 95.5 8.15 
Q3SYB5 SERPINB12 protein OS=Homo sapiens GN=SERPINB12 PE=2 SV=1 - [Q3SYB5_HUMAN] 2 2 2 2 183 20.9 5.87 
F8WBR5 Calmodulin OS=Homo sapiens GN=CALM2 PE=1 SV=1 - [F8WBR5_HUMAN] 10 1 1 1 65 7.4 4.01 
A0PJ54 PEX12 protein (Fragment) OS=Homo sapiens GN=PEX12 PE=2 SV=1 - [A0PJ54_HUMAN] 1 1 1 1 324 36.9 9.98 
B7Z5R3 Src family associated phosphoprotein 2, isoform CRA_c OS=Homo sapiens GN=SCAP2 PE=2 SV=1 - 
[B7Z5R3_HUMAN] 
3 1 1 1 187 21.6 4.46 
B4DHW6 cDNA FLJ54930, highly similar to Homo sapiens Dbf4-related factor 1 (DRF1), transcript variant 2, mRNA 
OS=Homo sapiens PE=2 SV=1 - [B4DHW6_HUMAN] 
3 1 1 1 154 16.7 10.2
7 
I3L234 Ribosomal L1 domain-containing protein 1 (Fragment) OS=Homo sapiens GN=RSL1D1 PE=1 SV=1 - 
[I3L234_HUMAN] 
1 1 1 1 98 11.6 9.74 
H7C1F9 Ral GTPase-activating protein subunit alpha-2 (Fragment) OS=Homo sapiens GN=RALGAPA2 PE=1 SV=1 
- [H7C1F9_HUMAN] 
2 1 1 2 1740 194.9 5.90 
Q9NVE4 Coiled-coil domain-containing protein 87 OS=Homo sapiens GN=CCDC87 PE=1 SV=2 - [CCD87_HUMAN] 1 1 1 1 849 96.3 8.59 
A8K5M9 Uncharacterized protein C15orf62, mitochondrial OS=Homo sapiens GN=C15orf62 PE=2 SV=1 - 
[CO062_HUMAN] 
1 1 1 1 175 19.7 8.50 
P08F94 Fibrocystin OS=Homo sapiens GN=PKHD1 PE=1 SV=1 - [PKHD1_HUMAN] 1 1 1 1 4074 446.4 6.57 
A0A075B6
Z2 
Protein TRAJ56 (Fragment) OS=Homo sapiens GN=TRAJ56 PE=4 SV=1 - [A0A075B6Z2_HUMAN] 2 1 1 1 21 2.2 10.2
9 
F4MH53 Ubiquitously transcribed tetratricopeptide repeat protein Y-linked transcript variant 39 OS=Homo sapiens 
GN=UTY PE=2 SV=1 - [F4MH53_HUMAN] 
1 1 1 1 1285 142.0 7.94 
Q7Z4M2 RASA1 protein (Fragment) OS=Homo sapiens GN=RASA1 PE=1 SV=1 - [Q7Z4M2_HUMAN] 8 1 1 1 313 36.5 8.78 
K7ERN1 E3 ubiquitin-protein ligase NEDD4-like (Fragment) OS=Homo sapiens GN=NEDD4L PE=1 SV=1 - 
[K7ERN1_HUMAN] 
6 1 1 1 639 74.1 5.16 
B4DWH5 cDNA FLJ53224, highly similar to Calpain-1 catalytic subunit (EC 3.4.22.52) OS=Homo sapiens PE=2 
SV=1 - [B4DWH5_HUMAN] 
5 1 1 1 660 75.8 6.29 
I3L1H9 Zymogen granule protein 16 homolog B (Fragment) OS=Homo sapiens GN=ZG16B PE=1 SV=1 - 
[I3L1H9_HUMAN] 
5 1 1 1 69 7.5 9.32 
- 184 - 
H7C0V3 Beta-chimaerin (Fragment) OS=Homo sapiens GN=CHN2 PE=1 SV=1 - [H7C0V3_HUMAN] 5 1 1 1 180 20.6 8.24 
Q6ZSX8 cDNA FLJ45139 fis, clone BRAWH3039623 OS=Homo sapiens PE=2 SV=1 - [Q6ZSX8_HUMAN] 1 1 1 2 136 15.5 10.0
7 
B4DL87 cDNA FLJ52243, highly similar to Heat-shock protein beta-1 OS=Homo sapiens PE=2 SV=1 - 
[B4DL87_HUMAN] 
3 1 1 1 170 18.5 6.95 
D9ZHQ0 Neuregulin 3 variant 6 OS=Homo sapiens GN=NRG3 PE=2 SV=1 - [D9ZHQ0_HUMAN] 1 1 1 1 239 27.2 7.44 
B2RBY7 cDNA, FLJ95770 OS=Homo sapiens PE=2 SV=1 - [B2RBY7_HUMAN] 3 1 1 1 380 41.6 5.27 
 
FGFR2-2 
Accession Description # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs 
MW 
[kDa] 
calc
. pI 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 4 26 27 134 623 62.0 5.2
4 
H6VRF8 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - [H6VRF8_HUMAN] 16 25 28 94 644 66.0 8.1
2 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 25 22 25 91 584 58.8 5.2
1 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - [K1C16_HUMAN] 40 7 15 49 473 51.2 5.0
5 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 13 12 19 44 639 65.4 8.0
0 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 44 7 15 48 472 51.5 5.1
6 
A0A024R
0Y2 
HCG30204, isoform CRA_a OS=Homo sapiens GN=hCG_30204 PE=4 SV=1 - [A0A024R0Y2_HUMAN] 17 14 14 22 2268 257.1 6.6
1 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] 14 4 10 15 590 62.3 7.7
4 
B4DRR0 cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A OS=Homo sapiens PE=2 SV=1 - [B4DRR0_HUMAN] 17 2 9 11 535 57.8 8.0
0 
F8VVB9 Tubulin alpha-1B chain (Fragment) OS=Homo sapiens GN=TUBA1B PE=1 SV=5 - [F8VVB9_HUMAN] 36 4 4 5 247 27.5 5.2
0 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] 1 3 3 6 110 11.3 6.5
4 
Q86W20 Protease serine 1 (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q86W20_HUMAN] 6 1 1 4 84 9.2 10.
27 
- 185 - 
A0A087W
WT3 
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=1 - [A0A087WWT3_HUMAN] 14 2 2 4 396 45.1 6.1
0 
Q53HF2 Heat shock 70kDa protein 8 isoform 2 variant (Fragment) OS=Homo sapiens PE=1 SV=1 - [Q53HF2_HUMAN] 39 3 3 5 493 53.5 5.8
6 
Q45KI0 Trypsin I (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q45KI0_HUMAN] 17 1 1 2 84 9.2 9.9
9 
Q14CN4 Keratin, type II cytoskeletal 72 OS=Homo sapiens GN=KRT72 PE=1 SV=2 - [K2C72_HUMAN] 12 1 3 3 511 55.8 6.8
9 
F8VV32 Lysozyme OS=Homo sapiens GN=LYZ PE=1 SV=1 - [F8VV32_HUMAN] 3 2 2 3 104 11.5 9.0
7 
J3QRT3 Uncharacterized protein KIAA0195 (Fragment) OS=Homo sapiens GN=KIAA0195 PE=1 SV=5 - 
[J3QRT3_HUMAN] 
1 1 1 2 89 9.5 6.7
6 
B3KX99 cDNA FLJ45019 fis, clone BRAWH3015825 OS=Homo sapiens PE=2 SV=1 - [B3KX99_HUMAN] 2 1 1 2 333 38.5 8.9
7 
P11498 Pyruvate carboxylase, mitochondrial OS=Homo sapiens GN=PC PE=1 SV=2 - [PYC_HUMAN] 3 2 2 2 1178 129.
6 
6.8
4 
C9JL25 60 kDa heat shock protein, mitochondrial (Fragment) OS=Homo sapiens GN=HSPD1 PE=1 SV=1 - 
[C9JL25_HUMAN] 
7 1 1 1 175 19.2 9.7
3 
O14942 Heat shock protein beta (Fragment) OS=Homo sapiens PE=4 SV=1 - [O14942_HUMAN] 12 1 1 1 130 14.1 4.7
9 
A1XP52 Catecholamine-regulated protein 40 OS=Homo sapiens PE=2 SV=1 - [A1XP52_HUMAN] 7 1 1 1 350 38.1 5.3
9 
Q5HY57 Emerin OS=Homo sapiens GN=EMD PE=1 SV=1 - [Q5HY57_HUMAN] 2 1 1 1 219 24.9 5.0
2 
P31151 Protein S100-A7 OS=Homo sapiens GN=S100A7 PE=1 SV=4 - [S10A7_HUMAN] 1 1 1 1 101 11.5 6.7
7 
C9IYG1 BRCA1-associated RING domain protein 1 (Fragment) OS=Homo sapiens GN=BARD1 PE=1 SV=1 - 
[C9IYG1_HUMAN] 
9 1 1 1 216 24.4 8.4
7 
A8K651 cDNA FLJ75700, highly similar to Homo sapiens complement component 1, q subcomponent binding protein 
(C1QBP), nuclear gene encoding mitochondrial protein, mRNA OS=Homo sapiens PE=2 SV=1 - 
[A8K651_HUMAN] 
2 1 1 1 282 31.4 4.8
4 
P05109 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 - [S10A8_HUMAN] 1 1 1 1 93 10.8 7.0
3 
B4E1L2 cDNA FLJ59602, highly similar to Lactotransferrin (EC 3.4.21.-) OS=Homo sapiens PE=2 SV=1 - 
[B4E1L2_HUMAN] 
15 1 1 1 151 16.5 9.9
4 
Q9H8G4 cDNA FLJ13649 fis, clone PLACE1011399, weakly similar to Homo sapiens CGI-72 protein mRNA OS=Homo 
sapiens PE=2 SV=1 - [Q9H8G4_HUMAN] 
3 1 1 1 150 16.5 9.1
0 
P12004 Proliferating cell nuclear antigen OS=Homo sapiens GN=PCNA PE=1 SV=1 - [PCNA_HUMAN] 3 1 1 1 261 28.8 4.6
9 
A8K0C1 Threonine synthase-like 2 OS=Homo sapiens GN=THNSL2 PE=1 SV=1 - [A8K0C1_HUMAN] 3 1 1 1 226 25.0 6.9
9 
- 186 - 
Q6ZSX8 cDNA FLJ45139 fis, clone BRAWH3039623 OS=Homo sapiens PE=2 SV=1 - [Q6ZSX8_HUMAN] 1 1 1 2 136 15.5 10.
07 
Q9NY61 Protein AATF OS=Homo sapiens GN=AATF PE=1 SV=1 - [AATF_HUMAN] 1 1 1 1 560 63.1 4.9
4 
Q8NEG4 Protein FAM83F OS=Homo sapiens GN=FAM83F PE=1 SV=1 - [FA83F_HUMAN] 1 1 1 1 500 55.5 8.1
9 
P58294 Prokineticin-1 OS=Homo sapiens GN=PROK1 PE=1 SV=1 - [PROK1_HUMAN] 1 1 1 1 105 11.7 8.5
9 
I3L379 Active breakpoint cluster region-related protein (Fragment) OS=Homo sapiens GN=ABR PE=1 SV=1 - 
[I3L379_HUMAN] 
6 1 1 1 117 13.6 7.1
4 
A8K383 cDNA FLJ75428, highly similar to Homo sapiens activating transcription factor 6 (ATF6), mRNA OS=Homo 
sapiens PE=2 SV=1 - [A8K383_HUMAN] 
2 1 1 1 670 74.5 8.2
2 
 
FGFR2-3 
Accession Description # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs 
MW 
[kDa] 
calc
. pI 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 2 30 30 165 623 62.0 5.2
4 
H6VRF8 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - [H6VRF8_HUMAN] 15 27 32 131 644 66.0 8.1
2 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 23 25 28 116 584 58.8 5.2
1 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 8 22 30 73 639 65.4 8.0
0 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - [K1C16_HUMAN] 32 9 18 56 473 51.2 5.0
5 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 31 6 18 53 472 51.5 5.1
6 
P04259 Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 SV=5 - [K2C6B_HUMAN] 10 1 20 43 564 60.0 8.0
0 
B4DWU6 cDNA FLJ51361, highly similar to Keratin, type II cytoskeletal 6A OS=Homo sapiens PE=2 SV=1 - [B4DWU6_HUMAN] 18 2 21 37 520 55.8 6.4
8 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] 15 8 18 37 590 62.3 7.7
4 
M0QZP4 Branched-chain-amino-acid aminotransferase OS=Homo sapiens GN=BCAT2 PE=1 SV=1 - [M0QZP4_HUMAN] 7 3 3 16 313 34.9 6.9
8 
- 187 - 
Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2 - [K1C17_HUMAN] 27 3 12 20 432 48.1 5.0
2 
A0A024R
0Y2 
HCG30204, isoform CRA_a OS=Homo sapiens GN=hCG_30204 PE=4 SV=1 - [A0A024R0Y2_HUMAN] 11 8 8 11 2268 257.1 6.6
1 
Q14CN4 Keratin, type II cytoskeletal 72 OS=Homo sapiens GN=KRT72 PE=1 SV=2 - [K2C72_HUMAN] 11 1 4 8 511 55.8 6.8
9 
A0A087
WYF5 
Salivary acidic proline-rich phosphoprotein 1/2 (Fragment) OS=Homo sapiens GN=PRH1 PE=4 SV=1 - 
[A0A087WYF5_HUMAN] 
8 1 1 3 140 14.0 11.
46 
B3KPS3 cDNA FLJ32131 fis, clone PEBLM2000267, highly similar to Tubulin alpha-ubiquitous chain OS=Homo 
sapiens PE=2 SV=1 - [B3KPS3_HUMAN] 
38 6 6 7 416 46.2 5.1
2 
B4E2A0 cDNA FLJ61543, highly similar to Desmoplakin OS=Homo sapiens PE=2 SV=1 - [B4E2A0_HUMAN] 6 4 4 6 1350 156.
2 
7.4
3 
A0A087
WWT3 
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=1 - [A0A087WWT3_HUMAN] 14 3 3 6 396 45.1 6.1
0 
Q53HF2 Heat shock 70kDa protein 8 isoform 2 variant (Fragment) OS=Homo sapiens PE=1 SV=1 - 
[Q53HF2_HUMAN] 
40 4 4 5 493 53.5 5.8
6 
Q8N1N4 Keratin, type II cytoskeletal 78 OS=Homo sapiens GN=KRT78 PE=2 SV=2 - [K2C78_HUMAN] 3 1 2 4 520 56.8 6.0
2 
Q45KI0 Trypsin I (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q45KI0_HUMAN] 17 1 1 3 84 9.2 9.9
9 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] 1 3 3 4 110 11.3 6.5
4 
Q19KS2 Lactoferrin (Fragment) OS=Homo sapiens PE=2 SV=1 - [Q19KS2_HUMAN] 15 4 4 5 353 39.1 9.0
3 
I3L1U9 Actin, cytoplasmic 2 (Fragment) OS=Homo sapiens GN=ACTG1 PE=1 SV=1 - [I3L1U9_HUMAN] 48 3 3 4 214 23.8 5.4
4 
O75556 Mammaglobin-B OS=Homo sapiens GN=SCGB2A1 PE=1 SV=1 - [SG2A1_HUMAN] 1 2 2 2 95 10.9 5.7
8 
Q86W20 Protease serine 1 (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q86W20_HUMAN] 6 1 1 2 84 9.2 10.
27 
B3KX99 cDNA FLJ45019 fis, clone BRAWH3015825 OS=Homo sapiens PE=2 SV=1 - [B3KX99_HUMAN] 2 1 1 3 333 38.5 8.9
7 
Q9GZZ8 Extracellular glycoprotein lacritin OS=Homo sapiens GN=LACRT PE=1 SV=1 - [LACRT_HUMAN] 2 2 2 2 138 14.2 5.5
0 
P61626 Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1 - [LYSC_HUMAN] 3 3 3 3 148 16.5 9.1
6 
J3QRT3 Uncharacterized protein KIAA0195 (Fragment) OS=Homo sapiens GN=KIAA0195 PE=1 SV=5 - 
[J3QRT3_HUMAN] 
1 1 1 2 89 9.5 6.7
6 
B2R4M6 Protein S100 OS=Homo sapiens PE=2 SV=1 - [B2R4M6_HUMAN] 2 2 2 3 114 13.2 6.1
3 
- 188 - 
Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 - [DSG1_HUMAN] 1 1 1 3 1049 113.
7 
5.0
3 
A0A024
R1X8 
Junction plakoglobin, isoform CRA_a OS=Homo sapiens GN=JUP PE=4 SV=1 - [A0A024R1X8_HUMAN] 2 1 1 2 745 81.7 6.1
4 
Q7Z612 Acidic ribosomal phosphoprotein P1 OS=Homo sapiens PE=2 SV=1 - [Q7Z612_HUMAN] 4 1 1 1 113 11.4 4.3
6 
H0YGI8 Stress-induced-phosphoprotein 1 (Fragment) OS=Homo sapiens GN=STIP1 PE=1 SV=1 - 
[H0YGI8_HUMAN] 
3 1 1 1 137 15.9 6.1
9 
O95968 Secretoglobin family 1D member 1 OS=Homo sapiens GN=SCGB1D1 PE=1 SV=1 - [SG1D1_HUMAN] 1 1 1 1 90 9.9 9.2
5 
Q5VSP4 Putative lipocalin 1-like protein 1 OS=Homo sapiens GN=LCN1P1 PE=5 SV=1 - [LC1L1_HUMAN] 2 1 1 1 162 17.9 5.0
0 
P31151 Protein S100-A7 OS=Homo sapiens GN=S100A7 PE=1 SV=4 - [S10A7_HUMAN] 1 1 1 1 101 11.5 6.7
7 
A0A087
WYX2 
Histone lysine demethylase PHF8 OS=Homo sapiens GN=PHF8 PE=1 SV=1 - [A0A087WYX2_HUMAN] 2 1 1 1 303 33.8 10.
08 
F8WE04 Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=1 SV=1 - [F8WE04_HUMAN] 2 1 1 1 186 20.4 9.0
6 
F8WCJ1 Eukaryotic translation initiation factor 5A OS=Homo sapiens GN=EIF5A2 PE=1 SV=1 - 
[F8WCJ1_HUMAN] 
8 1 1 1 105 11.7 9.1
4 
Q590G7 UTY (Fragment) OS=Homo sapiens GN=UTY PE=4 SV=1 - [Q590G7_HUMAN] 83 1 1 1 226 23.2 7.9
6 
Q9HB00 Desmocollin 1, isoform CRA_b OS=Homo sapiens GN=DSC1 PE=4 SV=1 - [Q9HB00_HUMAN] 2 1 1 1 840 93.8 5.5
3 
B4DYE2 Kinesin-like protein OS=Homo sapiens PE=2 SV=1 - [B4DYE2_HUMAN] 2 1 1 1 1234 139.
8 
6.1
3 
Q7Z350 Putative uncharacterized protein DKFZp686L0695 OS=Homo sapiens GN=DKFZp686L0695 PE=2 SV=1 - 
[Q7Z350_HUMAN] 
1 1 1 1 549 62.1 6.3
7 
B7Z639 cDNA FLJ54938, weakly similar to Mus musculus transmembrane and tetratricopeptide repeat containing 
1 (Tmtc1), mRNA OS=Homo sapiens PE=2 SV=1 - [B7Z639_HUMAN] 
3 1 1 1 591 66.7 8.7
6 
Q4ZG32 Putative uncharacterized protein EPB41L5 (Fragment) OS=Homo sapiens GN=EPB41L5 PE=4 SV=1 - 
[Q4ZG32_HUMAN] 
2 1 1 1 533 60.6 7.9
6 
A8K651 cDNA FLJ75700, highly similar to Homo sapiens complement component 1, q subcomponent binding 
protein (C1QBP), nuclear gene encoding mitochondrial protein, mRNA OS=Homo sapiens PE=2 SV=1 - 
[A8K651_HUMAN] 
2 1 1 2 282 31.4 4.8
4 
A0A087
WTG3 
Cullin-3 OS=Homo sapiens GN=CUL3 PE=1 SV=1 - [A0A087WTG3_HUMAN] 1 1 1 1 342 39.1 9.4
8 
I3L1H9 Zymogen granule protein 16 homolog B (Fragment) OS=Homo sapiens GN=ZG16B PE=1 SV=1 - 
[I3L1H9_HUMAN] 
5 1 1 1 69 7.5 9.3
2 
Q7Z5L4 Spermatogenesis-associated protein 19, mitochondrial OS=Homo sapiens GN=SPATA19 PE=2 SV=2 - 
[SPT19_HUMAN] 
1 1 1 1 167 19.2 6.9
6 
- 189 - 
Q15203 Prothymosin alpha OS=Homo sapiens PE=4 SV=2 - [Q15203_HUMAN] 18 1 1 1 73 8.2 3.7
6 
A0A075
B6Z2 
Protein TRAJ56 (Fragment) OS=Homo sapiens GN=TRAJ56 PE=4 SV=1 - [A0A075B6Z2_HUMAN] 2 1 1 2 21 2.2 10.
29 
Q96PE2 Rho guanine nucleotide exchange factor 17 OS=Homo sapiens GN=ARHGEF17 PE=1 SV=1 - 
[ARHGH_HUMAN] 
1 1 1 1 2063 221.
5 
6.2
9 
B7Z5R3 Src family associated phosphoprotein 2, isoform CRA_c OS=Homo sapiens GN=SCAP2 PE=2 SV=1 - 
[B7Z5R3_HUMAN] 
3 1 1 1 187 21.6 4.4
6 
B3KM59 cDNA FLJ10361 fis, clone NT2RM2001256, highly similar to Anaphase-promoting complex subunit 1 
OS=Homo sapiens PE=2 SV=1 - [B3KM59_HUMAN] 
1 1 1 1 306 32.9 7.4
0 
Q562R1 Beta-actin-like protein 2 OS=Homo sapiens GN=ACTBL2 PE=1 SV=2 - [ACTBL_HUMAN] 1 1 1 1 376 42.0 5.5
9 
B3KPM8 cDNA FLJ31974 fis, clone NT2RP7008167, weakly similar to 85.1 kDa PROTEIN IN GREB-FEOA 
INTERGENIC REGION OS=Homo sapiens PE=2 SV=1 - [B3KPM8_HUMAN] 
2 1 1 1 995 111.
7 
8.7
2 
Q96QW
8 
DJ576K7.1 (FK506 binding protein 12-rapamycin associated protein 1) (Fragment) OS=Homo sapiens 
GN=FRAP1 PE=4 SV=1 - [Q96QW8_HUMAN] 
3 1 1 1 895 102.
9 
7.2
8 
H0Y8C6 Importin-5 (Fragment) OS=Homo sapiens GN=IPO5 PE=1 SV=1 - [H0Y8C6_HUMAN] 1 1 1 1 1099 123.
8 
5.0
6 
Q0KH84 Kell blood group antigen Cellano (Fragment) OS=Homo sapiens GN=KEL PE=4 SV=1 - 
[Q0KH84_HUMAN] 
9 1 1 1 177 20.4 5.9
1 
Q8TC04 Keratin 23 (Histone deacetylase inducible) OS=Homo sapiens GN=KRT23 PE=2 SV=1 - 
[Q8TC04_HUMAN] 
1 1 1 1 422 48.1 6.5
4 
Q6ZSX8 cDNA FLJ45139 fis, clone BRAWH3039623 OS=Homo sapiens PE=2 SV=1 - [Q6ZSX8_HUMAN] 1 1 1 1 136 15.5 10.
07 
 
IGFR-1 
Accession Description # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs 
MW 
[kDa] 
calc
. pI 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 23 29 32 159 584 58.8 5.2
1 
H6VRF8 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - [H6VRF8_HUMAN] 14 27 31 149 644 66.0 8.1
2 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 2 31 31 125 623 62.0 5.2
4 
- 190 - 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - [K1C16_HUMAN] 32 15 26 71 473 51.2 5.0
5 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 8 16 25 68 639 65.4 8.0
0 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 34 6 21 56 472 51.5 5.1
6 
P04259 Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 SV=5 - [K2C6B_HUMAN] 10 3 22 53 564 60.0 8.0
0 
B4DWU6 cDNA FLJ51361, highly similar to Keratin, type II cytoskeletal 6A OS=Homo sapiens PE=2 SV=1 - [B4DWU6_HUMAN] 15 2 21 42 520 55.8 6.4
8 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] 14 8 16 35 590 62.3 7.7
4 
Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2 - [K1C17_HUMAN] 29 3 14 21 432 48.1 5.0
2 
A0A024R
0Y2 
HCG30204, isoform CRA_a OS=Homo sapiens GN=hCG_30204 PE=4 SV=1 - [A0A024R0Y2_HUMAN] 17 10 10 13 2268 257.1 6.6
1 
Q0IIN1 Keratin 77 OS=Homo sapiens GN=KRT77 PE=1 SV=1 - [Q0IIN1_HUMAN] 9 1 4 12 578 61.8 5.8
5 
B3KPS3 cDNA FLJ32131 fis, clone PEBLM2000267, highly similar to Tubulin alpha-ubiquitous chain OS=Homo sapiens PE=2 SV=1 - 
[B3KPS3_HUMAN] 
31 6 6 9 416 46.2 5.1
2 
Q53HF2 Heat shock 70kDa protein 8 isoform 2 variant (Fragment) OS=Homo sapiens PE=1 SV=1 - 
[Q53HF2_HUMAN] 
40 6 6 10 493 53.5 5.8
6 
Q9GZZ8 Extracellular glycoprotein lacritin OS=Homo sapiens GN=LACRT PE=1 SV=1 - [LACRT_HUMAN] 2 3 3 6 138 14.2 5.5
0 
A0A087
WWT3 
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=1 - [A0A087WWT3_HUMAN] 14 2 2 5 396 45.1 6.1
0 
Q14CN4 Keratin, type II cytoskeletal 72 OS=Homo sapiens GN=KRT72 PE=1 SV=2 - [K2C72_HUMAN] 13 1 4 6 511 55.8 6.8
9 
Q45KI0 Trypsin I (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q45KI0_HUMAN] 17 1 1 3 84 9.2 9.9
9 
I3L1U9 Actin, cytoplasmic 2 (Fragment) OS=Homo sapiens GN=ACTG1 PE=1 SV=1 - [I3L1U9_HUMAN] 48 3 3 5 214 23.8 5.4
4 
Q8N1N4 Keratin, type II cytoskeletal 78 OS=Homo sapiens GN=KRT78 PE=2 SV=2 - [K2C78_HUMAN] 1 2 3 4 520 56.8 6.0
2 
Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 - [HORN_HUMAN] 1 2 2 3 2850 282.2 10.
04 
C9JL25 60 kDa heat shock protein, mitochondrial (Fragment) OS=Homo sapiens GN=HSPD1 PE=1 SV=1 - 
[C9JL25_HUMAN] 
7 1 1 2 175 19.2 9.7
3 
A0A0A0
MRQ5 
Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 - [A0A0A0MRQ5_HUMAN] 6 2 2 3 97 10.7 8.7
2 
B2R4M6 Protein S100 OS=Homo sapiens PE=2 SV=1 - [B2R4M6_HUMAN] 2 2 2 3 114 13.2 6.1
3 
- 191 - 
O75556 Mammaglobin-B OS=Homo sapiens GN=SCGB2A1 PE=1 SV=1 - [SG2A1_HUMAN] 1 2 2 2 95 10.9 5.7
8 
E5RJN0 Heparan-alpha-glucosaminide N-acetyltransferase OS=Homo sapiens GN=HGSNAT PE=1 SV=1 - 
[E5RJN0_HUMAN] 
2 1 1 2 352 38.9 8.3
2 
Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 - [DSG1_HUMAN] 1 2 2 2 1049 113.7 5.0
3 
O14942 Heat shock protein beta (Fragment) OS=Homo sapiens PE=4 SV=1 - [O14942_HUMAN] 12 1 1 2 130 14.1 4.7
9 
B3KX99 cDNA FLJ45019 fis, clone BRAWH3015825 OS=Homo sapiens PE=2 SV=1 - [B3KX99_HUMAN] 2 1 1 3 333 38.5 8.9
7 
P61626 Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1 - [LYSC_HUMAN] 3 3 3 3 148 16.5 9.1
6 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] 1 2 2 2 110 11.3 6.5
4 
A0A087
WTG3 
Cullin-3 OS=Homo sapiens GN=CUL3 PE=1 SV=1 - [A0A087WTG3_HUMAN] 1 1 1 2 342 39.1 9.4
8 
Q5VSP4 Putative lipocalin 1-like protein 1 OS=Homo sapiens GN=LCN1P1 PE=5 SV=1 - [LC1L1_HUMAN] 2 2 2 2 162 17.9 5.0
0 
Q19KS2 Lactoferrin (Fragment) OS=Homo sapiens PE=2 SV=1 - [Q19KS2_HUMAN] 15 2 2 2 353 39.1 9.0
3 
P25311 Zinc-alpha-2-glycoprotein OS=Homo sapiens GN=AZGP1 PE=1 SV=2 - [ZA2G_HUMAN] 1 1 1 2 298 34.2 6.0
5 
P15924 Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 - [DESP_HUMAN] 5 2 2 2 2871 331.6 6.8
1 
Q86W20 Protease serine 1 (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q86W20_HUMAN] 6 1 1 1 84 9.2 10.
27 
J3QSA3 Polyubiquitin-B (Fragment) OS=Homo sapiens GN=UBB PE=1 SV=1 - [J3QSA3_HUMAN] 37 1 1 1 43 4.9 5.1
9 
F8WF65 Elongation factor 1-beta OS=Homo sapiens GN=EEF1B2 PE=1 SV=1 - [F8WF65_HUMAN] 4 1 1 1 29 3.1 4.4
6 
M0R1I1 Tubulin beta-4A chain (Fragment) OS=Homo sapiens GN=TUBB4A PE=1 SV=1 - [M0R1I1_HUMAN] 27 1 1 1 74 7.8 4.9
4 
P12004 Proliferating cell nuclear antigen OS=Homo sapiens GN=PCNA PE=1 SV=1 - [PCNA_HUMAN] 7 2 2 2 261 28.8 4.6
9 
H7C2X0 Translation initiation factor eIF-2B subunit epsilon (Fragment) OS=Homo sapiens GN=EIF2B5 PE=1 SV=1 - 
[H7C2X0_HUMAN] 
4 1 1 1 92 9.4 9.4
1 
G3V361 Calmodulin (Fragment) OS=Homo sapiens GN=CALM1 PE=1 SV=1 - [G3V361_HUMAN] 8 1 1 1 98 11.1 4.2
5 
Q7Z612 Acidic ribosomal phosphoprotein P1 OS=Homo sapiens PE=2 SV=1 - [Q7Z612_HUMAN] 4 1 1 1 113 11.4 4.3
6 
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A0A0A0
MRX7 
Transcription factor TFIIIB component B'' homolog OS=Homo sapiens GN=BDP1 PE=1 SV=1 - 
[A0A0A0MRX7_HUMAN] 
5 1 1 1 846 95.5 8.1
5 
J3QRT3 Uncharacterized protein KIAA0195 (Fragment) OS=Homo sapiens GN=KIAA0195 PE=1 SV=5 - 
[J3QRT3_HUMAN] 
1 1 1 1 89 9.5 6.7
6 
P01040 Cystatin-A OS=Homo sapiens GN=CSTA PE=1 SV=1 - [CYTA_HUMAN] 1 1 1 1 98 11.0 5.5
0 
B4E1W3 cDNA FLJ51732, highly similar to Peroxisomal NADH pyrophosphatase NUDT12 (EC 3.6.1.22) OS=Homo 
sapiens PE=2 SV=1 - [B4E1W3_HUMAN] 
3 1 1 1 444 50.0 6.7
9 
F8WE04 Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=1 SV=1 - [F8WE04_HUMAN] 2 1 1 1 186 20.4 9.0
6 
A0A087
WXD2 
Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 OS=Homo sapiens 
GN=MAGI1 PE=1 SV=1 - [A0A087WXD2_HUMAN] 
7 1 1 1 980 106.8 6.4
6 
Q5HY57 Emerin OS=Homo sapiens GN=EMD PE=1 SV=1 - [Q5HY57_HUMAN] 2 1 1 1 219 24.9 5.0
2 
Q9HB00 Desmocollin 1, isoform CRA_b OS=Homo sapiens GN=DSC1 PE=4 SV=1 - [Q9HB00_HUMAN] 2 1 1 1 840 93.8 5.5
3 
Q59H71 Sodium channel protein type II alpha subunit variant (Fragment) OS=Homo sapiens PE=2 SV=1 - 
[Q59H71_HUMAN] 
7 1 1 1 1315 149.2 5.4
9 
Q5ZEY3 Glyceraldehyde-3-phosphate dehydrogenase (Fragment) OS=Homo sapiens GN=GAPD PE=2 SV=1 - 
[Q5ZEY3_HUMAN] 
6 1 1 1 86 9.2 9.7
2 
B7Z5R3 Src family associated phosphoprotein 2, isoform CRA_c OS=Homo sapiens GN=SCAP2 PE=2 SV=1 - 
[B7Z5R3_HUMAN] 
3 1 1 1 187 21.6 4.4
6 
C9JWI2 A disintegrin and metalloproteinase with thrombospondin motifs 9 OS=Homo sapiens GN=ADAMTS9 PE=4 
SV=1 - [C9JWI2_HUMAN] 
2 1 1 1 488 55.0 7.6
2 
P07737 Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 - [PROF1_HUMAN] 2 1 1 1 140 15.0 8.2
7 
V9GZN0 Histone H2A gene (lambda-HHG55) (Fragment) OS=Homo sapiens PE=4 SV=1 - [V9GZN0_HUMAN] 19 1 1 1 47 5.0 11.
90 
E9PN51 NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial (Fragment) OS=Homo sapiens 
GN=NDUFS8 PE=1 SV=1 - [E9PN51_HUMAN] 
6 1 1 1 110 12.4 9.9
8 
P31151 Protein S100-A7 OS=Homo sapiens GN=S100A7 PE=1 SV=4 - [S10A7_HUMAN] 1 1 1 1 101 11.5 6.7
7 
Q75MN6 Putative uncharacterized protein MLL3 (Fragment) OS=Homo sapiens GN=MLL3 PE=4 SV=1 - 
[Q75MN6_HUMAN] 
4 1 1 1 2185 239.3 6.0
6 
B2RDE0 cDNA, FLJ96567, highly similar to Homo sapiens propionyl Coenzyme A carboxylase, alpha 
polypeptide(PCCA), mRNA OS=Homo sapiens PE=2 SV=1 - [B2RDE0_HUMAN] 
2 1 1 1 703 77.4 7.0
6 
Q96QC0 Serine/threonine-protein phosphatase 1 regulatory subunit 10 OS=Homo sapiens GN=PPP1R10 PE=1 SV=1 - 
[PP1RA_HUMAN] 
1 1 1 1 940 99.0 9.1
7 
A0A075
B6Z2 
Protein TRAJ56 (Fragment) OS=Homo sapiens GN=TRAJ56 PE=4 SV=1 - [A0A075B6Z2_HUMAN] 2 1 1 1 21 2.2 10.
29 
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Q16378 Proline-rich protein 4 OS=Homo sapiens GN=PRR4 PE=1 SV=3 - [PROL4_HUMAN] 2 1 1 1 134 15.1 7.0
6 
P05109 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 - [S10A8_HUMAN] 1 2 2 2 93 10.8 7.0
3 
Q9UL72 Myosin-reactive immunoglobulin heavy chain variable region (Fragment) OS=Homo sapiens PE=2 SV=1 - 
[Q9UL72_HUMAN] 
5 1 1 1 118 12.9 6.5
8 
B4DJN9 cDNA FLJ57508, highly similar to Eukaryotic translation initiation factor 3 subunit 3 OS=Homo sapiens PE=2 
SV=1 - [B4DJN9_HUMAN] 
1 1 1 1 153 16.8 5.2
9 
A0A087
WUP6 
Transmembrane and coiled-coil domain-containing protein 3 (Fragment) OS=Homo sapiens GN=TMCO3 
PE=1 SV=1 - [A0A087WUP6_HUMAN] 
5 1 1 1 145 16.9 4.9
7 
E9PNW5 Uncharacterized protein C4orf50 OS=Homo sapiens GN=C4orf50 PE=4 SV=1 - [E9PNW5_HUMAN] 1 1 1 1 750 83.0 6.2
8 
J3QQW9 Polycomb protein SUZ12 OS=Homo sapiens GN=SUZ12 PE=1 SV=1 - [J3QQW9_HUMAN] 3 1 1 1 716 80.3 8.7
6 
A9NIU4 Obscurin isoform B (Fragment) OS=Homo sapiens GN=OBSCN PE=2 SV=1 - [A9NIU4_HUMAN] 4 1 1 1 1960 212.3 6.3
5 
A8K651 cDNA FLJ75700, highly similar to Homo sapiens complement component 1, q subcomponent binding protein 
(C1QBP), nuclear gene encoding mitochondrial protein, mRNA OS=Homo sapiens PE=2 SV=1 - 
[A8K651_HUMAN] 
1 1 1 2 282 31.4 4.8
4 
A0A0A0
MQU1 
Inverted formin-2 (Fragment) OS=Homo sapiens GN=INF2 PE=1 SV=1 - [A0A0A0MQU1_HUMAN] 6 1 1 1 717 78.8 5.5
8 
IGFR-2 
Accessio
n 
Description # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs 
MW 
[kDa] 
calc
. pI 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 2 31 32 257 623 62.0 5.2
4 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 23 31 35 172 584 58.8 5.2
1 
H6VRF8 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - [H6VRF8_HUMAN] 16 33 38 191 644 66.0 8.1
2 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 7 26 35 119 639 65.4 8.0
0 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 32 9 26 64 472 51.5 5.1
6 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - [K1C16_HUMAN] 33 11 24 59 473 51.2 5.0
5 
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P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] 16 11 22 49 590 62.3 7.7
4 
B4DRR0 cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A OS=Homo sapiens PE=2 SV=1 - [B4DRR0_HUMAN] 19 7 20 37 535 57.8 8.0
0 
Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2 - [K1C17_HUMAN] 27 3 15 24 432 48.1 5.0
2 
Q0IIN1 Keratin 77 OS=Homo sapiens GN=KRT77 PE=1 SV=1 - [Q0IIN1_HUMAN] 7 4 7 19 578 61.8 5.8
5 
Q6KB66 Keratin, type II cytoskeletal 80 OS=Homo sapiens GN=KRT80 PE=1 SV=2 - [K2C80_HUMAN] 9 1 2 15 452 50.5 5.6
7 
A0A024R
0Y2 
HCG30204, isoform CRA_a OS=Homo sapiens GN=hCG_30204 PE=4 SV=1 - [A0A024R0Y2_HUMAN] 13 10 10 13 2268 257.1 6.6
1 
Q86Y46 Keratin, type II cytoskeletal 73 OS=Homo sapiens GN=KRT73 PE=1 SV=1 - [K2C73_HUMAN] 11 2 5 12 540 58.9 7.2
3 
Q53HF2 Heat shock 70kDa protein 8 isoform 2 variant (Fragment) OS=Homo sapiens PE=1 SV=1 - [Q53HF2_HUMAN] 22 5 7 8 493 53.5 5.8
6 
B3KPS3 cDNA FLJ32131 fis, clone PEBLM2000267, highly similar to Tubulin alpha-ubiquitous chain OS=Homo sapiens 
PE=2 SV=1 - [B3KPS3_HUMAN] 
35 4 4 7 416 46.2 5.1
2 
Q45KI0 Trypsin I (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q45KI0_HUMAN] 17 1 1 3 84 9.2 9.9
9 
J3QRT3 Uncharacterized protein KIAA0195 (Fragment) OS=Homo sapiens GN=KIAA0195 PE=1 SV=5 - 
[J3QRT3_HUMAN] 
1 1 1 5 89 9.5 6.7
6 
F6KPG5 Albumin (Fragment) OS=Homo sapiens PE=2 SV=1 - [F6KPG5_HUMAN] 14 3 3 5 585 66.5 6.0
4 
B4DFN
9 
cDNA FLJ54303, highly similar to Heat shock 70 kDa protein 1 OS=Homo sapiens PE=2 SV=1 - 
[B4DFN9_HUMAN] 
30 3 5 5 572 62.4 5.6
9 
B7Z597 cDNA FLJ54373, highly similar to 60 kDa heat shock protein, mitochondrial OS=Homo sapiens PE=2 SV=1 - 
[B7Z597_HUMAN] 
9 2 2 3 564 60.0 5.7
4 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] 1 3 3 4 110 11.3 6.5
4 
Q8TBA
7 
HSP90AA1 protein (Fragment) OS=Homo sapiens GN=HSP90AA1 PE=2 SV=2 - [Q8TBA7_HUMAN] 15 4 4 5 638 73.8 5.1
6 
Q7Z612 Acidic ribosomal phosphoprotein P1 OS=Homo sapiens PE=2 SV=1 - [Q7Z612_HUMAN] 4 1 1 3 113 11.4 4.3
6 
Q8N1N
4 
Keratin, type II cytoskeletal 78 OS=Homo sapiens GN=KRT78 PE=2 SV=2 - [K2C78_HUMAN] 3 3 5 5 520 56.8 6.0
2 
I3L1U9 Actin, cytoplasmic 2 (Fragment) OS=Homo sapiens GN=ACTG1 PE=1 SV=1 - [I3L1U9_HUMAN] 65 4 4 4 214 23.8 5.4
4 
Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 - [HORN_HUMAN] 1 2 2 2 2850 282.
2 
10.
04 
A0A087
WUV8 
Basigin OS=Homo sapiens GN=BSG PE=1 SV=1 - [A0A087WUV8_HUMAN] 6 1 1 2 189 20.5 6.6
8 
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B3KX99 cDNA FLJ45019 fis, clone BRAWH3015825 OS=Homo sapiens PE=2 SV=1 - [B3KX99_HUMAN] 2 1 1 4 333 38.5 8.9
7 
O75556 Mammaglobin-B OS=Homo sapiens GN=SCGB2A1 PE=1 SV=1 - [SG2A1_HUMAN] 1 2 2 2 95 10.9 5.7
8 
B4E2A0 cDNA FLJ61543, highly similar to Desmoplakin OS=Homo sapiens PE=2 SV=1 - [B4E2A0_HUMAN] 6 3 3 3 1350 156.
2 
7.4
3 
Q86W2
0 
Protease serine 1 (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q86W20_HUMAN] 6 1 1 2 84 9.2 10.
27 
Q19KS2 Lactoferrin (Fragment) OS=Homo sapiens PE=2 SV=1 - [Q19KS2_HUMAN] 15 2 2 3 353 39.1 9.0
3 
Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 - [DSG1_HUMAN] 1 2 2 2 1049 113.
7 
5.0
3 
Q5ZEY3 Glyceraldehyde-3-phosphate dehydrogenase (Fragment) OS=Homo sapiens GN=GAPD PE=2 SV=1 - 
[Q5ZEY3_HUMAN] 
6 1 1 2 86 9.2 9.7
2 
Q04656 Copper-transporting ATPase 1 OS=Homo sapiens GN=ATP7A PE=1 SV=3 - [ATP7A_HUMAN] 1 1 1 2 1500 163.
3 
6.2
4 
H0YKZ7 Annexin (Fragment) OS=Homo sapiens GN=ANXA2 PE=1 SV=1 - [H0YKZ7_HUMAN] 16 1 1 2 119 13.0 8.1
3 
Q9GZZ
8 
Extracellular glycoprotein lacritin OS=Homo sapiens GN=LACRT PE=1 SV=1 - [LACRT_HUMAN] 2 2 2 2 138 14.2 5.5
0 
B4DNE
0 
cDNA FLJ52573, highly similar to Elongation factor 1-alpha 1 OS=Homo sapiens PE=2 SV=1 - 
[B4DNE0_HUMAN] 
35 2 2 3 395 42.6 9.0
1 
A0A087
WYX2 
Histone lysine demethylase PHF8 OS=Homo sapiens GN=PHF8 PE=1 SV=1 - [A0A087WYX2_HUMAN] 2 1 1 4 303 33.8 10.
08 
A0A0A0
MRQ5 
Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 - [A0A0A0MRQ5_HUMAN] 6 2 2 2 97 10.7 8.7
2 
Q3SYB5 SERPINB12 protein OS=Homo sapiens GN=SERPINB12 PE=2 SV=1 - [Q3SYB5_HUMAN] 2 2 2 3 183 20.9 5.8
7 
P31151 Protein S100-A7 OS=Homo sapiens GN=S100A7 PE=1 SV=4 - [S10A7_HUMAN] 1 1 1 2 101 11.5 6.7
7 
B4DHR
1 
cDNA FLJ53009, highly similar to Calreticulin OS=Homo sapiens PE=2 SV=1 - [B4DHR1_HUMAN] 5 2 2 2 212 24.3 5.1
1 
Q5VSP4 Putative lipocalin 1-like protein 1 OS=Homo sapiens GN=LCN1P1 PE=5 SV=1 - [LC1L1_HUMAN] 2 2 2 2 162 17.9 5.0
0 
F8WF6
5 
Elongation factor 1-beta OS=Homo sapiens GN=EEF1B2 PE=1 SV=1 - [F8WF65_HUMAN] 4 1 1 1 29 3.1 4.4
6 
F8WE0
4 
Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=1 SV=1 - [F8WE04_HUMAN] 3 2 2 2 186 20.4 9.0
6 
A0A024
RC29 
Desmocollin 3, isoform CRA_b OS=Homo sapiens GN=DSC3 PE=4 SV=1 - [A0A024RC29_HUMAN] 3 1 1 1 896 99.9 6.1
0 
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D6W50
7 
HCG1990625, isoform CRA_a OS=Homo sapiens GN=hCG_1990625 PE=4 SV=1 - [D6W507_HUMAN] 11 1 1 1 146 16.6 6.1
3 
G3V361 Calmodulin (Fragment) OS=Homo sapiens GN=CALM1 PE=1 SV=1 - [G3V361_HUMAN] 8 1 1 1 98 11.1 4.2
5 
E5RJN0 Heparan-alpha-glucosaminide N-acetyltransferase OS=Homo sapiens GN=HGSNAT PE=1 SV=1 - 
[E5RJN0_HUMAN] 
2 1 1 1 352 38.9 8.3
2 
P07108 Acyl-CoA-binding protein OS=Homo sapiens GN=DBI PE=1 SV=2 - [ACBP_HUMAN] 5 1 1 1 87 10.0 6.5
7 
Q8IXY4 PHLDB2 protein OS=Homo sapiens GN=PHLDB2 PE=2 SV=1 - [Q8IXY4_HUMAN] 1 1 1 1 519 56.9 8.7
8 
A0A087
WXD2 
Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 OS=Homo sapiens 
GN=MAGI1 PE=1 SV=1 - [A0A087WXD2_HUMAN] 
7 1 1 1 980 106.
8 
6.4
6 
F8W07
9 
ATP synthase subunit beta, mitochondrial (Fragment) OS=Homo sapiens GN=ATP5B PE=1 SV=1 - 
[F8W079_HUMAN] 
4 1 1 1 284 30.2 8.2
9 
A9UFC0 Caspase 14 OS=Homo sapiens GN=CASP14 PE=2 SV=1 - [A9UFC0_HUMAN] 2 1 1 1 242 27.6 5.3
4 
Q5TDG
9 
DnaJ (Hsp40) homolog, subfamily C, member 16, isoform CRA_a OS=Homo sapiens GN=DNAJC16 PE=1 SV=1 
- [Q5TDG9_HUMAN] 
4 1 1 1 595 69.3 7.1
5 
B8ZZ54 10 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPE1 PE=1 SV=1 - [B8ZZ54_HUMAN] 4 1 1 1 47 5.2 4.7
2 
D3VVK
8 
Ataxin 3 variant ref (Fragment) OS=Homo sapiens GN=ATXN3 PE=2 SV=1 - [D3VVK8_HUMAN] 1 1 1 1 329 37.8 4.8
2 
B4DYE2 Kinesin-like protein OS=Homo sapiens PE=2 SV=1 - [B4DYE2_HUMAN] 2 1 1 1 1234 139.
8 
6.1
3 
B2R8Y4 cDNA, FLJ94117, highly similar to Homo sapiens actinin, alpha 3 (ACTN3), mRNA OS=Homo sapiens PE=1 
SV=1 - [B2R8Y4_HUMAN] 
4 1 1 1 901 103.
2 
5.6
0 
A0JLQ0 AZGP1 protein (Fragment) OS=Homo sapiens GN=AZGP1 PE=2 SV=1 - [A0JLQ0_HUMAN] 3 1 1 1 159 18.7 8.9
7 
P05387 60S acidic ribosomal protein P2 OS=Homo sapiens GN=RPLP2 PE=1 SV=1 - [RLA2_HUMAN] 1 1 1 1 115 11.7 4.5
4 
S4R3R2 Ankyrin repeat domain-containing protein 10 (Fragment) OS=Homo sapiens GN=ANKRD10 PE=1 SV=1 - 
[S4R3R2_HUMAN] 
1 1 1 1 121 13.4 5.0
8 
Q9HB0
0 
Desmocollin 1, isoform CRA_b OS=Homo sapiens GN=DSC1 PE=4 SV=1 - [Q9HB00_HUMAN] 2 2 2 3 840 93.8 5.5
3 
F8WCJ1 Eukaryotic translation initiation factor 5A OS=Homo sapiens GN=EIF5A2 PE=1 SV=1 - [F8WCJ1_HUMAN] 8 1 1 1 105 11.7 9.1
4 
A0A0C4
DFV9 
Protein SET OS=Homo sapiens GN=SET PE=1 SV=1 - [A0A0C4DFV9_HUMAN] 6 1 1 1 266 31.1 4.2
3 
Q8NFF2 Sodium/potassium/calcium exchanger 4 OS=Homo sapiens GN=SLC24A4 PE=1 SV=2 - [NCKX4_HUMAN] 1 1 1 1 622 69.0 7.5
2 
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Q9HBT
7 
Zinc finger protein 287 OS=Homo sapiens GN=ZNF287 PE=2 SV=1 - [ZN287_HUMAN] 1 1 1 1 754 87.5 8.4
8 
H9KV28 Protein diaphanous homolog 1 OS=Homo sapiens GN=DIAPH1 PE=1 SV=2 - [H9KV28_HUMAN] 5 1 1 1 1228 136.
8 
5.2
4 
Q5HY5
7 
Emerin OS=Homo sapiens GN=EMD PE=1 SV=1 - [Q5HY57_HUMAN] 2 1 1 1 219 24.9 5.0
2 
Q15203 Prothymosin alpha OS=Homo sapiens PE=4 SV=2 - [Q15203_HUMAN] 18 1 1 1 73 8.2 3.7
6 
A8K651 cDNA FLJ75700, highly similar to Homo sapiens complement component 1, q subcomponent binding protein 
(C1QBP), nuclear gene encoding mitochondrial protein, mRNA OS=Homo sapiens PE=2 SV=1 - 
[A8K651_HUMAN] 
4 2 2 2 282 31.4 4.8
4 
A0A024
R3V9 
HCG37498, isoform CRA_b OS=Homo sapiens GN=hCG_37498 PE=4 SV=1 - [A0A024R3V9_HUMAN] 5 1 1 1 92 11.0 9.7
4 
B4DI19 cDNA FLJ59524, highly similar to Cysteinyl-tRNA synthetase (EC 6.1.1.16) OS=Homo sapiens PE=2 SV=1 - 
[B4DI19_HUMAN] 
4 1 1 1 662 75.6 6.6
0 
D3DXE
0 
HCG20684, isoform CRA_b OS=Homo sapiens GN=hCG_20684 PE=3 SV=1 - [D3DXE0_HUMAN] 1 1 1 1 296 33.2 7.2
1 
E9PPR4 Transcriptional activator Myb OS=Homo sapiens GN=MYB PE=1 SV=1 - [E9PPR4_HUMAN] 25 1 1 1 103 12.4 6.1
9 
P05109 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 - [S10A8_HUMAN] 1 1 1 2 93 10.8 7.0
3 
P01040 Cystatin-A OS=Homo sapiens GN=CSTA PE=1 SV=1 - [CYTA_HUMAN] 1 1 1 1 98 11.0 5.5
0 
Q53RS7 Putative uncharacterized protein LBP-9 (Fragment) OS=Homo sapiens GN=LBP-9 PE=4 SV=1 - 
[Q53RS7_HUMAN] 
1 1 1 1 32 3.6 4.8
9 
A0A024
R1X8 
Junction plakoglobin, isoform CRA_a OS=Homo sapiens GN=JUP PE=4 SV=1 - [A0A024R1X8_HUMAN] 2 1 1 1 745 81.7 6.1
4 
P07737 Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 - [PROF1_HUMAN] 2 1 1 1 140 15.0 8.2
7 
I3L234 Ribosomal L1 domain-containing protein 1 (Fragment) OS=Homo sapiens GN=RSL1D1 PE=1 SV=1 - 
[I3L234_HUMAN] 
1 1 1 1 98 11.6 9.7
4 
M0R1V
7 
Ubiquitin-60S ribosomal protein L40 (Fragment) OS=Homo sapiens GN=UBA52 PE=1 SV=1 - 
[M0R1V7_HUMAN] 
36 1 1 1 63 7.1 5.3
6 
Q6ZSX8 cDNA FLJ45139 fis, clone BRAWH3039623 OS=Homo sapiens PE=2 SV=1 - [Q6ZSX8_HUMAN] 1 1 1 3 136 15.5 10.
07 
L0R5A1 Alternative protein CSF2RB OS=Homo sapiens GN=CSF2RB PE=4 SV=1 - [L0R5A1_HUMAN] 1 1 1 1 108 11.6 11.
30 
Q8TC57 Meiosis 1 arrest protein OS=Homo sapiens GN=M1AP PE=1 SV=1 - [M1AP_HUMAN] 1 1 1 1 530 59.3 6.8
7 
D9ZHQ
0 
Neuregulin 3 variant 6 OS=Homo sapiens GN=NRG3 PE=2 SV=1 - [D9ZHQ0_HUMAN] 1 1 1 1 239 27.2 7.4
4 
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Q8WVQ
1 
Soluble calcium-activated nucleotidase 1 OS=Homo sapiens GN=CANT1 PE=1 SV=1 - [CANT1_HUMAN] 1 1 1 1 401 44.8 6.0
9 
Q5KSL6 Diacylglycerol kinase kappa OS=Homo sapiens GN=DGKK PE=1 SV=1 - [DGKK_HUMAN] 1 1 1 1 1271 141.
7 
5.5
3 
Q9NZP
6 
Nuclear pore-associated protein 1 OS=Homo sapiens GN=NPAP1 PE=1 SV=2 - [NPAP1_HUMAN] 1 1 1 1 1156 120.
9 
8.6
9 
P12004 Proliferating cell nuclear antigen OS=Homo sapiens GN=PCNA PE=1 SV=1 - [PCNA_HUMAN] 3 1 1 1 261 28.8 4.6
9 
Q4LDE5 Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1 OS=Homo sapiens 
GN=SVEP1 PE=1 SV=3 - [SVEP1_HUMAN] 
3 1 1 1 3571 389.
9 
5.5
0 
F5GXD8 Stress-induced-phosphoprotein 1 OS=Homo sapiens GN=STIP1 PE=1 SV=1 - [F5GXD8_HUMAN] 4 1 1 1 138 15.6 8.2
5 
F8W06
1 
Iron-sulfur protein NUBPL (Fragment) OS=Homo sapiens GN=NUBPL PE=1 SV=1 - [F8W061_HUMAN] 5 1 1 1 133 14.3 8.1
0 
A0A087
WU05 
C-Maf-inducing protein OS=Homo sapiens GN=CMIP PE=1 SV=1 - [A0A087WU05_HUMAN] 4 1 1 1 586 65.2 5.9
4 
H3BR41 Exportin-6 (Fragment) OS=Homo sapiens GN=XPO6 PE=1 SV=5 - [H3BR41_HUMAN] 4 1 1 1 143 17.0 7.3
7 
B4DHH
8 
cDNA FLJ56865, highly similar to Transcriptional regulator ATRX (EC 3.6.1.-) OS=Homo sapiens PE=2 SV=1 - 
[B4DHH8_HUMAN] 
3 1 1 1 858 98.1 6.7
1 
Q6ZRA
8 
cDNA FLJ46514 fis, clone THYMU3032798, highly similar to Focal adhesion kinase 2 (EC 2.7.1.112) OS=Homo 
sapiens PE=2 SV=1 - [Q6ZRA8_HUMAN] 
1 1 1 1 596 68.0 5.6
0 
A8MXP
8 
Reticulocalbin-2 OS=Homo sapiens GN=RCN2 PE=1 SV=1 - [A8MXP8_HUMAN] 2 1 1 1 216 24.8 4.4
2 
Q68DE
6 
Putative uncharacterized protein DKFZp781A0353 (Fragment) OS=Homo sapiens GN=DKFZp781A0353 PE=2 
SV=1 - [Q68DE6_HUMAN] 
3 1 1 1 1017 116.
7 
6.7
4 
H0Y6T0 Nuclear receptor coactivator 7 (Fragment) OS=Homo sapiens GN=NCOA7 PE=1 SV=1 - [H0Y6T0_HUMAN] 9 1 1 1 177 20.7 7.1
5 
H7C1F9 Ral GTPase-activating protein subunit alpha-2 (Fragment) OS=Homo sapiens GN=RALGAPA2 PE=1 SV=1 - 
[H7C1F9_HUMAN] 
2 1 1 1 1740 194.
9 
5.9
0 
F2WJ44 Cytochrome c oxidase subunit 1 OS=Homo sapiens GN=COX1 PE=3 SV=1 - [F2WJ44_HUMAN] 1 1 1 1 513 57.0 6.7
0 
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PDGFRB-1 
Accessio
n 
Description # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs 
MW 
[kDa] 
calc
. pI 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 2 30 31 204 623 62.0 5.2
4 
H6VRF8 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - [H6VRF8_HUMAN] 17 30 34 196 644 66.0 8.1
2 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 22 28 32 140 584 58.8 5.2
1 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 9 23 32 98 639 65.4 8.0
0 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 36 7 23 56 472 51.5 5.1
6 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - [K1C16_HUMAN] 32 3 16 43 473 51.2 5.0
5 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] 19 9 20 37 590 62.3 7.7
4 
B4DRR0 cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A OS=Homo sapiens PE=2 SV=1 - [B4DRR0_HUMAN] 20 4 16 27 535 57.8 8.0
0 
Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2 - [K1C17_HUMAN] 26 1 13 19 432 48.1 5.0
2 
Q0IIN1 Keratin 77 OS=Homo sapiens GN=KRT77 PE=1 SV=1 - [Q0IIN1_HUMAN] 7 2 5 15 578 61.8 5.8
5 
Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 - [HORN_HUMAN] 1 2 2 5 2850 282.2 10.
04 
Q14CN4 Keratin, type II cytoskeletal 72 OS=Homo sapiens GN=KRT72 PE=1 SV=2 - [K2C72_HUMAN] 8 1 4 11 511 55.8 6.8
9 
F6KPG5 Albumin (Fragment) OS=Homo sapiens PE=2 SV=1 - [F6KPG5_HUMAN] 14 3 3 5 585 66.5 6.0
4 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] 1 3 3 5 110 11.3 6.5
4 
Q45KI0 Trypsin I (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q45KI0_HUMAN] 17 1 1 3 84 9.2 9.9
9 
Q99456 Keratin, type I cytoskeletal 12 OS=Homo sapiens GN=KRT12 PE=1 SV=1 - [K1C12_HUMAN] 1 1 3 5 494 53.5 4.7
8 
Q8N1N
4 
Keratin, type II cytoskeletal 78 OS=Homo sapiens GN=KRT78 PE=2 SV=2 - [K2C78_HUMAN] 4 2 3 4 520 56.8 6.0
2 
Q86W2
0 
Protease serine 1 (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q86W20_HUMAN] 6 1 1 3 84 9.2 10.
27 
A0A075
B6Z2 
Protein TRAJ56 (Fragment) OS=Homo sapiens GN=TRAJ56 PE=4 SV=1 - [A0A075B6Z2_HUMAN] 2 1 1 18 21 2.2 10.
29 
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B4E2A0 cDNA FLJ61543, highly similar to Desmoplakin OS=Homo sapiens PE=2 SV=1 - [B4E2A0_HUMAN] 6 4 4 4 1350 156.
2 
7.4
3 
F8WCJ1 Eukaryotic translation initiation factor 5A OS=Homo sapiens GN=EIF5A2 PE=1 SV=1 - [F8WCJ1_HUMAN] 8 2 2 3 105 11.7 9.1
4 
Q9GZZ
8 
Extracellular glycoprotein lacritin OS=Homo sapiens GN=LACRT PE=1 SV=1 - [LACRT_HUMAN] 2 3 3 3 138 14.2 5.5
0 
O75556 Mammaglobin-B OS=Homo sapiens GN=SCGB2A1 PE=1 SV=1 - [SG2A1_HUMAN] 1 2 2 2 95 10.9 5.7
8 
Q7Z612 Acidic ribosomal phosphoprotein P1 OS=Homo sapiens PE=2 SV=1 - [Q7Z612_HUMAN] 4 1 1 2 113 11.4 4.3
6 
J3QSA3 Polyubiquitin-B (Fragment) OS=Homo sapiens GN=UBB PE=1 SV=1 - [J3QSA3_HUMAN] 37 1 1 2 43 4.9 5.1
9 
Q9HB0
0 
Desmocollin 1, isoform CRA_b OS=Homo sapiens GN=DSC1 PE=4 SV=1 - [Q9HB00_HUMAN] 2 3 3 3 840 93.8 5.5
3 
J3QRT3 Uncharacterized protein KIAA0195 (Fragment) OS=Homo sapiens GN=KIAA0195 PE=1 SV=5 - 
[J3QRT3_HUMAN] 
1 1 1 2 89 9.5 6.7
6 
F8VV32 Lysozyme OS=Homo sapiens GN=LYZ PE=1 SV=1 - [F8VV32_HUMAN] 3 2 2 2 104 11.5 9.0
7 
L0R5A1 Alternative protein CSF2RB OS=Homo sapiens GN=CSF2RB PE=4 SV=1 - [L0R5A1_HUMAN] 1 1 1 3 108 11.6 11.
30 
Q5VSP4 Putative lipocalin 1-like protein 1 OS=Homo sapiens GN=LCN1P1 PE=5 SV=1 - [LC1L1_HUMAN] 2 1 1 2 162 17.9 5.0
0 
A0A087
WXD2 
Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 OS=Homo sapiens 
GN=MAGI1 PE=1 SV=1 - [A0A087WXD2_HUMAN] 
7 1 1 2 980 106.
8 
6.4
6 
H9KV28 Protein diaphanous homolog 1 OS=Homo sapiens GN=DIAPH1 PE=1 SV=2 - [H9KV28_HUMAN] 5 1 1 2 1228 136.
8 
5.2
4 
B4DK31 cDNA FLJ54634, highly similar to Acetyl-CoA carboxylase 1 (EC 6.4.1.2) OS=Homo sapiens PE=2 SV=1 - 
[B4DK31_HUMAN] 
9 2 2 2 306 35.6 6.3
8 
F8VRZ4 Tubulin alpha-1A chain (Fragment) OS=Homo sapiens GN=TUBA1A PE=4 SV=1 - [F8VRZ4_HUMAN] 30 2 2 2 112 12.2 5.7
7 
Q5HY5
7 
Emerin OS=Homo sapiens GN=EMD PE=1 SV=1 - [Q5HY57_HUMAN] 2 2 2 2 219 24.9 5.0
2 
C9JTX5 Actin, cytoplasmic 1 (Fragment) OS=Homo sapiens GN=ACTB PE=1 SV=1 - [C9JTX5_HUMAN] 44 2 2 2 80 8.5 5.3
5 
Q19KS2 Lactoferrin (Fragment) OS=Homo sapiens PE=2 SV=1 - [Q19KS2_HUMAN] 12 1 1 2 353 39.1 9.0
3 
B4DHW
6 
cDNA FLJ54930, highly similar to Homo sapiens Dbf4-related factor 1 (DRF1), transcript variant 2, mRNA 
OS=Homo sapiens PE=2 SV=1 - [B4DHW6_HUMAN] 
3 1 1 2 154 16.7 10.
27 
B3KX99 cDNA FLJ45019 fis, clone BRAWH3015825 OS=Homo sapiens PE=2 SV=1 - [B3KX99_HUMAN] 2 1 1 2 333 38.5 8.9
7 
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Q3SYB5 SERPINB12 protein OS=Homo sapiens GN=SERPINB12 PE=2 SV=1 - [Q3SYB5_HUMAN] 2 1 1 1 183 20.9 5.8
7 
Q6UXS
9 
Inactive caspase-12 OS=Homo sapiens GN=CASP12 PE=2 SV=2 - [CASPC_HUMAN] 1 1 1 1 341 38.8 6.0
2 
A0A087
WUV8 
Basigin OS=Homo sapiens GN=BSG PE=1 SV=1 - [A0A087WUV8_HUMAN] 6 1 1 1 189 20.5 6.6
8 
G3V361 Calmodulin (Fragment) OS=Homo sapiens GN=CALM1 PE=1 SV=1 - [G3V361_HUMAN] 8 1 1 1 98 11.1 4.2
5 
C9IYG1 BRCA1-associated RING domain protein 1 (Fragment) OS=Homo sapiens GN=BARD1 PE=1 SV=1 - 
[C9IYG1_HUMAN] 
9 1 1 2 216 24.4 8.4
7 
Q7RTY
7 
Ovochymase-1 OS=Homo sapiens GN=OVCH1 PE=2 SV=2 - [OVCH1_HUMAN] 1 1 1 1 1134 125.
0 
8.3
2 
B4DNE
0 
cDNA FLJ52573, highly similar to Elongation factor 1-alpha 1 OS=Homo sapiens PE=2 SV=1 - 
[B4DNE0_HUMAN] 
35 2 2 2 395 42.6 9.0
1 
A8K651 cDNA FLJ75700, highly similar to Homo sapiens complement component 1, q subcomponent binding protein 
(C1QBP), nuclear gene encoding mitochondrial protein, mRNA OS=Homo sapiens PE=2 SV=1 - 
[A8K651_HUMAN] 
2 1 1 1 282 31.4 4.8
4 
P05109 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 - [S10A8_HUMAN] 1 1 1 1 93 10.8 7.0
3 
A0A087
WUI6 
Progesterone-induced-blocking factor 1 OS=Homo sapiens GN=PIBF1 PE=1 SV=1 - [A0A087WUI6_HUMAN] 2 1 1 1 698 83.1 5.6
2 
H3BQB
6 
Stathmin domain-containing protein 1 OS=Homo sapiens GN=STMND1 PE=2 SV=1 - [STMD1_HUMAN] 1 1 1 1 276 31.0 8.4
7 
E9PN25 Heat shock cognate 71 kDa protein (Fragment) OS=Homo sapiens GN=HSPA8 PE=1 SV=1 - [E9PN25_HUMAN] 35 1 1 1 132 14.6 6.5
5 
Q96MA
3 
cDNA FLJ32709 fis, clone TESTI2000695, weakly similar to KINESIN HEAVY CHAIN (Fragment) OS=Homo 
sapiens PE=2 SV=1 - [Q96MA3_HUMAN] 
4 1 1 1 648 73.5 5.3
1 
Q2Y0W
8 
Electroneutral sodium bicarbonate exchanger 1 OS=Homo sapiens GN=SLC4A8 PE=1 SV=1 - [S4A8_HUMAN] 1 1 1 1 1093 122.
9 
6.6
8 
A0A024
R1X8 
Junction plakoglobin, isoform CRA_a OS=Homo sapiens GN=JUP PE=4 SV=1 - [A0A024R1X8_HUMAN] 2 1 1 1 745 81.7 6.1
4 
P12004 Proliferating cell nuclear antigen OS=Homo sapiens GN=PCNA PE=1 SV=1 - [PCNA_HUMAN] 3 1 1 1 261 28.8 4.6
9 
Q8TC57 Meiosis 1 arrest protein OS=Homo sapiens GN=M1AP PE=1 SV=1 - [M1AP_HUMAN] 1 1 1 1 530 59.3 6.8
7 
P07737 Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 - [PROF1_HUMAN] 2 1 1 1 140 15.0 8.2
7 
Q16378 Proline-rich protein 4 OS=Homo sapiens GN=PRR4 PE=1 SV=3 - [PROL4_HUMAN] 2 1 1 1 134 15.1 7.0
6 
P47989 Xanthine dehydrogenase/oxidase OS=Homo sapiens GN=XDH PE=1 SV=4 - [XDH_HUMAN] 1 1 1 1 1333 146.
3 
7.6
6 
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Q3KRF4 Uncharacterized protein OS=Homo sapiens GN=LOC285033 PE=2 SV=1 - [Q3KRF4_HUMAN] 1 1 1 1 121 13.2 9.8
9 
Q53SG
8 
Putative uncharacterized protein FLJ22527 (Fragment) OS=Homo sapiens GN=FLJ22527 PE=4 SV=1 - 
[Q53SG8_HUMAN] 
6 1 1 1 199 22.8 9.9
2 
B2R4M
6 
Protein S100 OS=Homo sapiens PE=2 SV=1 - [B2R4M6_HUMAN] 2 1 1 1 114 13.2 6.1
3 
A0JLQ0 AZGP1 protein (Fragment) OS=Homo sapiens GN=AZGP1 PE=2 SV=1 - [A0JLQ0_HUMAN] 3 1 1 1 159 18.7 8.9
7 
Q53GS
1 
MutS homolog 2 variant (Fragment) OS=Homo sapiens PE=2 SV=1 - [Q53GS1_HUMAN] 1 1 1 1 878 98.2 5.6
3 
Q4ZG8
4 
Putative uncharacterized protein LRP2 (Fragment) OS=Homo sapiens GN=LRP2 PE=4 SV=1 - 
[Q4ZG84_HUMAN] 
4 1 1 1 3881 435.
5 
5.1
4 
H7C2J5 Piezo-type mechanosensitive ion channel component 1 (Fragment) OS=Homo sapiens GN=PIEZO1 PE=1 SV=1 
- [H7C2J5_HUMAN] 
4 1 1 1 88 10.5 7.2
4 
Q5TCD
1 
Isoleucine--tRNA ligase, cytoplasmic (Fragment) OS=Homo sapiens GN=IARS PE=1 SV=1 - [Q5TCD1_HUMAN] 5 1 1 1 330 38.3 6.1
9 
H7C1F9 Ral GTPase-activating protein subunit alpha-2 (Fragment) OS=Homo sapiens GN=RALGAPA2 PE=1 SV=1 - 
[H7C1F9_HUMAN] 
2 1 1 1 1740 194.
9 
5.9
0 
Q6ZSX8 cDNA FLJ45139 fis, clone BRAWH3039623 OS=Homo sapiens PE=2 SV=1 - [Q6ZSX8_HUMAN] 1 1 1 2 136 15.5 10.
07 
 
PDGFRB-2 
Accessio
n 
Description # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs 
MW 
[kDa] 
calc
. pI 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 2 31 32 181 623 62.0 5.2
4 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 21 26 31 156 584 58.8 5.2
1 
H6VRF8 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - [H6VRF8_HUMAN] 16 30 35 164 644 66.0 8.1
2 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 8 24 33 87 639 65.4 8.0
0 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 41 13 24 63 472 51.5 5.1
6 
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P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - [K1C16_HUMAN] 32 4 16 49 473 51.2 5.0
5 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] 17 10 20 38 590 62.3 7.7
4 
B4DRR0 cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A OS=Homo sapiens PE=2 SV=1 - [B4DRR0_HUMAN] 20 3 15 26 535 57.8 8.0
0 
Q0IIN1 Keratin 77 OS=Homo sapiens GN=KRT77 PE=1 SV=1 - [Q0IIN1_HUMAN] 7 3 6 14 578 61.8 5.8
5 
A0A024R
0Y2 
HCG30204, isoform CRA_a OS=Homo sapiens GN=hCG_30204 PE=4 SV=1 - [A0A024R0Y2_HUMAN] 11 13 13 15 2268 257.1 6.6
1 
Q6KB66 Keratin, type II cytoskeletal 80 OS=Homo sapiens GN=KRT80 PE=1 SV=2 - [K2C80_HUMAN] 9 1 2 9 452 50.5 5.6
7 
Q14CN4 Keratin, type II cytoskeletal 72 OS=Homo sapiens GN=KRT72 PE=1 SV=2 - [K2C72_HUMAN] 8 1 4 9 511 55.8 6.8
9 
F6KPG5 Albumin (Fragment) OS=Homo sapiens PE=2 SV=1 - [F6KPG5_HUMAN] 14 4 4 7 585 66.5 6.0
4 
P15924 Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 - [DESP_HUMAN] 6 5 5 9 2871 331.
6 
6.8
1 
Q45KI0 Trypsin I (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q45KI0_HUMAN] 17 1 1 5 84 9.2 9.9
9 
Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 - [HORN_HUMAN] 1 2 2 4 2850 282.
2 
10.
04 
Q8N1N
4 
Keratin, type II cytoskeletal 78 OS=Homo sapiens GN=KRT78 PE=2 SV=2 - [K2C78_HUMAN] 5 3 5 6 520 56.8 6.0
2 
Q53HF2 Heat shock 70kDa protein 8 isoform 2 variant (Fragment) OS=Homo sapiens PE=1 SV=1 - [Q53HF2_HUMAN] 41 5 5 7 493 53.5 5.8
6 
F8WCJ1 Eukaryotic translation initiation factor 5A OS=Homo sapiens GN=EIF5A2 PE=1 SV=1 - [F8WCJ1_HUMAN] 8 3 3 5 105 11.7 9.1
4 
Q9GZZ
8 
Extracellular glycoprotein lacritin OS=Homo sapiens GN=LACRT PE=1 SV=1 - [LACRT_HUMAN] 2 4 4 5 138 14.2 5.5
0 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] 1 3 3 4 110 11.3 6.5
4 
O75556 Mammaglobin-B OS=Homo sapiens GN=SCGB2A1 PE=1 SV=1 - [SG2A1_HUMAN] 1 2 2 3 95 10.9 5.7
8 
Q2M2I5 Keratin, type I cytoskeletal 24 OS=Homo sapiens GN=KRT24 PE=1 SV=1 - [K1C24_HUMAN] 16 1 3 4 525 55.1 4.9
6 
Q8N53
2 
TUBA1C protein OS=Homo sapiens GN=TUBA1C PE=2 SV=1 - [Q8N532_HUMAN] 34 3 3 4 325 36.6 7.9
6 
Q99456 Keratin, type I cytoskeletal 12 OS=Homo sapiens GN=KRT12 PE=1 SV=1 - [K1C12_HUMAN] 1 1 3 5 494 53.5 4.7
8 
Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 - [DSG1_HUMAN] 1 2 2 4 1049 113.
7 
5.0
3 
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Q8TBA
7 
HSP90AA1 protein (Fragment) OS=Homo sapiens GN=HSP90AA1 PE=2 SV=2 - [Q8TBA7_HUMAN] 14 2 2 3 638 73.8 5.1
6 
A0A087
WYX2 
Histone lysine demethylase PHF8 OS=Homo sapiens GN=PHF8 PE=1 SV=1 - [A0A087WYX2_HUMAN] 2 1 1 6 303 33.8 10.
08 
F8VV32 Lysozyme OS=Homo sapiens GN=LYZ PE=1 SV=1 - [F8VV32_HUMAN] 3 2 2 3 104 11.5 9.0
7 
Q19KS2 Lactoferrin (Fragment) OS=Homo sapiens PE=2 SV=1 - [Q19KS2_HUMAN] 12 2 2 3 353 39.1 9.0
3 
Q5HY5
7 
Emerin OS=Homo sapiens GN=EMD PE=1 SV=1 - [Q5HY57_HUMAN] 2 2 2 3 219 24.9 5.0
2 
A0A024
R1X8 
Junction plakoglobin, isoform CRA_a OS=Homo sapiens GN=JUP PE=4 SV=1 - [A0A024R1X8_HUMAN] 2 2 2 3 745 81.7 6.1
4 
B2R4M
6 
Protein S100 OS=Homo sapiens PE=2 SV=1 - [B2R4M6_HUMAN] 2 1 1 2 114 13.2 6.1
3 
V9GZN
0 
Histone H2A gene (lambda-HHG55) (Fragment) OS=Homo sapiens PE=4 SV=1 - [V9GZN0_HUMAN] 19 1 1 2 47 5.0 11.
90 
J3QRT3 Uncharacterized protein KIAA0195 (Fragment) OS=Homo sapiens GN=KIAA0195 PE=1 SV=5 - 
[J3QRT3_HUMAN] 
1 1 1 2 89 9.5 6.7
6 
C9IYG1 BRCA1-associated RING domain protein 1 (Fragment) OS=Homo sapiens GN=BARD1 PE=1 SV=1 - 
[C9IYG1_HUMAN] 
9 1 1 2 216 24.4 8.4
7 
Q08ES8 Cell growth-inhibiting protein 34 OS=Homo sapiens PE=2 SV=1 - [Q08ES8_HUMAN] 4 2 2 2 177 20.1 9.6
0 
B4DNE
0 
cDNA FLJ52573, highly similar to Elongation factor 1-alpha 1 OS=Homo sapiens PE=2 SV=1 - 
[B4DNE0_HUMAN] 
35 2 2 3 395 42.6 9.0
1 
A0A087
WTG3 
Cullin-3 OS=Homo sapiens GN=CUL3 PE=1 SV=1 - [A0A087WTG3_HUMAN] 1 1 1 2 342 39.1 9.4
8 
A0A0A0
MRQ5 
Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 - [A0A0A0MRQ5_HUMAN] 6 2 2 2 97 10.7 8.7
2 
Q7Z350 Putative uncharacterized protein DKFZp686L0695 OS=Homo sapiens GN=DKFZp686L0695 PE=2 SV=1 - 
[Q7Z350_HUMAN] 
1 1 1 2 549 62.1 6.3
7 
A1L378 STRC protein OS=Homo sapiens GN=STRC PE=2 SV=1 - [A1L378_HUMAN] 4 1 1 2 1002 110.
6 
5.1
7 
F8WF6
5 
Elongation factor 1-beta OS=Homo sapiens GN=EEF1B2 PE=1 SV=1 - [F8WF65_HUMAN] 4 1 1 1 29 3.1 4.4
6 
Q96MA
3 
cDNA FLJ32709 fis, clone TESTI2000695, weakly similar to KINESIN HEAVY CHAIN (Fragment) OS=Homo 
sapiens PE=2 SV=1 - [Q96MA3_HUMAN] 
4 1 1 2 648 73.5 5.3
1 
B3KX99 cDNA FLJ45019 fis, clone BRAWH3015825 OS=Homo sapiens PE=2 SV=1 - [B3KX99_HUMAN] 2 1 1 2 333 38.5 8.9
7 
Q7Z612 Acidic ribosomal phosphoprotein P1 OS=Homo sapiens PE=2 SV=1 - [Q7Z612_HUMAN] 4 1 1 1 113 11.4 4.3
6 
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Q5SQH
5 
DEAH (Asp-Glu-Ala-His) box polypeptide 16, isoform CRA_a OS=Homo sapiens GN=DHX16 PE=1 SV=1 - 
[Q5SQH5_HUMAN] 
3 1 1 1 560 63.5 6.7
6 
Q86W2
0 
Protease serine 1 (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q86W20_HUMAN] 6 1 1 1 84 9.2 10.
27 
Q5VSP4 Putative lipocalin 1-like protein 1 OS=Homo sapiens GN=LCN1P1 PE=5 SV=1 - [LC1L1_HUMAN] 2 1 1 1 162 17.9 5.0
0 
A0A087
WUV8 
Basigin OS=Homo sapiens GN=BSG PE=1 SV=1 - [A0A087WUV8_HUMAN] 6 1 1 1 189 20.5 6.6
8 
J3QSA3 Polyubiquitin-B (Fragment) OS=Homo sapiens GN=UBB PE=1 SV=1 - [J3QSA3_HUMAN] 37 1 1 1 43 4.9 5.1
9 
M0R1I1 Tubulin beta-4A chain (Fragment) OS=Homo sapiens GN=TUBB4A PE=1 SV=1 - [M0R1I1_HUMAN] 27 1 1 1 74 7.8 4.9
4 
Q6UXS
9 
Inactive caspase-12 OS=Homo sapiens GN=CASP12 PE=2 SV=2 - [CASPC_HUMAN] 1 1 1 1 341 38.8 6.0
2 
A0A0A0
MS48 
DENN domain-containing protein 1A OS=Homo sapiens GN=DENND1A PE=1 SV=1 - [A0A0A0MS48_HUMAN] 4 1 1 1 459 52.0 8.5
0 
J3KSP2 60S ribosomal protein L38 (Fragment) OS=Homo sapiens GN=RPL38 PE=1 SV=1 - [J3KSP2_HUMAN] 4 1 1 1 21 2.6 9.9
9 
F8WCH
0 
Actin, gamma-enteric smooth muscle OS=Homo sapiens GN=ACTG2 PE=1 SV=1 - [F8WCH0_HUMAN] 43 1 1 1 52 5.6 6.4
9 
H0YKZ7 Annexin (Fragment) OS=Homo sapiens GN=ANXA2 PE=1 SV=1 - [H0YKZ7_HUMAN] 16 1 1 1 119 13.0 8.1
3 
B7Z532 cDNA FLJ51028, highly similar to 60 kDa heat shock protein, mitochondrial OS=Homo sapiens PE=2 SV=1 - 
[B7Z532_HUMAN] 
7 2 2 2 245 26.7 5.2
2 
Q59GI5 Dynamin 1 isoform 2 variant (Fragment) OS=Homo sapiens PE=2 SV=1 - [Q59GI5_HUMAN] 4 1 1 1 600 68.8 7.6
8 
H0YGI8 Stress-induced-phosphoprotein 1 (Fragment) OS=Homo sapiens GN=STIP1 PE=1 SV=1 - [H0YGI8_HUMAN] 3 1 1 1 137 15.9 6.1
9 
Q5ZEY3 Glyceraldehyde-3-phosphate dehydrogenase (Fragment) OS=Homo sapiens GN=GAPD PE=2 SV=1 - 
[Q5ZEY3_HUMAN] 
6 1 1 1 86 9.2 9.7
2 
Q5TDG
9 
DnaJ (Hsp40) homolog, subfamily C, member 16, isoform CRA_a OS=Homo sapiens GN=DNAJC16 PE=1 SV=1 
- [Q5TDG9_HUMAN] 
4 1 1 1 595 69.3 7.1
5 
Q3SYB5 SERPINB12 protein OS=Homo sapiens GN=SERPINB12 PE=2 SV=1 - [Q3SYB5_HUMAN] 2 1 1 1 183 20.9 5.8
7 
P10599 Thioredoxin OS=Homo sapiens GN=TXN PE=1 SV=3 - [THIO_HUMAN] 1 1 1 1 105 11.7 4.9
2 
Q7Z5L4 Spermatogenesis-associated protein 19, mitochondrial OS=Homo sapiens GN=SPATA19 PE=2 SV=2 - 
[SPT19_HUMAN] 
1 1 1 1 167 19.2 6.9
6 
P31151 Protein S100-A7 OS=Homo sapiens GN=S100A7 PE=1 SV=4 - [S10A7_HUMAN] 1 1 1 1 101 11.5 6.7
7 
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B4DL87 cDNA FLJ52243, highly similar to Heat-shock protein beta-1 OS=Homo sapiens PE=2 SV=1 - [B4DL87_HUMAN] 3 1 1 1 170 18.5 6.9
5 
P05109 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 - [S10A8_HUMAN] 1 1 1 2 93 10.8 7.0
3 
Q96L96 Alpha-protein kinase 3 OS=Homo sapiens GN=ALPK3 PE=2 SV=2 - [ALPK3_HUMAN] 1 1 1 2 1907 201.
1 
7.5
8 
Q9H70
0 
cDNA: FLJ21617 fis, clone COL07481 OS=Homo sapiens PE=2 SV=1 - [Q9H700_HUMAN] 1 1 1 1 244 27.6 9.2
2 
B4DHW
6 
cDNA FLJ54930, highly similar to Homo sapiens Dbf4-related factor 1 (DRF1), transcript variant 2, mRNA 
OS=Homo sapiens PE=2 SV=1 - [B4DHW6_HUMAN] 
3 1 1 1 154 16.7 10.
27 
L0R5A1 Alternative protein CSF2RB OS=Homo sapiens GN=CSF2RB PE=4 SV=1 - [L0R5A1_HUMAN] 1 1 1 1 108 11.6 11.
30 
B3KM5
9 
cDNA FLJ10361 fis, clone NT2RM2001256, highly similar to Anaphase-promoting complex subunit 1 OS=Homo 
sapiens PE=2 SV=1 - [B3KM59_HUMAN] 
1 1 1 1 306 32.9 7.4
0 
Q96PE2 Rho guanine nucleotide exchange factor 17 OS=Homo sapiens GN=ARHGEF17 PE=1 SV=1 - [ARHGH_HUMAN] 1 1 1 1 2063 221.
5 
6.2
9 
H0YEU
5 
Histone-binding protein RBBP4 (Fragment) OS=Homo sapiens GN=RBBP4 PE=1 SV=1 - [H0YEU5_HUMAN] 10 1 1 1 167 19.0 5.5
3 
A6NCS4 Homeobox protein Nkx-2.6 OS=Homo sapiens GN=NKX2-6 PE=1 SV=1 - [NKX26_HUMAN] 1 1 1 1 301 32.1 9.8
8 
I3L234 Ribosomal L1 domain-containing protein 1 (Fragment) OS=Homo sapiens GN=RSL1D1 PE=1 SV=1 - 
[I3L234_HUMAN] 
1 1 1 1 98 11.6 9.7
4 
A0A075
B6Z2 
Protein TRAJ56 (Fragment) OS=Homo sapiens GN=TRAJ56 PE=4 SV=1 - [A0A075B6Z2_HUMAN] 2 1 1 2 21 2.2 10.
29 
Q96AY2 Crossover junction endonuclease EME1 OS=Homo sapiens GN=EME1 PE=1 SV=2 - [EME1_HUMAN] 1 1 1 1 570 63.2 7.0
5 
P12004 Proliferating cell nuclear antigen OS=Homo sapiens GN=PCNA PE=1 SV=1 - [PCNA_HUMAN] 3 1 1 1 261 28.8 4.6
9 
P05387 60S acidic ribosomal protein P2 OS=Homo sapiens GN=RPLP2 PE=1 SV=1 - [RLA2_HUMAN] 1 1 1 1 115 11.7 4.5
4 
Q53SG
8 
Putative uncharacterized protein FLJ22527 (Fragment) OS=Homo sapiens GN=FLJ22527 PE=4 SV=1 - 
[Q53SG8_HUMAN] 
6 1 1 4 199 22.8 9.9
2 
H7C1L6 Cullin-3 (Fragment) OS=Homo sapiens GN=CUL3 PE=1 SV=1 - [H7C1L6_HUMAN] 3 1 1 1 192 22.6 8.6
9 
E5RGW
4 
Nucleophosmin (Fragment) OS=Homo sapiens GN=NPM1 PE=1 SV=1 - [E5RGW4_HUMAN] 3 1 1 1 59 6.9 4.4
8 
H7C0X2 Major facilitator superfamily domain-containing protein 6 (Fragment) OS=Homo sapiens GN=MFSD6 PE=1 
SV=1 - [H7C0X2_HUMAN] 
1 1 1 1 271 30.1 5.9
4 
F8VSC5 SCY1-like protein 2 (Fragment) OS=Homo sapiens GN=SCYL2 PE=1 SV=1 - [F8VSC5_HUMAN] 2 1 1 1 681 77.0 7.0
5 
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I3L1H9 Zymogen granule protein 16 homolog B (Fragment) OS=Homo sapiens GN=ZG16B PE=1 SV=1 - 
[I3L1H9_HUMAN] 
5 1 1 1 69 7.5 9.3
2 
B4E3A8 cDNA FLJ53963, highly similar to Leukocyte elastase inhibitor OS=Homo sapiens PE=2 SV=1 - 
[B4E3A8_HUMAN] 
2 1 1 1 341 38.7 6.6
7 
H7C1F9 Ral GTPase-activating protein subunit alpha-2 (Fragment) OS=Homo sapiens GN=RALGAPA2 PE=1 SV=1 - 
[H7C1F9_HUMAN] 
2 1 1 1 1740 194.
9 
5.9
0 
H0YHR
3 
Protein phosphatase Slingshot homolog 1 (Fragment) OS=Homo sapiens GN=SSH1 PE=1 SV=1 - 
[H0YHR3_HUMAN] 
2 1 1 1 95 11.0 4.9
4 
Q6ZSX8 cDNA FLJ45139 fis, clone BRAWH3039623 OS=Homo sapiens PE=2 SV=1 - [Q6ZSX8_HUMAN] 1 1 1 3 136 15.5 10.
07 
A8K651 cDNA FLJ75700, highly similar to Homo sapiens complement component 1, q subcomponent binding protein 
(C1QBP), nuclear gene encoding mitochondrial protein, mRNA OS=Homo sapiens PE=2 SV=1 - 
[A8K651_HUMAN] 
2 1 1 1 282 31.4 4.8
4 
 
Control peptide 1 
Accession Description # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs 
MW 
[kDa] 
calc. 
pI 
H6VRF8 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - [H6VRF8_HUMAN] 15 24 27 142 644 66.0 8.12 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 2 25 25 126 623 62.0 5.24 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 7 25 26 78 584 58.8 5.21 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 12 16 23 66 639 65.4 8.00 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 18 5 13 47 472 51.5 5.16 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - [K1C16_HUMAN] 16 7 13 41 473 51.2 5.05 
B4DRR0 cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A OS=Homo sapiens PE=2 SV=1 - [B4DRR0_HUMAN] 17 8 16 26 535 57.8 8.00 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] 15 9 16 27 590 62.3 7.74 
F5GWP8 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2 - [F5GWP8_HUMAN] 13 1 7 12 349 40.3 4.94 
Q14CN4 Keratin, type II cytoskeletal 72 OS=Homo sapiens GN=KRT72 PE=1 SV=2 - [K2C72_HUMAN] 13 1 4 7 511 55.8 6.89 
Q6KB66 Keratin, type II cytoskeletal 80 OS=Homo sapiens GN=KRT80 PE=1 SV=2 - [K2C80_HUMAN] 10 2 3 6 452 50.5 5.67 
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Q9GZZ8 Extracellular glycoprotein lacritin OS=Homo sapiens GN=LACRT PE=1 SV=1 - [LACRT_HUMAN] 2 3 3 5 138 14.2 5.50 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] 1 3 3 4 110 11.3 6.54 
B4E2A0 cDNA FLJ61543, highly similar to Desmoplakin OS=Homo sapiens PE=2 SV=1 - [B4E2A0_HUMAN] 6 4 4 5 1350 156.2 7.43 
Q45KI0 Trypsin I (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q45KI0_HUMAN] 17 1 1 3 84 9.2 9.99 
Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 - [HORN_HUMAN] 1 2 2 3 2850 282.2 10.0
4 
P61626 Lysozyme C OS=Homo sapiens GN=LYZ PE=1 SV=1 - [LYSC_HUMAN] 3 3 3 5 148 16.5 9.16 
A0A024R
0Y2 
HCG30204, isoform CRA_a OS=Homo sapiens GN=hCG_30204 PE=4 SV=1 - [A0A024R0Y2_HUMAN] 13 3 3 3 2268 257.1 6.61 
Q86W20 Protease serine 1 (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q86W20_HUMAN] 6 1 1 2 84 9.2 10.2
7 
B3KX99 cDNA FLJ45019 fis, clone BRAWH3015825 OS=Homo sapiens PE=2 SV=1 - [B3KX99_HUMAN] 2 1 1 3 333 38.5 8.97 
Q19KS2 Lactoferrin (Fragment) OS=Homo sapiens PE=2 SV=1 - [Q19KS2_HUMAN] 15 2 2 3 353 39.1 9.03 
B2R4M6 Protein S100 OS=Homo sapiens PE=2 SV=1 - [B2R4M6_HUMAN] 2 2 2 2 114 13.2 6.13 
A0A075B
6Z2 
Protein TRAJ56 (Fragment) OS=Homo sapiens GN=TRAJ56 PE=4 SV=1 - [A0A075B6Z2_HUMAN] 2 1 1 14 21 2.2 10.2
9 
Q5VSP4 Putative lipocalin 1-like protein 1 OS=Homo sapiens GN=LCN1P1 PE=5 SV=1 - [LC1L1_HUMAN] 2 2 2 2 162 17.9 5.00 
A0A0A0
MS99 
Multidrug resistance-associated protein 1 OS=Homo sapiens GN=ABCC1 PE=1 SV=1 - 
[A0A0A0MS99_HUMAN] 
5 1 1 2 1215 134.9 6.46 
I3L1U9 Actin, cytoplasmic 2 (Fragment) OS=Homo sapiens GN=ACTG1 PE=1 SV=1 - [I3L1U9_HUMAN] 47 2 2 2 214 23.8 5.44 
Q5HY57 Emerin OS=Homo sapiens GN=EMD PE=1 SV=1 - [Q5HY57_HUMAN] 2 1 1 1 219 24.9 5.02 
Q9HB00 Desmocollin 1, isoform CRA_b OS=Homo sapiens GN=DSC1 PE=4 SV=1 - [Q9HB00_HUMAN] 2 1 1 1 840 93.8 5.53 
J3KSP2 60S ribosomal protein L38 (Fragment) OS=Homo sapiens GN=RPL38 PE=1 SV=1 - [J3KSP2_HUMAN] 4 1 1 1 21 2.6 9.99 
J3QRT3 Uncharacterized protein KIAA0195 (Fragment) OS=Homo sapiens GN=KIAA0195 PE=1 SV=5 - 
[J3QRT3_HUMAN] 
1 1 1 1 89 9.5 6.76 
Q16378 Proline-rich protein 4 OS=Homo sapiens GN=PRR4 PE=1 SV=3 - [PROL4_HUMAN] 2 2 2 2 134 15.1 7.06 
J3QSA3 Polyubiquitin-B (Fragment) OS=Homo sapiens GN=UBB PE=1 SV=1 - [J3QSA3_HUMAN] 37 1 1 1 43 4.9 5.19 
O75556 Mammaglobin-B OS=Homo sapiens GN=SCGB2A1 PE=1 SV=1 - [SG2A1_HUMAN] 1 1 1 1 95 10.9 5.78 
Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 - [DSG1_HUMAN] 1 1 1 1 1049 113.7 5.03 
A9UFC0 Caspase 14 OS=Homo sapiens GN=CASP14 PE=2 SV=1 - [A9UFC0_HUMAN] 2 1 1 1 242 27.6 5.34 
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H0YCE4 Uncharacterized protein C1orf105 (Fragment) OS=Homo sapiens GN=C1orf105 PE=4 SV=1 - 
[H0YCE4_HUMAN] 
2 1 1 1 125 14.4 9.25 
Q762B6 ATP7A protein OS=Homo sapiens GN=ATP7A PE=2 SV=1 - [Q762B6_HUMAN] 3 1 1 2 274 30.1 6.87 
Q9NXJ9 cDNA FLJ20203 fis, clone COLF1334 OS=Homo sapiens PE=2 SV=1 - [Q9NXJ9_HUMAN] 3 1 1 1 697 77.6 5.50 
P05109 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 - [S10A8_HUMAN] 1 1 1 1 93 10.8 7.03 
C9IYG1 BRCA1-associated RING domain protein 1 (Fragment) OS=Homo sapiens GN=BARD1 PE=1 SV=1 - 
[C9IYG1_HUMAN] 
9 1 1 1 216 24.4 8.47 
P31151 Protein S100-A7 OS=Homo sapiens GN=S100A7 PE=1 SV=4 - [S10A7_HUMAN] 1 1 1 1 101 11.5 6.77 
A0PJ54 PEX12 protein (Fragment) OS=Homo sapiens GN=PEX12 PE=2 SV=1 - [A0PJ54_HUMAN] 1 1 1 1 324 36.9 9.98 
Q8N1N4 Keratin, type II cytoskeletal 78 OS=Homo sapiens GN=KRT78 PE=2 SV=2 - [K2C78_HUMAN] 1 1 1 1 520 56.8 6.02 
H7C013 Serum albumin (Fragment) OS=Homo sapiens GN=ALB PE=1 SV=1 - [H7C013_HUMAN] 9 1 1 1 197 22.8 6.34 
F5H1K5 DNA repair protein RAD52 homolog OS=Homo sapiens GN=RAD52 PE=1 SV=1 - [F5H1K5_HUMAN] 9 1 1 1 99 10.8 6.25 
A0A087
WYX2 
Histone lysine demethylase PHF8 OS=Homo sapiens GN=PHF8 PE=1 SV=1 - [A0A087WYX2_HUMAN] 2 1 1 1 303 33.8 10.0
8 
E5RHF2 COP9 signalosome complex subunit 5 (Fragment) OS=Homo sapiens GN=COPS5 PE=1 SV=1 - 
[E5RHF2_HUMAN] 
4 1 1 1 151 16.6 5.06 
U3KQU9 POU domain, class 2, transcription factor 2 (Fragment) OS=Homo sapiens GN=POU2F2 PE=1 SV=1 - 
[U3KQU9_HUMAN] 
10 1 1 1 65 6.9 5.78 
H0YCG5 Serine/threonine-protein kinase PAK 1 (Fragment) OS=Homo sapiens GN=PAK1 PE=1 SV=1 - 
[H0YCG5_HUMAN] 
11 1 1 1 244 27.2 4.77 
Q96MA3 cDNA FLJ32709 fis, clone TESTI2000695, weakly similar to KINESIN HEAVY CHAIN (Fragment) OS=Homo 
sapiens PE=2 SV=1 - [Q96MA3_HUMAN] 
4 1 1 1 648 73.5 5.31 
B4DNN6 cDNA FLJ52003, highly similar to Homo sapiens nucleoredoxin (NXN), mRNA OS=Homo sapiens PE=2 SV=1 
- [B4DNN6_HUMAN] 
2 1 1 1 126 14.2 4.48 
L0R5A1 Alternative protein CSF2RB OS=Homo sapiens GN=CSF2RB PE=4 SV=1 - [L0R5A1_HUMAN] 1 1 1 1 108 11.6 11.3
0 
A6NNE9 E3 ubiquitin-protein ligase MARCH11 OS=Homo sapiens GN=MARCH11 PE=2 SV=3 - [MARHB_HUMAN] 1 1 1 1 402 43.8 6.92 
Q53GE3 Pyruvate dehydrogenase E1 component subunit alpha (Fragment) OS=Homo sapiens PE=2 SV=1 - 
[Q53GE3_HUMAN] 
1 1 1 1 390 43.2 8.06 
E9PF46 Acylphosphatase OS=Homo sapiens GN=ACYP2 PE=1 SV=1 - [E9PF46_HUMAN] 2 1 1 1 97 10.3 8.69 
G3V507 Protein arginine N-methyltransferase 5 OS=Homo sapiens GN=PRMT5 PE=1 SV=1 - [G3V507_HUMAN] 8 1 1 1 42 4.0 6.39 
G3V3Y2 Fibulin-5 (Fragment) OS=Homo sapiens GN=FBLN5 PE=1 SV=1 - [G3V3Y2_HUMAN] 5 1 1 3 91 9.9 6.37 
G3V3C9 Unconventional myosin-Va OS=Homo sapiens GN=MYO5A PE=1 SV=1 - [G3V3C9_HUMAN] 10 1 1 1 47 5.4 5.29 
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H0YI30 Growth/differentiation factor 11 (Fragment) OS=Homo sapiens GN=GDF11 PE=1 SV=1 - [H0YI30_HUMAN] 2 1 1 1 380 42.3 8.06 
B4DSC8 cDNA FLJ53181, highly similar to Probable global transcription activator SNF2L2 (EC 3.6.1.-) (Fragment) 
OS=Homo sapiens PE=2 SV=1 - [B4DSC8_HUMAN] 
3 1 1 1 715 83.4 8.59 
E5RJS1 Protein EFR3 homolog A (Fragment) OS=Homo sapiens GN=EFR3A PE=1 SV=1 - [E5RJS1_HUMAN] 2 1 1 1 133 15.2 7.09 
Q6ZSX8 cDNA FLJ45139 fis, clone BRAWH3039623 OS=Homo sapiens PE=2 SV=1 - [Q6ZSX8_HUMAN] 1 1 1 1 136 15.5 10.0
7 
B4DZ83 cDNA FLJ59792, highly similar to Homo sapiens outer dense fiber of sperm tails 2-like (ODF2L), transcript 
variant 1, mRNA OS=Homo sapiens PE=2 SV=1 - [B4DZ83_HUMAN] 
2 1 1 1 582 67.4 6.60 
A0A096L
NN3 
Transcriptional regulator ATRX (Fragment) OS=Homo sapiens GN=ATRX PE=1 SV=1 - 
[A0A096LNN3_HUMAN] 
5 1 1 1 528 59.4 6.34 
 
Control Peptide 2 
Accession Description # Proteins 
# Unique 
Peptides 
# Peptides # PSMs # AAs 
MW 
[kDa] 
calc. 
pI 
H6VRF8 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 - [H6VRF8_HUMAN] 16 27 30 154 644 66.0 8.12 
P35527 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - [K1C9_HUMAN] 2 27 27 141 623 62.0 5.24 
P13645 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - [K1C10_HUMAN] 25 23 26 87 584 58.8 5.21 
P35908 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 - [K22E_HUMAN] 12 20 28 77 639 65.4 8.00 
P02533 Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - [K1C14_HUMAN] 42 6 15 57 472 51.5 5.16 
P08779 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - [K1C16_HUMAN] 39 4 11 45 473 51.2 5.05 
P13647 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - [K2C5_HUMAN] 16 9 17 34 590 62.3 7.74 
B4DRR0 cDNA FLJ53910, highly similar to Keratin, type II cytoskeletal 6A OS=Homo sapiens PE=2 SV=1 - [B4DRR0_HUMAN] 17 2 11 22 535 57.8 8.00 
Q04695 Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2 - [K1C17_HUMAN] 31 1 7 13 432 48.1 5.02 
Q14CN4 Keratin, type II cytoskeletal 72 OS=Homo sapiens GN=KRT72 PE=1 SV=2 - [K2C72_HUMAN] 13 1 4 10 511 55.8 6.89 
A0A024R0Y2 HCG30204, isoform CRA_a OS=Homo sapiens GN=hCG_30204 PE=4 SV=1 - [A0A024R0Y2_HUMAN] 13 4 4 6 2268 257.1 6.61 
Q9GZZ8 Extracellular glycoprotein lacritin OS=Homo sapiens GN=LACRT PE=1 SV=1 - [LACRT_HUMAN] 2 3 3 6 138 14.2 5.50 
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Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 - [HORN_HUMAN] 1 3 3 4 2850 282.2 10.04 
Q45KI0 Trypsin I (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q45KI0_HUMAN] 17 1 1 4 84 9.2 9.99 
P81605 Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - [DCD_HUMAN] 1 3 3 3 110 11.3 6.54 
A0A087WW
T3 
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=1 - [A0A087WWT3_HUMAN] 14 3 3 3 396 45.1 6.10 
B3KX99 cDNA FLJ45019 fis, clone BRAWH3015825 OS=Homo sapiens PE=2 SV=1 - [B3KX99_HUMAN] 2 1 1 3 333 38.5 8.97 
A0PJ54 PEX12 protein (Fragment) OS=Homo sapiens GN=PEX12 PE=2 SV=1 - [A0PJ54_HUMAN] 1 1 1 3 324 36.9 9.98 
Q19KS2 Lactoferrin (Fragment) OS=Homo sapiens PE=2 SV=1 - [Q19KS2_HUMAN] 15 3 3 3 353 39.1 9.03 
B2R4M6 Protein S100 OS=Homo sapiens PE=2 SV=1 - [B2R4M6_HUMAN] 2 1 1 2 114 13.2 6.13 
F8VV32 Lysozyme OS=Homo sapiens GN=LYZ PE=1 SV=1 - [F8VV32_HUMAN] 3 2 2 2 104 11.5 9.07 
Q8N532 TUBA1C protein OS=Homo sapiens GN=TUBA1C PE=2 SV=1 - [Q8N532_HUMAN] 25 2 2 2 325 36.6 7.96 
Q5HY57 Emerin OS=Homo sapiens GN=EMD PE=1 SV=1 - [Q5HY57_HUMAN] 2 2 2 2 219 24.9 5.02 
Q5VSP4 Putative lipocalin 1-like protein 1 OS=Homo sapiens GN=LCN1P1 PE=5 SV=1 - [LC1L1_HUMAN] 2 2 2 3 162 17.9 5.00 
I3L1U9 Actin, cytoplasmic 2 (Fragment) OS=Homo sapiens GN=ACTG1 PE=1 SV=1 - [I3L1U9_HUMAN] 47 2 2 2 214 23.8 5.44 
M0R1I1 Tubulin beta-4A chain (Fragment) OS=Homo sapiens GN=TUBB4A PE=1 SV=1 - [M0R1I1_HUMAN] 27 1 1 1 74 7.8 4.94 
F8WF65 Elongation factor 1-beta OS=Homo sapiens GN=EEF1B2 PE=1 SV=1 - [F8WF65_HUMAN] 4 1 1 1 29 3.1 4.46 
H0YDD8 60S acidic ribosomal protein P2 (Fragment) OS=Homo sapiens GN=RPLP2 PE=1 SV=1 - 
[H0YDD8_HUMAN] 
2 1 1 1 92 9.1 4.46 
M0QZK8 Uncharacterized protein OS=Homo sapiens PE=4 SV=1 - [M0QZK8_HUMAN] 4 1 1 1 103 11.6 4.92 
Q5D862 Filaggrin-2 OS=Homo sapiens GN=FLG2 PE=1 SV=1 - [FILA2_HUMAN] 1 1 1 1 2391 247.9 8.31 
Q3SYB5 SERPINB12 protein OS=Homo sapiens GN=SERPINB12 PE=2 SV=1 - [Q3SYB5_HUMAN] 2 2 2 2 183 20.9 5.87 
Q86W20 Protease serine 1 (Fragment) OS=Homo sapiens GN=PRSS1 PE=3 SV=1 - [Q86W20_HUMAN] 6 1 1 1 84 9.2 10.2
7 
O95968 Secretoglobin family 1D member 1 OS=Homo sapiens GN=SCGB1D1 PE=1 SV=1 - [SG1D1_HUMAN] 1 1 1 1 90 9.9 9.25 
P12273 Prolactin-inducible protein OS=Homo sapiens GN=PIP PE=1 SV=1 - [PIP_HUMAN] 1 1 1 1 146 16.6 8.05 
J3QSA3 Polyubiquitin-B (Fragment) OS=Homo sapiens GN=UBB PE=1 SV=1 - [J3QSA3_HUMAN] 37 1 1 1 43 4.9 5.19 
Q6UXS9 Inactive caspase-12 OS=Homo sapiens GN=CASP12 PE=2 SV=2 - [CASPC_HUMAN] 1 1 1 1 341 38.8 6.02 
P01040 Cystatin-A OS=Homo sapiens GN=CSTA PE=1 SV=1 - [CYTA_HUMAN] 1 1 1 1 98 11.0 5.50 
A8MXP8 Reticulocalbin-2 OS=Homo sapiens GN=RCN2 PE=1 SV=1 - [A8MXP8_HUMAN] 2 1 1 1 216 24.8 4.42 
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A8K2T2 cDNA FLJ75519 (Fragment) OS=Homo sapiens PE=2 SV=1 - [A8K2T2_HUMAN] 4 1 1 1 1173 130.7 9.01 
Q9HB00 Desmocollin 1, isoform CRA_b OS=Homo sapiens GN=DSC1 PE=4 SV=1 - [Q9HB00_HUMAN] 2 1 1 1 840 93.8 5.53 
G3V4X3 Protein NDRG2 OS=Homo sapiens GN=NDRG2 PE=1 SV=1 - [G3V4X3_HUMAN] 1 1 1 1 77 8.9 7.21 
P31151 Protein S100-A7 OS=Homo sapiens GN=S100A7 PE=1 SV=4 - [S10A7_HUMAN] 1 1 1 1 101 11.5 6.77 
A0A0A0MR
Q5 
Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 - [A0A0A0MRQ5_HUMAN] 6 1 1 1 97 10.7 8.72 
Q8N1N4 Keratin, type II cytoskeletal 78 OS=Homo sapiens GN=KRT78 PE=2 SV=2 - [K2C78_HUMAN] 1 1 1 1 520 56.8 6.02 
E5RG02 Putative serine protease 46 OS=Homo sapiens GN=PRSS46 PE=5 SV=1 - [PRS46_HUMAN] 1 1 1 1 174 19.3 9.10 
B4DKX6 cDNA FLJ53584, highly similar to Desmoplakin (Fragment) OS=Homo sapiens PE=2 SV=1 - 
[B4DKX6_HUMAN] 
4 1 1 1 954 112.2 6.73 
F8W7D1 C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8 OS=Homo sapiens GN=CPAMD8 
PE=1 SV=1 - [F8W7D1_HUMAN] 
4 1 1 2 503 56.0 7.84 
A0A075B6G
4 
Protein crumbs homolog 1 OS=Homo sapiens GN=CRB1 PE=4 SV=1 - [A0A075B6G4_HUMAN] 6 1 1 1 674 74.6 5.59 
A9UFC0 Caspase 14 OS=Homo sapiens GN=CASP14 PE=2 SV=1 - [A9UFC0_HUMAN] 2 2 2 2 242 27.6 5.34 
Q8TDD1 ATP-dependent RNA helicase DDX54 OS=Homo sapiens GN=DDX54 PE=1 SV=2 - [DDX54_HUMAN] 1 1 1 1 881 98.5 10.0
2 
Q02413 Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 - [DSG1_HUMAN] 1 1 1 1 1049 113.7 5.03 
Q08AM8 SH3 domain containing ring finger 2 OS=Homo sapiens GN=SH3RF2 PE=1 SV=1 - [Q08AM8_HUMAN] 2 1 1 1 729 79.3 9.96 
A0A075B6Z
2 
Protein TRAJ56 (Fragment) OS=Homo sapiens GN=TRAJ56 PE=4 SV=1 - [A0A075B6Z2_HUMAN] 2 1 1 10 21 2.2 10.2
9 
Q9H6A9 Pecanex-like protein 3 OS=Homo sapiens GN=PCNXL3 PE=1 SV=2 - [PCX3_HUMAN] 1 1 1 1 2034 221.9 6.64 
P05109 Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 - [S10A8_HUMAN] 1 1 1 1 93 10.8 7.03 
Q9H4H8 Protein FAM83D OS=Homo sapiens GN=FAM83D PE=1 SV=3 - [FA83D_HUMAN] 2 1 1 1 585 64.4 6.54 
Q59F77 Phosphoinositide phospholipase C (Fragment) OS=Homo sapiens PE=1 SV=1 - [Q59F77_HUMAN] 2 1 1 1 901 101.7 6.42 
B7Z2C0 cDNA FLJ59621, highly similar to Liprin-beta-2 OS=Homo sapiens PE=2 SV=1 - [B7Z2C0_HUMAN] 5 1 1 1 520 57.9 8.91 
A0A087WW
F0 
Protein IGHV3-64 OS=Homo sapiens GN=IGHV3-64 PE=1 SV=1 - [A0A087WWF0_HUMAN] 9 1 1 1 75 8.3 8.73 
H7C1F9 Ral GTPase-activating protein subunit alpha-2 (Fragment) OS=Homo sapiens GN=RALGAPA2 PE=1 
SV=1 - [H7C1F9_HUMAN] 
2 1 1 1 1740 194.9 5.90 
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- 214 - 
Appendix B: Table of accession numbers from MS 
Proteins detected by mass spec which showed up in sample duplicates ordered by the accession number and uniprot description 
Accesion Description Expressed in 
HEK293T 
SH3 domain Comment 
A0A024R0Y2 HCG30204, isoform CRA_a OS=Homo 
sapiens GN=hCG_30204 PE=4 SV=1 - 
[A0A024R0Y2_HUMAN] 
Y N  
A0A024R1X8 Junction plakoglobin, isoform CRA_a 
OS=Homo sapiens GN=JUP PE=4 SV=1 - 
[A0A024R1X8_HUMAN] 
Y N  
A0A024RC29 Desmocollin 3, isoform CRA_b OS=Homo 
sapiens GN=DSC3 PE=4 SV=1 - 
[A0A024RC29_HUMAN] 
N 
 
- Contamination 
A0A075B6Z2 Protein TRAJ56 (Fragment) OS=Homo 
sapiens GN=TRAJ56 PE=4 SV=1 - 
[A0A075B6Z2_HUMAN] 
- - 21 amino acid long 
peptide 
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A0A087WTG3 Cullin-3 OS=Homo sapiens GN=CUL3 PE=1 
SV=1 - [A0A087WTG3_HUMAN] 
Y N  
A0A087WUV8 Basigin OS=Homo sapiens GN=BSG PE=1 
SV=1 - [A0A087WUV8_HUMAN] 
Y N  
A0A087WWT3 Serum albumin OS=Homo sapiens GN=ALB 
PE=1 SV=1 - [A0A087WWT3_HUMAN] 
N - Contamination 
A0A087WXD2 Membrane-associated guanylate kinase, 
WW and PDZ domain-containing protein 1 
OS=Homo sapiens GN=MAGI1 PE=1 SV=1 
- [A0A087WXD2_HUMAN] 
Y N Has WW domain which 
binds proline-rich motifs 
A0A0A0MRQ5 Peroxiredoxin-1 OS=Homo sapiens 
GN=PRDX1 PE=1 SV=1 - 
[A0A0A0MRQ5_HUMAN] 
Y N  
A8K651 cDNA FLJ75700, highly similar to Homo 
sapiens complement component 1, q 
subcomponent binding protein (C1QBP), 
nuclear gene encoding mitochondrial 
protein, mRNA OS=Homo sapiens PE=2 
SV=1 - [A8K651_HUMAN] 
- N  
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A9UFC0 Caspase 14 OS=Homo sapiens 
GN=CASP14 PE=2 SV=1 - 
[A9UFC0_HUMAN] 
N  Contamination 
B2R4M6 Protein S100 OS=Homo sapiens PE=2 
SV=1 - [B2R4M6_HUMAN] 
- N  
B3KPS3 cDNA FLJ32131 fis, clone PEBLM2000267, 
highly similar to Tubulin alpha-ubiquitous 
chain OS=Homo sapiens PE=2 SV=1 - 
[B3KPS3_HUMAN] 
Y N  
B3KRK8 cDNA FLJ34494 fis, clone HLUNG2005030, 
highly similar to VIMENTIN OS=Homo 
sapiens PE=2 SV=1 - [B3KRK8_HUMAN] 
- N  
B3KX99 cDNA FLJ45019 fis, clone BRAWH3015825 
OS=Homo sapiens PE=2 SV=1 - 
[B3KX99_HUMAN] 
- N  
B4DHW6 cDNA FLJ54930, highly similar to Homo 
sapiens Dbf4-related factor 1 (DRF1), 
transcript variant 2, mRNA OS=Homo 
sapiens PE=2 SV=1 - [B4DHW6_HUMAN] 
- N  
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B4DNE0 cDNA FLJ52573, highly similar to Elongation 
factor 1-alpha 1 OS=Homo sapiens PE=2 
SV=1 - [B4DNE0_HUMAN] 
- N  
B4DRR0 cDNA FLJ53910, highly similar to Keratin, 
type II cytoskeletal 6A OS=Homo sapiens 
PE=2 SV=1 - [B4DRR0_HUMAN] 
- N  
B4DVQ0 cDNA FLJ58286, highly similar to Actin, 
cytoplasmic 2 OS=Homo sapiens PE=2 
SV=1 - [B4DVQ0_HUMAN] 
- N  
B7Z1V3 cDNA FLJ54733, highly similar to General 
transcription factor 3C polypeptide 5 
OS=Homo sapiens PE=2 SV=1 - 
[B7Z1V3_HUMAN] 
- N  
B7Z597 cDNA FLJ54373, highly similar to 60 kDa 
heat shock protein, mitochondrial OS=Homo 
sapiens PE=2 SV=1 - [B7Z597_HUMAN] 
- N  
B7Z5E7 cDNA FLJ51046, highly similar to 60 kDa 
heat shock protein, mitochondrial OS=Homo 
sapiens PE=2 SV=1 - [B7Z5E7_HUMAN] 
- N  
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C9IYG1 BRCA1-associated RING domain protein 1 
(Fragment) OS=Homo sapiens GN=BARD1 
PE=1 SV=1 - [C9IYG1_HUMAN] 
Y N  
E5RJN0 Heparan-alpha-glucosaminide N-
acetyltransferase OS=Homo sapiens 
GN=HGSNAT PE=1 SV=1 - 
[E5RJN0_HUMAN] 
Y N  
E9PN25 Heat shock cognate 71 kDa protein 
(Fragment) OS=Homo sapiens GN=HSPA8 
PE=1 SV=1 - [E9PN25_HUMAN] 
Y N  
F6KPG5 Albumin (Fragment) OS=Homo sapiens 
PE=2 SV=1 - [F6KPG5_HUMAN] 
N - Contamination 
F8VV32 Lysozyme OS=Homo sapiens GN=LYZ 
PE=1 SV=1 - [F8VV32_HUMAN] 
N - Contamination 
F8WCH0 Actin, gamma-enteric smooth muscle 
OS=Homo sapiens GN=ACTG2 PE=1 SV=1 
- [F8WCH0_HUMAN] 
N  Contamination 
F8WCJ1 Eukaryotic translation initiation factor 5A 
OS=Homo sapiens GN=EIF5A2 PE=1 SV=1 
- [F8WCJ1_HUMAN] 
Y N  
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F8WE04 Heat shock protein beta-1 OS=Homo 
sapiens GN=HSPB1 PE=1 SV=1 - 
[F8WE04_HUMAN] 
Y N  
F8WF65 Elongation factor 1-beta OS=Homo sapiens 
GN=EEF1B2 PE=1 SV=1 - 
[F8WF65_HUMAN] 
Y - 29 amino acid long 
peptide 
G3V361 Calmodulin (Fragment) OS=Homo sapiens 
GN=CALM1 PE=1 SV=1 - 
[G3V361_HUMAN] 
Y N EF hand motifs, calcium 
binding 
G3V3Y2 Fibulin-5 (Fragment) OS=Homo sapiens 
GN=FBLN5 PE=1 SV=1 - 
[G3V3Y2_HUMAN] 
N - Contamination 
Calcium-binding EGF 
domain 
H0YDD8 60S acidic ribosomal protein P2 (Fragment) 
OS=Homo sapiens GN=RPLP2 PE=1 SV=1 
- [H0YDD8_HUMAN] 
Y N  
H6VRF8 Keratin 1 OS=Homo sapiens GN=KRT1 
PE=3 SV=1 - [H6VRF8_HUMAN] 
N - Contamination 
H7C1F9 Ral GTPase-activating protein subunit alpha-
2 (Fragment) OS=Homo sapiens 
Y N  
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GN=RALGAPA2 PE=1 SV=1 - 
[H7C1F9_HUMAN] 
H7C2X0 Translation initiation factor eIF-2B subunit 
epsilon (Fragment) OS=Homo sapiens 
GN=EIF2B5 PE=1 SV=1 - 
[H7C2X0_HUMAN] 
Y N  
I3L1U9 Actin, cytoplasmic 2 (Fragment) OS=Homo 
sapiens GN=ACTG1 PE=1 SV=1 - 
[I3L1U9_HUMAN] 
Y N  
J3QRT3 Uncharacterized protein KIAA0195 
(Fragment) OS=Homo sapiens 
GN=KIAA0195 PE=1 SV=5 - 
[J3QRT3_HUMAN] 
Y N  
J3QSA3 Polyubiquitin-B (Fragment) OS=Homo 
sapiens GN=UBB PE=1 SV=1 - 
[J3QSA3_HUMAN] 
Y N 43 amino acid peptide 
L0R5A1 Alternative protein CSF2RB OS=Homo 
sapiens GN=CSF2RB PE=4 SV=1 - 
[L0R5A1_HUMAN] 
N  Contamination 
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L8ECQ7 Alternative protein C10orf112 OS=Homo 
sapiens GN=C10orf112 PE=4 SV=1 - 
[L8ECQ7_HUMAN] 
- N  
O75531 Barrier-to-autointegration factor OS=Homo 
sapiens GN=BANF1 PE=1 SV=1 - 
[BAF_HUMAN] 
Y N HhH domain, bind DNA 
O75556 Mammaglobin-B OS=Homo sapiens 
GN=SCGB2A1 PE=1 SV=1 - 
[SG2A1_HUMAN] 
N - Contamination 
O95968 Secretoglobin family 1D member 1 
OS=Homo sapiens GN=SCGB1D1 PE=1 
SV=1 - [SG1D1_HUMAN] 
N - Contamination 
P01040 Cystatin-A OS=Homo sapiens GN=CSTA 
PE=1 SV=1 - [CYTA_HUMAN] 
Y, very low 
levels 
N Intracellular thiol 
proteinase inhibitor 
P02533 Keratin, type I cytoskeletal 14 OS=Homo 
sapiens GN=KRT14 PE=1 SV=4 - 
[K1C14_HUMAN] 
N - Contamination 
P05089 Arginase-1 OS=Homo sapiens GN=ARG1 
PE=1 SV=2 - [ARGI1_HUMAN] 
N - Contamination 
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P05109 Protein S100-A8 OS=Homo sapiens 
GN=S100A8 PE=1 SV=1 - [S10A8_HUMAN] 
N - EF-hand domains 
P07737 Profilin-1 OS=Homo sapiens GN=PFN1 
PE=1 SV=2 - [PROF1_HUMAN] 
Y N Binds actin 
P08779 Keratin, type I cytoskeletal 16 OS=Homo 
sapiens GN=KRT16 PE=1 SV=4 - 
[K1C16_HUMAN] 
N - Contamination 
P12004 Proliferating cell nuclear antigen OS=Homo 
sapiens GN=PCNA PE=1 SV=1 - 
[PCNA_HUMAN] 
Y N Phosphorylated by EGFR, 
DNA replication and DNA 
repair 
P13645 Keratin, type I cytoskeletal 10 OS=Homo 
sapiens GN=KRT10 PE=1 SV=6 - 
[K1C10_HUMAN] 
Y N  
P13647 Keratin, type II cytoskeletal 5 OS=Homo 
sapiens GN=KRT5 PE=1 SV=3 - 
[K2C5_HUMAN] 
N - Contamination 
P31151 Protein S100-A7 OS=Homo sapiens 
GN=S100A7 PE=1 SV=4 - [S10A7_HUMAN] 
N - EF-hand 
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P35527 Keratin, type I cytoskeletal 9 OS=Homo 
sapiens GN=KRT9 PE=1 SV=3 - 
[K1C9_HUMAN] 
N - Contamination 
P35908 Keratin, type II cytoskeletal 2 epidermal 
OS=Homo sapiens GN=KRT2 PE=1 SV=2 - 
[K22E_HUMAN] 
N - Contamination 
P50402 Emerin OS=Homo sapiens GN=EMD PE=1 
SV=1 - [EMD_HUMAN] 
Y N Stimulates actin 
polymerisation 
P61626 Lysozyme C OS=Homo sapiens GN=LYZ 
PE=1 SV=1 - [LYSC_HUMAN] 
N - Contamination 
P81605 Dermcidin OS=Homo sapiens GN=DCD 
PE=1 SV=2 - [DCD_HUMAN] 
Y N  
Q02413 Desmoglein-1 OS=Homo sapiens 
GN=DSG1 PE=1 SV=2 - [DSG1_HUMAN] 
N - Contamination 
Q04695 Keratin, type I cytoskeletal 17 OS=Homo 
sapiens GN=KRT17 PE=1 SV=2 - 
[K1C17_HUMAN] 
Y, very low 
levels 
N  
Q0IIN1 Keratin 77 OS=Homo sapiens GN=KRT77 
PE=1 SV=1 - [Q0IIN1_HUMAN] 
N - Contamination 
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Q14CN4 Keratin, type II cytoskeletal 72 OS=Homo 
sapiens GN=KRT72 PE=1 SV=2 - 
[K2C72_HUMAN] 
N - Contamination 
Q15203 Prothymosin alpha OS=Homo sapiens PE=4 
SV=2 - [Q15203_HUMAN] 
Y N  
Q16378 Proline-rich protein 4 OS=Homo sapiens 
GN=PRR4 PE=1 SV=3 - [PROL4_HUMAN] 
N - Possible recognised from 
one of the peptides 
Q19KS2 Lactoferrin (Fragment) OS=Homo sapiens 
PE=2 SV=1 - [Q19KS2_HUMAN] 
- N  
Q3SYB5 SERPINB12 protein OS=Homo sapiens 
GN=SERPINB12 PE=2 SV=1 - 
[Q3SYB5_HUMAN] 
N - Contamination 
Q45KI0 Trypsin I (Fragment) OS=Homo sapiens 
GN=PRSS1 PE=3 SV=1 - 
[Q45KI0_HUMAN] 
N - Contamination 
Q53HF2 Heat shock 70kDa protein 8 isoform 2 
variant (Fragment) OS=Homo sapiens PE=1 
SV=1 - [Q53HF2_HUMAN] 
Y N  
Q53SG8 Putative uncharacterized protein FLJ22527 
(Fragment) OS=Homo sapiens 
- N  
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GN=FLJ22527 PE=4 SV=1 - 
[Q53SG8_HUMAN] 
Q59H57 Fusion (Involved in t(12;16) in malignant 
liposarcoma) isoform a variant (Fragment) 
OS=Homo sapiens PE=2 SV=1 - 
[Q59H57_HUMAN] 
- N  
Q5D862 Filaggrin-2 OS=Homo sapiens GN=FLG2 
PE=1 SV=1 - [FILA2_HUMAN] 
N - Contamination 
Q5HY57 Emerin OS=Homo sapiens GN=EMD PE=1 
SV=1 - [Q5HY57_HUMAN] 
N - Contamination 
Q5VSP4 Putative lipocalin 1-like protein 1 OS=Homo 
sapiens GN=LCN1P1 PE=5 SV=1 - 
[LC1L1_HUMAN] 
- N  
Q5ZEY3 Glyceraldehyde-3-phosphate 
dehydrogenase (Fragment) OS=Homo 
sapiens GN=GAPD PE=2 SV=1 - 
[Q5ZEY3_HUMAN] 
Y N  
Q6B823 Histone H4 (Fragment) OS=Homo sapiens 
PE=3 SV=1 - [Q6B823_HUMAN] 
- N 43 amino acid peptide 
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Q6KB66 Keratin, type II cytoskeletal 80 OS=Homo 
sapiens GN=KRT80 PE=1 SV=2 - 
[K2C80_HUMAN] 
N - Contamination 
Q6UXS9 Inactive caspase-12 OS=Homo sapiens 
GN=CASP12 PE=2 SV=2 - 
[CASPC_HUMAN] 
- N  
Q6ZSX8 cDNA FLJ45139 fis, clone BRAWH3039623 
OS=Homo sapiens PE=2 SV=1 - 
[Q6ZSX8_HUMAN] 
- N  
Q7Z612 Acidic ribosomal phosphoprotein P1 
OS=Homo sapiens PE=2 SV=1 - 
[Q7Z612_HUMAN] 
- N  
Q86W20 Protease serine 1 (Fragment) OS=Homo 
sapiens GN=PRSS1 PE=3 SV=1 - 
[Q86W20_HUMAN] 
N - Contamination 
Q86YZ3 Hornerin OS=Homo sapiens GN=HRNR 
PE=1 SV=2 - [HORN_HUMAN] 
N - EF hand domains 
Q8N1N4 Keratin, type II cytoskeletal 78 OS=Homo 
sapiens GN=KRT78 PE=2 SV=2 - 
[K2C78_HUMAN] 
N - Contamination 
- 227 - 
Q96MA3 cDNA FLJ32709 fis, clone TESTI2000695, 
weakly similar to KINESIN HEAVY CHAIN 
(Fragment) OS=Homo sapiens PE=2 SV=1 - 
[Q96MA3_HUMAN] 
- N  
Q99456 Keratin, type I cytoskeletal 12 OS=Homo 
sapiens GN=KRT12 PE=1 SV=1 - 
[K1C12_HUMAN] 
N - Contaminaton 
Q9BRJ0 HECTD1 protein (Fragment) OS=Homo 
sapiens GN=HECTD1 PE=2 SV=2 - 
[Q9BRJ0_HUMAN] 
Y N  
Q9GZZ8 Extracellular glycoprotein lacritin OS=Homo 
sapiens GN=LACRT PE=1 SV=1 - 
[LACRT_HUMAN] 
N - Contamination 
Q9HB00 Desmocollin 1, isoform CRA_b OS=Homo 
sapiens GN=DSC1 PE=4 SV=1 - 
[Q9HB00_HUMAN] 
N - Contamination 
V9GZN0 Histone H2A gene (lambda-HHG55) 
(Fragment) OS=Homo sapiens PE=4 SV=1 - 
[V9GZN0_HUMAN] 
- N 47 amino acid peptide 
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Appendix C: C58 amino acid sequences 
C58: 
GGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLD
LSQPLEQYS PSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVKT 
 
C58 P800A: 
GGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLD
LSQPLEQYS PSYPDTRSSCSSGDDSVFSADPMPYEPCLPQYPHINGSVKT 
 
C58 P802A: 
GGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLD
LSQPLEQYS PSYPDTRSSCSSGDDSVFSPDAMPYEPCLPQYPHINGSVKT 
 
C58 P804A: 
GGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLD
LSQPLEQYS PSYPDTRSSCSSGDDSVFSPDPMAYEPCLPQYPHINGSVKT 
 
C58 P807A: 
GGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLD
LSQPLEQYS PSYPDTRSSCSSGDDSVFSPDPMPYEACLPQYPHINGSVKT 
 
C58 P810A: 
GGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLD
LSQPLEQYS PSYPDTRSSCSSGDDSVFSPDPMPYEPCLAQYPHINGSVKT 
 
C58 P813A:  
GGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLD
LSQPLEQYS PSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYAHINGSVKT 
 
C58 ∆3: 
GGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLD
LSQPLEQYS PSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGS 
 
C58 ∆6: 
GGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLD
LSQPLEQYS PSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHI 
 
C58 ∆9: 
GGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLD
LSQPLEQYS PSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQY 
 
C58 ∆12: 
GGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLD
LSQPLEQYS PSYPDTRSSCSSGDDSVFSPDPMPYEPCL 
 
C58 ∆15: 
GGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLD
LSQPLEQYS PSYPDTRSSCSSGDDSVFSPDPMPYE 
 
C58 ∆23: 
GGSPYPGIPVEELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLD
LSQPLEQYS PSYPDTRSSCSSGDDSVF 
 
